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The betaherpesviruses human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6) 
are investigated here as pathogens in Zambia, an HIV -1 endemic region where there was little 
previous data. In particular we assess the effects of these viruses on 'maternally HIV-l 
exposed' infants: HIV-l negative infants of HI V-I positive mothers. HCMV and HHV-6 are 
serious causes of morbidity and mortality in HIV / AIDS and are linked with AIDS 
progression, so in this thesis they are investigated in both HIV -1 infected and uninfected 
Zambian children, along with maternally HIV exposed infants, an under studied and growing 
group in Southern Africa. The aim ofthis thesis is to employ qualitative and quantitative PCR 
assays to determine betaherpesvirus prevalence, loads and genotypes in three independent 
Zambian paediatric cohorts: Two retrospective cohorts (141 infants hospitalized with fever 
and 36 childhood HIV-1 positive respiratory mortalities), and also one prospective cohort 
(812 infants taking part in a population-based study designed to test the efficacy of a 
micronutrient fortified feed supplement to improve growth and health) in which relationships 
between betaherpesvirus infection, duration of breast feeding, infant growth and morbidity 
were investigated. Prevalence and loads were highest within the symptomatic cohorts, 
although lower levels of both viruses were also detected in sera from healthy infants taking 
part in the prospective study. High load HCMV infections were shown here to be significantly 
more prevalent in maternally HIV -1 exposed infants. Genotyping analysis focused of two 
hypervariable glycoproteins (gO and gN), which in HCMV have been shown to form seven 
linked genotypes. Here we identified a new genotype (gN4d) and demonstrated linkage with 
g05, demonstrating now eight gO/gN linkages. Analyses of this data and that generated in 
other countries show these linkages are globally maintained. Conversely for HHV -6, whilst 
HHV-6B is the predominant strain for childhood infections in the V.S, Europe and Japan, in 
Zambia HHV-6A was identified in 84% ofinfant infections, suggesting emergence elsewhere. 
The prevalence of active betaherpesvirus infections through detection of viral sera-DNA was 
34-40% for HCMV and 8-13% for HHV-6, showing that primary infection with HCMV 
occurs much earlier in this region than in European and North American countries. Active 
HCMV infections were associated with inhibitory effects on growth and a trend for increased 
morbidity in HIV -1 exposed infants as measured by an increased rate of hospital referrals. 
HCMV seroprevalence was associated with anaemia and stunting, and breast feeding 
increased HCMV transmission, particularly in HIV -1 exposed infants. A micronutrient 
supplement with iron reduced anaemia. In summary, genotypes of HCMV and HHV-6 were 
identified and characterised in infant infections in this region, and analyses shows association 
with morbidity and growth delays for HCMV infected children, particularly with maternal 
HIV -1, a newly identified potential hazard for this population. 
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1.0 Introduction 
1.1 Herpesvirus classification 
Over 200 herpesviruses have been identified, mostly from mammals, birds and reptiles, which 
together form the family Herpesviridae. More recently herpesviruses have been found in both 
fish and amphibians, and also oysters, which through sequence analysis have been assigned to 
separate families: The Alloherpesviridae and Malacoherpesviridae respectively. Together 
these three families form the order Herpesvirales which likely diverged from a pre-historic 
common ancestor, with some structural and sequence similarities to large tailed DNA 
bacteriophages (Caudovirales}(McGeoch, Rixon, and Davison, 2006). Sequence analysis of 
the family Herpesviridae, has identified three sub-families: The alpha-, beta- and 
gammaherpesvirinae, derived from a common ancestor over 400 million years ago (McGeoch 
and Gatherer, 2005). The alphaherpesvirinae were originally defined due to their broad host 
range, rapid growth in culture and ability to establish latency in neuronal cells. The 
betaherpesvirinae have a more restricted host range but a broad cell-tropism. They replicate 
more slowly in vitro, spreading in tissue culture through cell-cell fusion forming syncytia and 
latency is established in haematopoietic progenitors and monocytes/macrophages. 
Gammaherpesvirinae establish latency in lymphoid tissue and the human 
gammaberpesviruses HHV -4 (EBV) and HHV -8 (KSHV)(Table 1) are both tumorigenic, a 
unique feature among the human herpes viruses. Together eight herpesviruses are known to 
infect humans as shown (Table 1). Data from Europe and North America has shown that two 
betaherpesviruses, HCMV and HHV -6, are pathogens in infants and are the main viral 
opportunistic infections in HIV I AIDS causing both morbidity and mortality (Clark et aI., 
1996; Knox and Carrigan, 1994; Kovacs et aI., 1999). In this thesis these viruses are 
examined in Zambia, a developing country in Southern Africa, an HIV -1 endemic region. 
Interactions are examined in HIV-I co-infected and maternally 'HIV-I exposed' but 
uninfected children, an increasing and under-recognized, poorly characterized group. 
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Virus Vernacular name (Abbreviation) Sub- Genome size Genome 
name family (kbp) Accession No. 
HHV-1 Herpes simplex virus 1 (HSV-1) a 152 NC 001806 
HHV-2 Herpes simplex virus 2 (HSV-2) a 155 NC 001798 
HHV-3 Varicella zoster virus (VZV) a 125 NC 001348 
HHV-4 Epstein Barr virus (EBV) V 172 NC 007605 
HHV-5 Human cytomegalovirus (HCMV) ~ 236 NC 006273 
HHV-6 Human herpesvirus 6 variant A (HHV-6A) ~ 159 NC 001664 
Human herpesvirus 6 variant B (HHV-6B) ~ 162 NC 000898 
HHV-7 Human herpesvirus 7 (HHV-7) ~ 153 NC 001716 
HHV-8 Kaposi's sarcoma associated herpesvirus (KSHV) V 138 NC 009333 
Table 1: The human herpesviruses 
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1.2 Betaherpesviruses 
Betaherpesviruses are species specific with three members of this subfamily infecting 
humans: Human herpesvirus 5 (HHV -5) (common name: human cytomegalovirus, HCMV), 
human herpesvirus 6 (HHV -6) and human herpesvirus 7 (HHV -7) (Table 1). Along with 
similar growth kinetics and sites of latency, sequence comparisons show similar gene 
organization, betaherpesvirus specific genes and closer similarity between conserved genes 
(Davison et aI., 2003; Gompels et aI., 1995). HCMV and HHV -6 are widespread, causing life-
long latent infections which are usually immunologically controlled in healthy individuals. In 
the immunosuppressed setting these infections can reactivate causing serious and life-
threatening illness, affecting a wide range of tissues and organ systems. 
Betaherpesvirus virions have a typical herpesvirus morphology and are composed of a double 
stranded DNA genome, encased in a 100-300 nm diameter icosahedral nucleocapsid 
(McGeoch, Rixon, and Davison, 2006; Roizman B, 2004). This comprises 162 capsomers: 
150 hexamers and 11 pentamers with the final pentameric position being occupied by the 
portal complex (McGeoch, Rixon, and Davison, 2006). Betaherpesvirus nucleocapsids are 
surrounded by a large globular tegument which is subtly pleomorphic. This in turn is 
surrounded by a lipid envelope, which is derived from host cell membrane, and is studded 
with evenly distributed spike-like glycoproteins (Mocarski, 2007; Yamanishi, 2007). 
HCMV has been widely studied initially due to its severe pathology in children who are 
congenitally infected, but later it emerged as one of the most important viral causes of 
morbidity and mortality in transplant recipients as reviewed (Britt, 2008). HCMV is also the 
main viral opportunistic infection in HIV / AIDS patients where it is a powerful marker of 
disease progression (Darwich et aI., 2008; Kovacs et aI., 1999; Nigro et aI., 1996; Williams et 
aI., 2001). Where there is a high prevalence of primary HCMV infections or high load 
reactivations during pregnancy there is a greater risk of transmitting HCMV from mother to 
child, transplacentally (Gouarin et aI., 2002; Gouarin et aI., 2001) or through breast milk 
(Murata et aI., 2009). Factors which may affect transmission include immunity which is 
affected by nutrition, and viral strain variation which may determine virulence. Hypervariable 
loci in what is generally a highly conserved genome may encode virulence factors that drive 
tropism and can be used to investigate strain differences. 
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HHV -6 was discovered later than HCMV, and primary infection is common in infancy, where 
it causes fever (Hall et aI., 1994; Portolani et aI., 1993). Febrile episodes are occasionally 
accompanied by a rash termed exanthem subitum (roseola infantum) but fever is the primary 
symptom of infection. The virus exists as two strain variants, HHV -6A and HHV -6B, which 
are genomically distinct (Dominguez et aI., 1999; Gompels, 2006). Primary infections causing 
fever in North America and Europe are predominantly found to be HHV -6B, although HHV-
6A is detectable in a around 3% of cases (Dewhurst et aI., 1993; Hall et al., 1994; Zerr et aI., 
2005). Both variants are linked with severe pathology in immunocompromised groups and 
several serious diseases in children and adults as reviewed (Gompels, 2004). HHV-6 
productively infects the same cells as HIV (CD4 T-celIs) (Lusso et aI., 1991b) and can cause 
disseminated infections in HIV/AIDS (Clark et aI., 1996). 
This thesis investigates the prevalence, viral loads and genotypes of these two 
betaherpesviruses in three paediatric cohorts from Zambia in Southern African, and assesses 
the effects of infant and maternal HIV -1 infection on childhood HCMV and HHV-6 
infections, and their effects on growth and morbidity. Betaherpesvirus prevalence, loads, 
genotypes and morbidity associations have not previously been defined for this population. 
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1.3 Human Herpesvirus 6 
1.3.1 Introduction 
HHV-6 was first isolated in 1986 and was named 'B-Iymphotropic virus' as it was found in 
patients with lymphoproliferative disorders (Salahuddin et aI., 1986), although it was later 
found to replicate mainly in T-Iymphocytes. The virus exists as two distinct strain variants 
characterised by the reference strains Ull 02 (HHV -6A) and Z29 (HHV -6B) both isolated in 
AIDS patients: UII02 from Uganda (Downing et aI., 1987) and Z29 from the Democratic 
Republic of Congo (then Zaire)(Lopez et aI., 1988). These two African strains, along with 
HST from Japan (lsegawa et aI., 1999), are the only fully annotated HHV -6 genomes to have 
been published: (Ul102 (NC 001 664)(Gompels et aI., 1995), Z29 ~C 000898)(Dominguez 
et aI., 1999) and HST (AB021506)(lsegawa et aI., 1999)). Additional strains have been typed 
by restriction analysis (Ablashi, 2006b) and HHV -6 does not appear to display the general 
recombination-driven mosaic character that has been described for HCMV, both within 
(Haberland, Meyer-Konig, and Hufert, 1999) and between genes (Rasmussen, Geissler, and 
Winters, 2003; Yan et aI., 2008), although very few clinical studies have rigorously 
genotyped HHV -6 at multiple loci. Studies from Europe and North America have identified 
HHV-6B primary infection as a major cause of high fever (Dewhurst et aI., 1993; Hall et aI., 
1994) which has been shown to be responsible for up to 20-40% of infant hospitalizations 
from febrile illness (Hall et aI., 1994; Portolani et aI., 1993) with a small minority (6%) of 
these children being diagnosed as having exanthem subitum (rash)(Hall et aI., 1994). A small 
proportion will have more serious complications, the most common being febrile seizures, but 
others such as respiratory, gastrointestinal and lymphatic complications have been 
documented (Asano et aI., 1994; Hall et aI., 1994; Okada et al., 1993). HHV -6A has also been 
identified in a minority of febrile paediatric primary infections, but is rare in Europe and 
North America, whereas in Zambia, in a cohort of hospitalized febrile infants, previous 
studies showed it may have a more equal prevalence to that ofHHV-6B (Gompels, 2004; 
Kasolo, Mpabalwani, and Gompels, 1997). However, the prevalence of HHV -6 variants in the 
general population was not defined, and is an objective of this thesis. Although both variants 
are linked with neurological disease, HHV -6A appears in some cases to be more pathogenic, 
linked with myocarditis (Bigalke et aI., 2007), and there is evidence for increased 
neurovirulence (De Bolle et al., 2005; Hall et aI., 1998), with a linkage to encephalitis (Yao et 
aI., 2009), syncytial giant cell hepatitis (Potenza et aI., 2008), Multiple Sclerosis (Alvarez-
Lafuente et aI., 2004; Alvarez-Lafuente et aI., 2006) and many case reports showing severe 
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disease, including fatalities, in adult immunocompromised patients as reviewed (Gompels, 
2004). 
1.3.2 HHV -6 Genome structure 
HHV -6 has a double stranded DNA genome up to 162 Kbp in length (Gompels et al., 1995; 
Isegawa et aI., 1999), composed of one unique region flanked by direct repeats. The VII 02 
HHV -6A reference genome contains 110 ORFs compared to 119 ORFs in Z29 HHV -6B. The 
two genomes display 90% identity with most variation being located in the direct repeats at 
the right-hand end of the unique region. This region, where nucleotide identity can drop to 
72% (Dominguez et al., 1999), encodes the immediate early (lE) genes, envelope 
glycoproteins and the viral chemokine V83 (French et aI., 1999). Isolated hypervariable loci 
are also found in more central positions such as V47 which shows 69.8% amino acid identity 
between reference strains VI102 and HST (Isegawa et al., 1999). 
1.3.3 HHV -6 cellular tropism and receptors 
Lytic infection in vivo occurs in CD4 positive T -lymphocytes, but HHV -6 can infect a range 
of different cell types in vitro such as haematopoietic cells (Kondo et aI., 1991), macrophages 
(Kempf et aI., 1997), dendritic cells (Asada et aI., 1999; Hirata, Kondo, and Yamanishi, 2001; 
Kakimoto et aI., 2002; Niiya et aI., 2004), NK cells (Lusso et al., 1993) and 10 T -cells (Lusso 
et aI., 1995), along with other structural cell types such as primary foetal astrocytes (He et aI., 
1996). Latency is established in monocytes and bone marrow progenitor cells (Luppi et al., 
1999). The two laboratory reference strain variants replicate in different immortalized T -cell 
lines: HHV -6A grows in HSB-2 and J Jhan cells whereas HHV -6B grows in Molt-3 and MT-
4 cells (Yamanishi, 2007). Also some ex vivo data suggest HHV -6A grows in both CD4+ve 
and CD8+ T-cells whereas HHV-6B is inefficient at infecting the latter (Grivel et aI., 2003). 
In oligodendrocytes HHV -6A caused lytic infection whereas HHV -6B was nonproductive 
(Ahlqvist et al., 2005). In other neuronal cells HHV -6A has been shown to be more 
neurovirulent (De Bolle et aI., 2005). 
One cell receptor for HHV -6 entry is CD46 (Santoro et aI., 1999), a complement regulator 
that is present in the membrane of all nucleated cells and interestingly, is also a receptor for 
the measles virus (Dorig et al., 1993; Naniche et aI., 1993). HHV-6A interacts with CD46 
through the viral gHlgLlgQIIgQ2 glycoprotein complex (section 1.3. 1 2)(Akkapaiboon et aI., 
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2004; Mori et aI., 2003), although a 'fusion from without' assay using CD46-transfected CHO 
cells showed that HHV -6B strain HST does not use CD46, and that glycoprotein gB is also 
essential for syncytium fonnation in this model system (Mori et aI., 2002). Interactions 
between other glycoproteins and other receptors have been demonstrated, such as between gB 
(U39) or gM (Ul 00) and heparin sulphate (Pfeiffer et aI., 1993), and there are likely further 
specific glycoprotein-receptor interactions. 
1.3.4 HHV-6 transmission and epidemiology 
HHV -6 is shed in saliva (Collot et al., 2002; Di Luca et aI., 1995; Suga et aI., 1998; Zhao et 
aI., 1997) but it is rarely detected in urine (Ashshi, Klapper, and Cooper, 2003; Li et aI., 2009) 
and there is no evidence of secretion in breast milk (Dunne and Jevon, 1993), which is a 
major route of transmission for HCMV(Murata et aI., 2009). In a large study in North 
America, cumulative detection of HHV -6 in saliva also rose to 77% by 2 years of age (Zerr et 
al., 2005) showing that horizontal transmission by the oral route is likely, either from mothers 
or carers and also between children (Tanaka-Taya et aI., 1996; van Loon et al., 1995). A 
different North American study found that after maternal antibody declined by around 6 
months the seroprevalence then increased with a comparable 80% of children being infected 
by 2 years of age (Hall et aI., 2006). In adults seroprevalence is between 70-100% 
(Bhattarakosol et al., 2001; Chua, Khairullah, and Hooi, 1996; Linhares et aI., 1991; 
Tolfvenstam et al., 2000; Ward et aI., 1993) but differences could be attributed to the different 
serological tests used, which may vary by up to 30% as described in one Danish study 
(Nielsen and Vestergaard, 1996). The prevalence of HHV -6 infections in Southern Africa is 
currently unknown, and this thesis aims to address this, assessing the prevalence of active 
infections in infant sera. 
HHV -6 was thought to be transmitted congenitally in roughly 1 % of neonates (Adams et al., 
1998; Dahl et al., 1999; Hall et aI., 2004; Hall et aI., 1994) although more recent data suggests 
this is primarily due to vertical genn-line transmission of chromosomally integrated HHV-6 
(Ward et aI., 2006). The pathogenicity of these genn-line infections is unclear and so it is 
largely postnatal primary infections that are associated with disease, typically acute febrile 
illness, with occasional cases of fatal complications (Hall et al., 1994). Data suggests 
congenital infections may be influenced by 'genn-line' integration: In 1993 a group of Italian 
researchers used restriction fragment analysis and Southern blotting on PBMCs from one 
multiple sclerosis patient and two with lymphoproliferative disorders, and identified 
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fragments containing viral sequences that were larger than the 170Kb viral DNA (strain OS) 
from infected HSB-2 cell lines (Luppi et aI., 1993). This was the first suggestion that the viral 
episome might in some cases integrate into the host genome. They then supported this with 
FISH (fluorescent in situ hybridization) analysis of the PBMCs (Peripheral Blood 
Mononuclear Cells), showing association of the HHV-6B genome with the telomeric repeats 
in the short arm of chromosome 17 (Torelli et aI., 1995). Other FISH studies from Japan 
(Daibata et aI., 1998; Daibata et aI., 1999; Tanaka-Taya et al., 2004) and the U.K (Clark et aI., 
2006; Ward et aI., 2006) also showed strong linkage between HHV -6 and the genome, 
resulting in 'chromosomal transmission'. The prevalence of chromosomally inherited HHV-6 
has been shown to be 0.8% in the U.K (Leong et aI., 2007). In North America it accounts for 
86% of congenital transmission (Hall et aI., 2008). 
1.3.5 HHV-6 infection in immunocompetent children 
As stated previously, maternal immunity to HHV -6 drops off in infants at about 6 months of 
age, from which point there is a steady accumulation of primary infections with up to 80% of 
infants being HHV -6 positive by two years of age (Hall et aI., 2006; Zerr et aI., 2005). 
Primary infection in North America (Dewhurst et aI., 1993; Hall et al., 2006), Europe (Ward, 
Thiruchelvam, and Couto-Parada, 2005) and Japan (Tanaka-Taya et aI., 1996; Yamamoto et 
aI., 1994), is primarily with the HHV -6B variant although some primary infections with 
HHV -6A have been detected (van Loon et al., 1995). Primary infection always results in fever 
(Zerr et aI., 2005), and whilst in many cases this will be self-resolving, HHV -6B has been 
shown to be responsible for between 20% (Italy (Portolani et aI., 1993)) to 40% (US (Hall et 
aI., 1994)) of infant hospitalizations. Episodes of high fever are sometimes accompanied by a 
rash (exanthem subitum) but primary HHV-6 infection in infants can give rise to more severe 
complications including pneumonia, convulsions, lymphadenopathy, hepatitis, bone marrow 
suppression, recurrent encephalitis and gastrointestinal problems (Oompels, 2004; Hall et aI., 
1994). Studies of primary infection with HHV -6 have been in children from North American, 
European and Japanese populations, where HHV -6B has been shown to be responsible for the 
vast majority of infections (irrespective of severity), with HHV -6A being identified in no 
more than 3% of cases (Dewhurst et aI., 1993; Hall et aI., 2006). Conversely, a study from 
Zambia (Southern Africa) found a considerably higher prevalence ofHHV-6A (40%) in a 
small cohort of hospitalized febrile infants aged 6-34 months (Kasolo, Mpabalwani, and 
Oompels, 1997). The comparative prevalence of HHV -6A and B in the population as a whole 
was not addressed however, and so will be analysed in this thesis. 
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1.3.6 HHV-6 and neurological disease 
HHV -6 has been associated with a wide range of diseases but due to its widespread presence 
within the population and a lack of studies measuring viral load, gene expression or using 
genotyping to distinguish between latent and lytic infection, causal disease correlations have 
been difficult to establish. HHV -6 encephalitis, indicated by detection of active infection in 
CSF, is an observed complication during primary infection (Suga et aI., 1993; Ward et aI., 
2005) which is also seen in immunocompromised patients (Ogata, 2009; Ogata et aI., 2010; 
Provenzale, van Landingham, and White, 2010), with extrahippocampal involvement in 
patients CSF PCR positive for HHV -6. Lobectomy studies detected replicating HHV -6B in 
hippocampal astrocytes of 60% of patients with mesial temporal lobe epilepsy (Theodore et 
aI., 2008). Recent data also supports a link between HHV -6 and a subset of patients with MS 
(Multiple Sclerosis). Active HHV -6 infections (as shown by detection ofIE viral RNA in 
peripheral blood) were demonstrated in 16% (all HHV-6A) ofRRMS (relapse remitting 
Multiple Sclerosis) patients compared to 0% of controls (Alvarez-Lafuente et aI., 2004; 
Alvarez-Lafuente et aI., 2006). but the same group showed that HHV -6A does not play an 
active role in SPMS (secondary progressive MS)(Alvarez-Lafuente et aI., 2007). Multiple 
Sclerosis is rare in black African populations, and the presentation is different to that seen in 
populations of European decent (Modi et aI., 2001). Variation within HHV -6 isolates found in 
different populations may partly explain differences in MS frequency and presentation. 
1.3.7 HHV -6 therapy 
In vivo studies provide some evidence for GCV (Ganciclovir) as an inhibitor of HHV-6 
disease after transplantation decreasing the rate of reactivations (Tokimasa et aI., 2002) and it 
has also been shown to reduce HHV -6 viral loads in both CSF and blood, and also in 
transplant recipients (Zerr et aI., 2002). The action of GCV is dependent on a viral kinase and 
that ofHHV-6 (U69) is not as efficient at phosphorylating the prodrug as that of HCMV and 
mutations in this loci cause resistance reducing the efficacy further (Manichanh et aI., 2001; 
Nakano et aI., 2009). Foscarnet and Cidofovir have also been said to be potent inhibitors of 
HHV -6 replication in vitro (Reymen et aI., 1995; Williams-Aziz et aI., 2005) and in vivo 
(Pohlrnann et aI., 2007) where they are often reserved as second line drugs to GCV. Mutations 
have also been found in the HHV-6 DNA polymerase gene (U38) which cause resistance to 
Foscarnet (Bonnafous et aI., 2007). Acyclovir and other thymidine-kinase dependent drugs 
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are only marginally effective against HHV-6 (Mel'nichenko, L'Vov N, and Galegov, 2009). 
There are currently no acceptable licensed drugs that have been developed specifically for 
HHV -6 through prospective studies. 
1.3.8 HHV -6 latency 
After primary infection (usually during infancy) HHV -6 establishes a latent infection that, as 
with all herpesvirus infections, remains for the lifetime of the host. During latency, the virus 
can be detected in certain cell types, such as monocytes/macrophages, salivary glands, lymph 
nodes, neuronal and kidney cells (Yoshikawa et aI., 1999). PCR analysis shows that after in 
vitro infection of macro phages with HHV-6, viral DNA can be detected long after antigen and 
cytopathic effect assays revert to being negative (Kondo et aI., 1991). The IEl and 1E210ci in 
HHV -6, as well as being lytic genes, have been shown in vitro to encode transcripts through 
splicing, that are specific to latently infected but not re-activated macrophages (Kondo et aI., 
2002). Similar transcripts have been detected, suggesting latent infection in an astroglioma 
cell line (Yoshikawa et aI., 2002). Latent infections will periodically reactivate in response to 
a range of stimuli such as stress or infection, especially where infections directly weaken 
immunity such as in HIV / AIDS, resulting in shedding of virus in blood and saliva (Di Luca et 
aI., 1995). Establishment of a latent infection with one strain during childhood is not 
protective against super-infection with different strains (or variants) as shown in an infant 
study where infections with multiple variants were observed (van Loon et aI., 1995). 
1.3.9 HHV -6 lytic replication cycle 
After entry to the cell, virions undergo de-envelopment and capsids are transported to the 
nucleus. Like all herpesviruses, HHV -6 expresses three temporal classes of lytic genes. Some 
differences were seen in splice patterns between HHV -6A and HHV -68 for lE loci such as 
U91 and U15-U20 (Mirandola et aI., 1998). Splice variants have also been observed for U83, 
the only chemokine to be encoded by HHV -6 (Dewin, Catusse, and Gompels, 2006). Viral 
DNA is released into the nucleus where Early genes are expressed and DNA replication 
creates concatameric repeats of the circular episome, generated by rolling circle replication. 
Subsequent cleavage and packaging results in progeny capsids that are exported into the 
cytoplasm. Immature capsids are first enveloped at the inner nuclear membrane, are then de-
enveloped, acquire tegument and are then re-enveloped probably in a membrane that is 
intermediate between the trans-golgi network and endosomes (Mori et aI., 2008). This same 
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study showed release ofvirons in multi-vesicular bodies which fuse with the plasma 
membrane. 
1.3.10 HHV-6 immunomodulation 
Like all viruses that target and replicate in T -cells, HHV -6 is inherently immunomodulatory 
through the physical mechanism of lytic replication but HHV -6 also has a variety of 
signalling mechanisms through which it modulates immune cell function (Table 3, Page 37). 
Infection down-regulates the CD46 receptor and up-regulates CD4, both of which affect 
immunity (Grivel et al., 2003; Santoro et aI., 1999). The virus can impair antigen presenting 
cells through suppression of IL-12 secretion, which is aT-cell stimulating factor (Smith et aI., 
2003; Smith et aI., 200S) and can induce T-cell adhesion markers (CD2, CD4 and 
others)(Furukawa et aI., 1994). HHV-6 infection induced HLA class I and MHC class II 
expression on DCs (Dendritic cells)(Kakimoto et aI., 2002). Both HHV-6A and HHV-6B 
destroy thymic grafts in SCID mice (Gobbi et aI., 1999). HHV -6 expresses one chemokine 
(U83)(French et al., 1999; Zou et aI., 1999) and two chemokine receptors (US1 and 
U12)(Isegawa et aI., 1998; Milne et aI., 2000). The U83A chemokine is a broad receptor 
agonist binding CCR1, CCR4, CCRS, CCR6 and CCR8 (Dewin, Catusse, and Gompels, 
2006). It has a very high affinity for CCRS and can inhibit HIV infection by CCRS-tropic 
strains (Catusse et al., 2007)(for interactions with HIV see section 1.3.13). The U51A 
chemokine receptor from HHV -6A binds specific inflammatory modulators including CCL5, 
affecting the spread of virus infected cells by chemotaxis and also evading immune regulation 
by chemokine diversion and down-regulation of CCLS (Catusse et aI., 2008; Milne et aI., 
2000). 
1.3.11 HHV-6 detection and diagnosis 
HHV -6 infections can be detected in clinical specimens by a range of techniques such as 
serology, antigenaemia, whole virus isolation, or PCR (Ward, 2005). The major limitation of 
antibody and antigen detection assays for the detection of HHV -6 is that the immunodominant 
epitopes of HHV -6A and B cross react, and so these classical techniques cannot differentiate 
between the two strain variants (Chandran et aI., 1992). Molecular techniques like peR can be 
used to differentiate HHV -6A and HHV -6B, but as their genomes show considerable 
conservation, careful selection of targets within and around variable loci is essential. 
Strategies include: selecting primers to give PCR products with different sizes for the two 
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strain variants, or selecting primers with a 3' mismatch that exclusively amplify just one of 
the variants, or designing Real Time PCR assays with probes specific for just one strain 
variant. This thesis employs a PCR strategy which uses conserved primers flanking a 
hypervariable locus and then sequencing PCR products to identify the strain variant. This 
method is more powerful than those outlined above in that it does not rely on known fragment 
sizes and probe sequences that may vary, and the sequence data generated can be used for 
more detailed phylogenetic analysis incorporating data from other studies. When detecting 
HHV -6 DNA by peR one must consider chromosomally integrated HHV -6 which is 
prevalent in up to 1 % of cases (Ward et aI., 2006). 
1.3.12 HHV-6 glycoprotein complexes and variation 
The identification of the first cellular receptor for HHV -6 was consistent with the broad 
cellular tropism discussed in section 1.3.3 (Santoro et aI., 1999): CD46 is a type 1 
glycoprotein and complement regulator that is found on all nucleated cells. For some strain 
variants this receptor is bound by the HHV-6 glycoprotein complex gHlgLlgQl/gQ2: 
Interestingly, whilst the gHlgLlgQlIgQ2 complexes ofHHV-6A strains UI102 and GS 
(Akkapaiboon et al., 2004; Mori et aI., 2003) and ofHHV-6B strains Z29 and PL-l (Pedersen 
et aI., 2006; Santoro et aI., 1999) bind CD46, the corresponding complex in HHV -6B strain 
HST does not (Mori et aI., 2002), suggesting components of this complex play a role in the 
differential effects of infections both between HHV -6A and B, but also between individual 
strains within each variant group. A further level of control may lie in the fact that CD46 
displays different glycosylation patterns on different cell types/tissuesllocations (Johnstone et 
aI., 1993). All herpesviruses contain certain conserved glycoproteins known to be involved in 
cell recognition, binding, entry and subsequent nuclear egress and cell-cell fusion processes. 
Glycoproteins gH and gL fall into this category but gQ 1 and gQ2 are unique to the 
roseolaviruses (HHV -6 and HHV -7, but not HCMV). They are encoded by the spliced 
products ofORFs U97-UI00, which show variation between HHV-6A and B of up to 72% 
(Isegawa et al., 1999). As stated in section 1.3.2, most variation is seen in the terminal regions 
of the genome, but some more centrally located loci are also highly variable. The U47 gene 
encodes a hypervariable glycoprotein, gO, which has homologues in all betaherpesviruses 
(Sadaoka, Yamanishi, and Mori, 2006) including HCMV (Huber and Compton, 1998). 
Previous data has suggested possible recombination between the two strain variants at this 
loci, with some U47 sequences displaying characteristics of both HHV-6A and HHV-6B 
(Gompels, 2006; Kasolo, Mpabalwani, and Gompels, 1997). HHV -6 glycoportein gO forms a 
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tripartite complex with gHlgL (Akkapaiboon et aI., 2004; Mori et aI., 2004) which is related 
to gHlgLlgQlIgQ2 and may have a pivotal role in the determination of cell tropism 
differences between HHV -6A and HHV -6B. Neighbouring U47 is U46, which encodes 
another hypervariable glycoprotein (gN). This gene also has a homologue in HCMV 
(UL 73)(Mach et aI., 2000). It has been previously shown in our lab that linkage 
disequilibrium exists between glycoproteins gO and gN in HCMV (Mattick et aI., 2004). The 
hypervariable U47 (gO) and U46 (gN) loci will be used to investigate HHV-6 strain variation 
in this thesis. 
1.3.13 HHV-6 infection and HIV/AIDS 
HHV -6 was first discovered in an AIDS patient with B-celllymphoma and was initially 
thought to be a possible causative agent of AIDS-associated lymphoma (Ablashi, 2006a). 
Therefore, from its very discovery in 1986 (Salahuddin et al., 1986), HHV -6 has been closely 
linked with HIV and much work has since been undertaken investigating possible clinical and 
molecular links between the two viruses. 
HHV -6 has been commonly detected by PCR at multiple tissue sites with increased HHV-6 
viral load in HIV I AIDS patients in the absence of HAART (Clark et aI., 1996). These HIV 
associated HHV -6 reactivations can result in disseminated infections (Knox and Carrigan, 
1994) and have been responsible for fatalities due to pneumonitis (Knox et aI., 1995) and 
encephalitis (Knox and Carrigan, 1995; Knox, Harrington, and Carrigan, 1995). Despite being 
first associated with B-Iymphocytes, it was shown that HHV -6 can only infect B-cells when 
they are first infected with EBV (Flamand et aI., 1993), whilst the native tropism of HHV -6 is 
primarily for T -cells (Lusso et aI., 1988). HHV -6 and HIV are both T -cell tropic and can 
infect the same T -cell simultaneously (Lusso et aI., 1989), and so how these two viruses 
interact both clinically and on a molecular level could be highly significant with respect to 
AIDS progression. HHV -6 gene products can activate HIV and also up-regulate the CD4 HIV 
receptor (Lusso et aI., 1991a). In AIDS progression with depleted CD4 counts there is less 
HHV -6 in the blood, likely because there are fewer cells for replication, but this leads to an 
increase in disseminated organ infections (Clark et aI., 1996; Emery et aI., 1999; Fairfax et aI., 
1994). There may be variant specific effects as only the HHV-6A chemokine U83A has been 
shown to block infection by an R5-tropic HIV strain through the CCR5 co-receptor (Catusse 
et aI., 2007; Dewin, Catusse, and Gompels, 2006). In addition, viral chemokine receptor 
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USIA expression, down regulates the human chemokine ligand CCLS (RANTES) which can 
reduce CCR5 activity (Catusse et aI., 2008). 
Several lines of tissue culture and clinical evidence suggest that HHV -6 might accelerate 
AIDS progression: A comparison of HHV -6 IgM prevalence rates (indicative of HHV-6 
reactivation) showed significantly higher prevalence in HIV positive symptomatic patients 
(60%), compared to HIV asymptomatic (40%) and HIV negative (19%) controls (Ablashi et 
aI., 1998). This is supported by molecular studies where high load HHV -6B has been found in 
tissue containing high load HIV at autopsy (Emery et aI., 1999). This correlation between 
viral loads may in part be due to the fact that both HHV -6A and HHV -68 can transactivate 
the HIV promoter, which may increase retroviral replication (Horvat, Wood, and 
Balachandran, 1989; Horvat et aI., 1991). Such a mechanism might also re-activate HIV from 
its proviral state: Infection of the ACH-2 line of human leukemic T cells carrying latent HIV 
with HHV -6 resulted in reactivation of HIV as measured by Reverse Transcriptase activity 
(Isegawa 2007). HHV -6 may also facilitate HIV to infect cell-types for which it usually shows 
negligible tropism: In tissue culture, HHV-6 (either variant) facilitated infection of two 
haematopoietic progenitor cell lines (HIV does not otherwise infect stem cells )(Furlini et aI., 
1996), likely through the up-regUlation of CD4 (Flamand et aI., 1998). HHV -6A infection of 
syncytiotrophoblasts induces HIV replication, suggesting co-infection in utero may increase 
the likelihood of mother to child transmission of HIV (Csome 2002). In a recent animal study, 
HHV -6A was shown to accelerate AIDS in Macaques (Lusso 2007). 
Conversely, there are also several studies suggesting a competitive and inhibitory relationship 
between HHV -6 and HIV: A study from Thailand following HHV -6 uptake in infants showed 
clearly delayed HHV -6 seroconversion in HIV positive, compared with HIV negative infants 
(Kositanont et aI., 1999). There are also several in vitro studies showing inhibition of HIV by 
HHV-6 (Carrigan, Knox, and Tapper, 1990; Levy, Landay, and Lennette, 1990; Pietroboni et 
aI., 1988) or HHV -6 gene products (Catusse et aI., 2007). 
As up to 100% of adult populations are HHV-6 positive (Bhattarakosol et aI., 2001; Chua, 
Khairullah, and Hooi, 1996; Linhares et aI., 1991; Tolfvenstam et aI., 2000; Ward et aI., 1993) 
and 80% of these primary infections occur before 2 years of age (Hall et aI., 1994; Zerr et al., 
2005), for countries in the above studies co-infections with HHV -6 are the norm in 
HIV / AIDS, with the two viruses displaying complex interactions that may be variant specific, 
and also differentially affected by the stage of disease progression (Dewin, Catusse, and 
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Gompels, 2006; Lusso et aI., 1989; Milne et aI., 2000). The prevalence of HHV -6 infections 
in Southern Africa, an HIV -1 endemic region, is not known. Determining HHV -6 prevalence 
and which strain variants are predominant in Zambia is an aim of this thesis. 
26 
1.4 Human Cytomegalovirus 
1.4.1 Introduction 
Human Cytomegalovirus (HCMV) is a member of the Betaherpesvirinae subfamily of the 
Herpesviridae. Its name (from the Greek cyto, "cell" and mega/o, "large") is derived from the 
fact that in tissue culture, infection gives rise to large syncytia, the result of fusion of the 
initially infected cell with its neighbours. The virus establishes latency in myeloid and bone 
marrow progenitors (Khaiboullina et aI., 2004; Sindre et aI., 1996) from which it may 
reactivate repeatedly during the lifetime of the host. These reactivations are often clinically 
silent but virus is shed in very high titres in saliva and urine, facilitating transmission. Primary 
HCMV infection can occur in children or adults and is generally self-limiting in 
immunocompetent hosts, with acute symptomatic primary infections generally limited to the 
immunocompromised host (Jarvis and Nelson, 2007). Congenital HCMV infections are the 
leading infectious cause of birth defects (Cannon and Davis, 2005), such as sensorineural 
hearing loss (Verbeeck et aI., 2008; Waiter et aI., 2008) and mental retardation (Cheeran, 
Lokensgard, and Schleiss, 2009). In immunocompromised individuals, such as transplant 
recipients and those with HIV I AIDS, HCMV infects a broad range of organ systems, and is a 
serious cause of morbidity and mortality, particularly in HIV co-infected children where it is a 
major pathogen (Chintu et aI., 2002; Kovacs et aI., 1999). 
1.4.2 HCMV genome structure 
The HCMV genome is the largest of all herpesviruses (-230-240 Kbp - GC 54-59%) and is 
the largest genome of any virus that infects humans (Davison et aI., 2003; Dolan et aI., 2004). 
Unlike HHV -6 which has just one unique region, HCMV has a class E isomerizing genome, 
composed of two unique regions (Unique long - UL and Unique short - Us) flanked by short 
inverted repeats, which facilitates four possible isoforms, present in the general population of 
viruses in equimolar amounts (Mocarski, 2007). The genome encodes between 166-252 open 
reading frames (Davison et aI., 2003; Murphy et aI., 2003b), although only approximately 45 
are essential for replication in fibroblasts (Dunn et aI., 2003). As with HHV -6 and other 
herpesviruses, HCMV genes are divided into three sequentially expressed kinetic classes, 
which are expressed (in vivo or in vitro) in a temporal cascade. These three classes of genes 
are interspersed throughout the genome (Landolfo et aI., 2003). The UL region ofHCMV is 
essentially collinear with the unique region ofHHV-6 and there are up to 70 ORFs with 
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sequence similarity to HHV -6 (Gompels et aI., 1995). The function of many genes has not 
been detennined directly, but has been proposed based on their homology to genes in other 
herpesviruses. Experimental verification remains the only sure way of confinning gene 
function, which might vary between different herpesviruses with some genes even being 
redundant. Clinical strains quickly acquire deletions and rearrangements when grown in tissue 
culture (Dolan et aI., 2004). Deleted regions may encode virulence detenninants not required 
for growth in vitro (Wang and Shenk, 2005b). The HCMV genome carries 30-50 ORFs with 
sequence characteristics indicative of possible glycoprotein genes. Whilst many of these 
genes are highly conserved between clinical strains, some of them display hypervariation and 
can be used for genotyping and for studying recombination (Bradley et aI., 2008; Stanton et 
aI., 2005; Yan et al., 2008). 
1.4.3 HCMV cellular tropism and receptors 
HCMV cellular tropism may be detennined by viral membrane proteins and also host cell 
transcription factors (Sinzger, Digel, and Jahn, 2008). HCMV can and initiate gene expression 
in a variety of vertebrate cell types, including epithelial and endothelial cells, fibroblasts, 
smooth muscle cells, neurons, monocytes and macrophages (Isaacson, F eire, and Compton, 
2007; Plachter, Sinzger, and Jahn, 1996; Sinzger et aI., 1995), resulting in virus replication in 
a wide range of organ systems. HCMV infection in glandular and ductal epithelial cells in the 
salivary glands, kidneys, breast milk ducts, and genital organs allows infectious virus to be 
shed into a range of bodily fluids such as saliva, urine, cervical secretions and semen as 
reviewed (Mocarski, 2007). This broad host range may be supported by a single conserved 
interaction between the virus and a universal receptor, but the search for a definitive receptor 
for HCMV has proved problematic. A more likely explanation, is that over several hundred 
million years of co-evolution, the continuous jousting between virus and host has given rise to 
several viable virus-receptor interactions, as have been found with the alpha- and gamma-
herpesviruses (Spear and Longnecker, 2003). Furthennore, the function of some of these 
interactions may be limited to 'tethering' of the virus, and distinct interactions may be 
necessary for entry (Isaacson, Feire, and Compton, 2007). 
Serial passage of wild type HCMV strains in tissue culture quickly leads to loss of genetic 
material and highly passaged tissue culture strains often show marked differences. Sequence 
and infectivity analysis have identified a region comprising 19 ORFS (UL 133-UL 150) which 
is lost in the AD169 and Towne vaccine strains due to serial passage in fibroblasts (Cha et aI., 
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1996; Prichard et aI., 2001). For AD169, subsequent culture in endothelial cells can rescue 
endothelial tropism however, suggesting loss of tropism was due to a much smaller, reversible 
mutation (Gema et aI., 2003). In the case of AD169 this was due to a frame shift mutation in 
UL131A (Davison et aI., 2003) and the whole UL128-131 locus appears to be essential for 
endothelial cell tropism (Hahn et aI., 2004; Wang and Shenk, 2005a), and is also implicated in 
dendritic, epithelial and leukocyte cell tropism (Gerna et aI., 2005). There is some evidence to 
suggest that clinical isolates might often contain mixed populations of different strains, and 
that culturing conditions selects for strains with an appropriate tropism (Grazia Revello et aI., 
2001), although it seems clear that culture can also drive highly significant mutations, some of 
which are reversible in plaque-purified viruses (Gerna et aI., 2003). All three UL 128-UL 131 
gene products form a complex with gH-gL and evidence shows this complex drives 
endothelial and dendritic cell tropism (Gerna et aI., 2005; Wang and Shenk, 2005b). 
Studies in fibroblasts show that cellular platelet-derived growth factor-a receptor (PDGFR-
a)(Soroceanu, Akhavan, and Cobbs, 2008) is a critical receptor for HCMV and is blocked by 
neutralizing antibodies to glycoprotein gB. Glycoprotein gO (UL 74) has been shown to have 
a role in cell fusion (Paterson et aI., 2002) and two recent studies suggest it has a chaperone 
function in transporting other glycoproteins to the cell surface (Jiang et aI., 2008; Ryckman, 
Chase, and Johnson, 2010). The UL74 gene is hypervariable but there is no evidence for 
recent immune selection (Mattick et aI., 2004) and so variation may have evolved as an 
adaption to replication in different cell types and may therefore play a role in tropism. 
Furthermore, the UL 74 gene has been shown to be linked to another hypervariable 
glycoprotein gene, UL 73 (gN) (Mattick et aI., 2004), and in this thesis these two loci are used 
to investigate the genotypes present in Southern Africa, a region from which very little 
HCMV genotype data has been collected previously. 
29 
1.4.4 HCMV transmission and epidemiology 
HCMV has no natural reservoir other than in humans, where transmission occurs by direct or 
in-direct person-to-person contact. High loads have been demonstrated in saliva and urine 
(> 107copies/ml and > 105copies/ml respectively)(Kearns et al., 2002; Yoshikawa et aI., 2005) 
but the main route of transmission in infants is through breast milk (Jim et aI., 2009; Kerrey et 
aI., 2006; Schleiss, 2006a; Schleiss, 2006b). The virus can also be isolated from a broad range 
of other bodily fluids/excretions including blood, tears, oropharyngeal secretions, faeces, 
semen, cervical and vaginal secretions (Mocarski, 2007). Primary HCMV infections mainly 
occur during childhood or adolescence (later than HHV -6) and are usually asymptomatic 
(occasionally they can cause fever or mononucleosis), after which latency is established for 
the lifetime of the host. Even in healthy children, sub-clinical viral shedding is common, with 
rates (determined by viral culture) in North American day care centres, ranging from 15-30% 
in children under two years of age (Bale et aI., 1999; Noyola et al., 2005). HCMV 
seronegative child care providers have a 20% risk of seroconverting over their first 12 months 
of work, which rises to 40% after their second year (Murph et aI., 1991). In Africa, a study 
from the Gambia established that children shed more virus than their mothers and that loads 
in urine were the highest. They suggest that transmission through bed wetting between 
siblings, and to or from mothers, is the most common route of transmission (Bello, 1992). It 
has been suggested that another major route of HCMV infections is through sexual 
transmission, and studies have shown condom use is protective, suggesting semen is a major 
route of HCMV transmission (Carre et aI., 1997; Robain et al., 1998). Condom use may well 
be associated with other more hygienic practices however, such as hand washing or fewer 
sexual partners. As well as being transmitted horizontally, HCMV can also be transmitted 
vertically either in utero or during birth. These congenital HCMV infections (see section 
1.4.3) are the major cause birth defects in immunocompetent children where they can cause a 
range of physical and mental disabilities. 
HCMV is endemic and within any given population seroprevalence rates increase steadily 
with age (Mocarski, 2007; Staras et aI., 2006). There are differences in seroprevalence rates 
between different groups and the reasons for these observations are not clear. One study found 
that the average seroprevalence in the US was 54% for men and 64% for women. They also 
grouped by race and found higher seroprevalence among some ethnic minority groups (Staras 
et aI., 2006). Another American study, looking at young women, found that those from ethnic 
minority American groups contract HCMV earlier (Colugnati et aI., 2007). Previous studies 
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have found higher seroprevalance to be linked with lower socioeconomic status (Stagno et aI., 
1982). At the start of this thesis there was evidence for different seroprevalence rates in 
different countries, including three from West Africa (Table 2). A current hindrance is that 
different studies use different diagnostic kits for measuring HCMV IgG antibody which 
makes comparisons between different studies difficult. There is currently very little data on 













Adult healthy HIV-ve blood donors 
Adult healthy HIV-ve blood donors 
Adult healthy HIV-ve blood donors 
Adult healthy blood donors 
India (Delhi) 95% Adult healthy HIV-ve blood donors 
Turkey 94% Adult healthy HIV-ve blood donors 
Table 2: Comparison of HCMV seroprevalence in different countries 
Reference 
(Maiga et al., 2003) 
(Gargouri et al., 2000) 
(Ledru et al., 1995) 
(Olaleye, Omilabu, and Baba, 
1990) 
(Kothari et al., 2002) 
(Ataman et al., 2007) 
1.4.5 HCMV congenital infection and maternal seroprevalence 
Congenital HCMV is generally defined by the detection of viral DNA in blood spots on 
Guthrie cards (Mosca and Pugni, 2007). It is an extremely damaging infection initiated by 
either primary or reactivated infection in the mother during pregnancy, and is the major viral 
cause of paediatric mental and physical disability affecting 0.2-2.2% ofnewboms (Barbi et 
aI., 2006; Stagno et aI., 1986). Around 7-11 % of infected foetuses are then born with 
symptoms (Griffiths and WaIter, 2005; Kenneson and Cannon, 2007), with a neonatal 
mortality rate of 20-30% (Gaytant et aI., 2002; Ross et aI., 2006). Of those congenitally 
infected (both symptomatic and asymptomatic), up to 28% will develop late sequelea (Nigro 
et aI., 2005). Symptoms may include growth retardation, hepatosplenomegaly, jaundice, 
pneumonia, gastrointestinal, retinal, and neurological disease such as sensorineural hearing 
loss (Adler, Nigro, and Pereira, 2007; Griffiths, 2004; Ogawa et aI., 2007; Stagno et aI., 1986; 
Vancikova and Dvorak, 2001). In the United States these infections have been estimated to 
cause around 400 infant deaths and a further 8000 permanent disabilities per year, affecting 
more children than several better-known childhood conditions such as Down Syndrome, Fetal 
Alcohol Syndrome and Spina Bifida (Cannon and Davis, 2005). The impact of HCMV is 
likely to be underestimated as children who develop late sequelae are not always followed up. 
The seroprevalence of HCMV among women of child bearing age in North America has been 
shown to be higher in some ethnic minority groups (Colugnati et aI., 2007). Evidence for 
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higher HCMV seroprevalence in ethnic minority groups was also found in the U .K, also 
independently linked with lower socioeconomic status and parity (Too key, Ades, and 
Peckham, 1992). The main cause of congenital HCMV infection in populations of low 
seroprevalence is maternal primary infection during pregnancy and increased viral load 
(Gouarin et aI., 2001; Lazzarotto et aI., 2007; Satilmis et aI., 2007; Stagno et al., 1982) 
suggesting that populations with high seroprevalence will have fewer primary infections 
during pregnancy and hence lower rates of congenital HCMV. However, data from high 
seroprevalence populations in Africa shows that the rate of congenital HCMV is actually 
higher probably due to prevalent high load maternal reactivations or secondary infections 
during pregnancy. In a study from the Gambia HCMV seroprevalence in pregnant mothers 
was 87% and they found that 14% of infants contracted congenital HCMV (Bello and 
Whittle, 1991). More recently rates of3.9% (Kaye et aI., 2008) and 5.4% (van der Sande et 
aI., 2007) have been published but these are still significantly higher than the 1 % of live births 
seen in Europe and North America (Alford et al., 1990; Kenneson and Cannon, 2007; Stagno 
and Whitley, 1985), where congenital infection was initially thought to be more common. In 
populations with reduced immunity due to HIV or malnutrition, early primary or congenital 
HCMV infections with high loads could be a significant cause of morbidity and mortality, 
which is investigated here. 
1.4.6 HCMV treatment and prevention 
HCMV drugs have been most extensively studied in immunocompromised patients as it is in 
this patient group that the virus causes the most severe disease. Ganciclovir, valganciclovir 
(oral ganciclovir), cidofovir, foscamet and fomivirsen, have been licensed for the treatment of 
HCMV diseases in the U.K and U.S (Schreiber et aI., 2009). Intravenous ganciclovir was 
shown to reduce developmental delays in congenitally infected infants with CNS disease 
(Oliver et aI., 2009) and there is also evidence for prevention of sensorineural hearing loss 
(Lackner et aI., 2009). Ganciclovir is administered intravenously, through a sustained release 
surgical implant, or as the pro-drug valganciclovir which is administered orally and has 
increased gastrointestinal absorption. The National Institute of Allergy and Infectious 
Diseases (NIAID) in the U.S has completed phase 11 trials on the bioavailability and dosing of 
valganciclovir vs intravenous ganciclovir in congenitally infected infants 
(www.clinicaltrials.gov - NCT00031434) and they are now recruiting for a phase III trial to 
assess the efficacy of valganciclovir to reduce the prevalence of mental retardation and 
hearing loss in congenitally infected infants (www.clinicaltrials.gov - NCT00466817). 
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Foscamet and cidofovir are only given intravenously and fomivirsen as an intravitreous 
injection for the treatment of HCMV retinitis (Jabs and Griffiths. 2002). As HCMV infection 
is normally mild and self-resolving in the immunocompetent setting, the use of these drugs is 
reserved for only the most severe cases of HCMV infection in otherwise healthy patients. In 
the HIV I AIDS setting Ganciclovir prophylaxis is recommended for patients of all ages, with 
CD4 counts ofless than 50 cells/JlI (Masur, Kaplan, and Holmes, 2002), although in lower 
income countries availability of anti-HCMV drugs is highly restricted. In this setting, curative 
treatment with valganciclovir may be an economically more feasible intervention in the 
treatment of disseminated HCMV disease, especially pneumonia, associated with HIV I AIDS. 
In this setting, when pneumonia patients do not respond to antibacterial treatment, HCMV is 
strongly implicated (Chintu et aI., 2002; Mocarski, 2007). 
Artesunate has been shown to inhibit HCMV in vitro and in vivo (Kaptein et aI., 2006). As an 
anti-malarial drug this is widely available in tropical low income countries where it could be 
an affordable alternative to treatment with the HCMV -specific drugs discussed above. HCMV 
synthesis is also sensitive to compounds that inhibit polyamine synthesis such as 
desferrioxamine (Cinatl et aI., 1995). Then more recently 4-benzyloxy-gamma-sultone 
derivatives have been investigated as non-nucleoside inhibitors of HCMV (De Castro et aI., 
2009), and HCMV lE expression has been inhibited by dihydro-beta-agarofuran 
sesquiterpenes isolated from the plant genus Euonymus (Pusztai et al.. 2008). Another plant 
with extracts showing anti HCMV activity is Sasa albo-marginata (Sakai et aI., 2008). 
MicroRNAs are integral to CMV pathology, affecting both host and viral gene expression and 
so they may present a new class of antiviral target (Dolken, Pfeffer, and Koszinowski, 2009). 
Interestingly linked with HIV, HAART therapy has recently been suggested to have an 
inhibitory effect on HCMV viral load (Mihailescu et aI., 2008), likely through restoring the 
host immune response to HCMV. This has positive implications for the treatment ofHCMV 
disease in HIV/AIDS patients, in regions where HIV is endemic and anti-retrovirals are 
becoming more widely available. Another novel strategy is the linking of known drugs 
together such has been attempted for zidovudine and foscarnet via an actadecylglycerol 
residue (Schott et aI., 2009). As well as treatment with antiviral drugs, other more specific 
therapies are also being investigated such as adoptive T -cell therapy (Brestrich et aI., 2009). 
HCMV has been identified as one of the most pressing viral targets for vaccine development 
(Arvin et al., 2004), largely due to the impact of congenital HCMV disease in North America. 
There is also data to suggest that HCMV seropositive individuals have a significantly lowered 
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life expectancy due to immune senescence (Hadrup et aI., 2006; Khan et aI., 2002). The 
mechanism may include the virus gradually swamping immune capacity, depleting the pool of 
naive T -cells available to fight other infections. The role of HCMV in immune senescence is 
now under further investigation and has implications for HIV positive populations where 
HCMV is more widespread (Kaye et aI., 2008). An effective vaccine could hence have broad 
reaching benefits. In the 1970s the Towne strain ofHCMV was generated through 125 serial 
passages in vitro. The resulting virus was highly attenuated and did not cause disease, but 
failed to illicit neutralizing antibody responses and could not protect seronegative parents 
from being infected by their seropositive children (Adler et aI., 1995). Since then, many 
different vaccine strategies have been developed but at the time of writing this thesis none 
have yet been licensed. 
1.4.7 HCMV latency 
As with other herpesviruses, an understanding of latency is integral to elucidating the 
molecular mechanisms that determine pathology. HCMV has evolved latency switches that 
allow it to persist at very low levels in certain cell types, a characteristic that likely evolved as 
a means of avoiding the host immune response (Sinclair and Sissons, 2006). The main 
difference between lytic and latent HCMV infection is that the former is marked by high 
levels of lE gene expression whereas lE transcripts are not seen in undifferentiated monocytes 
in which latent HCMV DNA has been detected (Mendelson et aI., 1996; Taylor-Wiedeman, 
Sissons, and Sinclair, 1994). Highly sensitive PCR strategies have demonstrated the presence 
of HCMV DNA in healthy HCMV -seropositive individuals (Larsson et aI., 1998; Taylor-
Wiedeman et aI., 1991), suggesting that as few as 1 in 10,000 PBMCs may carry the latent 
HCMV episome (Sinc1air and Sissons, 2006). Cell sorting experiments have then been used to 
identify peripheral blood monocytes as the major site in healthy carriers for the latent HCMV 
episome (Larsson et al., 1998; Taylor-Wiedeman et aI., 1991). HCMV DNA is found in CD34 
positive myeloid progenitors but only in monocytes and not PBNLs (Polymorphonuclear 
Leukocytes) (Taylor-Wiedeman et aI., 1993; Taylor-Wiedeman et aI., 1991) which are also 
derived from myeloid progenitors, also the site of latency for HHV -6 (Y oshikawa et aI., 
1999). 
There has been no latent origin of replication identified for HCMV as there has been for EBV 
(Sinclair and Sissons, 2006). It has been difficult to identify transcripts that are associated 
with maintenance of this latent state, as naturally infected DNA positive myeloid cells are 
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present in such small numbers and it is not possible to enrich for them. Studies have therefore 
largely relied on infecting differentiating myeloid cultures (Kondo, Kaneshima, and Mocarski, 
1994; Reeves et aI., 2005a; Reeves et aI., 2005b). Cultures will carry the genome for several 
weeks without producing infectious virions but these same cultures can also be re-activated to 
lytic infection. Microarray studies also failed to identify transcripts that were specifically 
associated with latency (Challacombe et aI., 2004; Goodrum et aI., 2002; Zhu et aI., 1998). 
Southern blotting has identified an HCMV transcript (UL81-82/LUNA) that may affect 
inhibition of lytic gene expression through inhibiting the MIEP (Major Immediate Early 
Promoter)(Bego et aI., 2005) and has been shown to be associated with acetylated histones in 
naturally latently infected cells (Reeves and Sinclair, 2009). Infection studies in human 
primary CD34 positive cells have compared wild-type and recombinant knockouts, and 
shown that UL138 is necessary for latency (Goodrum et aI., 2007; Petrucelli et aI., 2009). 
Cellular transcription factors have also been identified that both promote (NF -KB, CREB and 
Spl) and repress (YYl and ERF) MIEP (Sinclair and Sissons, 2006), possibly mediating 
HCMV transcription through the recruitment of enzymes that alter chromatin structures, a 
mechanism which has been suggested for other herpesviruses such as EBV (Amon and 
Farrell, 2005). It is the host cells balance of these transcription factors that either inhibit or 
promote lytic gene expression. Rather than the traditional view of latent and lytic infections as 
two clearly defined states of infection in phenotypically distinct cell types it may actually be 
more ofa gradient. Both LUNA (Bego et aI., 2005) and UL138 (Petrucelli et aI., 2009) can be 
detected in small amounts during lytic infection and so the transition between latent and lytic 
states may be a more continuous and dynamic process than once thought (Reeves and 
Sinclair, 2009). 
1.4.8 HCMV lytic replication cycle 
After receptor attachment (see section 2.3) entry to the cell is facilitated by multiple 
interactions between virion surface glycoproteins and cell surface receptors. The virus plasma 
membrane fuses with that of the cell, releasing both tegument proteins and the capsid into the 
cytoplasm. Studies using microtubule-de-polymerizing drugs (nocodazole and colchicine) 
have suggested HCMV capsids are transported to nuclear pores via the microtubule network 
(Ogawa-Goto et al., 2003) from where viral DNA enters the nucleus. After entry into the 
nucleus the HCMV genome circularizes to form an episome. Viral DNA replication occurs 
within three days post infection through the 'rolling circle' mechanism, with the generation of 
long concatamers which are then cleaved for packaging in to progeny capsids (Mocarski, 
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2007). Nucleocapsids are assembled within the nucleus and egress probably occurs via the 
envelopment de-envelopement pathway through the nuclear membranes (Gibson, 1996; 
Mocarski, 2007), possibly initiating at invaginations of just the inner nuclear membrane 
(Buser et aI., 2007; Dal Monte et aI., 2002) although there remains some debate over the exact 
mechanism (Pignatelli et aI., 2007). The capsids are then located to late endosomes where 
they are coated in tegument and undergo secondary envelopement in a membrane containing 
virion glycoproteins, before being released from the cell (Fraile-Ramos et aI., 2007). As with 
transport of mature capsids to the nucleus, there is evidence to suggest that immature particles 
are transported along microtubules, away from the nucleus towards the cell membrane 
(Sampaio et aI., 2005). Despite being non-essential in other herpesviruses, in 
betaherpesviruses such as HCMV, glycoprotein gN (UL 73)(studied here) has been shown to 
be required for virion morphogenesis (Mach et aI., 2007). Viral glycoproteins are present in 
large quantities on the cell membrane and this facilitates fusion with neighbouring cells. Thus 
cell free and cell-to-cell spread are distinct mechanisms with the latter important for intra-host 
spread and as a mechanism of immune evasion. 
1.4.9 HCMV immunomodulation 
There are over thirty HCMV genes with evidence for immunomodulatory functions either by 
similarity to other host or viral proteins or defined experimentally. These genes may affect 
classical and non-classical major histocompatibility complex protein function, leukocyte 
migration and activation, cytokine responses and host cell susceptibility to apoptosis. 
Interestingly, of all betaherpesvirus immunomodulatory genes only three have homologues in 
both betaherpesviruses (Table 3). The expression ofMHC Class I homologues on the surface 
of MCMV infected cells may contribute to evasion ofNK cell recognition (Farrell, Degli-
Esposti, and Davis-Poynter, 1999). UL16 binds MICB, ULBPl and ULBP2 and inhibits their 
interaction with NKG2D, suppressing NK clearance (Sutherland, Chalupny, and Cosman, 
2001). Human NK cell receptors for MHC class I belong to the NKG2 and killer cell Ig-like 
receptor (KIR) families. Certain NKG2 and KIR genotypes in HIV positive patients may be 
more strongly associated with HCMV disease than others (Price et aI., 2007). UL 18 encodes 
an MHC Class I homologue but unlike endogenous MHC class I it binds leukocyte 
immunoglobulin-like receptor (UR-I), which is expressed prominently on monocytes and B-
cells, but also on subsets ofNK and T -cells (Cosman, Fanger, and Borges, 1999). This may 
result in down regulation of DC, NK and T -cells, but there is also evidence for the activation 
of these same cells (Wagner, Ljunggren, and Achour, 2008; Wagner et aI., 2007). HCMV can 
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down regulate MHC class 11 in cell culture, but other than US2 (Tomazin et aI., 1999), other 



































HCMV Gene Family; Gene Name 
RLll family, IgG Fc·binding glycoprotein 
Membrane glycoprotein 
UL18 family, putative membrane glycoprotein; 
MHC class I homologue 
T·cell receptor V chain homologue 
GPCR family, virion envelope protein 
Membrane glycoprotein 
Putative membrane glycoprotein 




IgG Fc·binding glycoprotein, virion envelope 
glycoprotein 
Putative secreted protein 
UL146 family; putative secreted glycoprotein 
ULl46 family; secreted glycoprotein 
Membrane glycoprotein; TNF receptor 
homologue 
UL18 family; putative membrane glycoprotein; 
MHC class I homologue 
UL14 family; membrane glycoprotein 
Putative membrane protein 
US2 family; membrane glycoprotein 
US2 family; lE gene and membrane 
glycoprotein 
US6 family; putative membrane glycoprotein 
US6 family; membrane glycoprotein 
US6 family; membrane glycoprotein 
US6 family; membrane glycoprotein 
US12 family; putative multiple transmembrane 
protein, GPCR? 
GPCR family; virion envelope glycoprotein 
GPCR family; membrane protein 
Table 3: Betaherpesvirus immunomodulatory genes 
Adapted from Mocarski (Mocarski, 2007) 
Function 
Modulates antibody activity 
Inhibits natural killer (NK) cell cytotoxicity by 
downmodulating MICA·ULBP, NKG2D ligand 
LlR-lligand 
CC chemokine binding protein 
Constitutive signalling [HHV·6A, HHV·6B and HHV-7 
are chemokine receptors) 
Signal peptide binds HLA·E and inhibits NK cell 
cytotoxicity via CD94:NKG2A 
Directs MHC class I to Iysosomes 
Latency associated 
CC chemokine, binds CCR5 and can block HIV entry 
Membrane protein related to OX·2; modulation of 
antibody activity 
Putative CC chemokine, endothelial and epithelial cell 
tropism, complexes with gH :gL 
Putative CXC chemokine 
hCXCR2·specific CXC chemokine 
Regulates Iymphocyte activation via Band T· 
Iymphocyte attenuator (BTLA) 
Inhibits NK cytotoxicity by down regulating CD155 
Inhibits NK cytotoxicity 
Degradation of MHC class I and, pOSSibly, MHC class 11 
Inhibits processing an dtransport of MHC class I and, 
possibly MHC class 11 
Inhibits transported of antigen processing (TAP)-
mediated ER peptide transport 
Binds to MHC class I 
Delays trafficking of M HC class I 
Selective degradation of MHC class I 
Broad spectrum CC and CX3C chemokine receptor, 
mediates cellular activation and migration 
As well as encoding proteins that mimic or interact with MHCs, HCMV also encodes several 
proteins that affect the immune inflammatory system which directs leukocytes to the site of 
infection. Some of these resemble chemokine receptors (US27, US28, UL33 and UL78) but 
only one (US28) has been shown to bind chemokines (Gao and Murphy, 1994), and for this 
reason is the best characterized, and has no homologues in the other betaherpesviruses 
(Mocarski, 2002). US28 binds RANTES, MCP-l, MIP-la, MIP-l~ but binds most strongly 
with Fractalkine (Casarosa et aI., 2005; Kledal, Rosenkilde, and Schwartz, 1998) and can also 
signal constitutively (Casarosa et aI., 2001). US28 can also act as a co-receptor for HIV into 
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otherwise unsusceptible cells (Ohagen et aI., 2000) and also binds the KSHV chemokine, 
vMIP-2 (Kledal et aI., 1997; Kuhn, Beall, and Kolattukudy, 1995). US28 might have a role in 
inflammatory response and leukocyte migration and is pro-inflammatory (Mocarski, 2002). 
US28 confers chemotactic mobility in smooth muscle cells (Streblow et aI., 1999; Streblow et 
aI., 2003), which is inhibited by US28 binding to Fractalkine. Fractalkine binding to US28 
expressed on macrophages however produces strong migration suggesting that US28 
signalling is both cell- and ligand- specific (Vomaske et aI., 2009). HCMV also encodes 
chemokine-like genes: UL 146 encodes vCXCL-l which is another secreted homologue of 
human IL-8. This hypervariable chemokine (Bradley et aI., 2008) binds CXCR2 but not 
CXCRl (the human form binds both), but like IL-8 it can chemotax and degranluate 
neutrophils (Penfold et aI., 1999). HCMV encodes two IgG Fc receptors, the first has two 
copies per genome, located within the repeat regions (TRL 11 and IRL 11), and the second is 
the spliced product of UL 1181119 (Atalay et aI., 2002). The HCMV ORF UL 111 A encodes a 
homologue of human IL-lO which is spliced and only has 25% amino acid sequence identity 
with the human form (Kotenko et aI., 2000). Like human IL-l 0, it can inhibit the proliferation 
of mitogen-stimulated PBLs and reduced cell surface expression of MHC Class I and II on 
PBMCs (Spencer et aI., 2002), although more recent work has shown is may have an immune 
stimulatory role with respect to B-cells, possibly showing differential effects of lytic and 
latent viral transcripts (Spencer et aI., 2008). A different study has recently identified several 
isoforms, possibly with variable glycosylation patterns, but all are able to form a heterodimer 
with human IL-l 0 (Lin et aI., 2008). The studies summarized here demonstrate a complex and 
convoluted interaction between virus and host, with a myriad of selective pressures being 
exerted in both directions. Viral proteins that subvert the host immune system can also 
promote virus dissemination and are potential virulence determinants. 
1.4.10 HCMV detection and diagnosis 
HCMV was first discovered in the 1930s in biopsy/autopsy studies, through histological 
identification of 'owls eye inclusions' in kidney, liver or lung tissue. This is a highly specific 
way of detecting HCMV organ involvement but it is not very sensitive as it only accounts for 
20% of HCMV PCR-positive tissue (Mattes et aI., 2000). The virus has since been detected 
by other classical techniques, such as virus isolation and serology-based techniques to detect 
either HCMV -specific antibody or antigens, in human sera. Such tools are useful in 
establishing the prevalence of HCMV within a given population, but are not suited to 
following the clinical course of infection, such as assessing reactivation frequency of this 
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chronic infection in a specific bodily fluid or tissue. Molecular techniques such as PCR 
(Polymerase Chain Reaction) and qPCR (quantitative PCR) are much better suited to this kind 
of investigation. They are highly sensitive and highly specific methods of detecting the 
presence and amount of HCMV within a range of different specimen types such as whole 
blood, sera, urine, saliva, breast milk and tissue. RT -PCR (Reverse Transcriptase PCR) can 
also be used to assess the transcription levels of specific genes. In this thesis, qualitative and 
quantitative PCR are used to detect HCMV DNA in DNA-extracted whole blood, lung tissue 
and sera. Detection in sera correlates with active infection, reduces interference from latent 
virus and also eliminates sensitivity problems associated with a high cellular background. 
There are commercial kits available for qPCR (eg: COBAS A MPLICOR CMV Monitor Test 
(Roche» and also services (eg: 5500 Cytomegalovirus (CMV) Real-time qPCR (ViraCor» but 
commercial primer sequences are often undisclosed or contained within a mastermix and 
cannot be used for genotyping. Whilst commercial assays are highly specific, other in-house 
protocols are more sensitive and cost-effective (Boivin et aI., 1998; Herrrnann et aI., 2004), 
and have the advantage, through careful primer design, of being able to genotype different 
HCMV strains (Beyari et aI., 2005; Mattick et aI., 2004; Paterson et aI., 2002; Pignatelli, Dal 
Monte, and Landini, 2001). 
1.4.11 HCMV glycoprotein complexes 
Four glycoprotein complexes have been defined for HCMV: gCI (gB alone), gCII (gM/gN) 
(Gretch 1988), gCIII (gH/gLlgO) (Paterson 2004) and gH/gLlULI28-131 (Wang Shenk 
2005), which are known to function in the direct mechanics of cell tethering (Isaacson, Feire, 
and Compton, 2007; Kari and Gehrz, 1992) entry (Feire, Koss, and Compton, 2004) and 
egress (Jiang et aI., 2008) of progeny virions and tropism (Wang and Shenk, 2005a). 
However, genome analysis has suggested there may be as many as 50 HCMV glycoprotein 
genes, and so the real number and variety of these complexes may be considerably greater. 
There is evidence for cell binding and entry through glycoprotein gB (Soroceanu, Akhavan, 
and Cobbs, 2008) although previously the gH-gL complex has been implicated (Milne, 
Paterson, and Booth, 1998), with peptides from coiled-coil domains on both gB and gH being 
shown to block fusion (Lopper and Compton, 2004), suggesting HCMV has mUltiple entry 
mechanisms, possibly determining tissue/cell tropism or to circumvent entry inhibition due to 
host immunity. Hypervariable glycoproteins gO (UL74) and gN (UL73) are investigated in 
this thesis as potential determinants of virulence and/or tropism. Interestingly they both from 
complexes with more conserved proteins. 
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The gH-gL-gO complex was identified by immunoprecipitation and radio labelling techniques 
(Huber and Compton, 1997; Li, Nelson, and Britt, 1997; Paterson et aI., 2002) and shown to 
form in the ER maturing in the post Golgi (Huber and Compton, 1999; Theiler and Compton, 
2002). Initially a gO mutant (generated through creation of random transposon libraries of 
bacmids containing mutant herpesvirus genomes) was capable of only minimal replication in 
fibroblast cell culture, suggesting a role in fibroblast tropism (Hobom et aI., 2000). More 
recently studies using a different ~gO mutant showed similar low titres in fibroblast cell 
culture, but normal quantities of extracellular virus (Wille et aI., 2009). These results are in 
keeping with several studies showing a role for gO in cell-cell fusion and spread in both 
fibroblasts (Jiang et aI., 2008) and astrocytes (Paterson et aI., 2002), although retroviral 
vectors expressing AD 169 gO in CHO epithelial cells showed no increase in the observed 
syncytia after co-transfection with gH/gL and gO (Kinzler and Compton, 2005), supporting 
the idea that HCMV gO has a function that is species or cell-type specific. Recent data 
suggests that the gH-gL-gO complex is primarily a cellular egress complex in which gO acts 
as a chaperone (Ryckman, Chase, and Johnson, 2009). Both gH-gL and gH-gL-ULI28-
UL130 are required for endothelial/epoithelial cell tropism, and gH-gL alone for fibroblast 
cell tropism with gO being required for correct transport of gH-gL to the cell surface and 
incorporation into progeny virions (Wille et aI., 2009). There are other virion associated gO-
containing complexes (such as gO-gL) and these appear to arise in the post-Golgi 
compartment and are also likely involved in egress (Theiler and Compton, 2002). 
Glycoprotein gO contains a cleavable signal sequence, with the gH/gL/gO complex shown to 
anchor by the trans-membrane domain of gH (Theiler and Compton, 2001). 
The gMlgN complex (Mach et aI., 2000) binds heparin sulphate (Kari and Gehrz, 1992) but 
has also been shown to function intracellularly in nuclear assembly and egress (Mach et aI., 
2005; Mach et aI., 2007). This complex is conserved throughout the human herpesviruses 
where deletion of either or both components often has little effect on replication efficiency 
(Baines and Roizman, 1991; Masse et aI., 1999), whereas in HCMV, deletion of gM results in 
a replication-incompetent virus (Hobom et aI., 2000). Deletion of large parts of gM however, 
including C44 which forms a disulphide bridge with C90 on gN, has shown that large parts of 
gM are despensible (Mach et aI., 2005), but cytoplasmic tails express trafficking signals and 
are essential for HCMV assembly and replication (Krzyzaniak, Mach, and Britt, 2007). 
Likewise, the C-terminal domain of gN is required for virion morphogenesis (Mach et aI., 
2007). The gMlgN complex is also a target for neutralizing antibodies (Shen et aI., 2007; 
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Shimamura, Mach, and Britt, 2006). Certain gN genotypes may also have a latency associated 
functions inferred by them being more commonly detected in HCMV genomes extracted from 
monocytes taken from healthy blood donors (Pignatelli et aI., 2006) 
1.4.12 HCMV hypervariable glycoproteins 
Compared to rampantly emergent RNA viruses, variation in the herpesviridae during a single 
replication cycle is restricted due to lower error rates in DNA-dependant DNA polymerases. 
The rapid drift associated with viruses such as influenza or HIV, is not seen in herpesviruses, 
but over millennia, high levels of variation in select loci has been observed at levels similar to 
flu or HIV. Evolutionary modelling and genomic analysis suggest recombination is a common 
process by which novel HCMV strains may diverge (Gompels et aI., 1995; Mattick et aI., 
2004; McGeoch, Rixon, and Davison, 2006). The 14 known full length sequences of HCMV 
and studies identifying multiple loci in clinical isolates (Bale et aI., 2001; Cunningham et aI., 
2009; He et aI., 2006; Rasmussen et aI., 2002; Rasmussen, Geissler, and Winters, 2003) 
support the model of mosaics of different strains in the environment. Studies looking at 
conserved loci, such as UL55 (gB), have hence failed to identify genotype specific clinical 
outcomes (Coaquette et aI., 2004; Humar et aI., 2003; Sarcinella et aI., 2002). Whilst gB is a 
major virion glycoprotein responsible for cell recognition and binding, clinical differences 
between strains, such as virulence, tropism or disease outcome, are more likely to be 
determined by more variable loci. Such loci have been located towards the long unique and 
repeat boundaries (Cha et aI., 1996; Murphy et aI., 2003a), although interestingly there are 
two hypervariable genes (with variation mainly towards 5' termini), that are unique in that 
they are more centrally located (Gompels, 2006; Paterson et aI., 2002). These genes are UL 73 
(gN) and UL 74 (gO), discussed above with respect to their complex formation with gM and 
gH-gL respectively. These virion surface glycoproteins are encoded by neighbouring genes 
that overlap slightly (by 24 base pairs in AD 169) at their respective 3' ends, being encoded by 
opposite strands of the double stranded HCMV genome (Figure 2, Page 61). 
Further sequence analysis of the UL 73 gene initially identified four genotypes (gN 1, gN2, 
gN4 and gN4)(Pignatelli, Dal Monte, and Landini, 2001), but then phylogenetic analysis 
showed that gN4 can be divided into three tightly clustered genotypes (gN4a, gN4b and 
gN4c)(Pignatelli et aI., 2003a), making seven genotypes in total (Mattick et aI., 2004). 
Analysis ofUL74 has identified eight genotypes (gOla, gOlb, gOlc, g02a, g02b, g03, g04 
and g05)(Mattick et aI., 2004). Furthermore sequence analysis of strains from Europe, North 
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America and China showed these overlapping hypervariable loci form seven linked groups 
(Chen et aI., 2008; Mattick et aI., 2004; Pignatelli et aI., 2003a)(Table 4). This is in contrast to 
other herpesviruses, such as HHV -6 and HHV -8, where there is evidence for differences in 
African countries (Kasolo et aI., 1998; Kasolo, Mpabalwani, and Gompels, 1997; Kasolo et 
al., 2007). Linkage between HCMV genes is rare (Rasmussen et aI., 2002; Rasmussen, 
Geissler, and Winters, 2003) and so both HCMV gO and gN are good targets for analysis as 
regions which are likely to affect the virulence and tropism of different strains. At the start of 
this thesis nothing was known about HCMV genotypes in Africa and HCMV had not even 
been identified in Zambia - the study site for this thesis. In this thesis we use the gO/gN locus 
to investigate the strains present and genotype variation in three Zambian paediatric cohorts 
and compare these findings with those from other regions globally. 
Glycoprotein gO/UL74 Glycoprotein gN/UL73 Reference strain 
gOla gN1 AD169 
gOlb gN3a TR 
gOle gN4e Toledo 
g02a gN3b PH 
g02b gN2 HAN 36 
g03 gN4a HAN 39 
g04 gN4b Towne 
gOS gN4c Merlin· 










*Single example of gOS at the start of this thesis, initially linked with gN4c, the same as gO I c, suggesting some 
redundancy in linkage. In this thesis this is investigated further. 
1.4.13 HCMV infection and HIV/AIDS 
HCMV primary infections and reactivations are a major cause of morbidity and mortality in 
those suffering from HIV/AIDS. A North American study has shown significant increases in 
HCMV seroprevalence associated with HIV (60% in HIV negatives vs 95% in HIV positives) 
(Stover et aI., 2003). In populations where HCMV seroprevalence in the general population is 
very high, the effect of HIV infection on HCMV seroprevalence is not measurable, but there 
are correlations with HCMV viral loads, which are significantly reduced after HAART 
(Mihailescu et aI., 2008). In Cambodia HCMV sera viral loads were linked with death in 
HIV/AIDS patients, independently of other opportunistic infections, CD4 count and HAART 
(Micol et aI., 2009). 
42 
Studies have shown in children, that HCMV infections occur earlier among those who are 
HIV positive (Holland et aI., 2000; Likitnukul, Bhattarakosol, and Poovorawan, 2003). In 
HIV positive children, HCMV is linked with disease progression along with impaired brain 
growth and progressive motor defects (Kovacs et aI., 1999), pneumonitis (Williams et aI., 
2001) and infantile hepatitis (Shibata et aI., 2005). Studies in the US found higher rates of 
HCMV disease in children who were HIV positive. A significant association was observed 
between HCMV shedding, lower CD4 counts and higher HIV p24 concentrations (Chandwani 
et aI., 1996) along with a decrease in survival (Kitchen et aI., 1997). Also within HIV positive 
children, a U.S study found that the prevalence of active HCMV infection was significantly 
higher in symptomatic than in asymptomatic HIV positive children, with active infection 
detected in 70% of AIDS mortalities (Frenkel et aI., 1990). Active HCMV (and HHV-6) 
infections were also shown to be more common among children with HIV infection or those 
suffering from cancer (Leach et aI., 2002). There are also cases of sudden infant deaths among 
HIV positive babies due to generalized and disseminated HCMV infection (Brady et aI., 
1988). 
In the U.S, where co-infections of HCMV and HIV in children have mainly been studied, 
whilst extremely damaging, this is a relatively small population. In Africa studies are 
beginning to address the prevalence of HCMV and its potential impact on morbidity and 
mortality within the world's largest HIV positive paediatric populations. A study from South 
Africa found HCMV to be a major cause of pneumonia in HIV-infected infants (Jeena, 
Coovadia, and Chrystal, 1996) but at the start of this thesis there was little known about 
HCMV in Zambia. One autopsy study of HIV positive Zambian childhood respiratory 
mortalities found HCMV in lung tissue (by histopathology) in 42% for 0-5 month old infants 
(Chintu et aI., 2002). 
CD4 lymphopenia is likely a major cause of increased HCMV viral loads in HIV infected 
patients, with fewer circulating CD4 cells available to control HCMV viraemia. HIV and 
HCMV interactions can also occur within the same cell, where HCMV can transactivate the 
HIV LTR in cell lines carrying HIV proviral DNA (Davis et aI., 1987; Yurochko, Huong, and 
Huang, 1999) or form a pseudotype altering the HIV tropism (Margalith et aI., 1995). HCMV 
may also affect HIV when infecting a different/neighbouring cell, with cytokine release or 
antigen presentation possibly transactivating HIV proviral DNA (Clouse et aI., 1989; Peterson 
et aI., 1992), and with co-receptor (alternative receptor) up-regulation increasing HIV 
infection (Pleskoff et aI., 1997). Antibody dependent enhancement could also facilitate HIV 
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entry into cells which are usually non-permissive, but that are expressing an HCMV-encoded 
Fe receptor such as RLll (McKeating, Griffiths, and Weiss, 1990). Conversely, HIV has been 
shown to elicit effects on HCMV, with replication being shown to be up-regulated 2-3 fold in 
explanted lymphoid tissue co-infected with either CXCR4 or CCR5 tropic HIV (Biancotto et 
aI., 2008). The two viruses have also been shown to co-infect explanted human cervical tissue 
(Fox-Canale et aI., 2007). The molecular interactions between HCMV and HIV are 
bidirectional, and monitoring of viral co-infections in HIV positive patients, is probably 
equally as important as the monitoring of HIV. 
Many HIV positive patients will be co-infected with both HCMV and HHV -6 although there 
is little data on this from Southern Africa. Elsewhere, in severely immunocompromised 
patients, co-infections with both betaherpesviruses are common, resulting in severe pathology 
(Caselli et aI., 2006; DesJardin et aI., 1998; Dockrell et aI., 1997; Humar et aI., 2002). The 
various and sometimes contradictory in vitro interactions described above could be due to 
differential effects of different betaherpesvirus strain variants interacting with HIV in 
different cell types or patient groups. Interactions between HCMV and HIV may be further 
complicated by the presence of other chronic infections such as those caused by the 
gammaherpesviruses (EBV and KSHV), known to be causal in HIV associated malignancies 
and pathology (Birx, Redfield, and Tosato, 1986; Chang et aI., 1994). 
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1.5 HIV-l exposed uninfected infants 
1.5.1 Introduction 
Southern Africa is the centre of the global HIV pandemic, with rates of infection with HIV 
being as high as 33% among pregnant women in Botswana (Creek et aI., 2009). In this region 
HIV-l predominates (Chilongozi et aI., 2008) with seroprevalence among women of child 
bearing age being over 20% in neighbouring Zambia (CSO_Zambia, 2007). Maternal 
immunity is very important for controlling HCMV infections and so infants who's mothers 
are immune suppressed are likely to receive less protection through maternal antibody and 
possibly increased risk of HCMV transmission through breast milk. In recent years the roll 
out of ART (antiretroviral therapy) to HIV -1 positive African mothers has dramatically 
reduced the rate of MTCT (mother-to-child-transmission) of HIV -I so that now less than 10% 
of infants born to HIV-I positive mothers actually contract the virus (Coetzee et aI., 2005; 
Guay et aI., 1999; lackson et aI., 2003). In Zambia this means the remaining 90% are HIV-l 
exposed but uninfected and this accounts for 18% of the infant population as a whole. As the 
HIV-I pandemic expands, and as ART becomes more widely available, the number of infants 
who are HIV -1 exposed but uninfected is also set to expand, yet causes of morbidity and 
mortality in this group have been less well studied than in HIV -1 infected infants. At the start 
of this thesis there was data showing that compared to HIV -1 unexposed infants, HIV-I 
exposed infants suffer poorer health and development (Makasa et aI., 2007; Marinda et aI., 
2007; Otieno et aI., 2006; Thea et aI., 1993) but the reasons for this were not well defined. 
Some of these studies suggested poorer nutrition and increased exposure to infections as 
possible causes. 
1.5.2 Infection and morbidity in HIV -1 exposed infants 
Infants in tropical or sub-tropical regions of the globe are naturally exposed to a great number 
of pathogens - viruses, bacteria, fungi and parasites - than those in temperate countries. 
Opportunistic infections have been well studied in HIV -1 infected infants but much less so in 
those who are HIV-l exposed, in whom they may also be more prevalent and/or more 
persistent. Increased morbidity from infectious diseases such as malaria (Otieno et aI., 2006) 
and protozoal and bacterial diarrhoea (Thea et aI., 1993) is common in low income settings, 
along with viral diarrhoea caused by a wide range of species: Rota-, Noro-, Adeno-, Entero-
and Astro-viruses (Abba et aI., 2009; Silva et aI., 2008). HCMV also infects the gut, and can 
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cause lethal enteritis, often in immune compromised patients but also in those who are 
otherwise healthy (Middleton, 1996; Page et aI., 1998). HCMV infections may affect nutrient 
uptake, either directly through a localized gut infection, or indirectly by diverting energy 
resources away from the digestive tract to the immune system. Data on morbidity associated 
with common childhood viral infections in HIV -1 exposed infants is scarce, but the 
betaherpesviruses are known to be associated with increased morbidity and mortality in HIV-
1 infected infants (Kositanont et aI., 1999; Kovacs et aI., 1999) and hence the rationale for 
part of this thesis, to look at their effects on HIV -1 exposed infants and interactions with other 
markers of morbidity including anaemia, reported fever, rate of hospital referrals and survival. 
Anaemia is common in normal birth weight Zambian infants and increases with age, so that 
by 6 months of age up to 50% of infants are anaemic (van Rheenen et aI., 2008). In this region 
plasmodium falciparum malaria is endemic, and severe anaemia is a common complication 
linked with infant mortality (Biemba et al., 2000). HCMV is also known to cause anaemia in 
congenitally and perinatally infected infants (Distefano et aI., 2004) possibly through 
disruption of the differentiation ofhaematopoetic stem cells (He et aI., 2003). Primary 
infection with HHV -6 can sometimes cause anaemia (Kagialis-Girard et aI., 2006) but more 
significantly, it is a major cause of fever in infants and has been reported as responsible for up 
to 40% of infant hospitalizations in North America and Europe (Hall et aI., 1994; Portolani et 
aI., 1993). The possible effects of HCMV and HHV-6 infections on HIV-l exposed infants 
are not known and will be investigated in this thesis. 
1.5.3 Development and breast feeding in HIV -1 exposed infants 
HIV -1 infected infants are known to suffer impaired development but maternally HIV-l 
exposed infants have been less well studied. At the start of this thesis there were some 
preliminary reports which suggested that maternally HIV -1 exposed but uninfected infants 
also had poor development as recently reviewed (Filteau, 2009a). The factors contributing to 
this are not well defined although some hypotheses have been put forward. For example, 
during the thesis data was published from Zambia showing that HIV -1 exposed infants suffer 
from growth faltering (Makasa et aI., 2007). One contributing factor proposed was that HIV-l 
positive mothers are generally much less likely to breast feed or stop breast feeding early 
compared with HIV -1 negative mothers (Arpadi et aI., 2009). As well as improving growth, 
breast feeding has other developmental and immunological benefits that are less well 
understood. For example breast feeding is strongly associated with reductions in 
gastrointestinal and respiratory infections (Cesar et aI., 1999; Howie et aI., 1990), and 
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improved neurological development (Anderson, Johnstone, and Remley, 1999). The benefits 
of breast feeding are intuitive to many mothers but for those who are HIV-1 positive, and 
being faced with a 5-10% chance (and some may think it is greater) of transmitting HIV-1 to 
their child, it is not surprising that they either do not breast feed at all, or terminate breast 
feeding much earlier than they would do otherwise (Fadnes et aI., 2009). It is now an 
undisputed fact that for HIV -1 positive mothers, the longer they breast feed the more likely 
they are to transmit HIV -1 to their child (Coovadia and Bland, 2007). The position of the 
World Health Organization is that exclusive breast feeding is recommended in the 'first 
months oflife' (they do not specify to an exact age), unless available complementary feeding 
to breast milk is at AF ASS standards: 'acceptable, feasible, affordable, sustainable and 
safe'(Filteau, 2009a). What constitutes AFASS complementary nutrition for HIV-1 exposed 
infants is not clear and how this affects childhood infections, particularly common virus 
diseases and breast milk transmitted agents or their strain variants is not known and this is 
investigated in here in comparison to other cohorts which can be affected by HCMV and HIV. 
HCMV is known to be widely transmitted through breast milk and so is investigated in this 
thesis for effects on a range of outcomes with respect to HIV -1 exposure, duration of breast 
feeding and micronutrient fortification. 
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1.6 Aims and objectives 
This thesis aims to investigate genotype variation of betaherpesvirus infections in Zambian 
children. Assays will be designed and set up to screen two retrospective cohorts for both 
HCMV and HHV -6. These assays will then be optimized to screen a large population based 
cohort taking part in a complementary feeding micronutrient intervention. Prevalence of 
active infections and also seroprevalence will be analysed for effects on other markers of 
development and health, with a focus on maternally HIV -1 exposed infants. These aims will 
be met by the following objectives: 
a) Set up qualitative and quantitative PCR assays for measuring loads and genotyping of 
betaherpesviruses using the hypervariable loci which encode glycoproteins gO and gN 
b) Use of the above assays to screen three cohorts of Zambian children: 
HIV -1 infected respiratory mortalities 
Hospitalized fevers 
CIGNIS - Chilenje Infant Growth Nutrition and Infection Study 
c) Analyse betaherpesvirus genotypes present in this southern African region and 
comparing with other regions globally 
d) Analyse the effects ofbetaherpesvirus infection (both active infection and 
seroprevalence) on markers of development and health, including measures of virus 
infection and vaccine immunity, with respect to micronutrient interventions and 
maternal HIV -1 exposure 
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2.0 Materials and Methods 
2.1 Study Sites 
The three cohorts studied in this thesis were recruited at either UTH (University Teaching 
Hospital) or the Chilenje Clinic, both of which are in Lusaka, Zambia. Zambia has a 
population of roughly 11.7 million (World Health Statistics 2007)(Shibuya, 2007) and UTH is 
a 2000-bed referral hospital, serving approximately 60% of this population (Kasolo, 1999). 
Most of the patients attending UTH however come from within Lusaka, a capital city with a 
population of just over 1.3 million (Central Statistical Office Zambia - 2000 
census)(CSO_Zambia, 2000). Initial screening for betaherpesviruses was conducted at the 
UTH Virology Laboratory, with representative aliquots being taken back to LSHTM (London 
School of Hygiene and Tropical Medicine) for Real Time PCR and genotyping analysis. 
2.2 Patients and Samples 
This thesis presents analysis of three independent paediatric cohorts from Lusaka: 
a) 141 whole blood samples taken from children hospitalized with fever (excluding 
malaria and bacterial pneumonia). These were collected or submitted for routine 
clinical screening to UTH. All children in this cohort were resident in Lusaka (Kasolo, 
1999) and were aged between 6 and 34 months. DNA extraction was performed 
roughly 10 years prior to the work presented in this thesis. 
b) 36 lung tissue samples taken from HIV -1 positive paediatric respiratory mortalities 
(UTH, Zambia)(Chintu et aI., 2002). No other clinical or demographic data are 
available for this cohort. 
c) Paired sera samples (6 and 18 months) from a cohort of812 Zambian infants taking 
part in CIGNIS (Chilenje Infant Growth, Nutrition and Infection Study: UTH and 
Chilenje clinic, Lusaka, Zambia). This cohort also included a sub-set of infants who 
presented with fever herein termed the CIGNIS 'morbidity' samples. All CIGNIS 
infants were defined as HIV -1 infected, HIV -1 exposed (infants with negative or 
unknown HIV-l status, who's mother's are HIV-I positive), or HIV-I unexposed 
(mother HIV -1 negative and infant HIV -1 negative or unknown). 
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2.3 Ethics 
Ethical approval was granted for work on all three cohorts. The hospitalized fever cohort 
originated from a separate study of spent bloods for which ethical clearance was awarded by 
the ethical review board of The London School of Hygiene and Tropical Medicine (LSHTM), 
along with the joint University Teaching Hospital(UTH)/ University of Zambia(UNZA) ethics 
committee. The respiratory mortalities cohort originated from a Zambian study into the causes 
of paediatric respiratory failure for which ethical clearance was awarded by the joint 
UTHIUNZA ethics committee. The original study allowed for detection of HCMV by 
histopathology in lung tissue samples taken at autopsy. Permission was granted by the 
principal investigators of this study (Prof C Chintu and Dr F Kasolo) to follow up on this 
analysis for both HCMV and HHV-6 using molecular diagnostics. The CIGNIS study was 
awarded ethical clearance by both the LSHTM and UTHIUNZA ethics committees. 
2.4 DNA extraction 
DNA extractions were performed with a QIAamp DNA blood extraction kit (QIAGEN, 
Crawley, U.K) according to the manufacturers protocol. For the hospitalized fever cohort 
200JlI of whole blood were extracted and eluted in 200111 dH20. For the respiratory mortalities 
cohort, a small piece of tissue about 2mm2 was homogenized with a surgical blade and then 
DNA-extracted, eluted in IOOll1 of dH20. For the CIGNIS cohort 200JlI of serum was DNA-
extracted and eluted in 50JlI dH20. DNA extractions from clinical material were monitored 
using a qualitative assay for the human house keeping gene GAPDH, adapted from a 
previously published quantitative assay (Asahi-Ozaki et aI., 2006). 
2.5 DNA storage and transport 
Prior to DNA extraction all clinical material was stored at -80DC at the virology unit 
laboratory, UTH. Power-cuts are rare at this facility but freezer temperatures are monitored 
daily. Freezer break downs were dealt with swiftly by shifting samples to where there is spare 
capacity. To our knowledge the samples in this study were at no point thawed for an extended 
period allowing sample degradation. Extracted DNA was stored at the same facility at _20De. 
For transportation of DNA from Zambia to the UK, samples were precipitated in 1110 volume 
of 3M sodium acetate, and 2 volumes of 100% ethanol, then transported at room temperature. 
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Upon arrival they were chilled to -20°C, centrifuged at 13,OOOrpm for 10 minutes after which 
the ethanol was removed and they were allowed to air-dry for 10 minutes. Samples were then 
re-suspended in the appropriate volume of nuclease free water. 
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2.6 Qualitative peR 
Qualitative PCR reactions were made up in 25JlI: 12JlI GoTaq® Green Master Mix (Promega, 
Southampton, U.K), 2.5JlI of each primer (lOJlM), 1-5JlI of template DNA made up to 7ul 
with dH20. Thermal cycling parameters were 95°C for 2 min, then 40 cycles of 95°C for 30 
sec, annealing at 59°C for 30 sec and extension at 72 °C for 2 min, followed by a final 
extension step of 72°C for 5 min. Generally 20Jlls of product was run on an Ethidium 
Bromide-stained 1-2% agarose gel where positive bands were extracted using a MinElute Gel 
Extraction Kit (QIAGEN, Crawley, U.K) (Manufacturer's_Protocol, 2008) and eluted in 15JlI 
of nuclease-free water ready for sequencing. All PCR assays included both positive and 
negative controls. Extracted DNA from virus-infected tissue culture supernatants of the 
AD169 laboratory adapted strain of HCMV, or the UII02 strain ofHHV-6. were used as 
positive controls. Two negative controls were included with every assay, one reagent control, 
and one control containing water kept in the sample storage room. 
2.7 PCR Primers and assay sensitivity 
Primers were designed with the assistance ofPrimer3 software (Rozen and Skaletsky, 2000) 
and then adjusted manually after cross-checking across multiple genotypes using ClustalW 
(Chenna et aI., 2003) where necessary (to minimise miss-matches between known genotypes). 
All primers and probes were synthesized by and purchased from Sigma-Aldrich (Dorset, UK), 
with sequences detailed in Appendix A. Genomic locations of primers and targets were as 
shown (Figure 2). The sensitivity of all primer pairs was determined through assaying serial 
ten-fold dilutions of cloned PCR products representing each target. The sensitivity of 
individual primer pairs was as shown for both HCMV and HHV -6 (Figure 1) 
2.8 PCR contamination prevention 
Facilities at the UTH and LSHTM laboratories each comprise three separate rooms for PCR. 
At the UTH samples are DNA-extracted in a category 2 hood in room one. PCR reagents are 
stored and prepared in room two. DNA is then added to samples back in room 2 with 
thermocyclers and gel running equipment all being located in room three. At the LSHTM the 
set up is similar, with three separate rooms for reagent storage and set-up, DNA storage and 
addition, and thermocycling and electrophoresis. All reagents were aliquoted to prevent repeat 
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freeze thaws and reduce risk of contamination. The protocol in place should any 
contamination be detected was the disposal of all reagents, thorough cleaning of all surfaces 
and pipettes in all 3 labs with vircon followed by 70% ethanol, and re-stocking with new 
reagents. Two incidents of contamination were noted, likely arising from carriage of PCR 
product clones into the reagent set-up room. On both occasions the above protocol was 
implemented successfully and at no point was there any evidence to suggest that clinical 
samples had become contaminated. 
2.9 Cloning 
PCR products were cloned into the pCR@4-TOPO® vector using the TOPO TA Cloning® Kit 
for Sequencing (Invitrogen, Paisley, U.K) (Manufacturer's_Protocol, 2006). Briefly, cloning 
reactions (PCR product, vector, salt and water) were set up in 6fll and incubated at room 
temperature for 5 minutes. 2fll of this reaction were then transfected in to 25fll of TOP 10 
Chemically Competent Cells (Invitrogen, Paisley, U.K). The transfection reaction was 
incubated on ice for 30 mins, followed by a 30 second heat shock at 42°C, after which 250111 
of SOC medium were added prior to incubation for 1 hour at 37°C in a shaking incubator 
(200rpm). 5-50fll aliquots were then plated on selective plates (Ampicillin 5flg/I . .tl) and 
incubated over night at 37°C. Selected colonies were then re-spread and after 24 hours 
subsequent double-colony purified clones were selected and dropped in to 3ml cultures 
(Ampicillin 5flg/fll). After a further 16 hour incubation, plasmid DNA was extracted from 
1.5mls ofa 3ml culture using a Miniprep (Invitrogen, Paisley, U.K) (Manufacturer's_Protocol, 
2005). The remainder was used to make a glycerol stock (500ul sterile glycerol and 500ul 
culture) and stored at -80°C. From the Miniprep DNA was eluted in 50!!1 of nuclease free 
sterile water and DNA concentrations were measured using a Nanodrop spectrophotometer 
(NanoDrop Products, Wilmington, DE, USA, supplied in U.K by Thermo Fisher Scientific, 
Loughborough). 
2.10 Preparation of plasmid standard dilution curves 
Plasmid copy numbers were calculated (Appendix B) and aliquots prepared containing 2xl06 
copies/!!!. 10 fold serial dilutions (I O!!l in 90!!1) were then prepared down to 2x 10-1 copies/ill. 
Reactions were then set up as described previously but with 5!!1 of template (so highest 
dilution of2xl06 copies/!!l is equivalent to 107 absolute copies) and 3fll dH20 (instead of lfll 
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template and 7Jll dH20, as previously). Using 5Jll template improved reproducibility assaying 
serial dilutions. Sensitivities of assays for HCMV gB, gO and gN along with HHV -6 gO and 
gN are shown (Figure 2). 
2.11 Sequencing 
Sequencing reactions for both forward and reverse strands of PCR products were set up in 
10J-ll using 1 Jll of sequencing mix, 3 Jll of sequencing buffer (AB I v3.1), 1 J-ll of primer (1 J-lM), 
4Jll of nuclease free water and IJll of template DNA (For faint bands this was sometimes 
varied up to 3Jll, reducing the amount of water accordingly). Thermocycling parameters were 
94°C for 4 min, then 25 cycles of 96°C for 20 sec, 50°C for 10 sec and 72°C for 4 min. 
Sequencing reactions were done in 96-well plate format and products were then ethanol 
precipitated as follows: 62.5JlI of molecular grade ethanol, 24.5J-ll of dH20 and 3Jll of 3M 
sodium acetate were added to reach well (for multiple samples a mastermix of these three 
components made first and then 90111 were put in each well). The plate was then covered in an 
adhesive film and vortexed for 10 seconds and then left at -20°C for 20 minutes. This was 
followed by centrifugation at 3000g for 30 minutes after which plates were carefully inverted 
and the ethanol allowed to drain by gravity. The inverted plate was then spun for 15 seconds 
at 50g to remove residual ethanol. 150JlI of ice-cold 70% ethanol were then added to each 
well, the plate was covered with adhesive film and vortexed, and then a second centrifugation 
step at 3000g for 15 minutes. Ethanol removal was repeated in an identical manner and then 
10J-ll of HiDye Formamide (Applied Biosystems, Warrington, U.K) were added to each well. 
Plates were read on a 3730 DNA Analyser (Applied Biosystems, Warrington, U.K). 
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2.12 Bioinformatics 
Forward and reverse sequences were edited and compiled using ChromasPro software and 
grouped with established genotypes using BLAST (NCBI). Nucleotide polymorphisms were 
only accepted if present on both strands. Translations and alignments were constructed and 
analysed using the European Molecular Biology Open Software Suite (EMBOSS) and other 
online applications (eg. Transeq, ClustalW, Boxshade etc ... ). Phylogenetic analysis was 
undertaken using the Phylip3.67 suite of applications. Primarily alignments had to be 
generated in the phylip format (.ph) and then saved as plain text files (.txt). From these files 
100 bootstraps were generated (seqboot.exe) which were then fed into phylogeny programmes 
to generate maximum likelihood (prom!. exe) and parsimony (protpars. exe) trees. 
Consense. exe was then used to generate the consensus tree among 100 bootstraps. Distance-
based phylogenies of larger alignments were also generated (jiltch.exe). Resulting 
phylogenies were then viewed in treeview and edited in microsoji paint. 
2.13 Statistical analyses 
Nominal data were compared using Pearson's Chi-Squared unless there was a predicted value 
of <5 in which case Fishers exact test was used. Continuous variables were compared using a 
t-test for the equality of the means assuming equal variance. Analysis was undertaken in 
either Graphpad or SPSS 16. Additional statistical analysis was performed using ST ATA by 
the CIGNIS study statistician, Kathy Baisley (KB) 
2.14 Real Time peR 
HCMV DNA copy numbers were measured using a Real Time Taqman assay for HCMV gB 
using the previously described F AM-T AMRA labelled probe and primers (gB 1 and 
gB2)(adapted from (Mattes et aI., 2005». A FAM-TAMRA labelled probe was also designed 
to bind the HHV-6 U47 PCR product (derived from primers U47F and U47R) to be used in a 
Real Time Taqman assay for HHV-6. The U47 primers were chosen so as to provide a control 
for PCR product contamination in the primary screen with U46 primers. To facilitate 
comparison of HCMV and HHV -6 copy numbers between blood, serum and tissue cohorts a 
Taqman assay for quantification of the house keeping gene GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) was used (adapted from(Asahi-Ozaki et aI., 2006». PCR product 
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clones (TO PO-TA Cloning Kit, Invitrogen) were used to make IO-fold dilution series from 
106 down to 10-1 copies/Sill (template volume) for HCMV gB, HHV-6 U47 and GAPDH. 
These dilution series were assayed in duplicate with average Ct values for dilutions 106_102 
being used to construct standard curves. HCMV gB, U47 and GAPDH assays had sensitivity 
cut offs of 101, 102 and 102 copies/51l1 respectively, determined by the lowest dilution for 
which two positive results were obtained. Reactions were made up in 25111 in 96-well plate 
format: I 2 III of TaqMan® Universal PCR Master Mix (ABI), I III of each primer (lOIlM) and 
I III ofFAM-TAMRA labelled probe, 5f!1 of nuclease free water and 5f!1 of template DNA. All 
Real Time Taqman assays were run on a PRISM® 7000 (ABI) using the following cycling 
conditions: 50°C for 2 min, 95°C for 10 min and 60 cycles of 95°C for 15 sec and 60°C for 30 
sec. Where possible, samples were run in duplicate with the average HCMV or HHV -6 viral 
load being calculated, and where necessary, combined with GAPDH results to give a final 
value of copes/I 06 cells. For sequences of all primers and probes used in Real Time PCR see 
Appendix A. 
2.15 HCMV serology 
A serological screen was undertaken using an anti-cytomegalovirus IgG ELISA kit (DiaSorin 
S.p.A, Saluggia, Italy) as per the manufacturer's instructions. In brief, samples were diluted 
1:101 and IOOll1 was added to each well (which are coated with HCMV strain AD169) along 
with controls. The plate is then incubated for 1 hour at 37°C, followed by 5 washes with 
buffer. The secondary antibody (mouse anti-human IgG conjugated to horseradish preoxidase) 
is then added and the plate is incubated again for 1 hour at 37°C. After a further 5 washes with 
buffer 100111 ofsubstrate (chromogen) is added followed by a 30 minute incubation at room 
temperature away from direct light. After addition of 200 III of strop reagent absorbance is 
read within 30 minutes using a photometer at 450/630 and 405/630 nm. This assay was set up 
and conducted by an MSc project student, Kunda Musonda (KM). 
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3.0 HCMV DNA detection, loads & genotypes in three Zambian 
paediatric cohorts 
3.1 Introduction 
The aim of this chapter was to develop and implement PCR based assays for detecting active 
HCMV infections in Zambian children. This virus has not been well studied in Africa, 
particularly in southern regions at the centre of the HIV -1 pandemic where co-infections may 
cause serious morbidity and mortality as shown elsewhere (Kovacs et aI., 1999). HCMV has 
not been studied before in Zambia and the prevalence of active infections during childhood, 
and the genotypes present, are not known. PCR is a highly sensitive and specific technique for 
detecting viral infections and through the design of conserved primers flanking hypervariable 
loci, sequencing of PCR products will be used to genotype HCMV at the hypervariable UL 73 
(glycoprotein gN) and UL 74 (glycoprotein gO) genes. PCR assays were employed initially to 
screen the two retrospective cohorts: DNA-extracted blood from 141 infants hospitalized with 
fever (6-34 months of age), and DNA-extracted lung tissue samples from 36 HIV -1 positive 
children (0-16 yrs of age) who died from respiratory disease. After these analyses, a more 
sensitive assay (gB) was then used to screen DNA-extracted sera samples from a large 
prospective population-based cohort of healthy Zambian infants taking part in CIGNIS 
(Chilenje Infant Growth Nutrition and Infection Study), at both 6 and 18 months of age. PCR 
detection of HCMV in DNA-extracted sera is indicative of active infection as cell associated 
virus is excluded. After primary detection, all positive samples were subject to genotyping 
analysis using assays that target the two linked hypervariable loci, UL 74 and UL 73. HCMV 
viral loads will be determined using a Taqman based Real Time PCR assay (Mattes et aI., 
2005). The prevalence of active HCMV infections and loads will be analysed with respect to 
HIV -1 infection and exposure and genotypes present in this region will be compared with data 
from other regions globally. 
3.2 HCMV PCR assay design and strategy 
Assays were required for a high sensitivity primary qualitative screen for HCMV along with 
assays targeted for the sequencing of two hypervariable loci (UL 73 and UL 74). With the aim 
of obtaining good sequence data from samples with minimal levels of viral DNA, multiple 
sets of nested primer pairs were designed for both hypervariable targets, to increase sensitivity 
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and broaden sequence coverage (Figure 1). Alignments of the specific loci of eight published 
reference strains (AD169 NC 001347, Merlin NC 006273, Towne AC146851, Toledo 
AC146905, FIX AC146907, TR AC146906, PH AC146904 and TB40/E EF999921) were 
used in the design all HCMV assays, but primer sequences were largely based on that of the 
reference strain AD 169, with exceptions and mismatches noted below. 
As very little HCMV genotyping had been done previously in Southern Africa, a conserved 
target, UL55 (gB), was chosen to allow detection of all known genotypes and any novel 
HCMV strains that might be unique to this region. For this qualitative assay, primer 
sequences were taken from a previously published Real Time PCR assay (Mattes et aI., 2005) 
and checked against an alignment of the eight published HCMV reference strains along with 
selected other human herpesviruses (Appendix C). These primers should broadly detect all 
HCMV strains but should not cross-react with other human herpesviruses which may be 
present in the clinical samples. The assay was highly sensitive with a cut off of 1 absolute 
copy (Figure 1) and was used as the primary qualitative screen for HCMV. Sensitivity 
anal ysis was undertaken against the reference strain AD 169 only, as the primer sequences 
relatively conserved across all reference strains: Reference strain Towne contained one 
mismatch against both the forward and reference primers. Reference strain FIX contained 3 
mismatches against the reverse primer (gB2) but a highly related strain, Toledo, contained just 
one mismatch against the gB2 primer (Appendix C). 
The first of the two hypervariable targets was UL73, which encodes the hypervariable 
glycoprotein gN. An alignment was constructed of the same eight reference strains detailed 
above, plus two additional strains (Can4 and CanlO) so that all seven UL73 genotypes were 
represented (Mattick et aI., 2004). Primers were then designed for broad detection across this 
hypervariable locus, with mismatches kept to a minimum (Appendix D). External forward 
primer U730F was identical across all published reference strains, and the reverse primer 
U730R had just one mismatch against reference strain Towne. The internal primer pair 
(U73F and L73R) has been previously used in our lab (Mattick et aI., 2004). U73F contains 
up to four mismatches, with the corresponding reverse primer L 73R having up to eight 
mismatches, with these clustered towards the 5' terminus of the primer. A second internal 
primer pair (gN-Up/gN-lw)(Pignatelli et aI., 2003a) contained two mismatches in the forward 
primer, one of which was in the 3' terminal position and may exclude detection of strains like 
PH (gN3b) and TR (gN3a). The reverse primer gNlw contained 1 mismatch against Toledo 
and Merlin reference strains but not on the 3' terminal nucleotide. Three nested assays were 
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most sensitive using U73F/L73F or gNUp/gNlw internal to U730F/U730R, or gNUp/gNlw 
internal to U73F/L73R, all with the same·cut off of 10 absolute copies (Figure 1). 
The second hypervariable HCMV target was UL 74 which encodes the hypervariable 
glycoprotein gO. An alignment was constructed of the eight reference strains as previously, 
plus three additional reference strains (DM7, SW475 and SW17l5) so that all eight UL74 
genotypes were represented (Appendix E). External primers (0010/0020) contained one 
mismatch against strain PH in the forward primer (0010), but none in the reverse primer 
(0020). The first internal primer pair (gOUp/gOlw) contained no mismatches in the forward 
primer (gOUp), but 4 in the reverse (gOlw). A further internal primer pair (001/002) was 
available which has been previously used in our lab (Mattick et aI., 2004; Paterson et aI., 
2002). The 001 primer contained up to 4 mismatches and the 002 primer up to 6 
mismatches. None of the mismatches were at the 3' terminal nucleotide. The most sensitive 
assays using these gO primers were two nested assays using gO-Up/gO-lw internal to 
001010020, or 001/G02 internal to gOUp/gOlw, both with a cut off of 1 absolute copy 
(Figure 1). 
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Absolute Copies Sensit ivity 
l07106105104103102101100-ve 
HCMV UL55 gBl/gB2 [ Assay ...... ~~-.---- -
G01/G02 [ - --
- --
GOlO/G020 [ 
HCMV UL74 [ Assays gOUp/gOlw 
GOlO/G020 [ (nest) gOUp/gOlw ....... ........, ....... ......,. .............. .-..----
--'--- ................ .....,....., .... 
gOUp/gOlw [ (nest) G01/G02 --------
--------
U730F/U730R [ .~ ~-. "- " . - --, 
---,- -----
U73F/L73R [ 
HCMV UL73 gNUp/gNlw [ - -
- -
Assays 
U730F/U730R [ (nest) U73F/L73R -------
-- --- ~ --- - - ---
U730F/U730R [ (nest) gNUp/gNlw 
U73F/L73R [ (nest) gNUp/gNlw 
H HV-6A U46F/U46R [ ------
------
HHV-6B U46F/U46R [ 
HHV-6A U47F/U47R [ ----
HHV-6B U47F/U47R [ 
HHV-6B U47F/U47R [ 
HHV-6A + HHV-6B (1 :1) U47F/U47R [ 
----
Figure 1: peR assay sensitivity 
IO-fold serial dilutions of plasmid controls containing peR products for the respective primer pairs including 
nested reactions. It is noted that sensitivity in clinical samples containing excess background genomic DNA may 
differ. The U47F/U47R primers were up to two logs less sensitive against HHV-68, than HHV-6A, and so this 
dilution series was repeated twice to confirm. The rationale for the use of di fferent PCR assays is explained in 
chapters 3 and 4 for HCMV and HHV-6 respectively. 
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TRL UL55(gB) UL74(gO) IRL IRL TRs 
[I =JIF1 ~==~-+-~~~I=[I =IF===[I =:::J HCMV (220 Kbp) 
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UL74 (1401 bp) 
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. ...... ---
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__ _ _ G020 gO-1w G02 
gN-1w L73R U730R 
DRL U46(gN) U47(gO) DRR 
• 
---G01 gO-Up G010 
D -+- D HHV-6 (160 Kbp) 
U~55bP) "OV IL U47 (1857 bp) 
========~e~e~e==============~· • 
---
U460F U46F U46Up 
335 ' 
---
U46Up U46F U460F --U470R U47R ---UGU47F U47F U470F 
Figure 2: Betaherpesvirus genomes and primer locations 
Relative genomic locations of all betaherpesvirus PCR targets and primers used in this thesis_ For legibility the 
genome and gene lengths in this figure are not to scale but gene lengths in base pairs are given in parentheses. 
For HCMV, both UL73 and UL74 gene lengths are taken from the laboratory adapted reference strain AD169. 
These HCMV loci are hypervariable however and other available reference strains have lengths as follows: 
UL 73 from MerlinlToledolTowne = 408/408/411 bp respectively. Correspondingly for UL 74: 
MerlinlToledolTowne = 14191139511374bp. There are two published reference genomes for HHV -6: The gene 
lengths for U46 and U47 in the figure refer to reference strain U 1102. For reference strain 229, U46 is equal in 
length, but U47 is considerably longer at 2217bp. PCR product sizes are given in Appendix A. 
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3.3 Prevalence of active HCMV infection 
The two retrospective cohorts comprised hospitalized febrile infants (whole blood) and HIV-l 
positive respiratory mortalities (lung tissue and blood) where detection of high load HCMV 
suggests likely involvement in pathology. Both these sample sets were extracted from blood 
and so they were screened with a low sensitivity PCR assay designed to detect only those 
infants with high load replicating virus, and not those with latent infections. This assay used 
the 001/002 primers, which target the hypervariable UL 74 gene (Figure 2), and had a 
sensitivity of 104 absolute copies (Figure 1). We employed this assay with a view to obtaining 
direct genotype data from the sequencing of PCR products. Using this assay, the prevalence 
of active HCMV infections was 10% in the hospitalized fever cohort but 94% within the 
respiratory mortalities cohort (10% (141141) vs 94% (34/36), P < O.OOI)(Table 6). Using this 
assay, sequencing of the resulting PCR products enabled detection of strain variation within 
the N-terminal hypervariable region of UL 74 (data presented in section 3.8). 
For screening the CIONIS cohort comprising DNA-extracted sera taken from healthy 
Zambian infants, a more sensitive assay was required, as preliminary data from use of the 
0011002 assay did not yield any positives. Furthermore, we considered the possibility that 
primers designed over such a variable region may not detect novel variants. Searching the 
literature identified an HCMV Real Time PCR assay that targets the highly conserved UL55 
(glycoprotein gB) gene (Mattes et al., 2005). We used their gBl/gB2 primers (Figure 2) for 
qualitative PCR and in our hands this assay was highly sensitive, detecting 1 absolute copy 
(Figure 1). This level of sensitivity was more appropriate for detecting active but likely much 
lower load infections in the sera of otherwise healthy infants. Of 812 infants successfully 
enrolled onto CIONIS, 518 were screened with the HCMV gB assay at month 6. Of the 
remaining 294 infants: 99 did not provide enough blood for a virology aliquot to be taken, 
112 are not yet screened and 83 were screened but negative control indicated contamination. 
A total of396 infants were screened at month 18. Of the remaining 416 infants, 161 had 
withdrawn, 12 died, 54 did not provide enough sera, 61 are yet to be screened, 42 were 
contaminated and 86 await updated records from Zambia. Work is ongoing to complete this 
dataset. The prevalence of active HCMV infections as determined by detection of viral DNA 
in sera was 40% at month 6 and 34% at month 18. All of these samples were taken only from 
healthy infants. Mothers presenting at the clinic with sick children were asked to return when 
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the child was well. On occasion samples were taken from febrile infants and so in addition to 
the 6 and 18 month 'healthy' samples, there was also a small set of23 samples taken from 
CIGNIS infants who presented with fever on an unscheduled visit to the clinic (6) <18 
months). HCMV sera-DNA prevalence was significantly higher in these "morbidity samples' 
(65% (15/23)), compared with either month 6 «200/518): P = 0.011) or month 18 «(133/396): 
P = 0.002)(Figure 3a). 
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3.4 Prevalence of active HCMV infection by infant HIV-l status 
Where HIV -1 data was available, prevalence of active HCMV infections was compared 
between HIV -1 negative and positive infants (Table 6). In CIGNIS all infants completing the 
study are screened for HIV -1 by the standard WHO three-test protocol at 18 months of age. 
Of 178 infants with unknown HIV -1 status, 157 withdrew, 11 died and 10 HIV -1 serology 
records are missing or were not done. In the hospitalized fever and respiratory mortalities 
cohorts, HIV -1 diagnosis was by PCR to detect proviral DNA. Among the hospitalized fevers 
33% (471141) of infants were found to be HIV-l positive but HCMV DNA prevalence did not 
differ significantly by infant HIV -1 status (Table 6). All 36 infants in the respiratory 
mortalities cohort were selected as HIV -1 positive and this was confirmed using the proviral 
DNA assay. For the CIGNIS infants 18 months HIV -1 serology was available for 411 infants 
screened for HCMV at 6 months of age, and all 396 infants screened for HCMV at 18 months 
of age (Table 5). Prevalence of active HCMV infection did not differ significantly by infant 
HIV -1 status in either the healthy infants or among the 23 infants with morbidity (Figure 3b). 
On the CIGNIS study the number of HIV -1 infected infants is understated as HIV -1 status 
was not known for any infants who withdrew from the study. 
Cohort ~. Age HIV-l uninfected HIV-l infected P Totals· 
CIGNIS (healthy infants) 6m 40% (156/392) 53%(10/19) .265 40% (200/518)t 1Bm 33% (128/383) 39% (5/13) .705 34% (133/396) 
CIGNIS (morbidity) 6-18m 62% (B/13) 100% (2/2) .524" 65% (15/23)t 
Table 5: HCMV sera-DNA prevalence USIng g8 assay In the CIGNIS cohort stratified by mrant HIV-t 
status 
Significance was by Pearson Chi Squared or Fishers exact test (") if there was an expected value < 5. *The totals 
column includes infants of unknown HIV - I status (*). ND = Not done, NA = Not applicable. Significance 
between totals was as follows: t P = 0.011 
Cohort Age HIV-1 uninfected HIV-l infected P Totals· 
Fever (blood, n=141) 6-34m 7% (7/94) 15% (7/47) .163 10% (14/141)* 
Respiratory (lung, n=36) 0-16yr NO 94% (34/36) NA 94% (34/36)* 
Table 6: HCMV sera-DNA prevalence usmg GOl/G02 primers in the Fever and Autopsy cohorts 
stratified by infant HlV-t 
Significance was by Pearson Chi Squared or Fishers exact test (") if there was an expected value < 5. *The totals 
column includes infants of unknown HIV - I status (*). ND = Not done, NA = Not applicable. Significance 
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Figure 3: Prevalence of active HCMV infections was higher in samples from febrile infants 
Morbidity 
HCMV sera DNA prevalence at a) month 6, month 18, and in the small subset of samples from infants who 
presented with fever and donated an extra sera sample and b) sub-stratified by infant 18 month HIV -I status. 
Significance was by Pearson Chi Squared. 
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3.5 Prevalence of active HCMV infection by maternal HIV-l status 
In the population based study, CIGNIS, maternal HIV-1 serostatus was requested at 
recruitment. Of 812 mothers, 177 (22%) reported themselves as being HIV -1 positive, 564 
(70%) as HIV-1 negative and the remaining 71 (9%) either did not know their status or chose 
not to disclose it (Figure 4a). Infants were defined as either HIV-1 exposed (maternal HIV-1 
seropositive) or HIV -1 unexposed (maternal HIV -1 seronegative). The HIV -1 exposed 
grouping includes those with unknown HIV -1 status. We assessed prevalence of detectable 
HCMV sera-DNA in both HIV -1 exposed, and unexposed groups of Zambian infants (Table 
7). At 6 and 18 months, the prevalence ofHCMV sera-DNA was not significant different 
between HIV -1 exposed and HIV -1 unexposed infants (Table 7)(Figure 4b). These results 
show no link between the prevalence of detectable HCMV sera-DNA and HIV -1 exposure. 
Cohort Age HIV-1 unexposed HIV-1 exposed P Totals· 
CIGNIS (population 6 37% (132/359) 43%(41/96) .287 40% (200/518) 
study) 18 35% {95/274} 28% (22/78) .285 34% (133/396) 
CIGNIS (Morbidity) 6-18m 69% (9/13) 63% (5/8) 1.01\ 65% (15/23) 
Table 7: Prevalence of active HCMV infections IS unaffected by HIV-l exposure 
Significance was by Pearson Chi Squared or Fishers exact test (1\) if there was an expected value < 5. *The totals 
column includes subjects with mothers of unknown HIV -I status. 
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Month 6 Month 18 
Figure 4: Distribution of HIV-l status in mothers and infants plus prevalence of active HCMV was 
unaffected by HlV-t exposure 
a) Distribution of infants and their mothers on the CIGNIS study by HIV -1 status as determined by sera-antibody 
and b) prevalence of active HCMV infect ion determined by detection of HCMV sera-DNA, between HIV-I 
unexposed and HIV -1 exposed infants at 6 and 18 months. 
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3.6 HCMV and GAPDH Real Time Taqman PCR set up and qualitation 
Since detection by qualitative PCR of HCMV sera-DNA does not distinguish between normal 
primary infections that are immune controlled and severe infections with higher viral loads, a 
quantitative PCR assay was employed to investigate viral loads. The hypothesis was that 
infants with impaired immunity (either through HIV -1 infection or exposure) may be less able 
to control HCMV infections resulting in higher sera-DNA loads. We employed the Real Time 
Taqman PCR assay referred to in section 3.2 (Mattes et aI., 2005), using gBl/gB2 primers 
which target the highly conserved UL55 gene. A conserved target was essential for this assay 
as a Taqman probe might not bind consistently over variable sequence. As shown in appendix 
C, the g83 probe has just one mismatch with HCMV reference strains FIX and Toledo, but is 
otherwise identical in all HCMV strains known at the start of this thesis. Sensitivity of this 
assay was assessed using a plasmid standard of cloned gB 1 / gB2 PCR product form reference 
strain AD169. Plasmid copy number was measured and dilution series were prepared ranging 
from 2x 1 06 through to 2x 10-3 absolute copies/ill. 5 III of template from each dilution was then 
used giving a series from 107 through to 10-2 absolute copies. It was determined that standards 
with ~10 copies in 5111 of template were detectable in all 4 replicates (Figure 5a). Standards 
containing 1, 0.1 and 0.01 absolute copies were not detectable and so the cut off for the assay 
was defined as 10 absolute copies. In subsequent standard series, 1 absolute copy was 
sometimes detectable but not reproducibly so, likely due to Poisson error from making serial 
dilution series. For this reason, when analysing clinical samples with extremely low loads of 
the given target, detection may be intennittent. This same principal applies to the sensitivity 
and reproducibility of the qualitative PCR assays used in this study. 
Accuracy of the assay was then assessed by measuring the standard deviation of each standard 
across the quadruplicates for each dilution (Figure 5c). The Ct value standard deviation 
ranged between 0.22 and 0.64 (mean = 0.34), which corresponds to 95% confidence limits of 
between 17% and 56% either side of the mean. Ideally clinical samples should be measured 
multiple times (at least in triplicate) to get a more accurate measure of viral load. Due to the 
constraints on sample volumes available in the CIGNIS study, this was not possible. The cut 
off of 10 absolute copies corresponded to a sera-DNA load of 500 copies/ml sera. With many 
CIGNIS samples being only borderline detectable we grouped samples either side of a 1000 
copies/ml, a level which has been previously associated with pathology (Li et aI., 2003; 
Mattes et aI., 2005). 
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A B C 
Copies Mean Ct Standard 
Deviation 
10000000 18.065 0.22 
1000000 21.158 0.32 
100000 24.615 0.48 
10000 27.755 0.24 
1000 31.460 0.28 
100 34.643 0.23 

















10 0 101 10 2 10 3 10· 10 5 106 10 7 108 
Absolute copies 
D E F 
Copies* 95% confidence limitst 
9368308 8015167 10949889 
1094820 874574 1370532 
99308 71393 138139 
11229 9538 13220 
858 707 1040 
94 80 111 
11 7 17 
Figure 5: HCMV Real Time Taqman PCR assay sensitivity and accuracy 
Qualitation of HCMV Real Time Taqman assay showing a) amplification plots of replicate standards from 107 
copies down to 101 copies (left to right) and b) the resulting standard curve generated from mean Ct values for 
each dilution with bars indicating one standard deviation. The best-fit linear regression line (r2 = 0.999; slope = -
3.317) is shown as a dashed line. Standards were constructed from a plasmid containing cloned PCR product 
using primers gB I and gB2 (Appendix A). *Linear regression of column A vs column B gives a Y intercept of 
41.19 and a slope of -3 .317 so the calculated absolute copies from the mean Ct values is given by I O«column B-
4L19Y-33 17l . t calculated by adding or subtracting 1.96 standard deviations to the mean Ct value and then re-
calculating copy number using same equation. 
A consideration when measuring HCMV sera-DNA with quantitative PCR is the possibility 
of significant levels of cell breakage occurring during sample handling leading to leakage of 
intracellular/latent viral genomes that might artificially inflate the detectable sera-DNA viral 
load. To control against this we used Real Time Taqman assay to quantify human genomic 
DNA, targeting the GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) housekeeping 
gene (Asahi-Ozaki et aI. , 2006), to measure how many host cellular genome equivalents were 
present in the sera and from this calculate breakage. Compared with the HCMV Real Time 
Taqman assay, sensitivity was one log lower, with no detection observed in replicate dilutions 
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containing 10 absolute copies and a mean standard deviation across all dilutions of 0.79, 
making the accuracy of the GAPDH assay half that of the HCMV assay (compare error bars 
on Figure 5b and Figure 6a). Using the GAPDH assay, preliminary analysis ofa subset of 
CIGNIS sera samples from both month 6 and month18, demonstrated a median level of25570 
genome equivalents/m I of sera. When looking across both time points this corresponded to 
minimal levels of cell breakage, with over 82% (76/93) of samples analysed, having 
undergone less than 1 % breakage during sample spinning and aliquoting (Figure 6b). This 
assay was also used when analysing whole blood from the hospitalized fever cohort and lung 
tissue from the respiratory mortalities cohort, to normalise their HCMV and HHV -6 viral 
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Figure 6: GAPDH Real Time Taqman peR assay sensitivity and accuracy 
Qualitation ofGAPDH Real Time Taqman assay showing a) a standard curve of mean Ct values from replicate 
10-fold serial dilutions with error bars indicating one standard deviation. The best-fit linear regression line (r2 = 
0.999; slope = -3.515) is shown as a dashed line. Standards were constructed from a plasmid containing cloned 
PCR product using primers GAPup and GAPdown primers (Appendix A), and b) levels of human cellular DNA 
detected in CIGNIS sera. Solid lines indicate median loads whilst the dotted lines indicate calculated levels for I, 
10 and 100% cell breakage based on I ml of sera being derived from roughly 2mls of blood, which would contain 
approximately 107 cells. 
3.7 CIGNIS HCMV DNA loads by HIV-l status 
In the CIGNIS study, samples found to be positive by the first round qualitative screen for 
HCMV, were then analysed further using a Taqman Real Time PCR assay. HCMV sera-DNA 
was detected in 200 month 6 and 133 month 18 samples (section 3.2), of which 178 and 133 
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respectively were screened by the HCMV Real Time PCR assay to determine viral load. In 
the CIGNIS study, 92% of both month 6 and month 18 samples had HCMV viral loads of 
<1000 copies/ml sera. Here, detection of high load HCMV sera-DNA (> 1000 copies/ml sera -
associated with pathology in other studies (Li et aI. , 2003; Mattes et aI. , 2005)) is compared 
with both HIV -1 infection and exposure. As previously, the HIV -I exposed group includes 
both HIV-I negative and unknown infants, born to HIV-I positive mothers. When stratifying 
by HIV-l exposure, detection of high load HCMV sera-DNA was significantly associated 
with HIV-l exposed infants at baseline (2% (8/346) vs 7% (6/89), P = 0.046)(Table 8 and 
Figure 7). By month 18 this was no longer significant but analyses may be complicated as it 
only included those infants who had completed the study. 
Cohort Age HIV-l unlnfected HIV-llnfected P Totals· 
CIGNIS (population 6 3% (11/371) 0% (0/19) 1.0" 3% (14/495) t 
study) 18 3% (10/362) 0% (0/12) 1.0" 3% (10/375) * 
CIGNIS (Morbidity) 6-18m 39% (5/13) 50% (1/2) 1.0" 43% (9/21)t * 
HIV-l unexposed HIV-l exposed 
ClGNIS (population 6 2% (8/346) 7% (6/89) .046/\ 3% (14/495) 
study) 18 3% (7/257) 0% (0/75) .356" 3% (10/375) 
CIGNIS (Morbidity) 6-18m 39% (5/13) 38% (3/8) 1.0" 43% (9/21) 
Table 8: High load HCMV (>1000 coples/ml sera) was more prevalent m HIV-) exposed mfants 
Significance was by Pearson Chi Squared (t, :j: P < 0.001) or Fishers exact test (" ). "'The totals column includes 
subjects with unknown H IV -I infection or exposure status. 
The CIGNIS morbidity samples, along with having a higher prevalence ofHCMV (Figure 
3a), also had higher prevalence of high load HCMV when compared with either month 6 
(43% (9/21) vs 3% (14/495); P < 0.001) or month 18 (43% (9/21) vs 3% (10/375); P < 
0.00 I )(Table 8) although median viral loads did not differ significantly (Figure 8). Only 
healthy infants were sampled at months 6 and 18, and so the minority of infants who had high 
load HCMV likely had residual viraemia post active infection and were not perceived by the 
mother or study clinician to be unwell. In the morbidity samples, the prevalence of high load 
infections between HIV -1 exposed and un-exposed infants did not differ significantly (Table 
8 and Figure 7). 
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D HIV-1 unexposed 
.HIV-1 exposed 
P = 0.046 
,------, 
(5/13) (3/8) 
Month 6 Month 18 Morbidity 
Figure 7: High load HCMV at month 6 is 3 times as prevalent among HIV-1 exposed infants 
Prevalence of high load (>\000 copies/ml sera) HCMV infections by maternal HIV-I status. No month 18 high 
load HCMV infections were detected in HIV -I exposed infants. Significance is by Fishers exact test. 
3.8 HCMV DNA loads in CIGNIS morbidity, hospitalized fever and 
respiratory mortalities cohorts 
Direct comparisons between the population-based study (CIGNIS) and two retrospective 
cohorts were not always possible, as whilst all CIGNIS samples were DNA-extracted sera, the 
hospitalized fever samples were DNA-extracted whole blood and the respiratory mortalities 
samples were DNA-extracted lung tissue (mixed with blood). Using some estimates to control 
for volume differences some initial comparisons were made. As one volume of sera is 
generally spun from two volumes of blood, CIGNIS and hospitalized fever cohorts were 
compared using copies/ml sera or 0.5 times copies/ml blood respectively (Figure 8). The 
median HCMV load in the morbidity samples (non-hospitalized febrile infants) was 
significantly lower (2 logs) than in the hospitalized fever cohort (1283 copies/ml sera vs 
154253 copies/ml sera «Y2 the load measured in one ml of blood), which were collected from 
hospitalized febrile infants (Figure 8). The detection of higher loads in blood than in sera 
could be due to the detection of latent HCMV genomes as well as cell-free virus, but could 
also represent higher levels of replicating HCMV in these infants with hospitalized fever 
compared with febrile children who were not hospitalized. 
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Figure 8: High load HCMV prevalence between cohorts 
Distribution of HCMV high loads (> I 000 copies/m I) within CIGNIS month 6, month 18 and morbidity samples, 
as well as those from the hospitalized febrile infant cohort. As these hospitalized fever samples were DNA-
extracted whole blood (and CIGNIS samples were sera), hospitalized fever loads were halved as one volume of 
sera is derived from roughly two volumes of blood. Significance is by Fishers exact test. 
10· P < 0.001 
.!1 i • 
c 10' Cl) 
n; 
.~ 107 
== • i10 
•• Cl) ••• e 105 ~ ••• 
0 •• 
; 10 • C) • 
~ 10 3 •• 
-
• 
-Cl) 10 •• Cl) ••• 




Figure 9: HCMV loads in hospitalized fever and respiratory mortalities cohorts 
HCMV loads/l06 genome equivalents. 5111 of sample was assayed with a Real Time Taqman PCR assay 
targeting the HCMV UL55 gene and then also assayed with a second Real Time Taqman assay for the 
endogenous GAPDH gene. Lines represent median values with the significance between them measured by 
Fishers exact test. 
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The respiratory mortality samples comprised DNA-extracted lung tissue mixed with blood, 
and were all from HIV-I positive children (aged 0-16yrs) who died of respiratory disease. 
HCMV loads in this cohort were compared to those from the hospitalized fever cohort 
through normalization to cell number. The Real Time Taqman PCR assay for the endogenous 
GAPDH gene was used to measure the number of genome equivalents in each sample. 
HCMV load results are hence given as a ratio of HCMV copiesll 06 genome equivalents 
(Figure 9) (Griscelli et aI., 200 I). Overall the hospitalized fever samples clustered more 
tightly, and had a significantly higher median load of 8.06x 1 05 copies/l 06 genome equivalents 
(P < 0.001). Levels ofHCMV and GAPDH gave a much broader range of values up to 108 
copies/l 06 genome equivalents reflecting differences of viral loads within lung tissue as well 
as blood inflitration. HCMV loads were detected in both cohorts at levels consistent with 
active infection (Li et aI., 2003; Mattes et aI., 2005). 
3.9 HCMV genotype analysis 
Having identified HCMV in this paediatric population in an HIV -I endemic area, the next 
question was whether the same or different strains exist in Zambia compared with elsewhere. 
To answer this, the hypervariable linked genes UL 73 (glycoprotein gN) and UL 74 
(glycoprotein gO) were investigated. Samples from all three cohorts, found to be positive for 
HCMV through the primary screen, were subsequently analysed by PCR assays targeting the 
-0.45 Kb hypervariable N-terminal region of the 1.4 Kb UL74 gene, along with the entire 
-0.42 Kb of the smaller neighbouring UL 73 gene. Sequence data was most readily obtained 
from the two symptomatic cohorts due to higher viral DNA loads. All sequences were 
confirmed in both forward and reverse directions with selected novel sequences confirmed 
using a high fidelity thermal polymerase. 
3.9.1 HCMV UL 74 sequence alignment 
A nested PCR assay (GO 1 O-gOUp-gOlw-G020)(Figure 2) was used to amplify and 
sequence the N-terminal hypervariable region of the UL74 gene in all samples HCMV DNA 
positive from initial screens. Although the first round reaction was less sensitive, re-
constructions suggested the nested assays should be as sensitive as the primary screen (Figure 
1). In practice however, this was not the case, with genotypes being primarily detected in the 
respiratory mortalities and hospitalized fever cohorts where loads were higher. Of 396 HCMV 
DNA positive samples, a total of 56 UL 74 sequences were determined: 44 from the 
73 
respiratory mortality samples, 8 from the hospitalized fever samples and 4 from the CIGNIS 
samples. Alignments of the UL 74 sequences were constructed with 8 reference strains 
representing the eight established HCMV gO genotypes, with data from this study being 
grouped accordingly (Figure 10). Results show that the majority of sequences belonged to the 
gOIb (32% - 18/56) and g03 (18% - 10/57) groups, but with representatives of all eight 
genotypes being detected. Interestingly, all g05 sequences identified from Zambia, contained 
a 2 base pair N-terminal deletion, taking the accepted start methionine out of frame, 
suggesting leaky transcription and internal initiation on the first downstream methionine, 

































.•••• - .•.•...•••••.•••..... L ...•..... - ..... -- •••.•....••...•.....••.•...•...•. ---- ••••••••........•.....••....•.......•..•.........•••.•.••......••...•.•.•. 
...•. - ..•..••••.....•.•..•. L •........ - •...• -- •..•.....•....•..•.....•..•...... ---- ••...••...........••..•......•.........••.•••.••••••••..•......•.... . .•.. ' . 
..••. - •..•...•••••••••••.•• L ..•...•.. - •••.• -- ..• • •.•.••••.••••••.•.•••.••••••• ---- ............•........•.......•••...•.................................•.... 
· .... - ..•...•.•.•.••..••••• L •.•••••.• - •••.• -- •••••••.••••••••.•••••••.••••..•• ---- •••.••••.••.••••••••.•••.•..•••••••• , ••.•.••....•. , •.•.•••••.•••••• • •..••••. 
. ' •••• - •••••••• ' ••••••••••••• L ••••••••• - ••••• -- ••••••••••••• • • R ••••••••••••••••• ---- •••••••••••••••••.••••••••.•••.•.••••••••••••••••••••••••.••••••.•• • ••••• • 
•••• D- ••••••••• ~ ••••••••••• L ••••••••• - ••••• -- ••••••••••••••••••••••••••••••• • • ---- ••••••••••••••••••• H • • ••••••••• • ••••••••••••••••••••• ; •••.•••••••••••••••• 
• •••• - ••••••••••••••••••••• L ••••••••• - ••••• -- ••••••••••••••••••••••••• • ••••••• ---- •••••••• • ' ,' •• l: ••••••••• • • ', ' ••••••••••••••• • •••• ' , ' ••••••••••••••••••••••••• 











· .•• --GEl: . G. FNLF . . M . LT .. , F • •• .• RAAVRL-SVG . Y- - . S . K •.• T ••• QR • • KF •. • •• K .•• KO . Y •• • F--- . MTR . HI • . . • • •••• •. R •.•• •••• •. N. V .•.•.••• •• ..•• •••• • F. E •..•.••.••... S •. •• •. 
· •. • --GEl: . G . FNLF • . M . LT • •• F ••• •• RAAVRL- SVG . Y--. S . K .•• T ••• QR •• KF •.••• K •.• KD . Y .•• F---. MTR . HI • . . •••• • • •• R ••.• • , .• .. N. V . ... . •..•.•.••. ••• • F.E •.. •• .•.•••.• 5 •. • ••. 
· ••• - -GEl: .G . FNLF • . M . LT •.• F •.• • • RAAVRL-SVG. Y- -. S .K ••• T ••• QR •• KF •.• • • K •• • KD . Y •• • F-- - .MTR.HI •• ••.••••• • R ••.••••••. N . V ••••.••.•.••••••••• F . E • •••• •• . • •••. S •••••. 
•• •• - -GEl: .G . FNLF .• M . LT •.• F •••.• RAAVRL-SVG. Y--. S . K ••• T •.• QR •. KF ••• • • K •. • KO . Y •• • F- - - . MTR . HI • . ••••••••• R •••••• •• •. N . V ••.••••• • . • .••. • • • • F . E • •••• •••• . • .• S •••••• 
. •• . --GEl: . G . FNLF • • M.LT •• • F ..••• RAAVRL-SVG. Y- -. S . K ••• T ••• QR .. KF •. •• • K • • • KD . Y • • • F- -- . MTR .HI • • •••••.••• R •••••.• • .• N . V •••.•••••.•.•• . •••. F. E •. . . •••.•.. •. 5 ••. .. . 
· .•. - -GEl: .G . FNL F •. M. LT • •• F ... • • RAAVRL-5VG . Y--. S . K .•• T .•. QR •. KF •...• K ..• KO . Y • •• F--- . MTR .HI ••••• • .•••• R •• • ••• • .. • N . V •.••••. • • ••• • ••• .•. F . E •••.••• .• ... • S •••.•• 
• ..• - -GEl: .G. FNLF •• M . LT ••• F ••••• RAAVRL-SVG . Y--. S . K ••• T ••• QR •• KF •.••. K ..• KO. Y . .• F--- . MTR .HI ••••• •• • • •• R • •• •••••. • N . V •.••••.•• •• •••••..• F . E •••. •••. •.. •• S • • .•.• 
• . • . - - GEl. G. FNLF •• M. LT .•• F •••• • RAAVRL - SVG . Y- -. S . K ••• T •• • QR •. KF • •• • • K ••• KD . Y .• • F-- - . MTR .HI • ••••••..•• R • •• .•.•••. N . V •.••• • • • .. . .• •. • • • • F . E • • •• • •• .• ... • 5 ••...• 
• . • . --GEl . G . FNLF •• M. LT ••• F .•••• RAAVRL-5VG . Y--. S . K ••• T ••• QR •• KF •• ••• K •.• KO . Y .• • F--- .MTR .HI ••••.••.••• R .••.• •• ••• N . V •••••••••. • .••• • .. • F .E • . •. • • • .•..• • S • •..• • 
•••• - -GEl .G . FNLF •• M. LT •• • F •• •• • RAAVRL- 5VG. Y--. S . K ••• T ••• QR •• KF • •• • • K •• • KO. Y .• • F---. MTR .HI •• ••.••.••• R • .. . ..... . N . V . ••• • • •••...••.••• • F .E • .• • • ••. • •.. • 5 •••..• 
• •.. - - GEl .G. FNL F •• M. LT ••• F .•••• RAAVRL- SVG. Y- - . S . K ••. T ••• QR •• KF •• • •• K ••• KD . Y ••. F- -- . MTR .HI ••••••••..• R ••.•...••. N . V ••••••••.•...•.•• • . F .E •.. ••••.• ..•• S • ••••• 
• • •• --GEM . G. FNLF •• MTLT • •• F ••••• RAAVRL-SVG. Y--. S . K ••• T ••• QR •• KF •••• • K ••• KO . Y • •• F--- . MTR. HI • • ••. .• ••• • R ••• •• ••.•• N . V •• • •••••.••• • • • ••. • F .E • .• •.•.•• • ••• S •••••• 
• •• • - -GEM . G. FNLF •. MT LT ••• F .•.•• RAAVRL- SVG. Y--. S . K ••. T .•• QR •• KF •••• . K • • • KO . Y ••• F- - - . MTR .HI .• • ••.•.• " R •••• • • •• •. N . V ••••.•••.••..••... . F . E •. • • .•.•••••• 5 .•••• • 
• ... --GEM . G . FNLF .. MT LT ..• F . •• •• RAAVRL - SVG . Y-- . 5 . K • • . T ••. QR •• KF ••••. K ••• KD . Y • •• F--- . MTR . HI •. •••• •• • . • R ••••.. •• •• N . V ••.••••• •• ••• • • • •.. F . E • .••. • • • •• • • • 5 .••.•• 
· • . • --GEM . G. FNLF •• MT LT ••• F ••• • • RAAVRL-SVG . Y-- . S . K •• . T ••• QR •• KF ••.•. K ••• KO . Y ••• F-- - . MTR .H I • ••••. • ••. • R ••... • •.•• N . V . . . . . . . . .• • • . . • ••.• F . E .. • ••••.•••. • 5 • • •.•• 
· . .• --GEM . G . FNLF •• MT LT •• . F ••••• RAAVRL-5VG. Y- - .S .K .•. T •.• QR •• KF ••.•. K •.• KO . Y • •• F--- . MTR . HI •• •. •.•.• . • R ••• " • .•.• N. V •• • ••• • •••.••• •• • . • F .E ..•• ••• .... . . S •. •• .• 
• •.• --GEM . G. FNLF • • MT LT ••• F • •••• RAAVRL- SVG. Y- - . S . K ... T ••• QR •• KF ••.•. K ••• KO . Y •. • F---. MTR. HI •• .•• . •. • . • R ••..• • •.•. N . V •• . ••••..•. •• . • ••.• F . E ••••. • ••.•• .• S ••• . .• 
• •. • - -GEM . G . FNLF •• MT LT ••• F ••••• RAAVRL- SVG. Y--. S . K ••• T •.• QR • • KF .•••. K ••• KO. Y • • • F--- . MTR .HI •.•••.•. •• • R •••. • . •• •. N . V .•..•• • . • •.. • . • .•.• F .E •.••.•.•... . . S ....• • 
gOle .... --GOM. SIS .LF. I •• LTV •• F. I ••••• VR---PPG. Y--. L. T ••• T ••• Q ••• KF ••••• K ... REPY ••• F--- .MTR.H ••••••••• Q ••••••••••• R. O ••••••••••••••• .--: ••••••••• .- :-:-: . -: ••• • • S •••••• 
• ••• --GOM. SIS .LF . I •• LTV •• F. I ••••• VR---PPG. Y-- .L. T ••• T ••• Q ••• KF ••••• K ••• REPY ••• F--- .MTR.H • • ••••••• Q ••••••••••• R.D ••••••••••••••••••••••••••••••••••••• S •••••• 
• ••• --GDM. SIS .LF. I •• LTV •• F. I •• • •• VR---PPG. Y--. L. T ••• T ••• Q ••• KF ••••• K ••• REPY ••• F--- .MTR.H ••••••• • • Q ••••••••••• R. 0 .••. " •••..... ' .' ............•....••.• S •••••• 
· WG. G--EM . G. - NLL ••• WLT ••• FF ••••. GARSQRAPF • • - ----RIWHPTVLK •• K ••••••••• •• --PIPYIKYPQINTTRVQS - •. V •••••. Y .•.••..• R . E . V . H • • Y ••• • •• . •....•••• M • •••• RK .•. K . . S • • A • •• 
• WG. G--EM. G . - NLL •• • WLT •• • FF • • • •• GARSQRAPF. . -----RIWHPTVL K •• K •• • •••••••• --PI PYIKYPQINTTRVQS- •• V .••.• • Y •.. • ••.. R. E. V . H •• Y •••• • •.• •• •••••• M ••• • • RK ••• K •• 5 •• A •• • 
• .•. G--EM . G . -NLL • •. WLT ••• FF. ••.. SARSQRAPF • • - - - - - RIWHPTVLK . • K ••••••••••• --PIPYIKYPQINTTRVQS- • • V • ••.•• Y ••.•.••• R . E . V . H •• Y . • •... F .... . . • .. 1. . . .. RK • •• K .• S • • A ••• 
• ••• G--EM. G. - NLL ••. WLT ••• FF ••••• SARSQRAPF • • - - ---RIWHPTVLK •• K •••••••• ••• --PIPYIKYPQINTTRVQS - •• V . .• .. . Y . • •••••• R . E. V . H • • Y •••.•• F .. • •.. • .• 1. . . .. RK •• • K .• 5 •• A • • • 
g02b .. K.K-IL •• G •• RIFMVS--T ••• IFL •••• GALNV-PRG •• --.I.K.P.LKW.L.EQ ••• I.~ .K •• QSO.Y ••• P---QIT~ NYTQFI.TELKK •• L ••••• • •• R.E.V.H ••••••••••••••••••• M •• Q •• QK ••• • ••••••••• 
• .K.K-IL •• G •• RIFMVS--T ••• IFL •••• GALNV-PRG •• - - .1. K . P .LKW .L.EQB •• 1. •• K •• QSO. Y ••• P---QIT • NYTQF1. TEL1<K •• L •• • •• • •• R.E. V .H ••••••••••• , ••••••• M •• Q •• QK ••••••••••••• 
•• K.K-IL •• G •• RIFMVS--T ••• IFL •••• GALNV-PRG • • --.I.K.P.LKW.L.EQE •• I ••• K •• QSO.Y ••• P---QIT.NYTQFI.TELKK •• L •••• • ••• R.E.V.H ••••• •• .• • •• • •••••• M •• Q •• QK ••••••••••••• 
• .K. K-IL •• G •• RIFMVS--T ••• IFL •••• GALNV-PRG •• --. 1. K. P .LKW .L.EQE •• 1. •• K •• QSO. Y ••• P---QIT • NYTQF1. TELKK •• L •••••••• R.E. V . H ••••••••••••••• ' •••• M • • Q •• QK ••••• 0 •••••••• 
•• K.K-IL •• G •• RIFMVS--T ••• IFL •••• GALNV-PRG •• -- . I.K.P.LKW.L.EQB •• I ••• K •• QSO.Y ••• P---QIT.NYTQFI.TELKK •• L •••••••• R.E.V.H ••••••••••••••••••• M •• Q •• QK ••••••••••••• 
• ~ K.E-IL •• G.FRIFMVY--T ••• IFL •••• GALNV-PQG •• --. 1.K. P .LKW. L.EQ ••• 1. •• K •• QSO. Y ••• P---QIT • NYTQF1. TELKK •• L •••••••• R.E. V .H •••••••••••••• ~ •••• M •• Q •• QK ••• : ••••••••• 


























· ... G- -EM. G. FNLL .... LT . •• F . LL .•. ---S .ARVF. LPFPY . R ••.• N. RLAEIKW . Q. L. K . IG-ASQDY . KFFT IPT .. GLN-AVVT . ER .. DN .... ..... D .• •• M • .••• •. •• •....... . E •• Q . GRKMR .... S •.... • 
· . . . G--EM. G. FNLL •... LT ... F . LL ... ---S .ARVF .LPFPY .R .... N. RLAEIKW . Q . L . K . IG-ASQDY . KFFTIPT .• GLN- AVVT . ER . • DN .•••...•• D .• •. M •.•........ . .• •• .. E . • Q. GRKMR .... S .... •. 
· ... G--EM. G. FNLL . . .. LT . . . F . LL ... ---S . ARVF. LPFPY. R •.•. N. RLAEIKW . Q . L . K . IG-ASQDY . KFFTIPT .. GLN - AVVT. ER . . DN ..•.....• D . ... M •••••••••••••• •••• E •• Q . GRKMR •••. S ..... . 
· .•. G--EM . G . FNLL • ..• LT •.• F. LL .• . - --S . ARVF . LPFPY . R .... N. RLAEIKW . Q . L . K . IG-ASQDY. KFFTIPT • . GLN-AVVT . ER .. DN . ........ D .. .. M . ...•.... . .•.• .. •. E .. Q . GRKMR ... . S ..... . 
· ..• G--EM . G . FNLL . ..• LT •. . F. LL . . . - --5 .ARVF. LPFPY . R • .•. N. RLAEIKW . Q . L . K . IG - ASQDY. KFFTIPT . . GLN-AVVT. ER •• DN . ........ D .... M .. •.. .... ...•. .... E .. Q. GRKMR .... 5 ..... . 
· ... G--EM . G. FNLL . . .. LT ..• F. LL .•• ---S . ARVF . LPFPY. R .... N. RLAEIKW . Q. L . K . IG-ASQDY . KFFTIPT •. GLN-AVVT . ER .. DN ... ...•.• D .• .. M . .•. .... . ..... .... E . . Q. GRKMR . . .. 5 ..... . 
· ••• G--EM . G . FNLL ... . LT •.• F . LL .•. ---S . ARVF. LPFPY. R .. .. N. RLAEIKW . Q . L. K. IG - ASQDY . KFFTIPT •• GLN-AVVT . ER .. DN . • . ....•• D . ... M ............. •• ••. E •• Q . GRKMR ...• S .. ... . 
· . .. G--EM . G. FNLL .... LT ... F . LL . .. - --S . ARVF . LPFPY . R .... N. RLAEIKW . Q . L . K. IG-ASQDY . KFFTIPT .. GLN-AVVT . ER .. DN .. ... ... . D ... . M . . . . .. .. ... . ...... E .. Q . GRKMR .... 5 ... . . . 
· . .. G--EM. G . FNLL • . .. LT ... F . LL . . . ---S . ARVF. LPFPY . R .... N. RLAEIKW . Q . L. K. IG-ASQDY . KFFTIPT . • GLN-AVVT. ER •• DN . •••. ..• • D .... M . . ...... • . . .... ... E .. Q. GRKMR . .. . S ..... . 
· ... G--EM.G . FNLL •. • . LT . .. F . LL ... ---S .ARVF. LPFPY . R . . .. N. RLAEIKW . Q. L. K. IG-ASQDY . KFFTIPT .. GLN - AVVT . ER •• DN ......... D .... M ... .• . ....... • .... E •. Q. GRKMR .. .. S .. .. •. 
· ... G--EM.G . FNLL . ... LT . . . F . LL .• . ---S . ARVF . LPFPY . R .... N. RLAEIKW . Q. L. K. IG-ASQDY . KFFTIPT .. GLN -AVVT. ER •• DN .•. .....• D .... M ........... .••. .. . E .. Q. GRKMR .. . • S .• .. •. 
•••• G--EM.G.FNLF •• M.LT ••• F •••••• ---ITVARF.-------.K.QKA.EEER •• ~R •• QE.ASKTGDY.KFFTFP.Q.KLY.I.VE.KQ •• PNS •• • ••• R.H ••• H • ••• • HT •••••••• • ••• E •••• GQK ••• ••• S ••• I • • 
•• •• G--EM.G. FNLF •• M.LT ••• F . ••••• --- I AVARF. -------. K.QKA. EEER •••• R •• QE.A5KTGDY. KFFTFP .Q. KLY . I. VE.KQ •• PNS •••••• R.H • •• H ••••• HT • •••• •• ••••• E •••• GQK •••••• S ••• I. • 
•••• G--EM . G.FNLF •• M.LT ••• F •••••• ---IAVARF.-------.K.QKA.EEER •• • • R •• QE . ASKTGDY.KFFTFP.Q.KLY.I.VE.KQ •• PNS •••••• R.H ••• H ••••• HT •••••••••••• E • ••• GQK •• •• •• S ••• I •• 
••.• G--EM.G.FNLF • • M.LT •.• F •••••• ---IAVARF.----- --.K.QKA .EEER •••• R • • QE.ASKTGDY.KFFTFP.Q.KLY.I.VE.KQ •• PNS •• • ••• R.H • • • H ••••• HT •••• • ••• •••• E •••• GQK •••••• S ••• I •• 
~ ••• G--E~.FNLF •• M.LT ••• F •••••• ---IAVARF.---- - - ~ .K.QKA.EEER •••• R •• QE.~KTGDY.KFFTFP.Q.KLY.I.VE.KQ •• PNS ••••• • R.H ••• H ••••• HT •• • ~ ••••••• • E •••• GQK •••• H.S ••• I •• 
· . K .• MI. . KGl. . IML . ••. T . . • L . L . . • N. LVNSRGTR. S- - . PYT ••• YR •• El. KKQ . ED •• KR . MS. S . DG . RFLMYP. Q. KFHAIVIS . DK ... D .. •. ... R. D ..• HM . .• . ••. .. •• .....•. E . • .. . HK .. L ... . .... . . 
MI. . KGI. . IML .... T ... L. L ..• N . LVN5RGTR. S--. PYT ••• YR • . El. KKQ. ED . • KR.MS. S . DG. RFLMYP. Q. KFHAIVIS. DK ... D . . •. ... R. D ... HM . . . .••. ... •.• ..... E .. . .. HK .. L . .... ... . . 
Ml. . KGl. • IML .. •• T •.• L. L ..• N. LVNSRGTR. S--. PYT •.. YR .. El. KKQ . ED •• KR .MS. S . DG . RFLMYP . Q . KFHAIVIS . DK ... D .... •.• R . D . . • HM • . • . • . .•. ....... .. E .. ... HK . . L . . ... . ... . 
MI .. KGI •• IML .•.• T • .• L. L .. • N. LVNSRGTR . S- -. PYT ... YR .. El. KKQ. ED •• KR . MS. S . DG. RFLMYP . Q. KFHAIVI5 . DK ... D .. ••... R. D . •. HM •.••••.•.• .. .• .• •. E •. ... HK • . L ....••••• . 
MI •. KGI .. IML •. .. T ..• L . L ..• N . LVNSRGTR . S--. PYT •.. YR • . El . KKQ . ED .• KR . MS. S. DG . RFLMYP . Q . KFHAIVIS . DK .•. D . ..... . R. D ... HM ........... .• . . ... E . •• .. HK .. L ........• • 
MI •. KGl. . IML .• .. T ... L . L ... N . LVNSRGTR . S- -. PYT • . . YR .. El. KKQ . ED . • KR.MS. S. DG. RFLMYP . Q . KFHA I VI S. DK • .. D ..• • ... R. D . .. HM ...•...... ..•••• .. E • . . .. HK .. L ..... . .. • • 
MI .. KGI •. IML .... T . • . L.L .•. N . LVNSRGTR . S--. PYT ••. YR .. EI.KKQ.ED .. KR . MS . S . DG . RFLMYP . Q . KFHAIVIS.DK ••. D • . •• ... R. D . .. HM .. . . • . .• . ••. ...... E .. •• . HK . . L . ........ • 
MI .. KGl. • IML ... . T ... L . L . . . N. LVNSRGTR . S --. PYT ••• YR •• El. KKQ . ED .. KR . MS. S . DG. RFLMYP . Q . KFHAIVIS . DK ... D . ...... R . D ... HM ...•... . . ...••. ... E •• ... HK .• L .. ..... ..• 
Figure 10: HCMV UL 74 alignment 
N-terminal amino acid ClustalW alignment of all HCMV gO (UL 74) sequences in this study showing eight groups: N-terminal (residues 1-148 relative to AD 169) sequence for 8 reference strains with 
GenBank accession numbers (ADI 69-g01 a (NP _040008), TR-gOlb (ACI46906.1), Toledo-gOlc (AAN40079. I), PH-g02a (AC I46904) SW1715-g02b (AAN40066.1), SW475-g03(AAN40072.1), 
Towne-g04 (AAN40080. I) and Merlin-g05 (YP _08 I 522» along with 56 sequences obtained from the hospitalized fever (K), respiratory mortalities (N) and population-based (M6 or M 18 suffix) 
cohorts in this study. In the alignment, dots indicate identities relative to reference ADI69 sequence, whereas dashes indicate spaces inserted by ClustalW. Question marks indicate terminal regions that 







+2: W G K K R * * W * K A F L K L C S 
+3: 
>K141 
G E K R D D N G E R H S * N y A p 
DNA: ATGGGGAAAAAAGATGATAATGGTGAAAGGCATTCCTAAAATTATGCTCCT 
+ 1: ~ .•.. ~ .••.. ~ .... t\ .... R ..... Q ••••• l:l .•••• 0. ..•• f; •.. JL . ..I;l ••••• ? * N YAP 
+2: W G K K M I M V K GIP K I M L L 
+3: G E K R * * W * K A F L K L C S * 
Figure 11: Peptide alignment: strain K141 vs Merlin 
A 3 frame translation is shown flanking the initiation site in both Merlin reference strain and Zambian reference 
g05 genotype KI41. A 'GA' deletion (underlined) in Kl41-like sequences introduces a stop codon (~) into 
frame 1 (dashed line), suggesting internal initiation (solid line, KI41). 
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3.9.2 HCMV UL 73 sequence alignment 
A nested PCR assay (U730F-U73F-L 73R-U730R)(Figure 2) was used to amplify and 
sequence entire hypervariable UL 73 gene in all samples HCMV DNA positive from initial 
screens. Of 396 HCMV DNA positive samples, a total of 47 UL 73 sequences were 
determined: 28 from the respiratory mortality samples, 12 from the hospitalized fever samples 
and 6 from the CIGNIS samples. Alignments of the UL73 sequences were constructed with 7 
reference strains representing the seven established HCMV gN genotypes, with data from this 
study being grouped accordingly (Figure 12). The most prevalent genotype was gN3a (34% -
16/47) which is linked to gO 1 b, the most prevalent UL 7 4 genotype. The second most 
prevalent UL73 genotype was gNl (23% - 11147), although four ofthese sequences were 
from multiply infected samples and two from putative novel linkages (Table 10). The 
alignment of all available UL 73 sequences identified representative members of all 
established genotypes (Figure 12). Novel sequences were identified that group with the 
reference strain Merlin, which has previously been grouped with gN4c (Dolan et aI., 2004; 
Stanton et aI., 2005). Here analysis of multiple sequences similar to the Merlin gN identifies 
seven conserved amino acid substitutions (see XS in Figure 14) compared with the gN4c 
reference Toledo, defining a new gN genotype termed gN4d. These Merlin-like gN4d 
sequences are as divergent from gN4c as the other neighbouring genotype, gN4b, which is 
also defined by seven amino acid substitutions. This grouping was further confirmed by 
phylogenetic analysis (section 3.7). These new Merlin-like gN4d genotypes from Zambia 
were mainly from the respiratory mortalities cohort (Nlc, N12c, N1Sa, N24a, N29a, N30a 
and N36a) but there was also one from the hospitalized fever cohort (KI41). A second notable 








. ....................................................................... .. ............................................................................... .. .................... ... ............ .. ..................... ' 
- .................................................... ..... - .............................................................................................................. . ' ........................................... "" .. "" "" .................................... .. 
.................................................. .. .......................... .. .......................................................................... :. " ....................... . .... .. ............................................ .. ............ . " ... 
KIlO ••••• - •.•.•.••••••••••••• , .•••••••••• - ••••••••••••••.••..••..••.••• • •••.•.•••.•••••••.•••.•.••.••••••..••••.••..•.••••...••.• • .•.... . ..•••••.. 
K61 ..... - •••...........•...................•.•.....•..............•.••.••...••.....••..••••...• • .....•.•.....•.•...••......•..........••....... 
K190 - ••.......•••••••.•.•.•.••••.• - .••••. •. ....••.....•.•.....••...••..•......•....•.•.................•....... • ........ . ............•..... 
Kl37 •••.. - ..•.........•.••.••.•••••••.••.•••••••...••.•.••..••••••••••••••••••••.••.•.•.•••••..•••.••••.••..•.••••..•••.•••••.••••.. • •.•.•••.... 
NSa ••••• - •••••• • ••••••••••••••••••• • ••••••••••••••••.•..••.... • • • •••••••••••••••••••••••••••••.••••••••••••••••••••••••••••••••••••••••••••••• 
Nee ...•. - ...•.•.••..••......• . .... ~ ......... .•... : .•...••.•.•.•. • •.....•.........•...•...•.....•...•.•.•....•..••..•.•.. • ......•.......... . .... . . 
Nl7e ..••. - ••••• • •••• • ••.••••• • ••••••••..•... • •.•......•...•..••••..•••••..•....••.•.•••.•.•.•.•••• • • • .•..••••.•••...••. : ••.•. . •• • .•• • ••••••.•... 
































Continued. .. . 
• . CK . - ...... 11 .A. TG . • SS •.... •• S . . P-- . PS .... S. P •. SV ... T • .. . ... T •••• . R . . . . • . • . • . . • .. . • . . .• . .• • ... .. . •. . • .. . .. . . . . .•• • . . A 
· • CK . - ...... 11 . A . TG . • SS ..... .• P . . P--. PS .. . . S. P .. SV . .. T .. ... . . T . •... R . •• . • ••• • • • •••• •••• ••• •• ••••• ••• • ••• ••••• •• •••• •• : : : : : : : : : : : : : : : : : : : • : : : 
· . CK. - • •••.• 11 .A. TG .. SS •.. • ... P .. P-- . PS .... S . P .. SV . . • T . .... . . T ..... R .... • .................... .. . .••. .. .. . • . . ...... ' " " ..... . ... . .... " ... . . 
· .CK. - •.• .•. 11 . A . TG . . SS ...•... P . . P--. PS .... S. P .. SV .•• -- .•••.. T ..... R ... ' :': .......... . ..... • .. '..:...:..:...:.:..:...:...:." ... • . _. ~ ..••. . .. . .. . . . ... . .. .. .... . ... 
• •• K.-VI •• VF •••• A. G •••• S ••••••••• L. S •. S ••• • S •• •• T ... T- ••• MS •• S ••• T •• P •••••••••• K •• TH •••••••••.•• ', .' ••• ; ••••••• : •••• " • " •• • •••• • ••••••••••••• 
• •• K.-VI •• LF •••• A. G • • •• S ••••• • • • • L.S •• S •• • • S •••• T ••• T- ••• MS •• S ••• T •• P •••••••••• K •• TH •••••••••••• •• •••••••••••••• • ••• • " •••• •• •.... .• .••• 77?7 
• •• K. -VI •• LF •••• A.G •••• S • .••••••• L.S •• S •••• S •••• T ••• T- ••• MS •• S ••• T •• P •• " •••••• K •• TH ••••• " •••••••••• •• ••••••••••• " ••• " ••••••••••••••••••• 
• •• K. -VI •• LF •••• A.G •••• S •• ' ,' ••••• L.S •• S •••• S •••• T • • • T- • •• MS •• S ••• T •• P •••••• ; ••• K •• TH •••••••••• : ••••••••••••• • •••••••• " •••••• • •••••••••• • ••• 
• •• K.-VI •• LF • • •• A.G .••• S ••• • ••• • • L.S •• S •••• S •••• T ••• T- ••• MS •• S ••• T •• P •••••••••• K •• TH . ......... . . :~ ••••••••••••••••• • •• " ••••••••••••••••••••••• 
• •• K. -VI • • L F •••• A.G .••• S •.•.•••.. L .S •• S •••• S .••• T •.• T- ..• MS •• S ..• T . . P •••••••••• K •• TH ••••.•••• ' .••••••••.••••••• • •••••• " ••••••••••• • •••••••• • 
• •• K. -VI • • LF •••• A.G • ••• S •.••• , •.•.• L. S •• S •••• S .••• T ••• T- ••• MS •• S ••• T •• P •••••••••• K •• TH ........ .. , .•.••••••••••••••••••• 
• •• K . -VI •• LF •.•• A. G • ••• S •••••••• • L. S •. S .• • • S .• . . T • •• T- ••• MS •• S ••• T •• P •••••••••• K •• TH • • •••••••. . : ~ ••••••••••••••• • ••• : : : : : : : : : : : : : : : : : : : : : : : : : 
•• • K.-VI •• LF •••• A.G •••• S ••••••••• L.S •• S •••• S •••• T ••• T- ••• MS •• S ••• T •• P •••••••••• K •• TH ••••••.••• ' •••• ' . ' •.• ~ •.•••••••••••••••••••••• ' •••••••••••••• 
• •• T. -VI •• LF •••• A. G •••• S ••••••••• L. S •• S •••• S •••• T ••• T- •• • MS .• S • • • T •• P •••••• • ••• K •• TH •••••••••••••••• ' • .'. • • •• • • • • • • • • .,. ???? 
••• T.-VI. .LF •••• A.G •••• S ••••••••• L.S •• S •••• S •••• T ••• T- ••• MS •• S ••• T •• P •••••••••• K •• TH . . ............ ; • •• •.. • , . : ; .••••••••• • •• ::::::::::::::::::::: 1111 
• •• T. -VI •• LF •••• A.G •••• S ••••••••• L. S •• S •• • • S •••• T ••• T- ••• MS •• S ••• T •• P •••••••••• K •• TH •••••••••• ' .' •• , .~. , •••••••••••••••••••••••••••••••••••• 7??? 
• •• T. -VI •• LF •••• A.G •••• S ••••••••• L. S •• S •••• S •••• T ••• T- ••• MS •• S ••• T •• P ••.••••••• K •• TH •••••••••••••••• :: . ' .' ••••••••••••••••••••••••• • •••••••• 1 
• •• T . -VI •• LF •••• A.G •••• S ••••••••• L. S •• S ••• PS •••• T ••• T- ••• MS •• S ••• T • • P •••••••••• K •• TH •••••••••••••••••••••••••••••••••••••••••• , •••• • ••••• ?11? 
• •• T. -VI •• LF •••• A.G •••• S ••.•....• L.S • • S •••• S .S •• T ••• T- ••• MS •• S ••• T •• P •••••••••• K •• TH ••••••••••••••••••••••••••••••• " •.••••••••••••• • •.. 7171 
• •• N. - VI •• LF •••• A.G •••• S • ••• ••• •• L.S • • S ••.• S •••• T ••• T- ••• MS •• S ••• T •• P • ••••••••• K •• TH ••••••••••••••••••••••••••• • ••••••••••••••••••••••••••• 1 
• •• N.-y~F •• ..:.. . ~ . Q.:..~S.:... •••• ..,:.. ••• L.S,:.,:. S •• .:. .S •••• T •• • ..; T.: ••• ~:.2 ... T~.P ••• _ ••••••• K •• TH ••••••• R •• • •• '_'~ '..! "'~' :.,.""""""" ~ " .R ••••••••• ? 
· .. K. -R . . SF ... .. A . G. Y •• S ..•.•.• S . PSPP. S .. . . v . S .. SV . • . - •. P •• •• TTL .. • . PG ..•• N •••• K •• DH • • .. N • .•... •• .•....•.....•••.. • .•... • •. . •••• • .. •. ..... • . 
· •• N;,:,.R .. SF '. ' . :... .A.G. Y ~ S .... • .• S . PS PP . S ...• V . S .:.. . SV ... -. ;,P ... . TTL..:. .. . PG ... . N • • •• K . • DH . . .. N • • •••••••• •••• ••• •• ~ •.•• • •• '" ••..••• • • • ••.. • •.• , 
••••• - •••••• • • • • A.S.N-.T . TV •• PSPS.--.TRTLT . V .A •• T •••• T ••• RS •• S •••••••••• • •••••• •• ••••••••••••• ' •••• '~ •• ,; ••••• : ••• " •••••••••••••••••••• ~ .. • • 
• •••• - •.••••••• • • A.S .N-. T. TA •• PS PS • --. TRTLT. V .A •• T •••• T ••• RS •• S ••••••• , ~ ••••••••••••••••••••••••••••••••• • •••••••••• " ••••••••••••••••••••••• 1 
• •••• - ••••• • •••• A. S .N-. T. TA •• PSPS. --. TRTLT. V .A •• T •••• T ••• RS •• S ••••• , •••••••••••••••••••••••••••.•••••••••••••••••••••••• • ••••••••••••••••••• 
• •••• - • ...!...!,. • ...:...:. •••• A.S .N-. T ",TA •• _PSPS. --. TRTLT. V .A •• T •••• T ••• RS •• S ••••••••••••••••••• • •••••••••• ..!..: ••••••• .,., ••••••• " •••• '" • ••••••••••••••••••••• 
• .... - .•••. •• ••. A . S . N- HT . TA .. PSPS . --. THTST. V . A .• T . ..• T •• V . S • . S ..... . PG ... .. .. .. . P .. HN ...... • . .. ........... . ..... . ... • •.. ••. . • .. . -. -.... .... .. . 
• • ••. - •......... A.S.N-HT . TA •• PSPS . - -. THTST . V . A . . T .. . . T . • V. S .• S •. . • .. PG •. • ... . ... P . . HN ..... . .•.•... ••. . . ... . ... . . .. . '" . •. . . •. .. ... '" ...... . 
· . • . • - ..... . .... A . S . N- HT . TA .. PSPS . --. THTST. V . A .. T • .. • T . • V. S .. S .•••. • PG .... .• .... P .. HN .. " .... " ........ . ........ ' " '" .............. •. ... , . . 
· •••. - • ......... A . S . N- HT . TA .. PSPS . --. THTST. V . A .. T .... T . . V . S . . S •. •• .. PG • . . .• ... . , P .. HN .. • ....•....... . .... . . . •. •. .•. .. ....... . .....• .. .... . .. 
79 
~oledogN4c ": •••• -. :-•• ";" .... ~ ~A.S.N- :T :TA": PSPS:-':'"-.TRTST ~V ; S = A •• :-: ".T: ": A.S-.S •• -:-: A.PG. ": :-••• :-. :-7P7":"HN ••• n ••••••••••••••••••••••••••••••••••••••••••••••••••• 
N3la ••••• - •••••••••• A.S.N-. T .TA •• PSPS. --. TRTST. V .S.A ••••• T •• A.S-.S •••• A. PG •••••••••• P •• HN ••• N •••••••••••••••••••• • •••••••.•• i ••••••••••••••••••• ! 
N32a ~ ~~ • ..t '" ~. ~t.S.N~ T~.~TA •• PSPS~.TRTS'!:... v.li~ ••••• T •• A. S-.S •••• A.PG ••••.••••• _. P •• HN ••• N __ •••.•. , . u . •••••••• ' .'" • ..•••••••••. • •• .•••••• : •••••••• • •• ! 
x x x xx XX 
Merlin gN4d •• ••• - •••••• • ••••. S . N-. T. TA •• PRPS . --. THAST . V .A •••.•.. T •• A . S- . S •••. A . PG •.•.•••••• P •• HN ••. N .••• • • •• ••. • . " ••.•.••..•. • •. " .•..•••••.•• • . •.•••• . • 
K141 ..•. . - .. .• " ..•••.• S . N- . T .TA •. PRPS . -- . TDAST. V .A .•••.•• T •• A.S-. S • . •• A. PG . • .•.••••. P •• HN .• • N ••••••.••••••••.•••••• " • • •• •.•• . • . • ••. " •.••• . ••.••. 
Nlc •• C • • - •• • •••••••• . S.N- . T . TA •. PRPS . --. THAST . V . A •••.•.. T •• A . S-. S .••• A. PG .••••••••• P •• HN •.• N .••••.•••..•.•••.•.•.•.••••• " •••. • .•.•.•.... " ... " " . 
N1 2 c .• C •. - •••• " .••.•.• S. N-. T .TA . "PRPS . --. THAST . V .A .• • •. •• T .• A.S- . S •••• A. PG ••••.••••. P •• HN .•• N" .••.•.••• • .•••• • •••.• " •••••.••••••••• " •••••.•••.• • 
N18a •• C •• - •.•••.••.•. • S.N-. T . TA •. PRPS. --" THAST " V . A ..• ..•• T •• A . S- . S •• • • A. PG •.•.•••.•• P •• HN •.• N •• . • •. . •••.•.•••.•••• •• •• • •• ••••••••• • •• .••...•.• • . 
N2 4a •• C •• - .• •• • • •••• " . S .N-" T. TA •• PRPS . -- . THAST . V .A .•••••• T .• A . S-. S •.• • A . PG ••• • • •• ••• P •• HN ••• N •.. • .•••••• • .•••.••..•...•.. " ...•... • . • .. •• . . .•• ••. 
N2 9a . • C •• - •••••..•.. " . S.N-" T .TA •. PRPS . -- . THAST . V . A ..••.•• T •• A. S- . S .••• A. PG ••••• ••• •• P •• HN ••• N ••• •• • •• •••• .•••.•.•.•.•.• • . " •• . •• • . • •. . .. •..••••• . 
N30a •. C •• - ••••.•.••••• S . N-. T . TA • . PRPS. -- . THAST. V .A • • ••••• T •• A. S- . S . •.• A . PG •••••••• •• P •. HN ... N " .. " .•.••..••• ••. •• • .•...••..••.••. •• •.•..•. . •.. •• • 
N36a •• C •• - •.••.• •••• ". S . N-. T . TA • • PRPS . --. THAST. V .A •• ••.•• T •• A. S-. S •• • • A. PG •••••• • ••• P • • HN .•• N ••.•• . • .• •• . • " • • . •. •• • . •.••.•.•.••.• • • " •.••...•.••• 
Figure 12: HCMV UL73 Alignment 
Full-length amino acid ClustalW alignment of all HCMV gN (UL73) sequences in this study showing eight groups: Full length amino acid sequences (138 residues in the case of AD169) 
for 8 reference strains with GenBank accession numbers (ADI69-gN I (NP _040007), Can4-gN2 (AAL77764.1), TR-gN3a (ACI46906.1), PH-gN3b (ACI46904.1), Can I O-gN4a 
(AAL 77775"1), Towne-gN4b (AAG235 10. I ), Toledo-gN4c (AAG23509.1) and the newly defined genotype Merlin-gN4d (NC _006273), along with 47 sequences obtained from the 
hospitalized fever (K), respiratory mortalities (N) and population-based (M6 or M 18 suffix) cohorts in this study. In the alignment, an ' X ' indicates the residues that differentiate gN4c 
from gN4d, dots indicate identities relative to reference ADI69 sequence, whereas dashes indicate spaces inserted by ClustalW" Question marks indicate terminal regions that are 
unknown. Differences from each group's representative genotype sequence are in bold. In some cases these are an identity with AD 169 but have been included to highlight all differences 
within genotypes. 
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3.9.3 HCMV UL73 and UL74 phylogenetic analyses 
Previously phylogenetic studies of variation in both UL 73 (gN) (Pignatelli et aI., 2003a) and 
UL74 (gO)(Mattick et aI., 2004) through analyses of an excess of non synonymous to 
synonymous differences, have demonstrated evidence for positive selection. Interestingly, 
within the individual gN and gO genotypes they are all conserved forms in tightly defined 
clades. Here phylogenetic evolutionary distances have been investigated between amino acid 
sequences using the Neighbor-loining method (Saitou and Nei , 1987), confirming that the 
new Merlin-like strains from Zambia, form a new genotype (gN4d), clearly distinct from the 
closest neighbour, gN4c (Figure 13). Branch lengths represent number of amino acid 
substitutions per site and it is evident that the N-terminal of UL 74 (gO) is up to three times 
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Figure 13: Phylogenies clearly demonstrate eight distinct HCMV gN and gO genotypes 
Phylogenetic analyses of HCMV N-terminal gO and full-length gN defines the g05/gN4d linkage. Evolutionary 
relationships between amino acid sequences are shown using distance based trees using the Neighbor-Joining 
method (Saitou and Nei , 1987) generated using MEGA4. f software (Tamura et aI., 2007). The trees are drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. The evolutionary distances were computed using the Poisson correction method (Zuckerkandl, 1965) 
(assumes equal substitution rates between sites, and amino acid frequencies but corrects for multiple 
substitutions at the same site) and are in the units of the number of amino acid substitutions per site. All positions 
containing gaps and missing data were eliminated from the dataset (Complete deletion option) and bootstrap 
values are from 500 replicates. The reference sequences are as in Figure 10 and Figure 12 along with sequences 
from hospitalized fevers (K), respiratory mortalities (N) and CIGNIS (M6 or M 18 suffix), representing the 
genotypes and differences identified. 
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3.9.4 HCMV gO/gN linkages and mUltiple infections in Zambian children 
Previously seven HCMV gO/gN linkages had been defined (Mattick et aI., 2004) but the new 
gN4d genotype detected in Zambia linked with g05 in five samples (N13, N29, N30, N36 and 
K141) and also the reference strain Merlin, forming a new eighth linked genotype, g05/gN4d, 
that has not been defined previously (Table 9). The two most prevalent linkages were 
gOlb/gN3a and gOlalgNI but analysis was confounded by the difficulties ofgenotyping low 
load samples. Analysis of genotypes in samples where only single infections were detected 
showed evidence for seven out of the eight genotype linkages in Zambia (Table 9), but 
evidence for g02a1gN3b, g02b/gN2 and g04/gN4b were only seen in multiply infected 
samples. The high prevalence of multiple infections in the respiratory mortalities cohort (all 
of whom were HIV-l positive) was also confounding for analysing genotype prevalence, but 
is consistent with a role for HIV -I associated immunosuppression in permitting multiple re-
infections with HCMV. 14 of the 34 children in the respiratory mortalities cohort showed 
evidence for being infected simultaneously with more than one HCMV genotype. In ID N8 
(respiratory mortality) there was evidence for co-infection with up to four distinct HCMV 
strains. In the absence of multiple infection, there was evidence for four novel linkages: 
gOlb/gNI, g02b/gNl, g03/gN4d and gOlb/gN4d (Table 10), two of which there is evidence 
for elsewhere (8eyari et aI., 2005). As novel linkages cannot be confirmed without continuous 
sequence data across the two loci, these may be an artefact of mUltiple infections (Table 11). 
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Sample Cohort UL74 UL73 HIV Status Putative Linkage 
NS Autopsy 1a + g01a/gNl 
K60 Fever la 1 g01a/gNl 
N14 Autopsy la NO + gOla!? 
N22 Autopsy la NO + gOla!? 
40M6 CIGNIS la NO gOla/? 
lS6M18 CIGNIS la NO gOla!? 
321M18 CIGNIS 1a NO g01a!? 
K68 Fever NO + ?/gNl 
K166 Fever NO ?/gN1 
K180 Fever NO ?/gNl 
N2 Autopsy 1b 3a + g01b/gN3a 
N9 Autopsy 1b 3a + g01b/gN3a 
N15 Autopsy lb 3a + g01b/gN3a 
N19 Autopsy 1b 3a + g01b/gN3a 
N23 Autopsy lb 3a + g01b/gN3a 
N25 Autopsy lb 3a + g01b/gN3a 
N34 Autopsy 1b 3a + g01b/gN3a 
263M6 CIGNIS 1b 3a g01b/gN3a 
35M6 CIGNIS 1b 3a g01b/gN3a 
503M6 CIGNIS NO 3a ?/gN3a 
492M6 CIGNIS NO 3a + ?/gN3a 
133M18 CIGNIS NO 3a ?/gN3a 
26M18 CIGNIS NO 3a + ?/gN3a 
N31 Autopsy 1c 4c + gOlc1gN4c 
N32 Autopsy 1c 4c + g01c1gN4c 
178M18 CIGNIS 2a NO g02a1? 
K3 Fever NO 3b + ?/gN3b 
K146 Fever NO 3b + ?/gN3b 
K152 Fever NO 3b + ?/gN3b 
776M6 CIGNIS 2b NO g02b!? 
329M18 CIGNIS 2b NO g02b/? 
K57 Fever 3 4a + g03/gN4a 
K54 Fever NO 4a + ?/gN4a 
K141 Fever 5 4d g05/gN4d 
N13 Autopsy 5 4d + g05/gN4d 
N29 Autopsy 5 4d + g05/gN4d 
N30 Autopsy S 4d + gOS/gN4d 
N3 Autopsy 5 NO + g05!? 
N1 Autopsy NO 4d + ?/gN4d 
Table 9: HCMV UL73/uL74 linkages in Zambia 
HCMV UL73 and UL74 genotypes detected in all three cohorts, showing HIV-I status of the infant and 
evidence for seven gO/gN linked genotypes, as differentiated by white and grey shading. ND = Not Determined. 
Samples in which only one genotype was determined are included but with a question mark against the 
corresponding genotype in the linkage column. 
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Sample Cohort UL74 UL73 HIV Status Putative Linkage 
K190 Fever lb 1 gOlb/gN1 (novel) 
K61 Fever 2b + g02b/gN1 (novel) 
N20 Autopsy 3 4d + g03/gN4d (novel) 
N18 Autopsy 1b 4d + gOl b/gN4d (novel) 
N24 Autopsy lb 4d + gOl b/gN4d (novel) 
K33 Fever lb 1/3a multiple gN 
Nl0 Autopsy 2b 2/3a + multiple gN 
N21 Autopsy 2b 2/4b + multiple gN 
N17 Autopsy 1a/3 1 + multiple gO 
N33 Autopsy 1a14 + multiple gO 
Nl1 Autopsy 2b/3 4a + multiple gO 
N27 Autopsy lb/3 4b + multiple gO 
N28 Autopsy lb/4 4b + multiple gO 
N26 Autopsy 3/4 4b + multiple gO 
N36 Autopsy 1b/5 4d + multiple gO 
N12 Autopsy 3/4 4d + multiple gO 
N35 Autopsy 3/5 NO + multiple gO 
K142 Fever 1b/3 4c multiple gO 
N6 Autopsy 1a/3 1/4a + multiple gO and gN 
N7 Autopsy 2b/3 2/4a + multiple gO and gN 
NB Autopsy 1b/2a/3 1/3b + multiple gO and gN 
Table 10: HCMV UL74/UL73 novel and multiple linkages 
HCMV novel gO/gN linkages and multiply infected samples from the hospitalized fever (Fever) and respiratory 
mortalities (Autopsy) cohorts, showing HIV -I status of the infant and putative linkage. White and grey shading 
groups samples as novel , multiple gN, multiple gO or multiple gO and gN. ND = Not Determined. 
A0169 TR-BAC Toledo PH-BAC Can4 ZVS Towne Merlin 
Sample C1I .0 C1I U U C1I .0 .0 C1I .0 '0 
ID ..- ..-
..- <'l §, "'" N <'l N N <'l "'" ~ "'" In ~ ~ ~ ~ ~ ~ ~ ~ '6, ~ ~ ~ ~ ~ ~ 
K33 x x X 
N10 X x x 
N21 x x x 
N17 x x x 
N33 x x x 
N11 x x x 
N27 x x x 
N2B x x x 
N26 x x x 
N36 x x x 
N12 x x x 
N35 x x 
K142 x x x 
N6 x x x x 
N7 x x x x 
N8 x x x x x 
Table 11: HCMV UL73/UL74 multIple hnkages 
The 14 respiratory mortality and 2 hospitalized fever samples for which definitive evidence of multiple 
infections was detected. The eight reference strains are given horizontally showing established gO/gN linkages. 
Crosses indicate detection of that genotype by sequence analysis. Grey boxes indicate the detection of gO/gN 
genotypes that correspond to one the eight established genotypes. At the time of writing, the Can4 and ZVS 
reference linkages (g02b/gN2 and g03/gN4a) had not been confirmed by publication of a whole genome. 
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3.10 Discussion 
Detection ofHCMV sera-DNA indicates active infection. Among healthy Zambian infants, 
the prevalence of these active infections was 40% at month 6 and 34% at month 18, 
suggesting many primary HCMV infections in Zambia occur in early childhood. Prevalence 
was higher (65%) in the 23 morbidity sera samples that were submitted by CIGNIS 
participants reporting to the clinic with fever (9 of these infants were later admitted to 
hospital). These findings from Zambia are similar to another recent study of African infants in 
the Gambia, in which 90% of infants were shown to have undergone their primary HCMV 
infection by 12 months of age (Kaye et aI., 2008). In this study over 75% of infants were 
infected before they were 6 months of age. Exposure to HCMV was similar in both HIV-l 
positive and negative Zambian infants. With respect to maternal HIV-l status however (where 
numbers afforded power for analysis) whilst overall detection of sera-DNA was not 
significantly different, crucially, the prevalence of high load HCMV at month 6 was over 
three times greater among maternally HIV -1 exposed infants, and this may affect morbidity 
and development as assessed further in chapter 5. 
In this study, two symptomatic Zambian paediatric cohorts were also screened for HCMV 
DNA. These were both retrospective studies of symptomatic children, one detecting HCMV 
in DNA-extracted whole blood from Zambian infants hospitalized with fever, and the other 
from a set of DNA-extracted lung tissue samples taken from HIV -1 positive children who 
died of respiratory disease. HCMV DNA prevalence in the retrospective hospitalized fever 
cohort was 10%, considerably lower than in the population-based study (CIGNIS), but 
screening of both retrospective cohorts was undertaken before that of the prospective cohort, 
using less sensitive primers with the goal of identifying infections in which HCMV was 
contributing to pathology. Indeed whilst prevalence was lower, viral loads were much higher, 
with all 16 infections detected having loads of over 10,000 copies/ml sera. The highest 
HCMV DNA prevalence was seen within the respiratory mortalities, where 94% of children 
were found to be positive. It was also in this cohort that the highest viral load was identified, 
although due to variable proportions of tissue and blood, the range of normalised viral loads 
(copies/l06 cell genome equivalents) within this cohort was much broader than for the 
hospitalized fever cohort. These respiratory mortality samples were previously screened by 
histopathology, which identified HCMV as the 3rd most common diagnosis (Chintu et aI., 
2002). The PCR results presented here suggest that HCMV may in fact be ubiquitous in HIV-
1 associated paediatric respiratory disease in Zambia, underlying more common diagnoses 
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such as tuberculosis and other bacterial pneumonias, and possibly undermining treatment for 
these diseases. 
Previous analyses of relatively conserved loci (such as UL55, UL75 or UL115) (Rasmussen 
and Cowan, 2003; Rasmussen et aI., 2002), along with certain more variable loci (such as 
UL139, UL144 and UL146) (Bradley et aI., 2008; He et aI., 2006; Stanton et aI., 2005) have 
failed to demonstrate clear linkage disequilibrium between different genes, suggesting a 
mosaic morphology for the HCMV genome. However, we have genotyped two hypervariable 
loci (the UL 73 and UL 74 genes; glycoproteins gN and gO respectively) which have been 
shown to be linked in isolates from the U.S, Europe and Japan (Cunningham et aI., 2009; 
Mattick et aI., 2004; Yan et al., 2008). A likely explanation for this linkage is that, as they are 
neighbouring genes and overlap, they are less likely to be separated by recombination. Due to 
their hypervariability however, there is also the possibility that they interact, either directly or 
indirectly, and may in some way affect the biology of different strains, possibly as virulence 
determinants, or with respect to host cell tropism as has been suggested for UL 74 (Ryckman, 
Chase, and Johnson, 2010). Here we have identified all seven UL 73 and eight UL74 
established genotypes in Zambia, and through phylogenetic analysis have identified a new 
UL 73 genotype, gN4d, which links with the g05 group, as exemplified by the Merlin 
reference strain (Dolan et aI., 2004). 
The data in this thesis is the most comprehensive for HCMV genotypes in Africa. The results 
are further compared to all sequences published and also on the NCBI (National Centre for 
Biotechnology Information) database (Table 12). The prevalence of these UL74IUL73 linked 
genotypes appears to differ by geographical region, although different studies have focussed 
on different HCMV disease patient groups (Figure 14). The g04/gN4b linkage is significantly 
more prevalent in Japan (14/55 - 25%) than elsewhere (vs Europe and North America: 9179 P 
= 0.034, vs Southern Africa: 2/51 P = 0.002), but this study cohort was comprised exclusively 
of symptomatic post-natal and congenital infections (Yan et aI., 2008), and so the link may be 
with the patient group or the region. In Southern Africa it is gOIa1gNl and gO 1 b/gN3a that 
predominate, but they are no more prevalent here than elsewhere. A previous study from 
Malawi investigated both UL73 and UL74 in a study looking at transmission ofHCMV 
within family groups, identified three novel UL 73/UL 74 combinations (Beyari et aI., 2005). 
We have also shown some evidence of novel linkages, including two of those suggested by 
the Malawian study (gOlb/gNl and g02b/gNl)(Table 12). The prevalence of these 'novel' 
gO/gN linked genotypes (12/51 - 24%) is significantly higher in this HIV -1 endemic region 
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than in Japan (5/55 P = 0.043) or Europe and North America (1179 Chi squared is not 
calculable). For Southern Africa, these possibly represent artefacts of mUltiple infections in 
cohorts with prevalent HIV / AIDS, but these same multiple infections may also be facilitating 
recombination and the emergence of novel strains. 
In Europe and North America, a more balanced distribution of all genotypes is observed. 
Analysing the geographical distribution of different genotypes is hampered by the fact that 
these sequences were obtained from a considerable range of different clinical specimens from 
patients with different disease presentations. To completely confirm geographic differences in 
the distribution ofHCMV UL73IUL74 genotypes, population-based studies of which 
genotypes cause primary infection in healthy children are required. We have done this here 
for Zambia on the CIGNIS study, and whilst genotyping has proved difficult due to very 
limited samples volumes, we have found that 6/12 samples from healthy Zambian infants 
were likely from the gOI b/gN3a genotype (both loci were not typed), which is supported by a 
high prevalence of this same genotype in the two symptomatic cohorts. Whether this trend 
would continue with higher numbers, or whether asymptomatic primary infections in other 
regions would be predominantly gOlb/gN3a is unknown. Broadly, all eight genotypes are 
found globally, which is distinct from what was been shown for the related betaherpesvirus 
HHV-6 (Kasolo, Mpabalwani, and Gompels, 1997)(lnvestigated here in chapter 4), and also 
for the garnmaherpesvirus KSHV (Kasolo et aI., 1998; Kasolo et aI., 2007). The variation 
exhibited by HCMV UL 73 and UL 74 has been shown to have arisen in our distant past and is 
not the result of current immune selection as displayed by the more rapidly mutating RNA 
viruses (Mattick et aI., 2004). Possible forces of selection include geography, innate immunity 
or cell tropism factors. 
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Figure 14: Global distribution ofUL74fUL73 linkages 
Histogram showing prevalence of HCMV gO/gN linkages in three genetical1y distinct regions. 'Other' refers to 
novel linkages (generally not confirmed by read-through sequence but suggested by independent detection) 
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FUK74 4 4b g04/gN4b Cord-blood or Urine Congenital < 1 yr Van 2008 
X01 4 4b g04/gN4b Cord-blood or Urine Congenital < 1 yr Van 2008 
LV 4 4b g04/gN4b Urine Congenital < 1 yr Mattick 2oo4/Pignatelli 2001 
Davis 4 4b g04/gN4b Lab-adapted strain na na Mattick 2oo4/Pignatelli 2001 
Towne 4 4b g04/gN4b Lab-adapted strain Congenital na Rasmussen 2003 
3301 4 4b g04/gN4b Urine Congenital < 1 yr Cunningham 2009 
HAN23 4 4b g04/gN4b Bronch . lavage na na Davison (01/06/09) 
HAN22 4 4b g04/gN4b Bronch . lavage na na Davison (01/06/09) 
HAN17 4 4b g04/gN4b Bronch. lavage na na Davison (01/06/09) 
1B 4 4b g04/gN4b Urine TR na Mattick 2004 
70A 4 4b g04/gN4b Whole Blood na > 18 yrs Mattick 2004 
C110 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
C122 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
C14 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
C170 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
C185 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
C196 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
J60223 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
J60299 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
N22 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
C135 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
U07 4 4b g04/gN4b Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
N26 4 4b g04/gN4b* Lung biopsy AIDS mortality + < 18 yrs This Thesis (Bates 2008) 
N28 4 4b g04/gN4b* Lung biopsy AIDS mortality + < 18 yrs This Thesis (Bates 2008) 
B5u 4 1 g04/gNl Urine Asymptomatic < 18 yrs Beyari 2005 
E4 4 3a g04/gN3a Urine Asymptomatic < 18 yrs Beyari 2005 
Ei 4 3a t!04/t!N3a Saliva KSHV + > 18yrs Beyari 2005 
ASA01 5 4d g05/gN4d Cord-blood or Urine Congenital < 1 yr Van 2008 
FUK28 5 4d gOS/gN4d Cord-blood or Urine Congenital < 1 yr Van 2008 
Merlin 5 4d gOS/gN4d Urine Congenital < 1 yr Dolan 2004 
3157 5 4d g05/gN4d Urine Congenital < 1 yr Cunningham 2009 
JP 5 4d g05/gN4d Prostate tissue AIDS mortality + na Cunningham 2009 
HAN30 5 4d gOS/gN4d Bronch . lavage na na Davison (01/06/09) 
HAN19 5 4d g05/gN4d Bronch. lavage na na Davison (01/06/09) 
C149 5 4d gOS/gN4d Cord-blood or Urine Post-natal infection < 1 yr Van 2008 
K141 5 4d g05/gN4d Whole Blood Hospitalized Fever < 2 yrs This Thesis (Bates 2008) 
NB 5 4d g05/gN4d Lung biopsy AIDS mortality + < 18 yrs This Thesis (Bates 2008) 
N29 5 4d gOS/gN4d Lung biopsy AIDS mortality + < 18 yrs This Thesis (Bates 2008) 
N30 5 4d g05/gN4d Lung biopsy AIDS mortality + < 18 yrs This Thesis (Bates 2008) 
N36 5 4d g05/gN4d* Lung biopsy AIDS mortality + < 18 yrs This Thesis (Bates 2008) 
Table 12: Summary of all published UL73/UL74 genotypes 
HCMV UL 73 and UL 74 genotypes detected in this study combined with all available data globally. Where 
available, sample source and disease presentation are indicated along with HIV -I status and age. Grey boxes 
highlight samples displaying evidence for novel linkages. Asterisks mark samples in which additional genotypes 
were identified. Samples ASAO I, FUK28 and C 149 were published as gN4c (Yan et aI. , 2008) but re-analysis 
here has shown they are in fact members of the new gN4d clade. TR = transplant recipient. All HCMV UL 73 
and UL 74 sequences from this study were published in 2008 as referenced (Bates et aI., 2008). For sequences 
that are not as yet published, the date of submission to Genbank is given in brackets. 
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Analysing all available sequence data for HCMV UL 73, 59 different variants have been 
identified, divided between the 8 genotype groups (Figure 15). Of these, 11 have been 
detected solely in this study, with particular attention being drawn towards the genotype 
gN3a, which accounts for over half of these novel strains. This analysis also determined a new 
gN genotype gN4d which includes the Merlin reference strain, and revealed a new gO/gN 
linkage. An alignment was also constructed combining unique UL 74 sequences from this 
study with all those available (Figure 16), identifying a total of38 unique UL74 variants 
globally, and of these, 7 have been found exclusively in this study. We have also identified a 
unique gO N-terminal truncation from a 2bp deletion resulting in internal initiation required 
to express the gO glycoprotein. Analysis here of recent sequence depositions in Genbank 
show that at least another strain shows a similar deletion: HAN19 (Genbank submission, 
Davison). All these sequences could be investigated using biological assays as described 
above. 
In this chapter evidence for HCMV multiple infections and possible recombinations is 
presented for this paediatric population. We have also observed that active HCMV infections, 
as detected by sera-DNA, appear more frequent and at an earlier age than elsewhere. 
However, analysis suggests this is unlikely to be due to different strain variants in this region 
as all genotypes detected elsewhere were detected in this population. This is distinct from that 
observed for related betaherpesvirus HHV -6, as described in the next chapter. At the start of 
this study it was not known whether HCMV, or what strain genotypes of HCMV, were 
present in Zambia. In this study we have identified HCMV as common infection in Zambian 
infants, with high loads being associated with pathology. The high prevalence of HCMV in 
end-stage AIDS in Zambian children suggests possible application of anti-CMV drugs in the 
future, with a special focus on AIDS-associated pneumonia for which other bacterial 
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••••• - ••••• ••• •• A.S.N-.T .TA •• PSPS. --.TRTLT. V .11. •• T •••• T ••• RS •• 5 • ••• • ••• • • ••• ••••• •• • •• • •••••• • •• •• •••••••••••••••••••••••••••• • ••••• •••• ••••• 
• •••• - •••••••••• 11.. S .N-. T. TA •• PSPS. --. TRTLT . V .11. •• T •• •• T ••• RS • • S ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• , •• ••••• •••••• S . 
.K ••• BR •• ••• •••• A.S.N-. T . TV •• PSPS. --. TRTLT. V .11. •• T •••• T • •• RS •• 5 •• ••••• •••• • •••••••••• • ••••••••••••••• •••••• •••••••••••• •••• •••••••••••••••••• 
??? .- ••• ••• •••• A .S. N-. T • TV •• PSPS . --.TRTLT. V .11. •• T •••• T ••• RS •• S ••••••••••• .!...'..!..!.. ••••••••••• .!..!.. ••••• • ''':~'''' . ; ••••••••• • ••••••••••••••• • ??????? 
• •••• - • • •••• ••• • A . S . N- HT. TA •• PSPS. --. THTST . V . A •• T . •.• T •• V . S •. 5 •• •••• PG ..• ..••••. P . . HN ..• . •• . • ••..•••• • . • • ••. • •••. •••.• ••••• • •.••• . •••• . ••... 
• •••• - •••••• • ••• V .S.N-HT. TA •• PSPS. --. THTST. V . A . • T •••• T •• V .5 •• 5 ••• •• . PG •••.• ••• •• P •• HN •••• ••• • •... • •••.• ••••.• .• ••. . •.• .•. .•••• . • • •••••••••.• 
••••• - ••• •••• ••• A . S.N- HT. TA •• PSPS . --. THTST . V .A • • T •• .• T •• V . S • • S •••••• PG •• . ••••.•. P •• HO .•• •••..• .••• ••• . • ••.•••••••••• , ••....•• • •. .•• •.• ••••• • 
••••• - ••••••• •• • A . S . N-NT. TA •• PS PS . --. THTST. V . A •. T ...• T .• V . S •. S .. . .• . PG • •. . • •.. •. P • • HO .•• •••• . •.. • ••..•••.• . ••.••••• •. •••• .. • • •••••••.••.••.• 
••••• - •••••••••• A . S . N-NT . TA •• PS PS • --. THTST. V .A •• T ••.• T .• V . S • • S ••••. • PG •••.•••••. P •• HO ••...•••• . .••••• .•• . • . •• •• •••••. • •• ••.••••••• ••• . • .. ••• 
• •. . . - .. ... ..•.• A.S.N-NT . TA •• PSPS. - -. THTST . V . A • • T ••.• T •• V .S • • S •..••. PG • .•.• ••• • . P .• HN ••••. • .••.••.••. •• •• • '" . , ••• .• . • • ....• •. .. •..•.••••.•• 
• .-: •• - • • •• : -:-: ••• A.S. N-. T. TA •• PS PS • --. TRTST. V . S .11. ••••• T •• 11.. S-. S • ••• 11.. PG •• •• •••• •• P •• HN ••• N ••• :-:-•••• •• ••• ••• ••• : -:-::-: ...... ..... , ••• :- •• -:--. ~ . -~ ~-. --:'-
• •••• - •••••••••• A.S . N- . T . TA •• PSPS . --. TRTST. V .S.A ••••• T •• A .S- .5 •••• T. PG •• • ••••••• P • • HN ••• N ••••• • ••• , ••••••••••••• •• •• •••• •••• • •••• • •• ••• ••••• 








· .as. -v .. ' .' ... . . G .S. N-. T •• A •• PSPS . --. TRAST . V .A.A ••• S. T •• A . S- . S •••• A. PG •• • ~ ••• P •• HN ••• N •••••••• ' , ' ••.••••••••• • ••••••••••.•••• •• ••••••••••• 
X X X XX XX 
•••.• - ....•••••••. S . N-. T . TA .. PRPS . --. THAST. V . A ...•••• T •• A.S- . S ..•• A. PG ... .• •..•. P •. HN • .. N .. ••• •.. . ........•.. •• .... • ..•..•.•....•..•.. .•.•. . 
• . C •• - ••••• ••••••• S.N-. T. TA •. PRPS . --. THAST . V .A ....... T .. A.S-. S ...• A. PG .•.......• P • • HN .•• N ••.•.........••.......•..•.••.••.....••••••...•.... 
· ...• - •••••••••••• S .N-. T .TA •• PRPS. --. TOAST. V .A .••.•.. T • • A. S-. S . •• . A. PG •.....•••• P •• HN ... N .••• • •...•....••..... • •• •• ••...••. • . • .•.........•. • 
•..•• - ••.•..•..• , .S . N-. T .TA •• PRPS. --. THAST. V . A •••••.• T .• A. S-. S •••• A. PG ••• •••.... P •• HN .•• N ••.•...••••••..•.. . •••••. • •. ••. .....•. • • ••••...•... 
???.- ............ S .N-. T .TA •• PRPS. --. THAST. V .A ••••••• T •• V.S •• S ••••••• • ••• • • :- : ~ • •• .••....•••...••••••••• -•••••. • .•••.••••.••••• : •.•.•.•. ??????? 
Figure 15: HCMV UL73 alignment of all published sequences 
Amino acid ClustalW alignment of all unique HCMV gN (UL 73) genotypes showing all eight groups: Full length amino acid sequences (138 residues in the case of AD 169) for 8 reference 
strains with GenBank accession numbers (ADI69-gN I (NP _040007), Can4-gN2 (AAL77764.1), TR-gN3a (AC 146906.1), PH-gN3b (ACI46904.1), Can 10-gN4a (AAL77775.1), Towne-gN4b 
(AAG2351 0.1), Toledo-gN4c (AAG23509.1) and the newly defined genotype Merlin-gN4d (NC _006273)(Bates et aI. , 2008), along with representative sequences from Genbank showing all 
published variations from this and other studies. IDs with an asterisk mark hospitalized fever (K prefix), respiratory mortalities (N prefix) and asymptomatic (M6 or M 18 suffix) samples from 
this study. In the alignment, an ' X' indicates the residues that differentiate gN4c from gN4d, dots indicate identities relative to reference ADI69 sequence, whereas dashes indicate spaces 
inserted by ClustalW. Question marks indicate terminal regions that are unknown. Differences from each group's representative genotype sequence are in bold. In some cases these are an 
identity with AD 169 but have been included to illustrate the extent of intra-genotype variation. Other sequences from this study, identical to representative strains shown are as follows: gN I: 
ADI69 (N5a, N8c, N17a, N33a, K60, K61 , K68, KI03 , KIlO, K190, K137); gN2: N7c (NIOc); gN3a: BD (263M6, N2b, N9a, NlOa, N19a, N23a, N25a, N34a), K33 (492M6, 
503M6, 133M 18); gN4a: K57 (N6a, NIl a); gN4b: N28a (N21 a, N27b), and gN4c: Toledo (N31 a, N32a). The newly defined gN4d genotype group includes K 141 and N 18a as shown, plus 
sample sequences identical to N 18a: NI c, N 12c, N20c, N24a, N30a, N36a, and N29a. 
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AD169 gOla HGRKE-MMVRDVPKMVFLISISFLLVSFINCKVMSKA-LYNRP--WRGLVLSKIGKYKLOQLKLEILRQLETTISTKY----NVSKQPVKNLTMNMTEFPQYYlLAGPIQNYSITYLWFOFYSTQLRKPAKYVYSQYNHTAKTITFRPPPCGTVPS 
851 ••••• - • •••••••••••••••••••• L ......•.. - •••.• -- •..••..•• • •.••.•••..•........•.•• ---- ••••..••••••••.••.••.••.•••.••••••...••...........•.•••••.......••...•••.. 
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.... --GEM . G. FNLF .. M.LT ••• F ••••. RAAVRL-SVG . Y--. S . K .. . T . .. QR .. KF ..... K ... KO . Y ... F--- . MTR . HI ..• . .•.•.• . R •.. . ... . .• N. V . . . . .. . .... . .. .. . . . F. E .. . ..... . .. .. S . . . . . . 
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Towne g04 •••• G--EM.G.FNLF •• H.LT ••• F •••••• ~--ITVARF.-------.K.QKA.EEER •••• R •• QE.ASKTGOY. KFFTFP.Q. KLY.l.VE. KQ •• PNS •••••• R.H .•• H ••.•• HT •••••• ~ ••. E •••• GQK ...•. • S •• • I •• 





•••• G--EM.G.FNLF •• M.LT ••• F •••••• ---~VARF.-------.K.QKA.EEER •••• R •• QE.ASKTGOY. KFFTFP.Q.KLY . l.VE .KQ •• PNS ••••.. R.H .•. H .•. •• HT . ....• •• •••. E .•.• GQK .••• B.S ••• I •• 
•••• G--EM.G.FNLF •• M.LT ••• F •••••• ---IAVARF.-------. K.QKA.EEER •••• R •• QE.ASKTGOY. KFFTFP.Q. KLY.I.VE.KQ •• PNS • ••••• R.H ••• H ••••• HT •••••••••••. E •••• GQK •••••• S • •• I •• 
• ••• GE. R--G. FNLF •• M.LT ••• F •••••• ---IAVARF-------R. K.QKA. EEER •••• R •• QEIASKTGOYTKFFTFP.Q. KLY. 1. VE.KQ •• PNS •••••• R.H ••• H ••••• HT •••••• ~ . : •.. E •••• GQK .••••• S ••• I •• 
???G--EM.G.FNLF •• M.LT ••• F •••••• - - - I AVARF.-------. K.QKA.EEER •••• R •• QE.ASKTGOYNKLFTFP.Q.K(STOP) 
Merlin g05 • • K • . MI .. KGI .. IML .. .. T •.• L. L . .. N . LVNSRGTR . S --. PYT ... YR . . El. KKQ . EO .. KR.MS . S. OG . RFLMYP . Q . KFHAIV1S . OK ... O •. .• ... R. D . .. HM . . ...... . .. . ...... E • .. . . HK .. L ... . ..... . 




MI . . KGl • . lML . ... T ... L . L ..• N . LVNSRGTR . S--. PYT ... YR .. El . KKQ . ED .. KR.MS . S . DG . RFLMYP. Q . KFHAlVlS . DK • . . D ...... . R. D ... HM ... • . .•. . • •. . ..... E . ... . HK . . L . ..... . .. . 
• • K •. MI .. KGI .. IML • • • . T .. • L . L ... N. LVNSRGTR . S-- . PYT ••. YR .. EIHKKQ. ED . . KR . MS . S . DG . RFLMYP .Q . KFHAIVlS. DK ... D .. •.... RDD .•. HM ••• • • • • ••• • • •••••• E • . . .. HK . . L .. . . .. .. . . 
· .K .. MI . . KGl •. IML ... . T ... L. L .• SN. LVNSRGTR. S -- . PYT ... YR .. El. KKQ. ED . . KR.MS. S. DG. RFLMYP . Q . KS HAIVIS . DKS .. D ..•.... R. D ... HM •••••.•••• • .•• • ••• E ..... HK . . L ••• •• •••• • 
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Figure 16: HCMV UL 74 alignment of all published sequences 
Amino acid ClustalW alignment of all published unique HCMV gO (UL 74) genotypes showing all eight groups: N-terminal (residues 1-148 relative to AD 169) sequence for 8 reference strains with 
GenBank accession numbers (AD169-g01a (NP _040008), TR-gOlb (ACI46906.1), Toledo-gOlc (AAN40079.1), PH-g02a (ACI46904) SW1715-g02b (AAN40066.1), SW475-g03(AAN40072.I), 
Towne-g04 (AAN40080.1) and Merlin-g05 (YP _ OS1522» along with representative sequences from Genbank showing all published variations from this and other studies. IDs with an asterisk mark 
hospitalized fever (K prefix), respiratory mortalities (N prefix) and asymptomatic (M6 or M IS suffix) samples from this study. In the alignment, dots indicate identities relative to reference AD 169 
sequence, whereas dashes indicate spaces inserted by ClustalW. Question marks indicate terminal regions that are unknown. N-terminal spaces in two sequences (N3aa and K 141) indicate the effect of a 
2bp deletion that leads to internal initiation from a downstream methionine. C-terminal (STOP) signs in three sequences (Blu, H3u and Air) indicate the effect of substitutions/frame shifts leading to 
insertion ofa premature STOP codon. Differences from each group's representative genotype sequence are in bold. In some cases these are an identity with ADI69 but have written in to illustrate all 
differences within genotypes. Other sequences from this study identical to those shown in the alignment are as follows: gOla: S51 (K60, 40M6, N6bb, N22bb); gOlb: DM7 (K33, K57, K67, KS6, 
KI42), N2a (N9a, Nl5cc, NISbb, N19a, N23a, N24bb, N25a, N27bb, N34a, N36bb), SW990 (35MI8, 263M6), Riu (N2a); gOlc: Toledo (N3Ia, N32a); g02a: PH (N29cc), NSbb (178MI8); g02b: 15 
(K61, N7bb, NJOa, Nllbb, N2Ia), Aiu (Nllbb); g03: SW475 (N6a, N7a, N8a, Nlla, N12a, N17a, N20bb, N26a, N27b, N35bb); g04: N28a (N33a, N26bb, N28b) and g05: KI41 (N3aa, Nl3bb, 
N29b, N30bb, N35aa, N36a). 
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4.0 HHV-6 DNA detection, loads & genotypes in three Zambian 
paediatric cohorts 
4.1 Introduction 
The previous chapter presented the design and implementation of PCR assays for measuring 
the prevalence of HCMV active infections, loads and genotypes in three Zambian paediatric 
cohorts. In this chapter we describe assays for the detection of another betaherpesvirus, HHV-
6, and present a similar analysis of the prevalence of active infections, loads and genotypes 
present in the same three Zambian paediatric cohorts. Like for HCMV, the prevalence of 
active HHV -6 infections during infancy has not been well studied in Africa. We employed a 
PCR strategy to investigate HHV -6 prevalence and loads in the three cohorts. Assays were 
also designed to investigate strain variation through sequencing the U47 (glycoprotein gO) 
and U46 (glycoprotein gN) genes, homologues of HCMV UL74 and UL73 studied in the 
chapter 3. In HHV-6 these loci are less variable than in HCMV, showing divergence of up to 
7%. U46 is only published for three reference strains and no other sequence data is known. 
The design of primers in the conserved flanks of these variable loci allows the genotyping of 
strains with U46 or U47 genes similar to known sequences, as well as detecting potential 
novel strain variants or recombinants. In this chapter we also investigate relationships 
between the prevalence and loads of active HHV -6 infections, with HIV -1 infection and 
exposure. 
4.2 HHV -6 peR assay design and strategy 
peR assays were required for the detection and genotyping of HHV -6 in whole blood, lung 
tissue and sera from paediatric clinical specimens. Primers were designed using alignments of 
the U46 and U4710ci from the two HHV-6 reference strains UI102 (NC 001664) and Z29 
(NC 000898), representing HHV-6A and HHV-68 respectively. All primers (Appendix A) 
were designed to detect both strain variants although at some sites mismatches were 
unavoidable: Primers U470F, U46Up and U46R each contained one mismatched base pair 
(Appendix F), with primer U47F containing two mismatches (Appendix G). Clones for testing 
the sensitivity of internal primers were constructed using PCR products generated using the 
external U470RlR and U460FIR primers so that the effects of the mismatches in the U47F 
and U46R primers could be properly assessed. The U47FlU47R primers had a sensitivity of 
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103 absolute copies when measured using serial dilutions of clones of PCR products amplified 
from HHV-6A (strain UII02), but a lower sensitivity of 105 absolute copies when using 
clones containing PCR products derived from HHV -6B (strain NIl )(Figure I). This 
particularly low sensitivity was tested twice in duplicate using different clones and was 
consistent. A possible explanation may be the double mismatch in HHV -68 within the 
forward primer. We used this assay to screen the two retrospective cohorts (whole blood 
from141 hospitalized febrile infants and lung tissue from 36 HIV -1 positive respiratory 
mortalities) as this low sensitivity assay would only detect active infections likely involved in 
pathology. Primers targeting U46 (U46FIU46R) were considerably more sensitive, with an 
absolute cut off of 10 copies, which did not vary between the two strain variants. This assay 
was employed to measure the prevalence of sera-DNA in the CIGNIS cohort, in which all 
routine samples were taken from healthy children. Detection ofHHV-6 DNA in sera is 
indicative of active infection although loads are likely to be lower when compared with the 
two symptomatic cohorts. Strain variation was investigated in all three cohorts using U47 and 
U46 primers. 
4.3 Prevalence of active HHV -6 infection 
The prevalence of HHV -6 infections was first assessed in the two retrospective cohorts: 
DNA-extracted blood from 141 infants hospitalized with fever (6-34 months of age), and 
DNA-extracted lung tissue samples from 36 HIV-l positive children (0-16 yrs of age) who 
died from respiratory disease. These two cohorts were screened with a low sensitivity PCR 
assay (U47F1U47R primers). Using this assay HHV-6 had a blood-DNA prevalence of 5% in 
the fever cohort and a lung tissue-DNA prevalence of 72% in the respiratory mortalities 
cohort (Table 13). We then compared these prevalence rates with Zambian infants taking part 
in the CIGNIS study, who were screened for HHV6 by PCR in DNA-extracted sera at both 6 
and 18 months of age. Of the 812 infants enrolled in the study, 610 month 6 and 375 month 
18 samples were screened for HHV-6 using the more sensitive U46FIR PCR assay. The 
overall HHV -6 prevalence in the CIGNIS study was 8% at month 6, increasing significantly 
to 13% at month 18 (46/611 vs 52/399 P < O.OOI)(Table 13). In addition to the 6 and 18 
month samples, there was also a small set of 23 samples taken from CIGNIS infants who 
presented with fever at a non-scheduled time during the study. Prevalence ofHHV-6 
detection in sera-DNA in this set was 57%, significantly higher than in either the month 6 or 
month 18 sets (57% (13/23) vs 8% (46/611) P < 0.001 or 13% (52/399) P < 0.001). Overall, 
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the prevalence of HHV -6 active infections was highest in the respiratory mortalities and 
febrile samples from CIGNIS participants. 
4.4 Prevalence of active HHV-6 infection by infant HIV-l status 
In the hospitalized fever and respiratory mortalities cohorts, HIV -1 diagnosis was by detection 
of proviral DNA using PCR on DNA-extracted blood and lung tissue respectively. HIV -1 was 
detected in 33% (47/141) of the hospitalized febrile infants and was confirmed in all 36 
respiratory mortalities (they were selected as HIV -1 positive). The prevalence of HHV-6 
DNA did not differ significantly by infant HIV -1 status in the hospitalized febrile infants. 
The prevalence of HHV -6 infection in the respiratory mortalities cohort was extremely high 
(72% (26/36)) and was significantly greater than the prevalence seen in HIV -1 positive 
children within the hospitalized fever or CIGNIS cohorts (P < O.OOI)(Table 13), although did 
not differ significantly from the HHV -6 prevalence in HIV -1 positive infants in the CIGNIS 
morbidity samples (Table 13). In the main CIGNIS cohort HIV -I diagnosis was by serology 
at 18 months. Among the 480 infants screened for HHV -6 at 6 months of age the HIV-l 
prevalence was 4% (19/480). Infants with unknown HIV -1 status were largely those who had 
been withdrawn from the study before they could undergo their 18 month screen for HIV -1. 
Of327 infants who were screened for HHV-6 at both time points, just 4 (1.2%) were HHV-6 
sera-DNA positive at both month 6 and month 18. One ofthese infants was HIV -1 positive 
(the other three were negative and born to HIV-l negative mothers) and was admitted to 
hospital with protein energy malnutrition, tuberculosis and diarrhoea. This child died 11 days 
after submitting a morbidity sample which was also positive for HHV -6. Another child who 
submitted a morbidity sample died of pneumonia 7 months after being tested positive for 
HHV-6. 
Cohort Age HIV-l unlnfected HIV-llnfected P Totals· 
CIGNIS 6m 8%(38/461) 16% (3/19)3 .215/\ 8% (46/611)1 
18m 13% (49/384) 14% (2/14) .697/\ 13% (52/399)1.2 
CIGNIS (Morbidity) 6-18m 46% (6/13) 66% (2/3) 1.0/\ 57% (13/23)2 
Fever (blood, n=141) 6-34m 3% (3/94) 9% (4/47)4 .222/\ 5% (7/141) 
Autopsy (lung, n=36) 0-16yr NO 72% (26/36)3.4 NO 72% (26/36) 
Table 13: HHV-6 sera-DNA prevalence vs infant HIV-l 
Significance was by Pearson Chi Squared or Fishers exact test (1\) if there was an expected value < 5. *The totals 
column includes infants of unknown HIV -I status. Significance between totals was as follows: 'P = 0.005 2,3,4 P 
< 0.001 
4.5 Prevalence of active HHV-6 infection by HIV-l exposure 
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Maternal HIV-1 status was requested at recruitment on the CIGNIS study, which was 
primarily powered to look at HIV -J exposed but uninfected infants. At both 6 and 18 months, 
the prevalence ofHHV-6 sera-DNA was not significantly affected by HIV-l exposure (Table 
14). As stated in the previous section, there was a significant increase in HHV -6 sera-DNA 
prevalence at month 18 (13%) from month 6 (8%) (P = 0.005). This was only significant 
among HIV-I unexposed infants (9% (36/275) vs 13% (36/426); P = 0.048) with the number 
of HIV -I exposed infants being lower. This result differed to the HCMV results, where there 
were no significant differences between the prevalence of active HCMV infections between 
the two time points, possibly reflecting differences in the rate of uptake and also the 
frequency of detectable reactivations between the two betaherpesviruses. 
Cohort Age (m) HIV-l unexposed HIV-l exposed P Totals· 
CIGNIS 6 9% (36/426)3 6% (7/117) .381 8% (46/611)1 
18 13% (36/275)3 13% (10/78) .950 13% (52/399)1.2 
CIGNIS (Morbidity) 6-18m 42% (5/12) 63% (5/8) .410/\ 57% (13/23)2 
Table 14: HHV-6 sera-DNA prevalence vs maternal HIV-I 
Significance was by Pearson Chi Squared or Fishers exact test (1\) if there was an expected value < 5. ·The totals 
column includes infants and mothers of unknown HIV -I status. Significance between total s was as follows : 1 P = 
0.005, 2 P < 0.00 I, 3 P = 0.048 
4.5 HHV-6 Real Time Taqman peR set up and qualitation 
In chapter 3 we describe the use of two Taqman-based Real Time PCR assays for quantifying 
both HCMV and also the human house-keeping gene GAPDH. For HCMV we selected a 
previously published assay that targeted the highly conserved UL55 gene (glycoprotein gB), 
to facilitate the detection of possible novel strain variants that might be missed using primers 
designed to detect the highly variable gN and gO genes. For HHV -6 the gO and gN genes 
(U47 and U46) are also variable but less so than in HCMV, and preliminary sequence analysis 
was showing lower levels of variation (section 4.8). For these reason we chose to design a 
Taqman probe for use with the U47FlU47R primers, which had the smallest product size 
(208bp), most appropriate for use in a Real Time assay. 
Sensitivity of the HHV-6 U47 Real Time assay was assessed by measuring the probability of 
detection using dilution series of plasmid standards of cloned HHV -6A (U 1 102) PCR 
product. It was determined that standards with ~ 100 copies in 5f..ll of template were detectable 
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in 100% of 10 dilution series. Standards containing 10 absolute copies were detectable in 70% 
(7/10) of cases, whilst 5111 of template containing just one copy was detectable in only 10% 
(Ill 0). Accuracy of the assay was then assessed by measuring the standard deviation of each 
standard across the ten repeats (Figure 17). Values had a standard deviation of up to 45% (at 
101 copies) to 38% (at 107 copies), and so the viral loads measured using this assay were only 
accurate to roughly half a log. For the CIGNIS cohort, detection of 10 absolute copies 
corresponded to a load of 500 copies/m I sera with our extraction and assay protocol , but with 
many samples having undetectable or very low loads we have grouped loads as for HCMV, > 
or < than 1000 copies. For hospitalized fever and respiratory mortalities cohorts levels of 
HHV -6 DNA were much higher and are expressed as copies/ml whole blood or copiesll 06 
cell genome equivalents as determined by the GAPDH Real Time assays described in chapter 
3. Interestingly the U47F/U47R primers were several logs more sensitive when used in the 
Real Time assay (with different cycling conditions and the addition of a specific probe) than 
in the qualitative PCR assay, suggesting further optimization of the qualitative assay may 
improve sensitivity. 
o 2 6 
Log,. Absolute Copies (Expected) 
Figure 17: HHV-6 Real Time Taqman Standards 
Error bars indicate standard deviation. Measurements were taken using the formula y = (x-40.4)/-3.3 15 which 
was derived from the averages of the five highest standards (103 - 107 absolute copies). 
4.6 CIGNIS HHV-6 DNA loads by HIV-l status 
HHV -6 viral loads were measured and compared across the CIGNIS cohort and correlated 
with HIV -1 status in infants and their mothers. All samples found to be positive by the first 
round qualitative screen for HHV -6, were then analysed further using a Taqman Real Time 
PCR assay. A set of 91 HHV -6 positive samples (46 month 6 and 45 month 18) were assayed 
] 0] 
along with 13 HHV-6 positive CIGNIS morbidity samples. In the CIGNIS study, many 
samples had low HHV -6 levels of <1 000 copies/ml sera. Overall higher load infections were 
more commonly detected at month 6 (13% (6/46» than at month 18 (2% (1I45»(P value 
incaJculable)(Table 15). Due to low numbers sub-stratifying by infant HIV -1 status or 
maternal exposure was inconclusive, although there is the suggestion that HIV -1 exposed 
infants may be more likely to present with high load HHV -6 infections at 18 months. This is 
contrary to the effect seen for HCMV which showed high load infections were more common 
in exposed infants but only at the earlier time point. 
Age HIV-l unlnfected HIV-llnfected P Total· 
Month 6 13% (5/38) 0% (0/3) 1.0" 13% (6/46) 
Month 18 2% (1/44) NO NO 2% (1/45) 
Morbidity 0% (0/6) 0% (0/2) NO 0% (0/13) 
Age HIV-l unexposed HIV-l exposed P Total· 
Month 6 14% (5/35) 14%(1/7) LO" 13% (6/46) 
Month 18 0% (0/33) 13%(1/8) .195" 2% (1/45) 
Morbidity 0%(0/5) 0% (0/5) NO 0% (0/13) 
Table 15: High HHV-61oad stratified by both maternal and infant HIV-I status 
Significance was by Pearson Chi Squared or Fishers exact test ("). *The totals columns include subjects with 
unknown HIV-I infection or exposure status. 
4.7 HHV -6 and HCMV DNA loads in the respiratory mortalities cohort 
For HCMV, DNA loads were compared between the symptomatic cohorts. Due to limited 
sample volumes, HHV -6 DNA load data was not available for the hospitalized fever cohort 
and so comparisons are made here between HCMV and HHV-6 loads detected in the 
respiratory mortalities cohort alone, with both viral loads being normalized relative to cellular 
genome equivalents for comparison. Median values for the level of both viruses were similar 
although some HCMV infections had considerably higher loads, possibly representing active 
pulmonary HCMV infections at time of death in these children. 
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Figure 18: HHV-6 vs HCMV loads in respiratory mortalities cohort 
Comparison ofHHV-6 and HCMV viral loads in respiratory mortalities cohort. As DNA was extracted from 
variable quantities oflung tissue (interspersed with blood) viral loads were normalized to cell number using the 
GAPDH Real Time Taqman assay as described previously (Section 3.5). Bars represent median values. 
4,8 HHV -6 genotype analysis 
Genotypic analysis of HCMV focussed on the two linked hypervariable genes, UL 73 and 
UL74, which encode for the glycoproteins gN and gO respectively. The HHV-6 genome 
encodes homologues ofthese two glycoproteins (U46 and U47 respectively) and so these 
were the focus of genotyping analysis presented here for HHV -6. Although less variation is 
shown in these genes than for their homologues in HCMV, they differentiate between HHV-
6A and B, as well as showing intra-strain variation as previously for U47 (Gompels, 2006). 
When comparing amino acid sequences for HCMV gO (UL74), the N-terminal region 
analysed here varies by up to 34% and in the full length HCMV gN (UL 73), variation was up 
to 22%. The N-terminal region of HHV -6 gO (U47) varies by just 14% and then in gN (U46), 
variation was 6% at the amino acid level. The CIGNIS cohort was screened using primers that 
target the U46 gene (U46FIU46R). PCR products were hence sequenced directly from this 
primary screen. Further primer pairs were designed to detect the U47 gene, including the 
U47FlU47R primers that were used in the primary screen of the two retrospective cohorts 
(section 4.2). Confirmation for loci was shown using the hypervariable HHV -6 specific gene 
U83 (David Clark, personal communication). Within all three cohorts, samples were not 
always detected by both U46 and U47 primers (Table 17) with analysis sometimes inhibited 
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by limited sample volumes and/or low HHV -6 viral loads. Amongst all samples positively 
genotyped as HHV-6A or HHV-6B, the relative proportions of the two variants were then 
analysed. Samples in which both variants were detected at different loci were considered dual 
infections, although with complete genomic sequence only known for four reference strains 
globally (UII02, Z29, AJ and HST) the possibility of the existence of re comb in ants (as seen 
for HCMV) cannot be ruled out. In the CIGNIS cohort, the predominant variant detected was 
HHV-6A (85%), which was significantly more prevalent than either HHV-6B (3%, P < 0.001) 
or co-infections with both variants (12%, P < O.OOI)(Table 14). HHV-68 was significantly 
more likely to be detected as a co-infection than HHV -6A (80% (8/10) vs 12.3% (8/65), P = < 
0.001). In contrast, the respiratory mortalities cohort showed 74% of infections as HHV-6B 
alone. This was significantly greater than the prevalence of HHV -6A infections (15%, P < 
0.001) or co-infections (11 %, P < 0.001). 
Cohort Age (m) HHV-6A HHV-68 
CIGNIS 6 88% (30/34) 6% (2/34) 
18 82%(27/33) 0%(0/33) 
CIGNIS (m6 + m IS) 6 + IS S5% (57/67)a.b 3% (2/67)8 
CIGNIS (morbidity) 6-IS 100% (6/6) ND 
Fever 6-34 14% (\/7) 2S% (2/7) 
Autopsy O-ISyrs 15% (4/27)" 74% (20/27td 








The total of 67 infants in the CIGNIS cohort from 6 and IS months includes just one infant (lD37) who was 





































































































































































U47 Overall HIV 
















































































































U47 Overall HIV 

























































































































N26 Autopsy B B 
N28 Autopsy B B 
N33 Autopsy B B 
N35 Autopsy B B 






























HHV-6 genotypes detected at two different loci (U46, U47). 
Overall genotypes were denoted as 'A' (on Iy A detected at 
one or multiple loci) 'B' (only B detected at one or multiple 
loci), or 'A,B' (Different variants detected at different loci). 
ND indicates that the genotype ofa given loci was 'Not 
Determined'. Offour samples HHV-6 positive at both time 
points, two were genotyped at just one time point (*), one was 
genotyped at both time points (t) and one was not genotyped 
at either time point. HHV-6 sequences from this study were 
published in 2009 (Bates et al., 2009). 
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4.8.1 HHV-6 U46 sequence alignment 
The primary screen for HHV -6 targeted the U46 gene (glycoprotein gN) using primer pair 
U46F1U46R. U46 sequence data was obtained from the sequencing of this PCR product, 
although further primer pairs and nested sets were also used for some samples (Appendix F). 
HHV-6 U46 sequence was obtained from 23/27 respiratory mortality samples, 117 
hospitalized fever samples, 39/98 CIGNIS samples (M6 and M18 combined) and 4/13 
CIGNIS morbidity samples. Sequences were aligned using ClustalW software for both U46 
(Figure 19) and U47 (Figure 20). With respect to U46, all but one CIGNIS sample (321 M6) 
were found to be HHV -6A. Little variation was observed, seen in just four of these sequences. 
However, single nucleotide substitutions were identified in two samples that led to amino acid 
changes: 449M6 (K-R) and 226morb (F-S). In two other samples (324morb and 500M18) 
a thymidine deletion was observed that results in a frame shift resulting in premature 
termination suggesting a truncated glycoprotein gN with a novel 9 residue C-terminus. This 
deletion reduced a 7T to a 6T poly T motif, and was observed in two independent samples and 
in both directions. Such a truncation may result in a gN phenotype that is either knocked out 
or weakened. The U46 sequence obtained from respiratory mortalities sample N29 contained 
a two amino acid deletion, but all other U46 sequences from the respiratory mortalities cohort 
were identical to the reference strain Z29. The one hospitalized fever sample that was typed 
for U46 was also HHV -68, but contained a single nucleotide substitution encoding a L-P 
change. Some sequences had double peaks at selected residues, indicative of possible dual 
infections as shown in reconstructions ofHHV-6A + 8 PCR using cloned genes (as indicated 
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••••• G ••• R ••••• W •••••••••••• M •••• S •••••••••••••••••••••••••••••••••••••••••••••• 
••.•• G.X.R.X ••• W •••••••••••• M •••• S •••••••••••••••••••••••••••••••••••••••••••••• 
••••• G ••• R ••••• W •••••••••••• M •••• S •••••••••••••••••••••••••••••••••••••••••••••• 
••••• G ••• R ••••• W •••••••••••• M •••• S •••••••••••••••••••••••••••••••••••••••••••••• 
••••• G ••• R ••••• W •••••••••••• M •••• S •••••••••••••••••••••••••••••••••••••••••••••• 
••••• G ••• R ••••• W •••••••••••• M •••• S •••••••••••••••••••••••••••••••••••••••••••••• 
••••• G ••• R ••••• W •••••••••••• M •••• S ••••••••••••••••••••••.••••••••••.•••••••••••• 
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Figure 19: HHV-6 U46 alignment 
HHV-6 U46 amino acid sequence alignment (excluding the four C-terminal residues VKGY) showing two 
reference strains (UII02 - HHV-6A, and Z29 - HHV-68) along with those from the respiratory mortalities (N), 
hospitalized fever (K) and CIGNIS ('M6', 'MI8' or 'morb' suffix) cohorts. In the alignment, dots indicate 
identities relative to reference UI 102 sequence (HHV-6A). X's indicate double peaks that could not be resolved 
in either direction consistent with dual infection. Question marks indicate terminal regions that are unknown 
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4.8.2 HHV-6 U47 sequence alignment 
The U47 gene was also amplified and sequenced using three sets of primers. U47 DNA 
sequence data was obtained for, 26/27 respiratory mortality samples, 417 hospitalized fever 
samples and 45/98 HHV-6 positive CIGNIS samples (M6 and M18 combined) and just 1113 
morbidity samples. DNA sequence was edited as described and an amino acid sequence 
alignment was constructed using ClustalW software (Figure 20). As with U46, many 
sequences were identical to either the HHV -6A or HHV -68 reference sequences (U 11 02 and 
Z29 respectively). A similar proportion of sequences showed novel amino acid substitutions 
within both U46 (16% (10173» and U47 «(15% (13/85». However this rate of detection of 
novel sequences for both HHV -6 loci was significantly lower than for their respective HCMV 
homologues: HCMV UL73 «46% (22/48» and HCMV UL74 (52% (29/56». Of 15 
substituted amino acids with the U47 sequences, just two were previously shown in febrile 
Zambian infants (Kasolo et aI., 2007), suggesting broader variation within the population at 
large. Sequence for ID 514M6 contained a C-+A point mutation (on both forward and reverse 
strands) that introduces an in-frame stop codon, resulting in a HHV -6A protein of 173 























































































??????? ............................................................ . 
?????????? ......................................................... . 
?????????? ......................................................... . 
?????????? ......................................... " '" '" ., ...... . 
.......... S ............... S .......................••..•.••.••.•.•.... 
•••••.•••.••••••••••••• A ••••••••••••••••.••••••.••••.••••.••••••••••• 
••••••••••••••• P ••••••••••••••••••••••••••••••••••••••••••••••••••••• 
.••..••••••••••••..••••••••••...••..•• F •...•••.••••.••••.••.•........ 
•••••••••••••••••• P •••••••••••••••••••••••••••••••••••••••••••••••••• 
.••.•...•.........••.• S •...••..••••...•••..••.•..•.•.•••••.••.•.•.... 
•••.•..••.•...•.•••.. P ••...•••.•••••• S ••••.•..••••••.•••••.••.••..•.. 
•••••••••••••••••••••••••••••••• G •••••••••••••••••••••••••••••••••••• 
•••••••••••••• D •••••••• M ••••••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••.•••••.••.••••••••••••.•••••••••••••••••••••••• X ••••.• 
•••.••• I •••••.•.••••• X • XXXX •••••••••••••••••• XX •••••• EH •••••••••••••• 
?????????? .......... P •• PE1 ••••••••••••••• A ••• R •••••• EH ••••• ????????? 
D ••. Q .. I ............. P •• PE1 ••••• C •••••••••••• 1R •••••• EH •••••••••••••• 
D ••• Q •• I ............. P •• PE1 •••••••.•••••.•••• 1R •••.•• EH •.••••.••.•••• 
D ••. Q •• 1 ••••••••••••• P •• PE1 •••••••••••••••.•• 1R •••••• EH •••••••••••••• 
D ••• Q •• 1 •.•••••.••.•• P •• PE1 .••••••••..••••.•• 1R •••.•• EH .••..•..•••... 
D ••• Q •• 1 ••••••••••.•• P •• PE1 •••••••••••••.•••• 1R •••••• EH •••••••••••••• 
D ••• Q •. I ............. P .• PE I .................. I R •••••• EH •••••••••••••• 
D •.. Q •• 1 ••••.•.•.•••. P •• PE1 •.•••••••••.•••••• 1R •••.•• EH •••••••••••..• 
D ••• Q •• I ............. P •• PE1 •••••••••.•••••••• 1R •••••• EH •••••••••••••• 
D ••. Q •• 1 •.••••••••••• P •. PE1 •••••••••••••••••• 1R •••••• EH ..••.•.•••.•.. 
D ••• Q •• I ............. P •• PE1 •••••••••••••••••• 1R •••••• EH ••••••••••••.• 
D ••• Q •• I ............. P •• PE1 •••••••••••••••••• 1R •••••• EH ••••••.••••••• 
????? .. I .........•... P •• PE1 •••••••••••••••••• 1R •••••• EH •••••••••••••• 
D ••• Q •• I ............. P •• PE1 •••••••••••.•••••• 1R •••••• EH •••.••.••••••• 
D ••• Q •• I ............. P .• PE1 •••••••.•••••.•••• 1R ••••.• EH ••.••••••••••• 
D ••• Q •• I ••••.•••••.•• p •• PE1 ••••••.••••••.••.• 1R •••••• EH •••••••••••••• 
????????????????????????????????????????????????S .... EH ............. . 
D ••• Q •• I ............. P •• PE1 •••••.•.•••••.•••• 1R •••••• EH .••••••••••••• 
D ••• Q •• 1 ••••.•••••••• P •• PE1 •••••••••••••••••• 1R •••••• EH •••••••••••••• 
D ••• Q •. I ............. P •• PEI •..••••••••••••••• 1R •••••• EH •••••••••••••• 
D •.• Q •. I ............. P •• PE1 •.•••••••••.•••••• 1R ••••.• EH ..••.•••.•••.. 
D .•• Q •. 1 ••••.•••••••• P •• PE1 •••••••••••••••••• 1R •••••• EH •••••••••••••• 
D ••• Q •• I •.••.•••••••• P •. PE1 •.••.••.••.••••.•• 1R ••.... EH .••••.•••.•.•• 
?????????? .......... P •• PE1 •.•••••••••.•••••• 1R ••.••• EH ••••.••••••.•• 
D ••• Q •• I ............. P •• PE I .................. I R ••••.• EH •••••••.•••••• 
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N25(B) D ••• Q •• 1 ..••••••••••• P •• PE1 ••••••.••••••••••• 1R •••••• EH •••••••••••••• 
N26 ?????????? .......... P •• PE1 ••••••.••.••.•.•.• 1R ••.•.• EH •.•.•.••.•••.• 
N2B D •.• Q •• 1 ••••••••••••. P •• PE1 •.•••••••.••••.••• 1R ••.••• EH ••••..••••••.• 
N33 D •.• Q •• 1 .•••••.•••.•• P •• PE1 ••••••••••••••.••• 1R ••.••• EH •.•.•.•••••••• 
N35 D •.• Q •• I .••.•.•••..•. P •• PE1 •.••••••••••••••.• 1R ••••.• EH ••••••••.••••• 
Z29 D •.• Q •• 1 •••••.••••••• P •• PE1 •.•••••••••••••••• 1R ••.••• EH •••••••••••••• 
Figure 20: HHV-6 U47 alignment 
HHV-6 U47 amino acid sequence alignment ofa 69 amino acid section (residues 161-229 ofU47 from both 
references strain), showing two reference strains (U 11 02 - HHV -6A, and Z29 - HHV -6B) along with those from 
the respiratory mortalities (N), hospitalized fever (K) and CIGNIS ('M6', 'M 18' or 'morb' suffix) cohorts. The 
suffix 'Gi' indicates that the detection was on extracted DNA that had been archived using Genomiphi. The 
Suffixes '(A)' and '(B)' indicate where HHV-6A and B were detected in different amplifications of the same 
sample. In the alignment, dots indicate identities relative to reference U 11 02 sequence (HHV -6A). Question 
marks indicate terminal regions that are unknown. 
4.9 Discussion 
In this chapter we have shown for the first time active HHV -6 infections in a population of 
infants in Zambia. HHV-6 sera-DNA prevalence in the CINGIS cohort was 8% at 6 months, 
rising to 13% at 18 months of age. This is broadly consistent with a US study on cumulative 
detection of HHV -6 secretion in saliva by PCR, in which infection occurred at a rate of 
4.5%/month (Zerr et aI., 2005). HHV -6 active infections were significantly more prevalent 
within CIGNIS morbidity samples from infants hospitalized during the study. The overall rate 
of detection of HHV -6 active infections was significantly lower than that of HCMV, 
reflecting possibly slower uptake and shorter periods of active infection, or this could in part 
be explained by differences in assay sensitivity. No significant differences were seen in the 
prevalence of HHV -6 active infections by either infant or maternal HIV -I status, suggesting 
equal exposure but outcomes may be different. HHV -6 analysis of the two retrospective 
cohorts was undertaken with a PCR assay designed to detect only higher load infections that 
might be responsible for disease. In hospitalized febrile infants, there was no significant 
difference in the prevalence ofHHV-6 (DNA extracted whole blood) between HIV-l negative 
and positive infants. Conversely, prevalence of HHV -6 DNA detection was very high (72%) 
in lung tissue samples from HIV -1 positive children who died of respiratory disease. HHV-6 
loads in the respiratory mortalities study were high with a median of just over 100 copies/I 06 
genomes equivalents, although a previous study did not find any difference between HHV-6 
loads in lung tissue from patients with interstitial pneumonia and controls (Yamamoto et aI., 
2005). The respiratory mortalities studied here were all from children with end-stage AIDS 
however and, like HCMV, HHV-6 may be an important underlying infection which may 
respond to treatment. Chapter 5 contains further analysis on the clinical outcomes of this 
population-based study. 
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The predominant strain variant detected in healthy Zambian infants is HHV -6A. This finding 
is the exact opposite of that seen in studies in Europe or North America, where 97% of infant 
primary infections are caused by HHV -68 (Dewhurst et aI., 1993; Hall et aI., 2006; Zerr et aI., 
2005), and where HHV -6A is considered more prevalent in older individuals, especially those 
on immunosuppressive therapy or with HIV / AIDS (Ablashi et aI., 1998; Iuliano et aI., 1997; 
Secchiero et aI., 1995). In contrast to the population-based CIGNIS study, symptomatic HHV-
6 infections in Zambia, notably those associated with end-stage AIDS, were predominantly 
HHV-6B. It has been shown previously that HHV-6A products can infer an inhibitory effect 
on HIV-l CCR5-tropic strains, through the blocking of this co-receptor with the viral 
chemokine U83A and also stimulating the immune response which may protect against HIV-l 
(Catusse et aI., 2007). Interestingly, the same chemokine in HHV -68 (U838) does not bind 
CCR5 and chemattracts a different cellular subset (Luttichau et aI., 2003). These differences 
in the two HHV -6 strain variants, and the exclusive interaction of the A variant with the HIV-
1 co-receptor, suggest that the findings here that HHV -6A predominates in and HIV-l 
endemic region could have significant effects on the course of disease progression. 
Here we have genotyped HHV-6 primarily based on the analysis of two genes, U46 and U47, 
which encode the variable glycoproteins gN and gO respectively. Variation within the two 
glycoprotein genes is less than in the HCMV homologues and many strains show identical 
sequence to the two reference strains UII02 and Z29. The U47 gene has been analysed 
previously and so it was possible to combine sequences obtained here with those that have 
been previously published (Gompels, 2006)(Figure 21). This data shows mosaics of the U47 
gene that resemble aspects of both strain variants, providing evidence for recombination in 
this population where both strain variants are prevalent. The biological role of glycoproteins 
gO and gN (in both HHV -6 and HCMV) are worthy of further investigation which may shed 
light on function of this variation. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 VARIANT 
Z29 D Q I S N L S P F T P E I S L L I R E H T F B 
467M6Gi C B 
Zam3 E R M B/A 
Zam14 E R M L . B/A 
Zam15 E R M 
· 
N . . . B/A 





Zam50 E R M K B/A 
Zam317 E R M 
· · · 
. K Q B/A 




V P Q A/B 




S V P Q . A/B 




S . L P K A/B 
Zam5 E R M S 
· 
S V P K Q A/B 
Zam7 E R M 
· 
S S N 
· 
V P K A/B 




V P K Q L A/B 




S N V P K Q I . A/B 
Zam59 E R M S 
· 
S K N 
· · 
V P K Q L A 




S K N 
· 
V P K Q A 
Zam23 E R M 
· · 
S S K V P K Q A 




S K N G V P K Q A 
219M18 E R M S K N S V P K Q A 




S K N 
· · 
F V P K Q A 
174M18 E R M 
· 
. P S 
· 
S K N V P K Q A 
151M18 E R M 
· 
P S S K N V P K Q A 
556M6 E R M D 
· 
S M S K N V P K Q A 






A S K N 
· · 
V P K Q A 
206M18 E R M 
· 
S S S K N 
· 
V P K Q A 
U1102 E R M 
· 
S S K N 
· · 
V P K Q A 
Figure 21: HHV-6 U47 global alignment 
Alignment (adapted and including data from (Gompels, 2006» for an N-terminal portion of the HHV-6 U47 
gene showing only variable residues. Column numbers refer to amino acids 161, 165, 168, 173, 174, 175, 178, 
182, IS3, 184, IS5, 186, 187, 193, 198, 199, 206, 207, 214, 215, 223 and 226 relative to the l29 HHV -6B 
reference strain. Representative examples of all available variants are shown and other sequences from this 
study, identical to representative strains shown are as follows: HHV-6B: l29 (HST, 37M18Gi, 540M6), lam3 
(lamI3, Zaml8, Zam25 lam31, MBE, L9, MAR, BOU), lam5 (AJ) and HHV-6A: UI102 (lamB35, 
lamB63, ZamB66, lamB67, 37MIS, 39M18, 76MIS, 77MlS, 7SM18, 82M18Gi, 99M18, 109M18, 129MI8, 
13SM18, 143MIS, 163M18, 169M6,225MI8,278MlS,444M6,449M6,455M6,459M6,462M6,467M6, 
470M6,493M6,494M6,50IM6,503M6,504M6,507M6,514M6,538M6 
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Prior to this study, there was no HHV -6 strain variant data from a population based cohort in 
Africa. This despite the fact that the two major reference strains used to type HHV -6 variants 
were isolated from AIDS patients in Uganda (HHV-6A strain Ul102) and the Democratic 
Republic of Congo (HHV -68 strain Z29). Whilst in Europe and North America HHV -68 is 
responsible for over 97% of primary infections during infancy (Dewhurst et aI., 1993; Hall et 
aI., 1994), HHV -6A is thought to be a later infection and is associated more with neurological 
disorders (De Bolle et aI., 2005; Hall et aI., 1998) and there are many case reports of HHV -6A 
infections in immunosuppressed patient groups as reviewed (Gompels, 2004). In Zambia 
however, it was shown previously that HHV -6A and HHV -68 were of roughly equal 
prevalence in febrile infants (Kasolo, Mpabalwani, and Gompels, 1997). The most important 
finding here is that HHV -6A, not HHV -6B, is the predominant infection in healthy Zambian 
infants. This is juxtaposed against the predominance of HHV -68 in a group of HIV -1 positive 
children who died from respiratory disease, and raises questions as to whether our 
understanding of the epidemiology ofHHV-6 infections from European, North American and 
Japanese studies, can be applied globally. Primary HHV-6 infections occur during infancy 
and are largely acquired from the mother or from other close family members (van Loon et 
aI., 1995). Here we show that HHV -6A is endemic to Southern Africa, and may more recently 
have spread to other parts of the globe, where it may be responsible in part for some emerging 
diseases? 
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5.0 Betaherpesvirus infections in HIV-l exposed infants and 
effects on micronutrient fortification 
5.1 Introduction 
CIGNIS (Chilenje Infant Growth Nutrition and Infection Study) is a placebo controlled trial 
with the objective of testing the efficacy of a micronutrient fortified feed supplement to 
improve immunity and reduce stunting and morbidity in HIV -I negative Zambian infants 
born to HIV-I positive mothers. These 'HIV-I exposed' infants have been previously shown 
to suffer from impaired growth compared to 'HIV-I unexposed' infants (HIV-I negative 
infants of HIV -1 negative mothers )(Makasa et aI., 2007). Due to the expanding HIV-l 
pandemic, and with programmes to reduce mother-to-child transmission now in place in many 
countries, this HIV -1 exposed group is also expanding, but the reasons for impaired growth 
are not fully understood. 
The previous two chapters have established baselines in this population for betaherpesvirus 
prevalence and strain variants present. We have shown, as elsewhere, that both HCMV and 
HHV -6 are pathogens associated with severe morbidity in HIV -1 infected infants (Kositanont 
et aI., 1999; Kovacs et aI., 1999). We have also shown higher prevalence of high load HCMV 
(but not HHV-6) sera-DNA in HIV-I exposed infants, and in this chapter the effect of 
betaherpesvirus infections on these infants will be investigated further, as affected by a 
micronutrient fortification tested to improve development in HIV -I exposed but uninfected 
infants. HCMV and HHV-6 sera-DNA detection (indicative of active infections) and also 
HCMV sera-antibody detection at 18 months (a measure of overall seroprevalence) will be 
analysed with respect to other markers of immunity, nutrition and growth. HCMV 
seroprevalence was assayed by KM, an MSc project student (methods), and his results are 
further analysed here. Other members of the CIGNIS team have been involved in collecting a 
variety of data that are analysed here: Level of maternal education, family's socioeconomic 
status (determined by Asset Index Score), duration of breast feeding, haemoglobin levels, 
reported fever (defined as fever reported in the 3 days prior to sera sampling), responses to 
polio vaccination, rate of referrals and finally anthropometric data. Betaherpesvirus sera-
DNA, HCMV sera-antibody and HIV -I infection and exposure were cross tabulated with all 
nominal variables and significance of associations was assessed using P,earson' s Chi Squared. 
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The appendixes H-Q contain further statistical analyses performed by the study statistician, 
KB, which are related to some of the conclusions discussed. 
5.2 Effects of HIV-l infection and exposure on markers of morbidity and 
growth 
All mothers were asked at recruitment for their antenatal HIV -1 status, which in Zambia is 
routinely tested in the third trimester of pregnancy. Responses were scored as 'positive', 
'negative' or 'don't know/declined'. All infants who complete the study were tested for HIV-
1 at 18 months of age. This is standard procedure in Zambia and complies with guidelines laid 
out by the Ministry of Health. With this data, infants were defined as either HIV -1 infected 
(HIV -1 positive infant, irrespective of maternal HIV -1 status), HIV -1 exposed (HIV-l 
negative infants (including unknowns) of HI V-I positive mothers) and HIV-J unexposed 
(HIV-I negative infants (including unknowns) of HI V-I negative mothers. The CIGNIS study 
was population based and designed to study the effects of a micronutrient fortified feed 
supplement on morbidity and growth in HIV -1 exposed infants. Of a total of 812 mothers I 
taking part in the study, 564 (69.5%) were HIV-l negative, 177 (21.8%) were HIV-l positive 
and 71 (8.7%) either didn't know or chose not to disclose their status. With successful 
implementation of single dose Nevirapine therapy in Lusaka, rates of mother-to-child-
transmission have been reduced significantly. We found 8% (12/152) of infants who were 
born to HIV -1 positive mothers, were HIV -1 positive when they completed the study at 18 
months of age. There were 20 HIV -1 positive infants in total, 6 were born to HIV -1 negative 
mothers (likely due to postnatal infection) and 2 were born to mothers with unknown 
antenatal HIV -1 status. Correlations between infant HIV -1 status or HIV -1 exposure and other 
outcomes are summarized in table 18 and table 19 respectively (Pages 119 and 120). 
HIV -I is known to be transmitted vertically through breast milk (de Martino et aI., 1992). 
Mothers were surveyed and asked if they were breast feeding at recruitment. Their answers 
were scored as either 'yes' (currently breast feeding), 'no' (stopped breast feeding before 6 
months) or 'never' (study infant has never been breast fed). Low adherence to breast feeding 
among HIV -1 positive mothers is well documented (Fadnes et aI., 2009) and this is likely a 
major cause of growth faltering among HIV -1 exposed infants (Arpadi et aI., 2009). This is at 
the crux of the CIGNIS study which aims to improve growth and reduce morbidity in HIV-l 
I There were actually only 799 mothers but the 13 pairs of twins enrolled onto the study were treated as 26 
individual cases 
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exposed infants through an intervention with fortified feed supplement. In keeping with 
previous findings, HIV -1 exposed infants were significantly less likely to have been breast 
fed, with 27% (44/165) having never breast fed (compared to 0.5% (3/558) of HI V-I 
unexposed) and only 43% (71/165) breast feeding for 6 months or longer (compared to 93% 
(538/558) of HI V-I unexposed infants)(Table 19, Figure 22). Among HIV-l infected infants, 
75% (15/20) were still being breast fed at 6 months, demonstrating the known link between 
breast feeding and MTCT (Table 18, Figure 22). 
1 
.HIV-1 infected 1 
~HIV-1 exposed P < 0.001 
OHIV-1 unexposed (15/20) 
(538/558) 
(3/558) 
Never No Yes 
Breast feeding at recruitment 
Figure 22: Maternal HIV -1 infection associated with earlier cessation of breast feeding 
Prevalence of HIY -1 infected, exposed and unexposed infants by breast feeding duration. Significance is by 
Pearson Chi Squared. 
In this cohort, maternal education level bore no correlation to HIV -I infection (Table 18) or 
exposure (Table 19). Whilst HIV -1 exposed infants were significantly more likely to be from 
the low socioeconomic group (41 % (67/165) vs 31 % (1 75/558)(P = 0.027), the numbers of 
HIV -1 exposed infants did not differ significantly between middle and higher socioeconomic 
groups (Table 19). 
No study to date has assessed the uptake of oral polio vaccine in HIV -1 exposed but negative 
infants. Here we have measured vaccine titres in 18 month old Zambian infants by 
neutralization assay, and analysed them with respect to HIV-l infection or exposure. Polio 
neutralizing antibody titres were available for 11 HIV -1 positive infants on the CIGNIS study. 
35% of these infants failed to mount a protective response, and those who did mounted lower 
responses than among HIV -1 uninfected infants (Figure 23a). In contrast, the effects of HIV-l 
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exposure were not so severe, but still HIV -1 exposed infants were less likely to mount high 
response and more likely to have low or un-protective responses (Figure 23b). This suggests 
that humoral immunity in HIV -1 exposed infants could be impaired compared to that of HIV-
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Figure 23: Polio vaccine failures and lower responses were associated with "IV-) infection and exposure 
Percentage prevalence of un-protective, low, medium and high, polio neutralizing antibody titres by a) infant 
HIV-l status and b) HIV-l exposure. Infant HIV-I status was determined by detection of antibody at 18 months 
of age. HIV-I exposure was defined by maternal antenatal HIV-I status reported on recruitment as positive and 
infants 18 month antibody test being negative. Polio vaccine uptake was monitored by a neutralization assay 
with titres binned as un-protective «l/g), low C/g-1ln ), medium CI64-IISd and high ClI024.I/204g). Significance is 
by Pearson Chi Squared. 
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Category/ Infant HIV-l sera-Ab at 18 months 
month HIV·l Negative HIV·l Positive P 
DemoerlDhlcs 
Gender 
Male 47% (290/325) 50% (10/20) 
.807 
Female 53% (324/614) 50% (10/20) 
None 5%128/614) 10% (2/20) 
Primary 36% (162/614) 35% (7/20) 
Maternal Education Secondary 40% (243/614) 35% (7/20) .427 
Tertiary 28% (169/614) 15% (3/20) 
University 2% 112/614) 5% (1/20) 
Low 32" (198/614) 35" (7/20) 
5ocio-economic status Medium 38" (236/614 SO" (10/20) .352 
Hi~h 29" (180/614 15" (3/20) 
Never 7" (42/614) 10% (2/20) 
Breast feeding at baseline No 9% (58/614) 15% (3/20) .584 
Yes 84% (514/614) 75% (15/20) 
Morbidity 
Un-protective 2% (9/580) 35% (6/17) 
Polio Ab neutralization titre Low 8% (47/580) 35% (6/17) <.001··· 
(12 months) Medium 64% (369/580) 18% (3/17) 
High 27% (114/580) 12% (2/17) 
6 13% (81/614) 10% (2/20) .677 
Fever 18 11%(53/467) 0% (0/17) .141 
6 37% (225/605) 63% (12/19) .022·· 
Anaemic 18 29% (176/607) 63% (10/16) 
.004··· 
6 40" (156/392) 53% (10/19) .265 
HCMV sera-DNA 18 33" (128/383) 39" (5/13) .705 
6 8%(38/461) 16% (3/19) .249 
HHV-6 sera-DNA 18 13% (49/384) 14% (2/14) .697 
HCMV antibody 18 84" (376/450) 78% (7/9) .644 
Referral Rate 0.18 0.55 .002·· 
Died 0% (0/614) 5% (1/20) <.001··· 
Growth 
6 13%171/557) 12% (2/17) .905 
Stunted 18 20% (105/524) 29% (4/14) .433 
HIV·l Negative HIV·l Positive 
N= Mean N= Meln P 
6 556 0.0186 17 0.0076 0.970 
BMI-for-age 18 524 0.1203 14 -0.1043 0.435 
6 556 -0.4537 17 -1.0035 0.069· 
Weight-for-age 18 526 -0.5674 15 -0.7220 0.626 
6 557 -0.8131 17 -1.5888 0.007·· 
Length/height-for-age 18 524 -1.0817 14 -1.1579 0.809 
6 557 -0.1353 17 -0.7671 0.016·· 
Triceps skinfold-for-age 18 525 0.1739 15 -0.1440 0.194 
6 557 0.4473 17 -0.0335 0.110 
Subscapular skinfold-for-age 18 525 0.5174 15 -0.2133 0.006·· 
6 557 0.3215 17 -0.2341 0.048" 
Arm circumference-for-age 18 524 0.0789 15 -0.5153 0.041 0 • 
6 557 0.6481 17 0.3782 0.288 
Head circumference-for-age 18 525 0.5454 15 0.5607 0.954 
Table 18: HIV-I infected mfants have low polio vaccme response, mcreased anaemia, are stunted and 
have less fat 
Distribution of infants by HIV -I status (antibody test at 18 months) with respect to maternal education (as 
surveyed on recruitment), socioeconomic status (determined by Asset Index Score), breast feeding category 
(Never = not breast fed at baseline, No = breast feedings stopped before 6 months and Yes = breast feeding at 
and beyond 6 months), Polio antibody titres (measured by neutralization assay with titres binned as un-protective 
«I/S)' low (' /s-' /n), medium Ch,rl /m ) or high (>1/512», prevalence of reported fever (in the 3 days prior to clinic 
visit) and prevalence of anaemia (as defined by Hb levels of < 10.5 g/L) at both the month 6 and month 18 visits 
and anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -2.0. Mean z-
scores were compared by independent sample T test assuming equal variance and P values for nominal variab les 
were by Pearson Chi Squared. White boxes highlight significant findings, light grey indicates trends. Asterisks 
denote degree of significance • < 0.1 , •• <0.05, ••• <0.005 . ND = not done, NA = not applicable 
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HIV·l exposure 
Catelory/month (maternal reported status at recruitment) 
HIV-l unexposed HIV-l exposed P 
Demoaraphlcs 
Male 49% (273/558) 45% (74/91) 
.357 Gender Female 51% (285/558) 55% (91/165) 
None 5% (25/558) 7% (11/165) 
Primary 26% (145/558) 33% (55/165) 
Maternal Education Secondary 38% (213/558) 36% (60/165) .106 
Tertiary 30% (166/558) 21% (35/165) 
University 2% (9/558) 2% (4/165) 
Low 31% (175/558) 41% (67/165) 
Socio-economic status Medium 39% (219/558) 35% (57/165) .086· 
High 29% (164/558) 25% (41/165) 
Never 0.5% (3/558) 27% (44/165) 
Breast feeding at baseline No 3% (17/558) 30% (50/165) <.001"· 
Yes 93% (538/558) 43% (71/165) 
Morbidity 
Un-protective 1% (4/399) 3% (4/133) 
Polio Ab neutralization titre Low 7% (29/399) 13% (17/133) 
.016·· (12 months) Medium 63% (250/399) 65% (87/133) 
High 29% (116/399) 19% (20/133) 
6 12% (65/558) 13% (22/165) .559 
Fever 18 11% (40/359) 8% (8/104) .310 
6 38% (210/550) 37% (60/162) .792 
Anaemic 18 29% (121/417) 31% (43/141) .739 
6 37% (132/359) 43% (41/96) .287 
HCMV sera-DNA 18 35% (95/274) 28% (22/78) .285 
6 9% (36/426) 6% (7/117) .381 
HHV-6 sera-DNA 18 13% (36/275) 13% (10/78) .950 
HCMV antibody 18 85% (263/311) 82% (81/99) .517 
Referral Rate 0.21 0.35 .007· 
Died 0.5% (3/558) 5% (8/165) <.001··· 
6 11% (58/513) 18% (26/148) .044·· 
Stunted 18 18% (65/369) 30% (34/112) .003··· 
Growth 
HIV-1 unexposed HIV-1 exposed 
N= Mean N= Mean P 
6 512 0.0973 148 -0.1866 .010·· 
BMI-for-age 18 369 0.1759 112 -0.0037 .117 
6 512 -0.3752 148 -0.7413 .001··· 
Weight-for-age 18 371 -0.4745 112 -0.8679 .003··· 
6 513 -0.7799 148 -1.0424 .008·· 
Length/height-for-age 18 369 -1.0019 112 -1.4058 .001··· 
6 513 -0.0841 148 -0.3022 .027·· 
Triceps skinfold-for-age 18 370 0.2551 112 0.0321 .029" 
6 513 0.5287 148 0.1211 <.000··· 
Subscapular skinfold-for-age 18 370 0.5934 112 0.3990 .on· 
6 513 0 .4386 148 -0.0610 <.000·" 
Arm circumference-for-age 18 369 0.1934 112 -0.2656 <.000··· 
6 513 0.7254 148 0.3730 <.000··· 
Head circumference-for-age 18 370 0.6519 112 0.2648 .001·" 
Table 19: HIV-I exposed mfants are stunted and have consIstently lower anthropometrIc mean z-scores 
Distribution of infants by HIV -I exposure with respect to maternal education (as surveyed on recruitment), 
socioeconomic status (determined by Asset Index Score), breast feeding category (Never = not breast fed at 
baseline, No = breast feedings stopped before 6 months and Yes = breast feeding at and beyond 6 months), Polio 
antibody titres (measured by neutralization assay with titres binned as un-protective «1/8), low (' /8- 1/ 32 ), medium 
(1/64- 1/512) or high (>1/512 )), prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of 
anaemia (as defined by Hb levels of < 10.5 glL) at both the month 6 and month 18 visits and anthropometric 
markers of growth. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores were compared by 
independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi 
Squared. White boxes highlight significant findings, light grey indicates trends. Asterisks denote degree of 
significance * < 0.1, ** <0.05, *** <0.005. ND = not done, NA = not applicable 
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HIV -1 positive infants showed significantly higher levels of anaemia at both time points and 
did not show the decrease over the 12 month duration of the study seen with the HIV-l 
negative children, with prevalence of anaemia at month 18 remaining over 60% among HIV-l 
positives (Figure 24a), whereas for the population as a whole the prevalence of anaemia 
dropped significantly from 39% (3101798) to 30% (186/626) during the course of the study (P 
< 0.001). With respect to maternal HIV -1 status, prevalence of anaemia did not differ 
significantly at either time point (Figure 24b). 
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Month 6 Month 18 
Figure 24: Prevalence ofanaemia is higher in HIV-} infected infants but does not differ by maternal HlV-
I exposure. 
Anaemia was defined by a sera-haemoglobin concentration of less than 10.5 g/L. Significance is by Pearson Chi 
Squared. 
The primary outcome of the CIGNIS intervention was growth, and so infants taking part in 
the study had anthropometric measurements taken at 6, 9, 12, 15 and 18 months of age. Over 
the 12 months of the study, BMI (Body Mass Index)-, weight-, length-, triceps skinfold-, arm 
circumference- and head circumference-for-age z-scores all changed significantly describing 
the infants growth relative to their age. Here baseline (month 6) and endpoint (month 18) 
measurements are analysed with respect to HIV -1 infection and exposure. At baseline, HIV-I 
positive infants showed a trend for lower weight, but had significantly lower length, triceps 
skinfold and arm circumference mean z-scores. Their BMI and head circumference mean z-
scores did not differ significantly at recruitment. By 18 months of age, many of these 
differences were resolved, the only significant differences being lower mean z-scores for arm 
circumference and sub-scapular skinfold (Table 18). Compared with those who were HIV-I 
infected, HIV -1 exposed infants had poorer growth outcomes, having lower mean z-scores of 
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many anthropometric measures persisting to month 18. The exceptions just outside of 
significance were BMI and subscapular skinfold at month 18 (Table 19). The effects on length 
can also be expressed through prevalence of stunting (length-for-age z-score of less than -2), 
with HIV -1 exposed infants being almost twice as likely to be stunted by the time they are 18 
months old (Table 19). 
A total of 152 infants were referred at least once during the course of the study. The three 
most common primary diagnoses were acute diarrhoea (n = 40), malaria (n = 32) and 
pneumonia (n = 29). The remaining 51 primary diagnoses included 6 infants with protein 
energy malnutrition, 5 with skin infections and 4 with measles and a range of other infectious 
conditions. Referrals for treatment of physical injuries or deformities (Burns, Hernia, 
Phimosis and Talipes) were excluded from the analyses. Referral rates for sub-groups as the 
total number of referrals per 100 person years and were compared by the study statistician, 
KB, using the Cox regression methods and the Breslow method for ties. The referral rate was 
300% higher among HIV-I infected verses HIV-I uninfected children (0.55 vs 0.18, P = 
0.002)(Table 18), consistent with higher rates of morbidity due to HIV -1 infection (Appendix 
I, section 9.10.1). The rate of referrals was over 50% greater among HIV -1 exposed than 
among HIV -1 unexposed infants (0.35 vs 0.21, P = 0.007)(Table 19), also suggestive of 
higher rates of serious morbidity (Appendix J, section 9.10.2). 
There were a total of twelve deaths on the study (Table 20) and initially it looks as if 
mortalities are significantly higher among HIV -1 exposed infants than unexposed (Table 19). 
This is misleading however, as the HIV -1 status was only known for one of these twelve 
children (The mother of this child was actually HIV -1 negative from her antenatal record 
card), and so it is not known how many of the eight HIV -1 exposed infants were actually 
HIV -I infected. Therefore, with the current data set we cannot answer the question whether 
HIV -1 exposed but negative infants have a higher mortality rate than HIV -1 unexposed 
infants, but follow up studies may shed light on this as we track infants with HIV -1 positive 
mothers who we know were HIV -1 negative at 18 months and so were genuinely exposed to 
HIV -1 but uninfected in infancy. 
122 
Sample ID 
Age at death Maternal HIV-l Infant HIV-l status Final diagnosis (months) status 
664 7 Positive Unknown Meningitis 
743 16 Positive Unknown Acute diarrhoea 
177 8 Positive Unknown Pneumonia 
242 13 Positive Unknown Pneumonia 
610 10 Positive Unknown Pneumonia 
247 18 Positive Unknown Malaria 
313 8 Positive Unknown Malaria 
614 6 Positive Unknown Malaria 
69 13 Negative Unknown Acute diarrhoea 
672 8 Negative Unknown Pneumonia 
746 6 Negative Unknown Generalized con? 
70 9 Negative HIV-1 positive PEM (oedematous) 
Table 20: CIGNIS infant mortalities 
Age at death, maternal and infant HIV-I status of the twelve infants who died during the course of the study 
showing final diagnosis. PEM = Protein Energy Malnutrition 
We have established here that, compared with HIV -1 unexposed, HIV -1 exposed infants stop 
breast feeding earlier and are severely stunted with impaired growth. Whilst at 6 months, 
HIV -1 infected infants had significantly lower z-scores (compared with HIV -1 uninfected 
infants), by 18 months of age they had made up these differences and differed only in arm 
circumference and subscapular skinfold. For HIV -1 exposed infants however, all z-scores 
were significantly lower at 6 months, and by 18 months all but two were still significantly 
lower than for HIV -1 unexposed infants. Analysis of additive effects of HIV -1 exposure and 
breast feeding duration on developmental outcomes will be presented elsewhere by other 
members of the CIGNIS team. 
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5.3 Effects of betaherpesvirus active infection on markers of morbidity and 
growth 
As shown in chapters 3 and 4, the epidemiology of both HCMV and HHV -6 appears to differ 
in Zambia as compared with Europe, North America and Japan. In these regions studies have 
shown that whilst congenital infection with HCMV is an important cause of morbidity 
(Alford et aI., 1990; Ogawa et aI., 2007), primary infection with HCMV during infancy is 
rare. Here we have found HCMV sera-DNA to be readily detectable in up to 40% of infants. 
For HHV -6, sera-DNA was less prevalent, possibly due to slower uptake or shorter periods of 
viraemia associated with primary infection or reactivation, but also partly due to the assay 
being less sensitive. Whilst HIV -1 exposure did no correlate with detection of betaherpesvirus 
sera-DNA, there was a trend for high load HCMV infections to be more commonly detected 
in HIV -1 exposed infants. We concluded in chapter 3 that whilst both HIV -1 exposed and 
unexposed infants are equally exposed to HCMV, those with HIV-l positive mothers may be 
less capable of controlling either primary infection or reactivations, giving rise to transmission 
of high load viral infection to their children. 
In this chapter HCMV and HHV -6 sera-DNA detection (indicative of active infection) are 
analysed for effects on markers of morbidity and growth in infants taking part in the CIGNIS 
study. No correlations were seen between active betaherpesvirus detection and either maternal 
education, socioeconomic status or duration of breast feeding (Table 22, Page 130). Anaemia 
was common in infants taking part on the CIGNIS study but did not differ with respect to 
detection of active betaherpesvirus infections (Table 22 and Table 26), suggesting active 
infection with these viruses does not affect haemoglobin levels. Furthermore no significant 
correlation was seen between prevalence of anaemia and betaherpesvirus loads (data not 
shown). Looking at possible interactions between the two betaherpesvirus, HCMV active 
infection at month 6 correlated with decreased prevalence of active HHV -6 infections at 18 
months (Table 22). A possible interpretation of this is that early infection with HCMV may be 
indicative of earlier infection with HHV -6, and hence a decreased prevalence of active HHV-
6 at the later time point, although HHV -6 detection at month 6 was unaffected. Broadly levels 
of detection of HHV -6 were lower, suggesting less persistent periods of viraemia during 
primary infection or less frequent reactivations. Conversely, active HHV-6 at month 6 
correlated with high HCMV at month 18, suggesting those infants with early HHV -6 primary 
infections may have weakened immunity and hence more likely to shed HCMV at the later 
time point (Table 23, Page 131). 
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Active infections with HCMV or HHV -6 may affect anthropometric parameters, and so both 
month 6 and 18 month betaherpesvirus active infections were analysed for any effects on 
mean z-scores. At 6 months, BMI, subscapular skinfold and arm-circumference were 
significantly lower among infants with active HCMV infection than among those without 
(Table 22). These findings held when adjusted for maternal education, socioeconomic status 
and duration of breast feeding (Appendix H, section 9.8). The trend for lower weight in 
infants with an active HCMV infection did not hold when adjusted. Whilst the effect on arm 
circumference did persist to 18 months, detection at active infections at that time point did not 
correlate, suggesting that in older infants active HCMV infections cause less morbidity, 
possibly reflecting better developed immunity by 18 months (Table 23). These effects were 
not observed in older children, as HCMV active infection at 18 months did not correlate with 
any anthropometric outcomes (Table 23). The arm circumference of infants with active 
HCMV at 6 months was still significantly lower at 18 months but there was no other evidence 
to suggest that active HCMV infection at 6 months affected long term development, except a 
trend for increased referrals. Inversely, there was no evidence to suggest that impaired growth 
at 6 months was associated with active HCMV infection at 18 months. 
Sub-stratifying by HIV -1 exposure showed greater decreases in 6 month subscapular skinfold 
and arm circumference among HIV -1 exposed than among HIV -1 unexposed infants, but the 
effect on BMI lost significance in these sub groups (Figure 25a)(Table 24, Page 132). 
Furthermore, active HCMV infection had a differential effect on length at 18 months: In HIV-
1 unexposed infants, active HCMV infection was associated with increased length, but among 
HIV-l exposed infants it was associated with impaired growth and >3-fold increase in the 
prevalence of stunting (Figure 25b)(Table 24). Among HIV-l exposed infants detection of 
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Figure 25: Effect of M6 HCMV active infection on anthropometry is greater in HIV-l exposed infants 
Anthropometric mean z-scores at a) 6 months and b) 18 months stratified by both HCMV active infection (at 6 
months) and HIV-I exposure. Bars represent 1 standard deviation from the mean. Asterisks denote degree of 
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Figure 26: Effect of M18 HHV-6 active infection to impair growth among HIV-J exposed infants only 
Anthropometric mean z-scores at a) 6 months and b) 18 months stratified by both HHV-6 active infection (at 18 
months) and HIV-I exposure. Bars represent I standard deviation from the mean. Asterisks denote degree of 
significance * < 0.1, ** <0.05, *** <0.005. ND = not done, NA = not applicable 
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Unlike for HCMV, active HHV-6 infections (at either time point) did not correlate with 
anthropometric baseline data or outcomes in the population as a whole (Table 25 and Table 
26: Pages 133-134), but among HIV-I exposed infants, active HHV-6 infection at month 18 
was associated with wasting (Table 27, Page 135). This effect was significant for BMI, 
weight and head circumference at month 6 (Figure 26a) and BMI, triceps and subscapular 
skinfold at month 18 (Figure 26b), although at this latter time point there were only nine HIV-
I exposed infants who were HHV -6 positive and so power is low but the direction of the 
effect was the same for all parameters. Detection of HHV -6 at baseline did not show these 
effects on anthropometric parameters (at either time point) except triceps skinfold mean z-
score was lower in HIV -I exposed infants with an active HHV -6 infection at month 6. 
However there were only three HIV -I exposed infants infected with HHV -6 at month 6 (Data 
not shown). 
HCMV sera-DNA detection at 6 months was also analysed to see if these early active 
infections had an effect on hospital referral rates over the course of the study. Among the 
population as a whole, active HCMV at month 6 was linked with a trend for increased 
referrals (Appendix J, section 9.10.3) and adjusted analysis by the study statistician suggested 
this effect was primarily within HIV-I exposed infants (Appendix J, section 9.10.4). 
Of twelve children who died during the study, eight had HIV-I positive mothers and HIV-I 
infection was suspected (although not proven) by the medical officer in several of these cases. 
Four of these infants were screened for HCMV active infection at baseline, and three had 
active HCMV (Table 21). ID70 was HIV-l positive (HIV-I DNA PCR on admission-
although mother was antenatally HIV-I negative) and died of protein energy malnutrition 10 
months after recruitment, and was also positive for HHV -6 active infection. ID313 was HIV-I 
exposed and died from malaria 12 months after HCMV detection. The third child, ID743 was 
also HIV -I exposed and died from acute diarrhoea, almost immediately after recruitment and 
detection of active HCMV. Histopathological data were not available but it is a possibility 
that this last child died with HCMV involvement in the gut as has been documented in HIV-l 
positive infants elsewhere (Ukarapol et aI., 2002; Zanolla et aI., 200 I). 
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Sample ID 
Age at death Active HCMV Active HHV-6 Maternal HIV-l Final diagnosis (months) month 6 month 6 status 
664 13 NA No Positive Meningitis 
743 6 Yes No Positive Acute diarrhoea 
177 8 NA NA Positive Pneumonia 
242 13 No No Positive Pneumonia 
610 8 NA No Positive Pneumonia 
247 10 NA NA Positive Malaria 
313 18 Yes No Positive Malaria 
614 6 NA No Positive Malaria 
69 7 NA NA Negative Acute diarrhoea 
672 8 NA No Negative Pneumonia 
746 9 NA NA Negative Generalized con? 
70 16 Yes Yes Negative PEM (oedematous) 
Table 21: Active HCMV infection detected in 75% of infants who died 
Age at death and maternal HIV -1 status along with HCMV and HHV -6 active infections in the twelve infants 
who died during the course of the study showing final diagnosis. PEM = Protein Energy Malnutrition, NA = 
sample was not available. 
In summary, active HCMV infections at 6 months (but not at 18 months) were significantly 
associated with short term inhibitory effects on weight and peripheral fat. Among HIV-l 
exposed infants early active infections and later active HHV -6 infections were associated with 
growth inhibition. Active HCMV (but not HHV -6) infection at month 6 showed a trend 
towards a higher rate of hospital referrals and was detected in 75% of infant mortalities. 
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Catecory/ HCMV sera-DNA detected at month 6 
Month Necative Positive P 
DemOlraphlcs 
Gender 
Male 48% (154/318) 45% (90/200) 
Female 62% (164/318) 55% (110/200) .447 
None 4% (13/318) 6% (12/200) 
Primary 27% (87/318) 24% (48/200) 
Maternal Education Secondary 37% (117/318) 42% (84/200) .518 
Tertiary 29% (93/318) 27% (53/200) 
University 3% (8/318) 2% (3/200) 
Low 33% (105/318) 32% (64/200) 
Socio-economic status Medium 38% (121/318) 41% (81/200 .854 
High 29% (92/318) 28% (55/200 
Never 6% (19/318) 7% (14/200) 
Breast feeding at baseline No 7% (21/318 12% (23/200) .124 
Yes 87% (278/318) 82% (163/200) 
Morbidity 
Un-protective 3% (7/229) 3% (4/160) 
Polio Ab neutralization titre Low 9% (21/229) 12% (19/160) 
(12 months) Medium 62% (142/229) 65% (104/160) .581 
High 16% (59/229) 21% (10/114 
6 10% (33/318) 15% (29/200 .159 
Feyer 18 13% (30/235) 9% /13/149) .221 
6 42% (129/308) 40% (79/199) .625 
Anaemic 18 29% (70/241) 28% (46/163) .857 
6 7% (23/316 11% (20/191) .211 
HHV-6 sera-DNA 18 17% (33/199) 8% (10/127) .023·· 
HIV-1 infected 6 4% (9/245) 6% (10/166) .265 
HIV-1 exposed 18 20% (55/282) 24% (41/173) .287 
HCMVantibody 18 84% (158/189) 86% (100/116) .540 
Referral Rate 0.22 0.32 .080-
Died 0.3% (1/318) 1.5% (3/200 .133 
Growth 
Stunted 6 11% (32/293) 10% (17/172) .725 
18 19% (43/224) 20% (28/138) .799 
N= Mean N- Mean P 
6 293 0.1533 171 -0.0973 0.023·· 
BMI-for-age 18 224 0.1822 139 0.1081 0.516 
6 293 -0.3179 172 -0.5103 0.091· 
Weight-for-age 18 225 -0.5196 139 -0.5807 0.640 
Length/height-for-age 
6 293 -0.7519 172 -0.7907 0.726 
18 224 -1.0745 139 -1.0778 0.978 
TricepS skinfold-for-age 
6 293 -0.1344 172 -0.1731 0.713 
18 225 0.2671 138 0.1632 0.316 
subscapular skinfold-for-age 
6 293 0.6316 172 0.1956 0.000··· 
18 225 0.5646 138 0.4325 0.251 
6 293 0.5724 172 0.2474 0.002"· 
Arm circumference-for-age 18 225 0.2355 138 -0.0397 0.024·· 
Head circumference-for-age 
6 293 0.7010 172 0.6173 0.384 
18 225 0.5425 138 0.5554 0.906 
Table 22: Active HCMV mfectlon at month 6 correlates WIth lower BMI and lipodystrophy at month 6 
and shows trends towards lower weight plus weakened humoral immunity 
Table showing the distribution of infants by active HCMV infection (as determined by detection of HCMV DNA 
in sera by PCR) at month 6 with respect to maternal education (as surveyed on recruitment), socioeconomic 
status (determined by Asset Index Score), breast feeding category (Never = not breasf fed at baseline, No = 
breast feedings stopped before 6 months and Yes = breast feeding at and beyond 6 months), Polio antibody titres 
(measured by neutralization assay with titres binned as un-protective «I/g) , low (l /g_I /)2), medium (1 /64-1/512) or 
high (>1/512)), prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as 
defined by Hb levels of < 10.5 glL) at both the month 6 and month 18 visits and b) anthropometric markers of 
growth. Stunting was defined by a length-for-age z score of < -2 .0. Mean z-scores were compared by 
independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi 
Squared. White boxes highlight significant findings, light grey indicates trends. Asterisks denote degree of 
significance • < 0.1 , .. <0.05, ... <0.005. ND = not done, NA = not applicable 
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Cateaory/ HCMV sera-DNA detected at month 18 
month Neaatlve Positive P 
Demographlcs 
Male 49% (128/264) 49% (65/133) 
Gender Female 52% (136/264) 51% (68/133) .942 
None 4% (10/264) 3% (4/133) 
Primary 27% (72/264) 22% (29/133) 
Maternal Education Secondary 38% (99/264) 46% (61/133) .526 
Tertiary 30% (79/264) 29% (38/133) 
Universitv 2% (4/264) 1% (1/133) 
Low 35% (91/264) 24% (32/133) 
Socio-economic status Medium 37% (98/264) 45% (60/133) .096· 
High 28% (75/264) 31% (41/133) 
Never 7% (18/264) 5% (6/133) 
Breast feeding at baseline No 8% (22/264) 8% (11/133 .658 
Yes 85% (224/264) 87% (116/133) 
Morbidity 
Un-Drotective 2% (5/254) 3% (4/131) 
Polio Ab neutralization titre Low 10% (25/254) 10% (13/131) 
(12 months) Medium 59% (151/254) 66% (87/131) .346 
High 29% (73/254) 21% 27/131) 
6 10% (27/264) 11% (14/133) .926 
Fever 18 12% (30/255) 12% (14/118) .978 
6 38% (99/258) 38% (51/133) .996 
Anaemic 18 30% (79/261) 33% (43/132) .641 
6 7% (14/215) 15% (16/110) .018·· 
HHV-6 sera-DNA 18 12% (31/264) 15% (20/132) .340 
HIV-1 infected 6 3% (8/263) 4% (5/133) .705 
HIV-1 exposed 18 24% (56/235) 19% (22/117) .285 
HCMVantibody 18 85% (161/190) 83% (90/109) .623 
Referral Rate NO NO NO 
Died 0% (0/264) 0% (0/133) NA 
Growth 
Stunted 6 11% (25/229) 10% (12/121) .772 
18 17% (38/226) 24% (29/121) .108 
N= Mean N- Mean P 
6 228 0.0419 121 -0.0454 0.499 
BMI-for-age 18 226 0.1081 121 0.0599 0.665 
6 228 -0.4431 121 -0.4994 0.654 
Weight-for-age 18 227 -0.5718 121 -0.6226 0.683 
6 229 -0.8141 121 -0.7902 0.853 
Lenath/height-for-age 18 226 -1.0732 121 -1.0875 0.908 
6 229 -0.1810 121 -0.1235 0.632 
Triceps skinfold-for-age 18 227 0.2093 121 0.1757 0.749 
Subscapular skinfold-for-age 
6 229 0.5374 121 0.3389 0.128 
18 227 0.4599 121 0.5201 0.602 
Arm circumference-for-age 
6 229 0.4428 121 0.3480 0.420 
18 227 0.1814 121 0.0660 0.318 
Head circumference-for-age 
6 229 0.6818 121 0.6624 0.861 
18 227 0.5395 121 0.5288 0.927 
Table 23: Active HCMV infection at month 18 shows trends towards lower polio vaccine responses and 
higher prevalence of HHV-6 at month 6 
Table showing the distribution of infants by active HCMV infection (as determined by detection of HCMV DNA 
in sera by PCR) at month 6 with respect to maternal education (as surveyed on recruitment), socioeconomic 
status (determined by Asset Index Score), breast feeding category (Never = not breasf fed at baseline, No = 
breast feedings stopped before 6 months and Yes = breast feeding at and beyond 6 months), Polio antibody titres 
(measured by neutralization assay with titres binned as un-protective «1/8), low (1 /8-1/)2), medium (1 /64-1/512) or 
high (>1/512)), prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as 
defined by Hb levels of < 10.5 g/L) at both the month 6 and month 18 visits and b) anthropometric markers of 
growth. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores were compared by 
independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi 
Squared. White boxes highlight significant findings, light grey indicates trends. Asterisks denote degree of 
significance * < 0.1, ** <0.05, *** <0.005. ND = not done, NA = not applicable 
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HIV-l unexposed I Qjtelory/ HCMV sera-DNA detected at month 6 HIV-l exposed tate,ory/ HCMV sera-DNA detected at month 6 
1 month Negative Positive Ip month Negative Positive P 
Morbidity 
-
Un-protective 0%(0/159) 2%(2/103) Un-protective 5%(2/43) 0%(0/34) 
Polio Ab neutralization titre low 9% (15/159) 9%(9/103) 
.291 Polio Ab neutralization titre low 12% (5/43) 12% (4/34) (12 months) Medium 62% (98/159) 65% (67/103) (12 months) Medium 72% (31/43) 71% (24/34) .558 
-
High 29% (46/159) 25% (25/103) High 12% (5/43) 18% (6/34) 
Fever 6 10% (22/227) 11% (15/132) .615 6 11% (6/55) 20%(8/41) .237 
18 15% (24/162) 9%(9/100) .168 Fever 18 5%(2/44) 11% (3/28) .315 
Anaemic 6 43% (95/221) 35% (46/132) .131 Anaemic 6 42% (22/53) 40%(16/40) .883 18 29% (49/167) 27% (28/104) .668 18 28% (13/46) 25% (9/36) .741 
6 NA NA NA - 6 NA NA NA HCMV sera-DNA 
18 27% (37/137) 46% (39/84) .003*·· HCMV sera-DNA 23% (9/39) 38% (9/24) 18 .218 
HCMV antibody 18 83% (112/135) 88% (65/74) .349 HCMVantibody 18 86% (30/35) 80%(20/50) .558 
HHV-6 sera-DNA 6 8% (17/227) 12% (15/126) .166 HHV-6 sera-DNA 6 7%(4/55) 8% (3/39) .939 18 15% (20/137) 11% (9/85) .389 18 21% (8/39) 0% (0/24) .01S" 
Referra I Rate 0.19 0.27 .184 Referral Rate 0.38 0.54 .332 
Died 0%(0/227) 0%(0/132) NA Died 2% (1/55) 5%(2/41) .394 
Development 






N= Mean N= Mean P N= Mean N= Mean P 
- 6 210 0.2510 116 0.0484 0.112 6 47 -0.0787 35 -0.4040 .243 BMI-for-age 
18 156 0.2814 90 0.2012 0.561 
BMI-for-age 
18 - 40 -0.0338 30 0.0147 .865 
Weight-for-age 6 210 -0.2380 116 -0.3060 0.599 Weight-for-age 6 47 -0.5621 35 -0.9751 .153 
18 156 -0.4687 90 -0.3443 0.432 18 40 -0.7168 30 -1.0357 .319 
length/height-for-age 6 210 -0.7402 116 -0.5966 0.217 length/height-for-age 6 47 -0.8757 35 -1.1620 .240 18 156 -1.1047 90 -0.8062 0.044·- 18 40 -1.1403 30 -1.6953 .049" 
Triceps skinfold-for-age 6 - 210 -0.0906 116 -0.0066 0.493 Triceps skinfold-for-age 6 47 -0.1304 35 -0.3809 .340 
18 156 0.3502 90 0.2629 0.498 18 40 0.1353 30 0.2243 .710 
Subscapular skinfold-for-age 6 210 0.6883 116 0.4007 0.033-- Subscapular skinfold-for-age 6 47 0.5415 35 -0.2403 .013·· 
18 
-
156 0.6312 90 0.5543 0.567 18 40 0.5433 30 0.4943 .872 
Arm circumference-for-age 6 210 0.6633 116 0.4534 0.071· Arm circumference-for-age 6 47 0.3677 35 -0.2157 .040·· 
18 156 0.3384 90 0.1257 0.129 18 40 -0.0247 30 -0.3950 .273 
6 210 0.7714 116 0.7973 0.818 Head circumference-for-age 6 47 0.4689 35 0.2246 .288 Head circumference-for-age 
18 156 0.5962 90 0.7989_ cJ),.g9 18 40 0.3533 30 0.0927 .319 C_, 
---
-
Table 24: Active HCMV at month 6 effects length differentially by HlV-1 exposure 
Distribution of active HCMV in H IV -I unexposed and exposed infants with respect to polio antibody titres (measured by neutralization assay with titres binned as un-protective 
«1/8), low 08-1/32), medium e /64-1 /5I2) or high (>1/512», prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as defined by Hb levels of < 10.5 
glL) at both the month 6 and month 18 visits and anthropometric markers of development. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores were compared 
by independent sample T test assuming equal variance and P values for nominal variables were by Pears on Chi Squared. White boxes highlight significant findings, light grey 
indicates trends. Asterisks denote degree of significance * < 0. 1, ** <0.05, *** <0.005. NO = not done, NA = not applicable 
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category/ HHV-6 sera-DNA detected at month 6 
month Negative Positive P 
Oemographlcs 
Gender 
Male 49% (278/564) 40% (19/47 
.243 
Female 51% (286/564) 60% (28/47) 
None 6% (31/564) 2% (1/47) 
Primary 29% (164/564) 26% (12/47) 
Maternal Education Secondary 38% (214/564) 32% (15/47 .343 
Tertiary 26% (144/564) 36% (17/47) 
University 2% (11/564) 4% (2/47) 
low 33% (186/564) 42% (20/47) 
Socio-economic status Medium 38% (215/564) 36% (17/47 .348 
High 29% (163/564) 21% (10/47 
Never 6% (31/564) 9% (4/47) 
Breast feeding at baseline No 10% (5S/564) 6% (3/47) .547 
Yes 85% (478/518) 85% (40/47) 
Morbidity 
Un-protective 2% (10/417) 3% (1/36) 
Polio Ab neutralization titre low 9% (38/417 17%(6/36) 
(12 months) Medium 65% (271/417) 50% (18/36) .282 
High 24% (98/417) 11% (11/36) 
6 12% (70/564) 9% (4/47) .431 
Fever 18 11% (41/370) 8% (3/40) .487 
6 41% (229/555) 42% 119/45) .900 
Anaemic 18 31% (132/432) 33% (13/39) .719 
6 37% (171/464) 47% (20/43) .211 
HCMV sera-DNA 18 32% (94/295) 53% (16/30) .01S·· 
HIV-1 infected 4% (16/439 7% (3/41) .249 
HIV-1 exposed 22% (110/500) 16.3% (7/43) .381 
HCMVantibody 18 87% (287/331) 75% (18/24) .111 
Referra I Rate NO NO NO 
Died 1.2% (7/564) 2.1% (1/47) .607 
Growth 
Stunted 6 11% (58/527) 13% (4/31) .744 
18 20% (80/393) 17% (4/24) .662 
-
N= Mean N= Mean P 
6 526 0.0771 31 -0.1542 .297 
BMI-for-age 18 393 0.1184 24 0.1413 .919 
6 526 -0.4137 31 -0.4994 .703 
Weight-for-age 18 396 -0.5824 24 -0.4113 .503 
6 527 -0.8128 31 -0.6719 .514 
length/height-for-age 18 393 -1.1115 24 -0.8338 .261 
6 527 -0.1762 31 -0.0326 .474 
Triceps skinfold-for-age 18 395 0.1934 24 0.3054 .569 
6 527 0.4368 31 0.4023 .881 
Subscapular skinfold-for-age 18 395 0.4899 24 0.7346 .260 
6 527 0.3668 31 0.2213 .490 
Arm circumference-for-age 18 395 0.0573 24 0.1596 .665 
6 527 0.6552 31 0.6061 .796 
Head circumference-for-age 18 395 0.5286 24 0.5275 .996 
Table 25: Active HHV-6 mfechon at 6 months correlates With higher HCMV sera-DNA detection at 18 
months 
Table showing the distribution of infants by HHV -6 sera-DNA detection at 6 months with respect to maternal 
education (as surveyed on recruitment), socioeconomic status (determined by Asset Index Score), breast feeding 
category (Never = not breasf fed at baseline, No = breast feedings stopped before 6 months and Yes = breast 
feeding at and beyond 6 months), Polio antibody titres (measured by neutralization assay with titres binned as 
un-protective «1/8), low (118- 1/32)' medium e /64 -1 /5I2) or high (>1/512», prevalence of reported fever (in the 3 days 
prior to clinic visit) and prevalence of anaemia (as defined by Hb levels of < 10.5 glL) at both the month 6 and 
month 18 visits and b) anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -
2.0. Mean z-scores were compared by independent sample T test assuming equal variance and P values for 
nominal variables were by Pearson Chi Squared. White boxes highlight significant findings , light grey indicates 
trends. Asterisks denote degree of significance * < 0.1 , ** <0.05, *** <0.005. ND = not done, NA = not 
applicable 
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~telory/ HHV-6 sera-DNA detected at month 18 
month Nelative Positive P 
Demolraphics 
Gender 
Male 48%(167/347) 52% (27/52) 
Female 52% (180/347) 48% (25/52) .610 
None 4% (12/347) 8% (4/52) 
Primary 25% (87/347) 25% (13/52) 
Maternal Education Secondary 39% (136/347) 46% (24/52 .293 
Tertiary 31% (108/347) 19% (10/52) 
University 1%14/347) 2% (1/52) 
low 31% (107/347) 37% (19/52) 
Socio-economic status Medium 40%(137/347) 39% (20/52) .664 
High 30% (103/347) 25% (13/52 
Never 6% (20/347) 8%(4/52) 
Breast feeding at baseline No 9% (30/347) 6%(3/45) .692 
Yes 86% (297/347) 87% (45/52) 
Morbidity 
Un-protective 2% (8/336) 2% (1/50) 
Polio Ab neutralization titre low 11% (36/336) 21% ) 
(12 months) Medium 63% (210/336) 71% (10/14) .219 
High 24% (82/336) 7% (1/14) 
6 11% (37/347) 8% (4/52) .511 
Fever 18 12% (39/325) 10% (5/50) .682 
6 38% (131/341) 40% (21/52 .786 
Anaemic 18 31% (105/344) 36% (18/50) .435 
6 41% (117/283) 23% (10/43) .023·· 
HCMV sera-DNA 18 33% (112/345) 39% (20/51) .340 
HIV-1 infected 4% (12/347 4% (2/51) .867 
HIV-1 exposed 22% (68/307) 22% (10/46) .950 
HCMVantibody 18 83% (213/257) 91% (39/43) .196 
Referra I Rate NO NO NO -
Died 0% (0/347) 1.9% (0/51) NA 
Growth 
Stunted 6 11% 132/303} 10% (5/49) .940 
18 19% (57/301) 23% (11/47 .473 
N= Mean N= Mean P 
6 302 0.0275 49 -0.1214 .401 
BMI-for-age 18 301 0.1089 47 -0.0249 .387 
6 302 -0.4532 49 -0.5578 .544 
Weight-for-age 18 302 -0.5636 47 -0.7574 .263 
6 303 -0.8083 49 -0.8110 .987 
Length/height-for-age 18 301 -1.0573 47 -1.2113 .370 
6 303 -0.1606 49 -0.1608 .999 
Triceps skinfold-for-age 18 302 0.2212 47 0.0760 .321 
Subscapular skinfold-for-age 
6 303 0.4502 49 0.5292 .660 
18 302 0.4969 47 0.3623 .405 
6 303 0.4099 49 0.3710 .810 
Arm circumference-for-age 18 302 0.1390 47 0.1483 .954 
Head circumference-for-age 
6 303 0.7065 49 0.4865 .148 
18 302 0.5461 47 0.4917 .736 
Table 26: Active HHV-6 Infection at 18 months correlates With decreased prevalence of HCMV infection 
at 6 months 
Table showing the distribution of infants by HHV -6 sera-DNA detection at 18 months with respect to maternal 
education (as surveyed on recruitment), socioeconomic status (determined by Asset Index Score), breast feeding 
category (Never = not breasffed at baseline, No = breast feedings stopped before 6 months and Yes = breast 
feeding at and beyond 6 months), Polio antibody titres (measured by neutralization assay with titres binned as 
un-protective «I/g), low (l/g_I /32), medium (1/64-1/512) or high (>1/512)), prevalence of reported fever (in the 3 days 
prior to clinic visit) and prevalence of anaemia (as defined by Hb levels of < 10.5 glL) at both the month 6 and 
month 18 visits and b) anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -
2.0. Mean z-scores were compared by independent sample T test assuming equal variance and P values for 
nominal variables were by Pearson Chi Squared. White boxes highlight significant findings , light grey indicates 
trends. Asterisks denote degree of significance • < 0.1, .. <0.05, ... <0.005. NO = not done, NA = not 
applicable 
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HIV-l unexposed I ~te&Ory/ HHV-6 sera-DNA detected at month 18 HIV-l exposed I ~teaory/ HHV-6 sera-detection at month 18 I month Nqatlve Positive P month Nqative Positive P 
Morbidity .--
'" ~ 
Un-protective 1% (3/232) 0%(0/36) Un-protective 3% (2/65) 0%(0/10) 
Polio Ab neutralization titre low 10% (22/232) 3% (1/36) 
.378 Polio Ab neutralization titre low 12% (8/65) 10%(1/10) (12 months) Medium 63% (145/232) 61% (22/36) (12 months) Medium 66% (43/65) 60% (6/10) .808 
High 27% (62/232) 36% (13/36) High 19% (12/65) 30%(3.10) 
-, 6 10% (24/239) 11% (4/36) .771" 6 12% (8/68) 0%(0/10) .587" Fever Fever 18 13% (29/226) 14% (5/36) .793" 18 8% (5/63) 0%(0/9) 1.0" 
- 6 37% (87/236) 39% (14/36) .815 6 38% (25/66) 40% (4/10) 1.0" Anaemic 
18 29% (69/237) 33% (12/36) .606 Anaemic 18 31% (21/68) 50% (5/10) .287 
HCMV sera-DNA 6 39% (76/193) 31% (9/29) .389 6 44% (24/55) 0% (0/8) .02()1\" " 
18 34% (80/237) 39% (14/36) HCMV sera-DNA 25% (17/68) 50%(5/10) .546 18 .134 
HCMV antibody 18 83% (145/174) 88% (29/33) .513 HCMVantibody 18 
-
83% (44/53) 100%(7/7) .580 
6 . NA NA NA 6 11% (6/53) 0% (0/8) 1.0" HHV-6 sera-DNA HHV-6 sera-DNA 18 10% (19/198) 10% (3/29) 1.0" 18 NA NA NA 
Referral Rate NO NO NO Referral Rate 
-
NO NO NO 
Died 0%(0/239) 0%(0/36) NA Died 0%(0/68) 0%(0/10) NA 
Development -
6 . 9% (18/213) 6% (2/34) 1.0" - 6 15% (8/54) 33% (3/9) .184" Stunted Stunted 
18 
-
16% (34/212) 21% (7/34) .509 18 
-
28% (15/54) 33% (3/9) .707" 
Negative Positive 
- - "" -
Negative Positive 
N= Mean N= Mean P - N= Mean N= Mean P 
BMI-for-age 6 212 0.0844 34 0.0906 0.975 BMI-for-age 6 54 0.0128 9 -0.8289 0.045"· 
18 212 0.1489 34 0.0853 0.727 18 54 0.1843 9 -0.6633 0.030** 
Weight-for-age 6 212 -0.3399 34 -0.3174 0.908 Weight-for-age 6 54 -0.5483 9 -1.4689 0.038** 
18 212 -0.4741 34 -0.5741 0.617 18 54 -0.6922 9 -1.5567 0.055" 
length/height-for-age 6 213 -0.6940 34 -0.6688 0.885 length/height-for-age 6 54 -0.9643 9 -1.4756 0.174 
18 
-
212 -0.9563 34 -1.0441 0.657 18 54 -1.3461 9 -1.7489 0.318 
Triceps skinfold-for-age 6 - 213 -0.1253 34 -0.0718 0.782 Triceps skinfold-for-age 6 54 -0.0943 9 -0.4389 0.401 
18 212 0.2589 34 0.2429 0.928 18 54 0.3413 9 -0.5044 0.013"· 
Subscapular skinfold-for-age 6 213 0.5193 34 0.7106 0.351 Subscapular skinfold-for-age 6 54 0.3815 9 -0.1578 0.254 
18 212 0.5208 34 0.4759 0.806 18 54 0,7648 9 -0.1433 0.033·· 
Arm circumference-for-age 6 213 0.5203 34 0.5541 0.852 Arm circumference-for-age 6 54 0.3007 9 -0.4167 0.097" 
18 212 0.20n 34 0.3700 0.363 18 54 0.0889 9 -0.6978 0.087" 
Head circumference-for-age 6 213 0.8186 34 0.7218 0.598 Head circumference-for-age 6 54 0.5580 9 -0.1556 0.046·· 
18 212 0.6S61 34 0.6135 0.826 18 54 0.3424 9 -0.0222 0.354 
Table 27: Active HHV-6 at month 18 correlates with wasting in HIV-I exposed infants 
Distribution of active HCMV in HIV-I unexposed and exposed infants with respect to polio antibody titres (measured by neutralization assay with titres binned as un-protective 
«I/g), low (' /g-I /32 ), medium (' /64- l/sd or high (>1/512)), prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as defined by Hb levels of < 10.5 
g/L) at both the month 6 and month 18 visits and anthropometric markers of development. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores were compared 
by independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi Squared. White boxes highlight significant findings, light grey 
indicates trends. Asterisks denote degree of significance * < 0.1 , ** <0.05, *** <0.005 
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5.4 Effects of HCMV seroprevalence on markers of morbidity and growth 
The previous section has investigated correlations between detection of active betaherpesvirus 
infections with markers of morbidity and growth. Detection of active infection is not 
representative of overall exposure however, as our analysis represents just two 'snap shots' in 
infants at 6 and 18 months of age. In this section, results of a screen for HCMV antibody in 
18 month old infants on the CIGNIS study will be analysed with respect to morbidity and 
anthropometric data. 
Detection of HCMV antibody at 18 months correlated significantly with both maternal 
education and socioeconomic status (Table 28, Page 142). HCMV seroprevalence among 
infants born to university educated mothers was as low as 55% (Figure 27a) and among 
infants from the high socioeconomic group seroprevalence was 15% lower than among 
infants from lower or medium socioeconomic groups (Figure 27b). Sub-stratification by 
maternal HIV -1 status showed no significant differences in HCMV seroprevalence between 
HIV -1 exposed and unexposed infants, maternal education category or socioeconomic 
grouping (data not shown). There was also a significant correlation between HCMV 
transmission as measured by seroprevalence, and duration of breast feeding (Table 28). 
There was a trend for non-protective or low polio neutralizing antibody titres to be less 
prevalent among HCMV seronegative infants, but only among those who were HIV-l 
unexposed, possibly due to the association of HIV -1 exposure and weakened vaccine 
responses being stronger. Interestingly, the two HCMV seronegative, HIV -1 unexposed 
infants who failed to mount a protective polio response, were both positive for HCMV sera-
DNA at 6 months of age showing that they had been exposed to HCMV but had not 
seroconverted (Table 29, Page 143). 
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Figure 27: High maternal education and socioeconomic grouping are associated with lower HCMV 
seroprevalence 
Prevalence ofHCMV seropositive infants by a) level of mate mal education and b) socioeconomic grouping. 
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Figure 28: HCMV seroprevalence is higher in infants who have been breast fed 
Histograms showing HCMV seroprevalence by a) breast feeding grouping alone and b) breast feeding grouping 
and HIV-l exposure, Mother's were asked at recruitment (when infants were 6 months old) about their breast 
history: Never = not breast fed at all from birth, No = breast fed < 6 months but stopped before baseline, Yes = 
currently breast feeding at baseline. Significance is by Pearson Chi-Squared. 
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Figure 29: HCMV seroprevalence linked to increased anaemia but not among HIV-I exposed infants 
Prevalence of anaemia by a) HCMV seroprevalence and b) HCMV seroprevalence and HIV-I exposure, 
combining both time points to define those anaemic at one or both. Additive effects ofHCMV seroprevalence 
and maternal HIV -I status on the prevalence of anaemia at both month 6 (c) and month 18 (d). Anaemia here is 
defined by a haemoglobin level of less than 10.5 glL. Significance is by Pearson Chi-Squared. 
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HCMV seropositive infants were significantly more likely to be anaemic at 6 months of age, 
with this persisting as a strong trend at 18 months of age (Figure 29a)(Table 28). When 
grouping together infants who were anaemic at either or both time points, verses those who 
were not anaemic at either time point, HCMV seropositive infants were nearly twice as likely 
to be anaemic whereas the prevalence of anaemia across both time points was completely 
unaffected by maternal HIV -1 status (Figure 29b) as suggest previously (Figure 24b). 
Additive effects on the prevalence of anaemia were investigated by combining HCMV 
serology, with maternal HIV-l data. Interestingly, significant increases in prevalence of 
anaemia (at both 6 and 18 months) due to infection with HCMV are seen only in HIV-l 
unexposed infants (Figure 29c and d). The prevalence of anaemia in HIV -1 exposed infants 
was unaffected by HCMV seroprevalence suggesting that whilst overall HIV -1 exposure did 
not affect anaemia (Figure 24b), for the minority of infants who were HCMV seronegative, 
there was a trend for HIV -1 exposure to be linked with higher prevalence of anaemia, but 
within the low numbers of HCMV seronegative infants the difference was not significant. 
We then looked at the effects of HCMV seroprevalence on anthropometric data (Table 28). 
Looking at infant growth measurements taken at 6 months of age, being HCMV seropositive 
at 18 months was associated with a trend towards lower triceps skinfold but this was not 
supported by trends towards decreases in any other parameter at baseline. By 18 months 
however, triceps skinfold did not differ by HCMV seroprevalence, but being HCMV 
seropositive was now significantly associated with lower length/height, lower weight, and a 
smaller head circumference. This effect on length held when adjusted for maternal education, 
socioeconomic status and duration of breast feeding (P = 0.0 IS)(Appendix I, section 9.9.1) 
although the effect on weight and head circumference did not (Appendix 1, sections 9.9.2 and 
9.9.3). Concurrently, stunting was twice as prevalent in HCMV seropositive infants (22% 
(82/371) vs 11 % (8/73) P = 0.03)(Table 28)(Figure 30a) and there was a trend for this effect 
to be greater within HIV-I exposed infants (32% (25177) vs 11% (2/18) P = 0.071) (Figure 
30b). Whilst effects of HCMV seroprevalence on length at 18 months are significant in both 
HIV -I exposed and unexposed infants, the correlation with reduced head circumference was 
observed exclusively among HIV -1 exposed infants (Figure 31 )(Table 29). 
Finally, HCMV seroprevalence did not have a significant effect of rate of hospital referrals 
(Table 28)(Appendix J, section 9.10.5). In summary, infants who were HCMV seropositive at 
18 months of age were persistently anaemic and were significantly more likely to be stunted 
by 18 months and if HIV -1 exposed, have a lower head circumference. 
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Month 6 Month 18 HIV-1 unexposed HIV-1 exposed 
Figure 30: HCMV seroprevalence correlates with stunting with a trend for this to be exaggerated among 
HIV-l exposed infants 
Prevalence of stunting at a) both 6 and 18 months by HCMV seroprevalence and b) at 18 months alone sub-
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Figure 31: HCMV seropositive infants have a smaller head circumference only if HIV-l exposed 
Anthropometry mean z-scores at 18 months by HCMV antibody detection at 18 months sub-stratifying by HIV-I 
exposure. Bars represent 1 standard deviation from the mean. Mean z-scores were compared by independent 
sample T test assuming equal variance. Asterisks denote degree of significance '" < 0.1, ** <0.05, **'" <0.005. 
ND = not done, NA = not applicable 
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Category/ HCMV sera-antibody detection at month 18 
month HCMV seronegative HCMV seropOsitive P 
Oemosraphlcs 
Male 45% (34/76) 47% (180/384 
Gender Female 55% (42/76) 53% (204/384) .733 
None 0% (0/76) 5% (20/384) 
Primary 20% (15/76) 28% (108/384) 
Maternal Education Secondary 32% (24/76) 42% (162/384) <.001··· 
Tertiary 42% (32/76) 23% (88/384) 
University 7% (5/76) 2% (6/384) 
Low 22% (17/76) 35% (133/384) 
Socio-economic status Medium 29% (22/76) 41% (157/384) <.001··· 
High 49% (37/76) 25% (94/384) 
Never 20% (15/76) 4% (14/384) 
Breast feeding at baseline No 8% (6/76) 10% (38/384) <.001··· 
Yes 72% (5S/76) 87% (332/384) 
Morbidity 
Un-protective 4% (3/75) 1% (5/369) 
Polio Ab neutralization titre (12 Low 9% (7/75) 8% (30/369) 
months) Medium 63% (47/75) 64% (237/369) .444 
High 24% (18/75) 26% (97/3691 
6 15% (11/76) 13% (49/384) .685 
Fever 18 7% (4/59) 14% (42/294) .118 
6 28% (21/74) 42% (160/379) .026·· 
Anaemic 18 22% (17/76) 34% (128/381) .055· 
6 34% (16/47) 39% (100/258) .540 
HCMV sera-DNA 18 40% (19/48) 36% (90/251) .623 
6 12% (6/50) 6% (18/305) .111 
HHV-6 sera-DNA 18 8% (4/48) 16% (39/252) .196 
HIV-1 infected 3% (2/76) 2% (7/383) .644 
HIV-l exposed 27% (18/66) 24% (81/344) .517 
Referral Rate 0.18 0.26 .334 
Died NA NA NA 
Growth 
6 8% (6/73) 11% (41/372) .476 
Stunted 18 11% (8/73) 22% (82/371) .030·· 
HCMV seronegative HCMV seropOsitive 
N= Mean N= Mean P 
6 73 -0.0718 373 -0.0227 .741 
BMI-for-age 18 73 0.1229 371 0.0934 .823 
6 73 -0.4304 373 -0.4989 .654 
Weight-for-age 18 73 -0.3392 372 -0.6482 .035·· 
6 73 -0.6553 372 -0.8268 .188 
Length/height-for-age 18 73 -0.7033 371 -1.1756 <.001··· 
6 73 -0.3830 373 -0.1417 .079· 
Triceps skinfold-for-age 18 70 0.1244 363 0.1325 .947 
6 73 0.2474 373 0.4339 .222 
Subscapular skinfold-for-age 18 70 0.5209 363 0.4608 .653 
6 73 0.2579 373 0.3079 .730 
Arm circumference-for-age 18 69 0.0828 363 0.0451 .790 
Head circumference-for-age 
6 73 0.8300 373 0.6193 .102 
18 70 0.8061 363 0.4882 .015· · 
Table 28: HCMV seroprevalence IS associated with persistent anaemia and stunting and reduced head 
circumference at 18 months 
Distribution of infants by HCMV seroprevalence (determined by ELlSA at 18 months) with respect to maternal 
education (as surveyed on recruitment), socioeconomic status (determined by Asset Index Score), breast feeding 
category (Never = not breasffed at baseline, No = breast feedings stopped before 6 months and Yes = breast 
feeding at and beyond 6 months), Polio antibody titres (measured by neutralization assay with titres binned as 
un-protective «1/8), low (1 /8-1/32)' medium C/64-I/512) or high (>1/512)), prevalence of reported fever (in the 3 days 
prior to clinic visit) and prevalence of anaemia (as defined by Hb levels of < 10.5 glL) at both the month 6 and 
month 18 visits and anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -
2.0. Mean z-scores were compared by independent sample T test assuming equal variance and P values for 
nominal variables were by Pearson Chi Squared. White boxes highlight significant findings , light grey indicates 
trends. Asterisks denote degree of significance * < 0.1, ** <0.05, *** <0.005 . ND = not done, NA = not 
applicable 
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HIV-l unexposed I cateaoryl I HCMV sera-Ab detection at month 18 HIV-l exposed catqoryl HCMV sera-Ab detection at month 18 
I month I Negative Positive \p Month Negative Positive P 
Morbidity 
" " 
Un-protective 4% (2/47) 0.4% (1/255) Un-protective 6% (1/18) 
-
3% (2/76) 
Polio Ab neutralization titre Low 11% (5/47) 8% (19/255) 
.073· Polio Ab neutralization titre Low 6% (1/18) 9% (7/76) .880 (12 months) Medium 62% (29/47) 63% (160/255) (12 months) Medium 67% (12/18) 68% (52/76) 
High 23% (11/47) 29% (75/255) High 22% (4/18) 20%(15/76) 
6 15% (7/48) 23% (33/263) .698 Fever 6 17% (3/18) 9% (7/81) .307 Fever 
18 8% (3/37) 15% (30/205) . 287 18 .. 7% (1/14) 10% (6/61) .755 
6 24% (11/46) 41% (107/261) .028-- Anaemic 6 33% (6/18) 37% (29/78) .760 Anaemic 
18 17% (8/48) 36% (94/262) .009-- 18 33%(6/18) 30% (24/81) .757 
HCMV sera-DNA 6 28% (9/32) 37% (65/177) .349 HCMV sera-DNA 6 50%(5/10) 40% (20/SO) .558 
18 42% (14/33) 38% (65/173) .599 18 33% (3/9) 26% (13/51) .624 
HCMV antibody 18 NA NA NA HCMVantibody 18 NA NA NA 
HHV-6 sera-DNA 6 9% (3/34) 7% (15/209) .734 HHV-6 sera-DNA 6 20%(2/10) 3% (2/61) .034" 
18 
-
12% (4/33) 17% (29/174) .513 18 0%(0/9) 14% (7/51) .237 
Referral Rate 0.15 0.20 .506 Referral Rate 0.32 0.52 .542 
Died NA NA .. NA Died NA NA NA 
Development 
Stunted 6 4% (2/48) 10% (27/263) .181 Stunted 6 11% (2/18) 14% (11/81) .779 
18 7% (3/45) 20% (50/257) .037-- 18 11% (2/18) 33% (25/77) .071· 
" Negative Positive Negative Positive 
- -
. 
- N= Mean N= Mean P N= Mean N= Mean P . 
BMI-for-age 6 47 -0.0260 257 0.0725 0.594 BMI-for-age 6 16 -0.2150 77 -0.1506 .831 .-
18 44 0.1505 251 0.1413 0.957 18 16 -0.0488 73 .0.0023 .878 
Weight-for-age 6 47 -0.3343 257 -0.4144 0.672 Weight-for-age 
6 
-
16 -0.5750 77 .0.6736 .761 
18 44 -0.2575 252 -0.5868 o.on· 18 16 .0.4506 73 .0.8214 .279 
6 47 -0.5509 257 -0.8233 0.098· Length/height-for-age 6 16 -0.7175 77 .0.9713 .347 Length/height-for-age 
18 44 -0.6055 251 -1.1342 0.003-" 18 16 -0.6831 73 -1.3359 .034--
6 47 -0.2828 257 -0.0667 0.206 Triceps skinfold-for-age 6 16 .0.3888 77 .0.2792 .706 Triceps skinfold-for-age 
18 -" 44 0.2093 252 0.2199 0.945 18 16 0.0369 73 0.0086 .917 
Subscapular skinfold-for-age 6 47 0.3783 
257 0.5682 0.302 Subscapular skinfold-for-age 6 16 0.0800 77 0.1257 .892 
18 44 0.5625 252 0.5563 0.970 18 16 0.4413 73 0.3445 .759 
6 47 0.4160 257 0.4132 0.988 Arm circumference-for-age 6 16 -0.0288 77 0.0436 .815 Arm circumference-for-age 
18 43 0.2749 252 0.1444 0.433 18 16 .0.1938 73 .0.2144 .955 
6 47 0.8591 257 0.7031 0.342 Head circumference-for-age 6 16 0.7306 77 0.4540 .293 Head circumference-for-age 
18 44 0.7332 252 0.5962 0.408 18 16 0.9950 73 0.2149 .007--
--- --
Table 29: HCMV seroprevalence is associated with increased anaemia only in the HIV-J unexposed infants and decreases in head circumference are only in HIV-t 
exposed 
I 
Distribution of HCMV seroprevalence in HIV -I unexposed and exposed infants with respect to polio antibody titres (measured by neutralization assay with titres binned as un-
protective « I/S), low C/s-I /32 )' medium e lM" 1/512 ) or high (>1 /5d), prevalence of reported fever ( in the 3 days prior to clinic visit) and prevalence of anaemia (as defined by Hb levels 
of < 10.5 gIL) at both the month 6 and month 18 visits and anthropometric markers of development. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores were 
compared by independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi Squared. White boxes highlight significant findings, light 
grey indicates trends. Asterisks denote degree of significance • < 0.1, ** <0.05, ••• <0.005 
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5.5 Effect modification of micronutrient fortified feed supplement by HIV-l 
and HCMV infection and exposure 
5.5.1 Effects of trial on morbidity and growth 
Effects of HIV -1, HCMV and HHV -6 infection were assessed in infants who were being 
exposed to either a conventionally fortified or micronutrient fortified supplementary feed. 
Here initial results from the CIGNIS intervention are evaluated. The two feed supplements 
were primarily composed of maize meal (65%), beans (white and yellow)(15%), groundnuts 
(15%) and bambaranuts (5%). The micronutrient fortified feed supplement differed 
significantly in its micronutrient composition to the conventionally fortified feed supplement, 
with added vitamins, manganese, copper, selenium, calcium and phosphorus and significantly 
increased levels of iron, zinc and other core nutrients. The main analyses of these two fortified 
feed supplements are part of a separate study the CIGNIS team. In this thesis initial analysis 
examines the effects on betaherpesvirus infection. 
In the following analyses ofthe effects of the intervention subject IDs 475-542 were excluded 
as they were not properly blinded. Therefore a total of 743 infants and their mothers were 
recruited on to the CIGNIS study and successfully randomized, with 373 on the 
conventionally fortified and 370 on the micronutrient fortified feed supplement. 
Demographics such as maternal education, socioeconomic grouping and duration of breast 
feeding were distributed evenly between the two arms of the study consistent with successful 
randomization and blinding (Appendix R, Page 239), although there was a trend for a slight 
gender imbalance between the two arms but no effects on gender were observed with respect 
to the intervention or to HIV -1 or betaherpesvirus infections. Further, there were a similar 
number of HIV -1 exposed infants recruited onto each arm of the study and differential effects 
on HIV -1 exposed and unexposed infants will be investigated. 
At baseline the prevalence of anaemia was roughly 40% in both arms of the study (Appendix 
R, Page 239). The micronutrient fortified feed supplement was shown to significantly reduce 
the prevalence of anaemia to just 22% at 18 months compared with 40% in the conventionally 
fortified arm (P < 0.001). The intervention did not directly affect stunting or any other 
anthropometric outcomes and did not affect the prevalence of mortalities or the rate of 
hospital referrals (Appendix M Page 229 and Appendix R, Page 239, Table 1). Below the 
intervention is assessed for correlations with HIV -1 exposure and betaherpesvirus infections. 
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5.5.2 Effects between DIV -1 exposure and trial arms 
Looking at HIV -1 unexposed and exposed infants as separate groups, the effect of the 
micronutrient fortified feed supplement to reduce anaemia was greater among HIV -1 exposed 
infants, who on the micronutrient arm had a slightly higher (but not significant) prevalence of 
anaemia at baseline (Appendix R, Table 2, Page 239). There was a trend among HIV-l 
unexposed infants for head circumference to be not completely randomized at baseline but by 
the end of the study this difference had levelled out showing that the micronutrient 
fortification did not affect head circumference outcomes in either HIV -1 exposed or 
unexposed infants (Appendix R, Table 2, Page 239). 
We also showed above that HIV -1 exposure is linked with stunting and decreases in all 
anthropometric outcomes (Table 19), but when analysing the two feed arms separately, we 
found significant reductions in BMI and weight only in the micronutrient fortified arm 
(Appendix R, Table 3, Page 239). Consistent with trends towards lower anthropometric 
outcomes in HIV -1 exposed infants on the micronutrient arm, there was also a trend for an 
increased rate of hospital referrals due to HIV-l exposure but only in the micronutrient arm, 
together suggesting there could be some detrimental effect of the micronutrient feed 
supplement among HIV-l exposed infants. The rate of hospital referrals was 2-fold higher 
among HIV-l exposed infants on the micronutrient arm (0.21 vs 0.45, P = 0.004)(Appendix 
R, Table 3, Page 239 and Appendix N, Page 230) but HIV-I exposed infants on the 
conventional arm were no more likely to be referred. Further sub-stratifications by HIV-l 
exposure, breast feeding duration and socioeconomic status have been investigated by other 
members of the CIGNIS team who found that the micronutrient fortified feed supplement was 
actually beneficial for linear growth among HIV -1 exposed infants who were breast fed for 
less than 6 months. These results will be discussed further in section 5.6. 
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5.5.3 Effects between active HCMV infection and trial arms 
Having seen in the previous analysis that the effects of HIV -1 exposure on growth were 
increased in the micronutrient fortified arm, we then looked to see if infants who had an active 
HCMV infection at baseline were affected differentially by the intervention. The previously 
documented beneficial effect of the intervention on anaemia was observed in both HCMV 
sera-DNA positive and negative infants (Table 30, Page 146). In infants who had an active 
HCMV infection at baseline, the micronutrient fortified feed supplement showed trends for 
increasing triceps skinfold and head circumference at 18 months, but these effects were also 
visible at baseline so could be due to skewed randomization. We then looked at the effects of 
active HCMV infection within each study arm (Table 31, Page 148) and this skewed 
randomization was also apparent, with negative effects on month 6 anthropometry linked with 
HCMV sera-DNA detection only on the conventionally fortified arm. This makes further 
analysis difficult without adjusted methods. Detection of active HCMV at baseline had no 
significant effects on length at 18 months, in either treatment arm (Table 31), also after sub-
stratifying for HIV -1 exposure, adjusting for z-score at baseline, maternal education, 
socioeconomic status and duration of breast feeding (Appendix K, Page 220). In summary, 
the micronutrient fortified feed supplement reduced anaemia irrespective of active HCMV 
infection at baseline, but did not affect any other morbidity or growth parameters or the 
prevalence of mortalities or the rate of hospital referral (Table 30)(Appendix 0, Page 231). 
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HCMV sera-DNA month 6 negative HCMV sera-DNA month 6 positive 
Conventional Micronutrient P Conventional Micronutrient 
Morbidity -
Un-protect. 2% (2/110) 4% (4/102) Un-protect. 3% (2/69) 2% (1/67) 
Polio Ab neutralization titre (12 Low 8%(9/110) 9% (9/102) 
.821 Polio Ab neutralization titre Low 16% (11/69) 10%(7/67) 
months) Medium 65% (71/110) 62% (63/102) (12 months) Medium 68% (47/69) 73% (49/67) .732 
High 26% (28/110) 26% (26/102) High 13% (9/69) 15% (10/67) 
Fever 6 10% (15/146) 11% (16/147) .865 Fever 6 15% (13/87) 14% (12/85) .878 18 14" (14/103) 15" (16/108) .799 18 7" (4/59) 11% (7/62) .388 
6 41% (58/142) 44% (65/141) .595 Anaemic 6 38% (33/87) 44% (37/84) .416 Anaemic 18 42% (47/112) 19" (21/111) <.000*** 18 39% (27/70) 22% (15/68) .035** 
HCMV sera-DNA 18 28" (26/93) 29" (26/91) .926 HCMV sera-DNA 18 47" (25/53) 45" (22/49) .818 
HCMV antibody 18 83" (80/96) 84" (75/89) .863 HCMVantibody 18 89" (49/55) 82% (46/56) .297 
6 7" (10/145) 4% (6/146) .297 HHV-6 sera-DNA 6 5" (4/80) 8" (7/83) .382 HHV-6 sera-DNA 18 20%(19/93) 14" (13/91) .272 18 9" (5/55) 6% (3/49) .571 
HIV-l infected 4% (4/115) 5% (5/111) .693 HIV-l infected 6" (4/72) 4" (3/68) .756 
HIV-l exposed 19% (25/129) 17% (22/128) .649 HIV-l exposed 23" (17/75) 24% (18/76) .882 
Referra I Rate ,. 0.19 0.25 .396 Referra I Rate - 0.30 0.34 ,641 
Died 0.7" (1/146) 0%(0/147) .315 Died 2.3" (2/87) 1.2" (1/85) .574 
Growth 
Stunted 6 11" (16/146) 11% (16/147) .984 Stunted 6 13" (11/87) 7% (6/85) .220 18 17" (19/113) 22" (24/111) .361 18 23" (16/71) 19" (13/68) .620 
-
Conventional Micronutrient Conventional Micronutrient 
N= Mean N= Mean P . N= Mean N= Mean P 
- 6 146 0.1949 147 0.1133 .536 6 87 -0.1625 85 0.0400 .287 BMI-for-age 
18 - 113 0.1971 111 0.1671 .839 BMI-for-age 18 71 0.0317 68 0.1878 .347 
6 146 -0.2903 147 -0.3446 .690 Weight-for-age 6 87 -0.6695 85 -0.3473 .083*t Weight-for-age 18 113 -0.5138 112 -0.5254 .945 18 71 -0.7087 68 -0.4471 .172 
6 146 -0.7582 147 -0.7457 .916 Length/height-for-age 6 87 -0.9222 85 -0.6561 .200 Length/height-for-age 
18 113 -1.0784 111 -1.0705 .960 18 71 -1.2034 68 .{).9468 .179 
6 146 .{).0950 147 .{).1736 .531 Triceps skinfold-for-age 6 87 -0.3613 85 0.0194 .027
U t Triceps skinfold-for-age 18 113 0.2039 112 0.3309 .332 18 71 0.0319 68 0.2984 .089* 
Subscapular skinfold-for-age 6 146 0.7375 147 0.5264 .129 Subscapular skinfold-for-age 6 87 0.0523 85 0.3422 .127 
18 113 0.6014 112 0.5275 .602 18 71 0.2867 68 0.5825 .105 
Arm drcumference-for-age 6 146 0.5955 147 0.5493 .710 Arm drcumference-for-age 6 87 0.1248 85 0.3728 .149 
18 113 0.2751 112 0.1954 .608 18 71 .{).1139 68 0.0366 .408 I 
6 146 0.6702 147 0.7316 .590 Head circumference-for-age 6 87 0.4843 85 0.7534 .091·t Head circumference-for-age 18 113 0.5186 112 0.5666 .709 18 71 0.3686 68 0.7478 .040" I 
Table 30: Micronutrient fortification may increase head circumference in infants who had an HCMV active infection at 6 months 
Effect of micronutrient fortified feed supplement sub-stratified by HCMV infection at 6 months, on prevalence of other betaherpesvirus active infections (detection of sera-DNA), 
HIV -I infection (detection of antibody at 18 months), HIV -I exposure (determined by maternal antenatal HIV -I status), polio antibody titres (measured by neutralization assay with 
titres binned as un-protective «l/g), low C/g-1/ 32), medium CI6r 1/512) or high ( > 1/512», prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as 
defined by Hb levels of < 10.5 g/L) at both the month 6 and month 18 visits and anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -2.0. Mean 
z-scores were compared by independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi Squared. White boxes high light significant 
findings, light grey indicates trends. Asterisks denote degree of significance * < 0.1 , ** <0.05, *** <0.005. ND = not done, NA = not applicable t = groupings that were not 
randomized between treatment arms at baseline. 
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cmcorvl Conve/1tlc)Ml fortification - ~tqoryl Micronutrient fortiftcatlon HCMV sera-DNA HCMV sera-DNA HCMV sera-DNA HCMV sera-DNA month 





Un-protective 2% (2/110) 3% (2/69) Un-protective 4%(4/102) 2% (1/67) 
Polio Ab neutralization titre low 8% (9/110) 16% (11/69) 
.125 Polio Ab neutralization titre low 9% (9/102) 10% (7/67) (12 months) Medium 65% (71/110) 68% (47/69) (12 months) Medium 62% (63/102) 73% (49/67) .281 
High 26% (28/110) 13% (9/69) High 26% (26/102) 15% (10/67) 
Fever 6 10% (15/146) 15% (13/87) .289 6 11% (16/147) 14% (12/85) .466 
18 14% (14/103) 7% (4/59) .184 Fever 18 15% (16/108) 11%(7/62) 
-
.518 
Anaemic 6 41% (58/142) 38% (33/87) .662 Anaemic 6 44% (65/141) 44% (37/84) .991 18 42% (47/112) 39% (27/70) .650 18 19% (21/111) 22% (15/68) .611 
HCMV sera· DNA 18 28% (26/93) 47% (25/53) .019·· HCMV sera-DNA 18 29%(26/91) 45% (22/49) .052· 
HCMV antibody 18 83% (80/96) 89% (49/55) .335 HCMV antibody 18 84% (75/89) 82% (46/56) .737 
HHV-6 sera-DNA 6 7% (10/145) 5% (4/80) .573 HHV-6 sera·DNA 6 4% (6/146) 8% (7/83) .174 18 20% (19/93) 9% (5/55) .071· 18 
. -
14% (13/91) 6% (3/49) .148 
H IV -1 infected 4% (4/115) 6% (4/72) .495 HIV-1 infected 5% (5/111) 4% (3/68) .977 
HIV-l exposed 19% (25/129) 23% (17/75) .576 HIV-l exposed 17% (22/128) 24% (18/76) .258 
Referra I Rate 0.19 0.30 .120 Referral Rate 0.25 0.34 .311 
Died 0.7% (1/146) 2.3% (2/87) NA Died 0% (0/147) 1.2% (1/85) NA 
Growth 
Stunted 6 11% (16/146) 13% (11/87) .698 Stunted 6 11% (16/147) 7% (6/85) .338 18 17% (19/113) 21% (15/70) .435 18 22% (24/111) 19% (13/68) .688 
HCMV sera-DNA HCMV sera-DNA HCMV sent-DNA HCMV sera-DNA 
month 6 negative month 6 positive month 6 negative month 6 positive 
N= Mean N= Mean P N= Mean N= Mean P 
BMI·for-age 6 146 0.1949 87 ·0.1625 .028·· BMI-for-age 6 147 0.1133 85 0.0400 .641 
18 113 0.1971 71 0.0257 .306 18 111 0.1669 68 0.1878 .894 
Weight· for·age 6 146 -0.2903 87 ·0.6695 .020·· Weight-for-age 6 147 -0.3446 85 -0.3473 .987 
18 113 -0.5137 71 -0.6937 .334 18 112 -0.5274 68 -0.4471 .665 
Length/height-for-age 6 146 -0.7582 87 -0.9222 .335 Length/height-for-age 6 147 -0.7457 85 -0.6561 .527 
18 113 -1.0781 71 -1.1733 .571 18 111 -1.0735 68 -0.9468 .495 
Triceps skinfold-for-age 6 146 ·0.0950 87 -0.3613 .080· Triceps skinfold-for-age 6 147 -0.1736 85 0.0194 .183 
18 113 0.2039 71 0.0319 .247 18 112 0.3309 68 0.2984 .822 
Subscapular skinfold·for-age 6 146 0.7375 87 0.0523 .000··· Subscapular skinfold-for-age 6 147 0.5264 85 0.3422 .255 
18 113 0.6014 71 0.2867 .059· 18 112 0.5275 68 0.5825 .730 
6 146 0.5955 87 0.1248 .002··· Arm circumference-for-age 6 147 0.5493 85 0.3728 .229 Arm circumference-for-age 
18 113 0.2751 71 -0.1139 .024·· 18 112 0.1954 68 0.0366 .360 
Head circumference-for-age 6 146 0.6702 87 0.4843 .190 Head circumference-for-age 6 
147 0.7316 85 0.7534 .867 
'------- . . 
18 113 0.5186 71 0.3686 .326 18 112 0.5666 68 0.7478 .247 i 
Table 3 J: HCMV active infections were linked with reduced arm circumference and subscapular skinfold at 6 months only within the conventionally fortified arm 
Effect of micronutrient fortified feed supplement sub-stratified by HCMV seroprevalence, on prevalence of beta herpesvirus active infections (detection of sera-DNA), HIV-l 
infection (detection of antibody at 18 months), HIV-l exposure (detennined by maternal antenatal HIV-l status), polio antibody titres (measured by neutralization assay with titres 
binned as un-protective « I/g), low C/g-1/ 32) , medium C/w 1/ 512) or high (> I/sd), prevalence ofreported fever ( in the 3 days prior to clinic visit) and prevalence of anaemia (as defined 
by Hb levels of < 10.5 gIL) at both the month 6 and month 18 visits and anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores 
were compared by independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi Squared. White boxes highlight significant findings, 
light grey indicates trends. Asterisks denote degree of significance * < 0.1, ** <0.05, *** <0.005. ND = not done, NA = not applicable 
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5.5.4 Effects between HCMV seroprevalence and trial arms 
When looking at HCMV seronegative and seropositive infants, the effect of the micronutrient 
fortified feed supplement to reduce anaemia was similar in both arms, with greater 
significance among HCMV seropositive infants, the majority group (Figure 32 and Table 32, 
Page 151). Anthropometric outcomes were unaffected by the micronutrient fortified feed 
supplement irrespective of HCMV seroprevalence (Table 32). HCMV seroprevalence was 
shown previously to be associated with increases in anaemia and stunting, and decreases in 
weight, length and head circumference at 18 months (section 5.4). Interestingly the inhibitory 
effects ofHCMV seroprevalence on head circumference were significant only in infants on 
the conventionally fortified arm but not observed for the micronutrient arm (Figure 33)(Table 
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Figure 32: Micronutrient fortification reduces anaemia over the course of the study in both HCMV 
seronegative and HCMV seropositive infants 
Prevalence of anaemia compared between time points sub-stratified by trial arm in a) HCMV seronegative and 
b) HCMV seropositive infants. Anaemia here is defined by a haemoglobin level ofless than 10.5 glL. 
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Figure 33: HCMV seropositive infants have smaller heads only within conventionally fortified arm 
Anthropometric 18 month mean z-scores compared between HCMV seropositive and seronegative infants sub-
stratified by the conventionally fortified and micronutrient fortified trial arms. Bars represent one standard 
deviation from the mean. Mean z-scores were compared by independent sample T test assuming equal variance 
Asterisks denote degree of significance • < 0.1, •• <0.05, ••• <0.005. ND = not done, NA = not applicable 
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," J ~teaofY/ I HCMV seronegative Catqory/ HCMV seropositive . 
-
I month I Conventional Micronutrient P month Conventional I Mlaonutrient P 
Morbidity ., ,-.. 
-
Un-protective 3% (1/35) 5% (2/38) Un-protective 1% (2/181) 2% (3/181) 
Polio Ab neutralization titre LDw 6% (2/35) 13% (5/38) 
.669 
Polio Ab neutralization titre LDw 11% (20/181) 6% (10/181) 
(12 months) Medium 66% (23/35) 61% (23/38) (12 months) Medium 66% (119/181) 65% (117/181) .181 
High 26% (9/35) 21% (8/38) High 22% (40/181) 28% (51/181) 
Fever 6 
14% (5/35) 13% (5/38) .889 
Fever 
6 12% (22/184) 14% (26/189) .604 
18 4% (1/26) 10%(3/30) .373 18 14% (20/141) 15% (21/142) .885 
Anaemic 6 27% (9/34) 30% (11/37) .760 Anaemic 6 40% (72/182) 47% (87/186) .163 
18 31% (11/35) 13% (5/38) .059· 18 44% (81/183) 25% (46/187) <.001··· 
HCMV sera-DNA 6 27% (6/22) 42% (10/24) .306 HCMV sera-DNA 6 38% (49/129) 38% (46/121) .996 
18 38% (8/21) 40% (10/25) .895 18 35% (45/127) 36% (43/118) .870 
HHV-6 sera-DNA 6 9% (2/22) 11% (3/27) .816 HHV-6 sera-DNA 6 6% (9/149) 4% (6/148) .434 
18 10% (2/21) 8% (2/25) .855 18 16% (20/128) 16% (19/118) .919 
HIV-1 infected 3% (1/35) 3% (1/38) .953 HIV-l infected 2% (4/184) 2% (3/188) .682 
HIV-1 exposed 30% (9/30) 21% (7/33) .424 HIV-1 exposed 22% (37/166) 24% (40/168) .742 
Referral Rate 0.20 0.20 .948 Referral Rate 0.23 0.29 .405 
Died 0%(0/35) 0%(0/38) NA Died 0%(0/184) 0% (0/189) NA 
Growth 
Stunted 6 9%(3/35) 8% (3/38) .916 Stunted 6 10% (19/184) 12% (22/189) .685 
18 , 12% (4/34) 11% (4/36) .932 18 20% (37/182) 24% (42/179) .471 
-
.. 
-. Conventional Micronutrient Conventional Mlaonutrient 
N= Mean N= Mean P N= Mean N= Mean P 
BMI-for-age 6 35 
-{).0146 38 -{).1245 .663 BMI-for-age 6 - 184 0.0435 189 -{).0534 .441 
18 34 0.1600 36 0.1036 .830 18 182 0.0901 179 0,0852 .964 
Weight-fur-age 6 35 
-{).4429 38 -{).4189 .924 Weight-for-age 6 184 -{).4710 189 -{).5213 .690 
18 34 -{).3129 36 -{).3475 .897 18 182 -{).6493 181 -{).6380 .926 
length/height -for-age 6 
35 -{).7560 38 -{).5626 .385 Length/height-for-age 6 .- 184 -0.8603 189 -{).8484 .922 
18 34 -{).7065 36 -{).6933 .960 18 182 -1.1745 179 -1.1566 .878 
Triceps skinfold-for-age 6 35 
-{).4474 38 -{).3237 .635 Triceps skinfold-for-age 6 184 -0.1648 189 -{).1193 .681 
18 34 0.1418 36 0.lOS1 .893 18 182 0.0755 181 0.1899 .232 
Subscapular skinfold-for-age 6 35 0.2226 38 0.2703 .869 Subscapular skinfold-for-age 6 
184 0 .4693 189 0.3994 .570 
18 34 0.4447 36 0.5928 .595 18 182 0.4660 181 0.4555 .920 
Arm circumference-for-age 6 35 0.2n1 38 0.2403 .8n Arm circumference-for-age 6 
184 0.3218 189 0.2943 .818 
18 33 0.1091 36 0.0586 .855 18 182 0.0681 181 0.0220 .681 
Head circumference-for-age 6 35 0.8697 38 
0.7934 .723 Head circumference-for-age 6 
184 0.62n 189 0.6112 .8n 
18 34 0.9144 36 0.7039 .400 18 182 0.4282 181 0.5485 .247 . 
Table 32: Micronutrient fortification reduced anaemia at 18 months irrespective of HCMV seroprevalence 
Effect of micronutrient fortified feed supplement sub-stratified by HCMV seroprevalence, on prevalence of beta herpesvirus active infections (detection of sera-DNA), HIV-I 
infection (detection of antibody at 18 months), HIV-l exposure (detennined by maternal antenatal HIV-l status), polio antibody titres (measured by neutralization assay with titres 
binned as un-protective «'/g), low (' /g-' /32), medium (' /64-'/512) or high (>'/512)), prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as defined 
by Hb levels of < 10.5 glL) at both the month 6 and month 18 visits and anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores 
were compared by independent sample T test assuming equal variance and P values for nominal variables were by Pears on Chi Squared. White boxes highlight significant findings, 
light grey indicates trends. Asterisks denote degree of significance * < 0.1 , ** <0.05, *** <0.005. NO = not done, NA = not applicable 
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I CM:ecory/ I Conventional fortification I CM:ecory/ Micronutrient fortification 
,,' I month I HCMV sero-ve I HCMV serowe I p I month HCMV sero-ve HCMV serowe P 
MOfbIdIty -
un-protective 3% (1/35) 1% (2/181) Un-protective 5% (2/38) 2% (3/181) 
Polio Ab neutralization titre low 6% (2/35) 11% (20/181) 
.651 Polio Ab neutralization titre low 13% (5/38) 6% (10/181) .162 (12 months) Medium 66% (23/35) 66% (119/181) (12 months) Medium 61% (23/38) 65% (117/181) 
- High 26% (9/35) 22% (40/181) High 21% (8/38) 28% (51/181) ., 
Fever 6 14% (5/35) 12% (22/184) .701 Fever 6 13% (5/38) 14% (26/189) .922 
-
18 4% (1/26) 14% (20/141) .144 18 10%(3/30) 15% (21/142) .492 
6 27% (9/34) 40% (72/182) .148 Anaemic 6 30%(11/37) 47% (87/186) .056' Anaemic 
18 31% (11/35) 44% (81/183) .159 18 13% (5/38) 25% (46/187) .125 
HCMV sera-DNA 6 27% (6/22) 38% (49/129) .335 HCMV sera-DNA 6 42% (10/24) 38% (46/121) .737 
18 38% (8/21) 35% (45/127) .814 18 40%(10/25) 36% (43/118) .738 
6 9% (2/22) 6% (9/149) .586 6 11% (3/27) 4% (6/148) .127 HHV-6 sera-DNA 
18 . 10%(2/21) 16% (20/128) .465 HHV-6 sera-DNA 18 8% (2/25) 16% (19/118) .299 
HIV-l infected 3% (1/35) 2% (4/184) .804 HIV-l infected 3% (1/38) . 2% (3/188) .659 
HIV-l exposed 30% (9/30) 22% (37/166) .359 HIV-l exposed 21% (7/33) 24% (40/168) .747 
Referra I Rate 0,17 0.24 .482 Referral Rate .' 0.19 0,28 .443 
Died 0%(0/35) 0%(0/184) NA Died 0%(0/38) 0% (0/189) NA 
Growth 
Stunted 6 9% (3/35) 10% (19/184) .752 Stunted 6 8% (3/38) 12% (22/189) .501 
18 12% (4/34) 20% (37/182) .242 18 11% (4/36) 24% (42/179) .099' 
HCMV sero-ve HCMV sero+ve HCMV sero-ve HCMV sero+ve I 
- N= Mean N= Mean P N= Mean N= Mean P 
8MI-for-age 6 35 -0.0146 184 
0,0435 .794 8MI-for-age 6 38 -0.1245 189 -0.0534 .736 
-, 18 34 0.1600 182 0.0901 .731 18 36 0.1036 179 0.0852 .918 
Weight-for-age 6 35 -0.4429 184 -0.4710 .891 Weight-for-age 
6 38 -0.4189 189 -0.5213 .650 
18 34 -0.3129 182 -0.6493 .124 18 36 -0.3475 181 -0.6380 .159 
6 35 -0.7560 184 -0.8603 .628 Length/height-for-age 6 38 -0.5626 189 -0.8484 .156 Length/height-for-age 
18 34 -0.7065 182 -1,1745 .017" 18 36 -0,6933 179 -1.l566 .029" 
Triceps skinfold-for-age 6 35 -0.4474 184 -0.1648 .151 Triceps skinfold-for-age 6 38 
-0.3237 189 -0.1193 .290 
18 34 0.1418 182 0.0755 .705 18 36 0.1081 181 0.1899 .629 
6 35 0.2226 184 0.4693 .260 Subscapular skinfold-for-age 6 38 0.2703 189 0.3994 .546 Subscapular skinfold-for-age 
18 34 0.4447 182 0.4660 .912 18 36 0.5928 181 0.4555 .461 
6 - 35 0.2n1 184 0.3218 .817 6 38 0.2403 189 0.2943 .802 Arm circumference-for-age Ig 33 0.1091 182 0.0681 .845 
Arm circumference-for-age 18 36 0,0586 181 0.0220 .849 
-
6 35 0.8697 184 0.62n .182 Head circumference-for-age 6 38 0.7934 189 0.6112 .321 Head circumference-for-age 
18 34 0.9144 182 0,4282 .009" 18 36 0.7039 181 0.5485 .400 
Table 33: Micronutrient fortification may act to promote head growth in HIV-I exposed infants 
Effect ofHCMV seroprevalence sub-stratified by micronutrient fortified feed supplement, on prevalence of beta herpesvirus active infections (detection of sera-DNA), HIV-I 
infection (detection of antibody at 18 months), HIV-\ exposure (determined by maternal antenatal HIV-I status), polio antibody titres (measured by neutralization assay with titres 
binned as un-protective «l/g), low C/g- 1/ 32) , medium e /64-l /m) or high (> l/m )), prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as defined 
by Hb levels of < 10.5 gfL) at both the month 6 and month 18 visits and anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -2 .0. Mean z-scores 
were compared by independent sample T test assuming equal variance and P values for nominal variables were by Pearson Chi Squared. White boxes highlight significant findings, 
light grey indicates trends. Asterisks denote degree of significance * < 0, I, ** <0.05, *** <0.005. ND = not done, NA = not applicable 
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5.6 Discussion 
In this chapter betaherpesvirus active infections (sera-DNA detection at 6 and/or 18 months of 
age) and HCMV seroprevalence (sera-Ab detection at 18 months of age) have been 
investigated for effects on markers of morbidity and growth in HIV -1 exposed or unexposed, 
as well as HIV -I infected, Zambian infants. The study children were taking part in a 
nutritional intervention (CIGNIS) designed to test the efficacy of a micronutrient fortified 
feed supplement (over one that was conventionally fortified) to reduce morbidity and improve 
growth in HIV -1 exposed infants. 
At recruitment, 22% (1771799) of mothers reported themselves has being HIV -I positive. 
This rate is in keeping with national statistics which state that 23% of urban women of child-
bearing age (15-49yrs) are reported to be HIV -I positive (CSO _Zambia, 2007). All mothers 
in Lusaka are encouraged to have an HIV -I screen during pregnancy and those who are 
positive are administered Nevirapine therapy for the prevention ofMTCT (mother-to-child 
transmission)(Kuhn et aI., 2009). Without intervention transmission rates vary between 21-
43% but the administration of intrapartum Nevirapine has been shown to reduce rates by up to 
50% (Guay et aI., 1999; Jackson et aI., 2003). Infant HIV-I serostatus was determined for 152 
infants born to HIV -1 positive mothers, and 8% (121152) were HIV -1 positive at 18 months of 
age. There were eight other HIV -I positive infants. Two of these infants had mothers of 
unknown status, and the remaining six had mothers who were HIV -1 negative according to 
the survey they responded to at recruitment. We do not know if these were pre- or post-natal 
maternal HIV -1 infections, but of the eight infants, one died quite early into the study due to 
protein energy malnutrition. Even if all eight infants were born to HIV -1 positive mothers, the 
resulting 'maximum' rate of MTCT on this study would be 13% (20/151) which remains 
consistent with reductions reported elsewhere as a result of Nevirapine prophylaxis (Guay et 
aI., 1999; Jackson et aI., 2003). 
The study was not set up to focus on HIV-l infected infants and so their numbers were low, 
but some significant correlations were observed. Anaemia was more common in HIV-l 
infected infants throughout the study, and the micronutrient fortified feed supplement showed 
a trend to reduce anaemia among HIV-I infected infants. Interestingly, whilst in HIV-l 
infected infants some z-scores were significantly lower at baseline, by 18 months of age just 
two anthropometric parameters distinguished the HIV -1 infected from the uninfected infants: 
subscapular skinfold and arm circumference. This is consistent with previous studies showing 
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lipodystrophy in HIV-1 infected infants (Taylor et al.. 2004). Compared to HIV-l uninfected 
infants, the few who became HIV -1 infected (by 18 months of age) were significantly more 
likely to fail to mount a protective response to the polio vaccine. Protective responses were 
generally weaker as has been shown previously for both the polio and measles virus vaccines 
(Nair et aI., 2009; Tejiokem et al.. 2007). A possible mechanism for this is through HIV-I 
infection and malfunction of Th2 T -cells which bind to and promote B-cell proliferation and 
antibody production (Becker, 2007; Parker. 1993). 
In HIV -1 exposed infants, a significantly lower distribution of responses to the polio vaccine 
was also observed, clearly demonstrating that HIV -1 exposure is associated with weakened 
immunity. This combines with decreased adoptive immunity through breast milk, with HIV-l 
positive mothers being significantly less likely to breast feed. or more likely to terminate 
breast feeding earlier than HIV -1 negative mothers. This is also a probable major cause of 
impaired growth and development in HIV -1 exposed infants and lies at the very centre of the 
rationale for the CIGNIS trial which seeks to compensate for reduced breast feeding and 
improve growth and development in HIV -1 exposed infants. The prevalence of stunting 
among HIV -1 exposed infants on this study was significantly greater, characterized not only 
by significantly lower mean z-scores for length, but also decreased weight and peripheral fat. 
with most differences persisting to 18 months. These results are consistent with what has been 
published with respect to infant growth and HIV -1 exposure (Makasa et aI., 2007). Hospital 
referral rates were significantly higher among HIV -1 exposed infants suggesting a higher rate 
of serious morbidity. Mortalities were also more prevalent in HIV -1 exposed infants, but all 
five who died were of unknown HIV-1 status having not completed the study, and may well 
have been HIV -1 infected. More long term follow up after 18 month HIV -1 diagnosis will be 
required to establish whether mortality is greater in truly HIV -1 exposed uninfected infants as 
published previously (Marinda et aI., 2007). 
A serological screen for HCMV was undertaken on sera from 460 CIGNIS children at 18 
months of age showing the overall prevalence of HCMV to be 83%. This rate is in much 
higher than that seen in European and North American seroprevalence studies (Emery, 2001; 
Staras et al.. 2006) but is slightly lower than seen in studies from The Gambia (Kaye et aI., 
2008; Miles et aI., 2007) and Kenya (Chakraborty et aI., 2003). This relatively high 18 month 
HCMV seroprevalence is consistent with the prevalence of HCMV sera-DNA in this cohort. 
Interestingly HCMV sera-DNA prevalence did not correlate with HCMV seroprevalence, in 
that infants in whom HCMV sera-DNA was detected, were no more or less likely to be 
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HCMV seropositive than those who were negative for HCMV sera-DNA. One explanation for 
this is that exposure to HCMV by 18 months was almost universal in this population with 
some infants having antibody below the threshold of detection. This would mean that the 
serology data should be interpreted as 'detectable antibody at month 18' and it cannot be 
assumed that all infants without detectable antibody have not been exposed to the virus. 
Another explanation is the possible presence of false positives in the sera-DNA or 
seroprevalence analysis. All positives were scored from screens which contained the 
appropriate positive and negative controls although PCR is susceptible to transient 
contamination (especially so in tropical climates with limited air conditioning). Skewed 
randomization is also suggestive of contamination. Future studies should employ stricter 
controls and designed to allow enough sample for multiple screens. Due to limitations on 
sample volume on this large collaborative study a strategy of duplicate screens or extractions 
was not feasible. HHV-6 was less commonly detected than HCMV, although the assay used 
was less sensitive. A serological screen of 18 month sera is currently being undertaken. 
Preliminary results on a small subset of samples suggest 100% HHV -6 seroprevalence at 18 
months (KM, personal communication). It is known from studies in the U.S that primary 
HHV -6 infection occurs in up to 80% of infants by two years of age (Zerr et aI., 2005) and so 
if the earlier uptake in Zambia seen with HCMV is mirrored for HHV-6, we anticipate that all 
of the infants will be HHV -6 seropositive by 18 months of age. Our results suggest 
betaherpesvirus sera-DNAemia is common (significantly more so for HCMV than in HHV -6) 
and that these episodes of viral shedding in sera are normal in healthy infants but that they 
correlate with largely short term effects on morbidity and growth. 
HCMV seroprevalence and active betaherpesvirus infections and were first analysed for 
possible correlations with demographic parameters that have been previously shown to be 
associated with HCMV such as maternal education, socioeconomic status and duration of 
breast feeding (de Martino et aI., 1992; Dowd, Aiello, and Alley, 2009). HCMV 
seroprevalence was linked with lower socioeconomic status as previously, and also with 
increased duration of breast feeding which is a long established route of transmission for 
HCMV (Dworsky et aI., 1983; Murata et aI., 2009), but not HHV-6 (Kusuhara et aI., 1997). 
These data suggest that breast feeding may be considered a risk factor for mother-to-child-
transmission of both HIV-l and HCMV, both of which contribute to impaired growth and 
increased morbidity and moralities. 
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Duration of breast feeding did not correlate with prevalence of active HCMV infection at 6 
months, suggesting that the main window of transmission via breast milk is in early infancy. 
There are also other modes of transmission to consider with HCMV being shed in saliva and 
urine which are also known to contain high loads of HCMV and may influence transmission 
differentially in different populations (Mocarski, 2007). Furthermore, a study from The 
Gambia suggests that congenital infections are much more common in populations of high 
adult seroprevalence than thought previously (Kaye et aI., 2008), possibly due to more 
frequent or higher load maternal reactivations (van der Sande et aI., 2007), and this may 
contribute significantly as a mode of HCMV transmission in Zambia. Congenital or perinatal 
HCMV may be responsible for considerable levels of morbidity and impaired growth, with a 
back drop of high levels of maternal and infant immune suppression from either HIV -1 or 
other infections and also poor nutrition. In this study active HCMV infection at month 6 was a 
marker of morbidity as it was associated with a clear trend towards increased referrals. 
HCMV seroprevalence was also associated with a trend towards decreased risk of polio 
vaccine failure but only amongst HIV -1 unexposed infants, likely due to the association of 
HIV -1 exposure and weakened polio vaccine responses being stronger. Anaemia is common 
in Zambian infants (van Rheenen et aI., 2008), possibly due to a lack of dietary iron (Adetifa 
and Okomo, 2009) or common childhood infections such as malaria (Otieno et aI., 2006) or 
viral infections. Here HCMV seropositive infants were more likely to be anaemic as has been 
shown previously (Distefano et aI., 2004) possibly reflecting poorer dietary intake of iron 
linked with lower socioeconomic status or maybe through a direct effects of HCMV 
metabolising available iron (Crowe et aI., 2004). By 18 months however this difference loses 
significance but this is not due to the intervention, in that HCMV seroprevalence is not 
associated with significant increases in anaemia at 18 months in either arm of the trial. Iron 
intake of mothers in the third trimester of pregnancy is linked to anaemia in infants, with low 
body iron at birth being associated with more long term iron deficiency (lannotti et aI., 2006). 
Anaemia may be a marker for MTCT ofHCMV. It has already been shown to be an 
independent marker of MTCT of HIV -1 (Naniche et aI., 2008) and is a marker of worse 
prognosis and disease progression in HIV -1 positive infants (Consolini et aI., 2007). 
It has been previously demonstrated that the prevalence of various infections can affect 
growth in infants, including changes in both BMI and head circumference (Prentice and 
Darboe, 2008). In the CIGNIS study active HCMV at month 6 was associated with lower 
BMI and lower peripheral fat, but these effects did not tend to persist throughout the study. 
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Conversely, HCMV seroprevalence is significantly associated with stunting and also lower 
weight at 18 months suggesting more long term inhibitory effects on growth. Interestingly, 
the detrimental correlation of HCMV seroprevalence and head size affected only HIV-l 
exposed infants, suggesting these two infections may be combining to impair head growth. A 
plausible explanation may be that congenital HCMV is significantly more frequent among 
HIV -1 exposed infants and that the effects on head circumference are unique to congenital 
HCMV whereas those on length are also a result of postnatally acquired HCMV infection. 
Analysis of Bailey testing results is being undertaken by other members of the CIGNIS team 
and it will be interesting to see if the effect ofHCMV and HIV-I on head size also correlates 
with impaired mental development. 
Finally we have assessed the impact of betaherpesvirus infections on the efficacy of a 
micronutrient fortified feed supplement to improve growth and reduce morbidity in Zambian 
infants. Overall the intervention significantly reduced the prevalence of anaemia likely due to 
the fact that the micronutrient fortified feed supplement contained nearly 40 times more iron 
than the conventionally fortified feed (250mg vs 6.5mg per Kg baked flour). These effects on 
anaemia were independent of HIV -1 exposure, HCMV seroprevalence or prevalence of active 
HCMV infections. The intervention did not have a significant overall effect on 
anthropometric outcomes, but sub-stratifying by HIV -I, HCMV and breast feeding groupings 
uncovered some interesting and significant effects: Analysis by the CIGNS team showed that 
the micronutrient fortified feed supplement was seen to benefit a sub-group: It improved 
linear growth among HIV -1 exposed infants who were not breast feeding at recruitment 
(Filteau, 2009b), and within this sub-group, HCMV seropositive infants were significantly 
longer if on the micronutrient enriched feed supplement than on the conventional supplement 
(P = O.022)(Appendix L, analysis by KB, study statistician). This finding show's that the 
micronutrient fortified feed supplement had real benefits for a sub-group of children: HIV-I 
exposed, HCMV seropositive and breast fed <6 months. But conversely, HIV-I exposed, 
HCMV seropositive infants also showed a significantly greater rate of referrals (P = 0.023) 
(Appendix P, analysis by KB, study statistician), largely due to infectious causes. A total of 
14 infants within this group were referred to hospital, 10 of whom were suffering with 
infections: five with malaria, two with skin infections, two with acute diarrhoea and one with 
pneumonia. The micronutrient fortified feed supplement may be promoting growth in this 'at 
risk' group but increased iron may be promoting infections resulting in increased 
hospitalizations. HIV -1 exposed, HCMV seropositive infants, account for around 15% of 
Zambian infant population. This is a sizeable group to be at risk of higher rates of referral in 
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response to micronutrient fortification of complementary feeds, especially if benefits to the 
majority of infants are marginal. These findings and the effects of HHV -6 in this respect are 




This thesis presents analysis of human betaherpesvirus infections, in one prospective and two 
retrospective, paediatric cohorts from Zambia, a country at the epicentre of the HIV-1 
pandemic. Analysis of the two retrospective cohorts provided insight into the prevalence and 
loads of these two viruses in hospitalized fevers (n = 141) and HIV-l positive respiratory 
mortalities (n = 36). The prospective cohort were taking part in a nutritional intervention 
study (Chilenje Infant Growth Nutrition and Infection Study - CIGNIS)(n = 812) which 
facilitated the first population based analysis of betaherpesvirus infections in this region, 
looking at viral sera-DNA prevalence and loads at both 6 and 18 months of age along with 
HCMV seroprevalence at 18 months. Data were collected from the CIGNIS cohort on infant 
and maternal HIV-l status, demographics, prevalence of anaemia and reported fever, rates of 
hospital referrals and mortalities, and growth. This prospective cohort provided the largest 
data set and was used to assess the effects of betaherpesvirus infections on HIV -1 exposed but 
uninfected infants, a new and expanding group in this region known to suffer from severe 
growth retardation and increased morbidity (Makasa et aI., 2007). 
6.2 Betaherpesvirus prevalence in three Zambian paediatric cohorts 
The prevalence and loads of HCMV and HHV -6 were first analysed in two retrospective 
Zambian paediatric cohorts: DNA-extracted lung tissue from HIV -1 positive paediatric 
respiratory mortalities, and DNA-extracted whole blood from infants hospitalized with fever. 
The respiratory mortalities displayed a significantly higher prevalence of HCMV than HHV-6 
(94% vs 72%) although both were commonly detected, and loads normalized to cell number 
did not differ significantly between the two viruses. The higher prevalence of HCMV DNA 
correlates with the fact that it is known to infect the lungs and cause pneumonia and was 
previously commonly detected by histology in this cohort (Chintu et aI., 2002). These two 
betaherpesviruses are not routinely monitored in Zambia, but are known to accelerate HIV-l 
progression (Chakraborty et aI., 2003; Kositanont et aI., 1999; Kovacs et aI., 1999; Nigro et 
aI., 1996) and are important causes of morbidity and mortality in late stage AIDS which may 
respond to treatment. 
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This thesis has also established that active betaherpesvirus infections are common in healthy 
Zambian infants, and that the epidemiology of these infections in this region is quite distinct 
from that seen in other regions globally. CIGNIS was the first population based study of 
HHV -6 in this region but it was not designed to measure the cumulative incidence of primary 
HHV -6 infection as elsewhere. Prevalence of sera-DNA detection at two time points (8% at 6 
months, 13% at 18 months) suggested possible earlier uptake ofHHV-6 than in North 
America where 10% of infants were cumulatively infected by 6 months of age, rising to 80% 
by 18 months (Zerr et aI., 2005). HHV-610ads in the CIGNIS cohort were generally low and 
we did not identify any infants in whom we suspected chromosomally integrated HHV -6, 
which has been documented to have a prevalence of up to 1 % in some European countries 
(Leong et aI., 2007; Ward et aI., 2006). Earlier uptake ofHHV-6 would be consistent with our 
findings here from the first Zambian survey of HCMV seroprevalence which found 83% of 
infants to be seropositive by 18 months of age (Kunda Musonda, MSc Thesis), with active 
infections being detected in 40% of infants at 6 months of age. This is consistent with a much 
smaller study from Kenya which used exactly the same assay, but a more sensitive DNA 
extraction protocol (specific for viral DNA thus reducing background interference from 
human genomic DNA), to find 90% (n = 20) of HIV -1 exposed infants to be sera-DNA 
positive, although this study lacked an HIV -1 unexposed control group (Slyker et aI., 2009). 
This early uptake has also been seen in other African countries (Bello, 1992; Kaye et aI., 
2008) but is in stark contrast to the epidemiology ofHCMV infection elsewhere, where 
uptake is known to be much later with seroprevalence rates in North American children <2 
yrs of age being reported between 15-30% (Bale et aI., 1999; Noyola et aI., 2005) or 30% in 
children from New Zealand aged 3-5 yrs old (O'Brien et aI., 2009). The prevalence seen here 
in Zambia is similar to that recorded in elderly populations in the U.K (Vyse, Hesketh, and 
Pebody, 2009). 
These early infections with HCMV in Africa are particularly interesting in light of a recent 
study from Malawi (Zambia'S eastern neighbour), which found significantly lower (2-6 fold) 
median percentages ofCCR7 positive naIve and central memory T-cells, but higher CCR7 
negative effector and stable memory T -cells in Malawi. The study then assessed the effect of 
HCMV, with seropositive (36%) U.K adolescents having proportionately fewer truly naIve T-
cells than those who were seronegative (64%). This comparison was not possible in the 
Malawian cohort as all 59 adolescents studied were HCMV seropositive (Ben-Smith et aI., 
2008). They suggest that in high disease burden countries, the greater natural exposure to 
many infections may be driving earlier ageing of the immune system, and that HCMV may 
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play a major role in this. Profound CD8 T -cell differentiation of CMV -specific T -cells was 
also observed in a study of 12 month old Gambian infants (Miles et aI., 2007). Several studies 
have shown a link between HCMV seroprevalence and ageing as reviewed (Emery, 2001; 
Karrer et aI., 2009) with HCMV seropositivity being linked with major differences in the 
magnitude of lymphoid subsets in healthy European adults (Chidrawar et aI., 2009; Pita-
Lopez et aI., 2009). Data from the U.S shows that in seropositive adults, the percentage of 
HCMV -specific T -cells in the peripheral memory was around 10% for both CD4+ and CD8+ 
subsets (Sylwester et aI., 2005). Furthermore many of these committed HCMV-specific 
memory cells are, to varying degrees, dysfunctional (Ouyang et aI., 2004). Considering the 
number of pathogens most people have been exposed to by adulthood, this displays an 
extraordinary bias towards HCMV and is possibly the result of continual viral re-activation 
and immune stimulation maybe in concert with defects in apoptosis. The early uptake in 
infants and high seroprevalence of HCMV reported in this thesis may be significant factors 
contributing to ill health in Zambia, undermining efforts to combat a broad range of infectious 
diseases, due to an accelerated onset of immune senescence with age when compared with 
populations from temperate climates. Such geographical differences have also been observed 
in the prevalence of other herpesviruses. Interestingly VZV seroprevalence is generally lower 
in tropical compared to temperate countries (Kjersem and Jepsen, 1990; Saha et aI., 2002), the 
complete opposite of that observed here for HCMV. 
HIV-l is endemic in Zambia and both HCMV (seroprevalence, sera-DNA loads and 
genotypes) and HHV-6 (sera-DNA loads and genotypes) have been analysed here on the 
prospective CIGNIS study within HIV -1 infected, HIV -1 exposed and HIV -1 unexposed 
healthy Zambian infants. This analysis showed trends, at both month 6 and month 18, for 
higher prevalence of HCMV and HHV -6 sera-DNA detection among HIV -1 positive infants 
but these differences were not significant with the low numbers of HIV -1 infected infants 
studied. Whilst prevalence of active HCMV or HHV -6 infections did not change significantly 
with respect to maternal HIV -1 status, high load HCMV infections were significantly (two-
fold) more prevalent among HIV -1 exposed infants. The study was confounded however in 
that infants who were sick were less likely to give a blood sample and more likely to be 
withdrawn before completing the study. In a subgroup of 23 infants who were referred to 
hospital, the prevalence of both betaherpesviruses was significantly higher than in that of the 
general population, and in the case of HCMV higher loads were significantly more prevalent 
also. 
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6.3 Betaherpesvirus genotypes 
6.3.1 HCMV genotypes 
HCMV genes are mostly highly conserved between strains but a significant number of genes 
exhibit variation and have been extensively used for genotyping (Bradley et aI., 2008; 
Pignatelli, Dal Monte, and Landini, 2001; Stanton et aI., 2005). Linkage between these 
variable loci is rare due to the high frequency of recombination. a key characteristic of the 
HCMV genome (Haberland, Meyer-Konig, and Hufert, 1999; Rasmussen, Geissler, and 
Winters, 2003). Furthermore, efforts to link specific disease presentations or outcomes with 
specific genotypes have generally failed to draw firm conclusions (Arista et aI., 2003; Dal 
Monte et aI., 2004; Pignatelli et aI., 2003b; Rosen et aI., 1998; Rossini et aI., 2005; Sarcinella 
et aI., 2002; Trincado et aI., 2000). Whilst linkage is rare, two neighbouring hypervariable 
glycoprotein genes, UL73 and UL74, have been shown to be linked forming eight linked 
genotypes (Mattick et aI., 2004; Yan et aI., 2008) and these were used to genotype HCMV in 
.the three cohorts studied in this thesis. Here we have shown that all eight linked genotypes are 
present in Southern Africa as in other regions, which is distinct from similar studies on other 
herpesviruses (Kasolo et aI., 2007). There may be some subtle trends for certain genotypes to 
be more prevalent in some regions but this analysis is confounded in that data comes from 
different clinical sources in different regions: The majority of Japanese sequence comes from 
congenital and infant primary infections whereas the majority of sequence data from Southern 
Africa comes from AIDS-related respiratory mortalities. The sequence data from North 
America and Europe is largely from congenital infections and transplant recipients. In 
Southern Africa, the epicentre of the AIDS pandemic, putative novel linkages (or mixed 
infections) were more commonly detected than elsewhere. Whilst this thesis does not present 
direct evidence of novel recombinants in this region, the combination of a high prevalence of 
multiple infections, lowered immunity due to HIV -1 or other factors, early HCMV primary 
infections, and the innate propensity for HCMV strains to recombine, make a strong argument 
for future studies isolate and sequence whole virus from this region. Whether the linkage 
between UL 73 and UL 74 is positional or functional (or both) will require further work using 
biological assays to exam interactions between these two proteins in vitro and in vivo. 
Sequence data from this thesis and elsewhere suggest the possible existence of HCMV strains 
with defective or truncated glycoproteins. Again, biological assays are required to determine 
the possible clinical relevance of such variants. I have constructed a C-terminally GFP-
labelled gOI b clone as a potential starting point for such analysis. Both UL 74 and UL 73 are 
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glycoproteins thought to be involved in cell binding and/or virion egress. The use of labelled 
clones would allow transfection experiments mismatching gO and gN genotypes in assays 
looking at tropism, fusion, or intracellular localization. Such work may lead to the 
construction of recombinant viruses to examine the effects of gO/gN recombinants during 
natural infection in vitro. 
6.3.2 HHV -6 genotypes 
The molecular epidemiology of HCMV and HHV -6 are quite distinct. Whilst HCMV readily 
recombines with certain variable loci having up to 14 genotypes (Bradley et aI., 2008), HHV-
6 is generally known to exist as one of two distinct strain variants, with strong linkage across 
the entire length of the genome. These two strain variants are termed HHV -6A and HHV -68. 
In Europe and North America infant primary infections are overwhelmingly with HHV -6B 
(Dewhurst et aI., 1993; Hall et aI., 1994; Zerr et aI., 2005). In these regions HHV -6A is a later 
infection, is more neurotropic (Aberle et aI., 1996; Hall et aI., 1998) and more prevalent in 
immunocompromised patients (Ablashi et aI., 1998; Iuliano et aI., 1997; Nitsche et aI., 2001; 
Secchiero et al., 1995). A previous study of febrile infants had suggested HHV -6A may be 
more common in Zambia (Kasolo, Mpabalwani, and Gompels, 1997) and in this thesis we 
confirm this to be true, with the first ever population based study of HHV -6 strain prevalence 
in this region, demonstrating that HHV -6A is actually the predominant HHV -6 primary 
infection in this region, being detected in 85% of active HHV -6 infections. This finding was 
supported by the fact that HHV -6A was detected at a similarly high prevalence and with 
sequence variation at two loci (U46 and U47). These data suggest that HHV -6A is the 
primary strain variant in Southern African maybe being better adapted to host genetic factors 
in these populations, and that elsewhere HHV -6A may be more emergent. Some leading 
researchers in the HHV -6 field have recently proposed, largely based on clinical data and 
growth in cell culture differences, the re-classification of HHV -6A and B to HHV -9 and 
HHV-I0 respectively. The data presented in this thesis and previous data from our group 
(Gompels, 2006) provide some evidence for possible recombination between the two strain 
variants, and in light of the scarcity of complete genome sequences published on Genbank 
(there are only three), the proposed re-classification may be slightly premature and studies 
should be commenced, likely employing next generation sequencing technology, to fully 
sequence a diverse range of isolates from geographically distinct locations. Whilst this thesis 
does evidence a unique epidemiology for HHV -6A primary infections in infants from this 
Southern African region, geographical differences in seroprevalence (Sarmati et aI., 2004) and 
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genotypes (Kasolo et aI., 1998; Kasolo, Mpabalwani, and Gompels, 1997) are established for 
the gammaherpesvirus KSHV, and also for the alphaherpesvirus VZV (Quinlivan et aI., 
2002). In the case of KSHV, the presence of childhood endemic Kaposi' s Sarcoma in Zambia 
demonstrates how infection with the same herpesvirus can have diverse clinical outcomes in 
different regions, possibly due to the interplay between host factors and key variable genes. 
6.4 CIGNIS morbidity and mortality 
CIGNIS is a placebo controlled trial designed to test the efficacy of a micronutrient fortified 
feed supplement to reduce morbidity and mortality and improve growth and development in 
HIV -1 exposed uninfected Zambian infants. With the roll out of PMTCT programmes this is 
an expanding group which have been previously shown to suffer higher morbidity and 
mortality (Marinda et aI., 2007) and impaired growth (Makasa et aI., 2007) compared to HIV-
1 unexposed uninfected children, with premature cessation of breast feeding implicated as the 
key causal factor (Arpadi et aI., 2009). This thesis assesses the effect of the micronutrient 
fortified feed supplement, HIV -1 infection and exposure and betaherpesvirus infections, on 
specific markers of morbidity such as prevalence of anaemia, reported fever and rate of 
hospital referrals, along with mortality. 
HIV -1 infected infants showed significantly weaker neutralizing antibody responses to the 
polio vaccine and a higher prevalence of anaemia throughout the study, the latter of which 
was to some extent alleviated by the micronutrient fortified feed supplement. HIV -1 infected 
infants also suffered significantly higher rates of referral and associated mortalities although 
numbers were too low to assess the effect of the intervention on these outcomes. HIV-l 
exposed infants (compared to HIV-l unexposed infants) were significantly more likely to 
have never been breast fed or to terminate breast feeding early as shown previously (Arpadi et 
al., 2009). Associations with weakened polio vaccine responses were seen in both HIV-l 
infected and exposed infants, although increased anaemia seen in HIV -1 infected infants was 
not observed in HIV -1 exposed infants, with the micronutrient fortified feed supplement 
reducing anaemia irrespective of HIV -1 exposure. HIV -1 exposed infants showed a general 
trend towards increased referrals but of great importance, this was significant only in the 
micronutrient arm of the study, suggesting that the micronutrient fortified feed supplement is 
combining with HIV -1 exposure to drive referrals. There may be positive effects among HIV-
1 unexposed infants though, with a trend towards decreased mortalities in infants on the 
micronutrient fortified feed supplement. 
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Detection of active HCMV infections at baseline was associated with a trend towards 
increased referrals (irrespective of HI V-I exposure). In this context, active HCMV infection 
at month 18 and active HHV -6 infection at either time point are scheduled to be analysed for 
associations with referral rates. HCMV seroprevalence at 18 months of age was associated 
with a trend towards stronger neutralizing antibody responses to the polio vaccine although 
any such benefit was negated among HIV -1 exposed infants. HCMV seroprevalence was also 
associated with a roughly 50% increase in the prevalence of anaemia throughout the study (at 
both time points). This could be an observation of a direct causal effect of HCMV 
metabolizing dietary iron (Crowe et aI., 2004) but there could be additional indirect effects 
such as increased prevalence of other infections known to cause anaemia such as Malaria, 
among HCMV seropositive infants. The micronutrient fortified feed supplement reduced 
levels of anaemia in both HCMV seropositive and seronegative infants. 
Broadly, the micronutrient fortified feed supplement did not significantly reduce the rate of 
referrals or the prevalence of reported fever, betaherpesvirus active infections or mortalities. 
The intervention was successful at reducing the prevalence of anaemia overall, but among 
HIV -1 exposed, HCMV seropositive infants the intervention appears to be driving 
hospitalization, with raised iron levels possibly causing oxidative stress and exacerbating 
infection. 
6.5 CIGNIS growth 
The CIGNIS study was not powered to examine HIV -1 infected children but even in this 
small group, there was some evidence of fat redistribution in the small group of HIV -1 
infected infants on the study which has been previously documented (Taylor et aI., 2004). 
Interestingly, persistent stunting or wasting were not associated with HIV -1 infection but it 
could be that significant numbers of this group were withdrawn from the study or died. 
Conversely, HIV-l exposed infants showed significantly impaired growth by almost all 
anthropometric measures compared to HIV -1 unexposed infants as suggested in this region 
previously (Makasa et aI., 2007). 
The micronutrient fortified feed supplement did not appear to significantly affect growth 
parameters in either HIV -1 unexposed or exposed infants, the association of HIV -1 exposure 
with wasting was observed only on the micronutrient arm of the study. This effect is the result 
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of divergent trends, with the micronutrient reducing wasting in HIV -1 unexposed, but 
increasing it in HIV -1 exposed infants. This same divergent trend is seen for length. What 
component of the micronutrient fortified feed supplement could be responsible for this 
differential growth interaction with HIV-I exposure? Of the markers assessed in this study the 
only significant effect of the micronutrient overall was its ability to reduce anaemia, likely 
through provision of a 40-fold increase in the concentration of dietary iron. An excess of iron 
can be detrimental and it is possible that HIV -I exposed infants are less well equipped to 
maintain iron homeostasis, due to malfunctions in intestinal transport, extracellular and 
intracellular regulation (Collard, 2009), and that this affects growth as well as the prevalence 
of infections as discussed above. However, more detailed analyses by other members of the 
CIGNIS team found the micronutrient fortification was able to reduce stunting in a sub-group 
of HI V-I exposed infants, those who stopped breast feeding before 6 months of age (FiIteau, 
2009b). 
Active HCMV infections at baseline were associated with some short term decreases in length 
and peripheral fat and stunting at 18 months in HIV-I exposed infants. HCMV seroprevalence 
was associated with long term stunting and wasting, and with breast milk shown here (as 
elsewhere) to be a common mode of transmission, extended breast feeding is a risk factor for 
MTCT of HCMV and associated growth inhibition. Interestingly, among HIV -1 exposed 
infants only, HCMV seroprevalence was also associated with a long term inhibition on head 
circumference, the developmental effects of which are under investigation through analysis of 
Bailey testing results, and initial findings show that decreased motor skills are associated with 
decreased head circumference and so it is possible that this will correlate with HCMV 
seroprevalence. 
6.6 Future Work 
There is still much work to be done on the CIGNIS project analysing data from Bailey testing, 
micronutrient and immunological data, and also long term follow up for possible effects of 
the intervention on mortalities. More broadly within the context of the betaherpesvirus 
infections presented in this thesis, there will be further multivariate adjusted analysis of HHV-
6 and HCMV results with HIV -1 and the micronutrient intervention. More genotyping data 
will be collected for HCMV and particularly for HHV -6 which is a distinct strain variant 
causing infant primary infections in this region. Next generation sequencing technology could 
be used to complete several whole genome sequences for HHV -6 strains isolated in this 
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region and elsewhere, and could also be used to sequence the whole gO/gN locus of HCMV 
from archived strains and/or new cohorts. One could then assess whether increased prevalence 
of multiple infections, higher viral loads and reduced immune surveillance due to HIV, may 
be facilitating the emergence of novel recombinant HCMV or HHV -6 strains, which may be 
causing infant infections here. 
Data from this thesis form the basis and rationale for possible functional assays to determine 
the role ofhypervariable HCMV glycoproteins such as gO and gN. We have constructed a C-
terminally labelled gOlb-GFP clone as an initial step in this direction, with a view to 
investigating the effects of gO/gN mismatches on cell-cell fusion or other functional assays. 
Results of such experiments may lead to the use of bacmids to construct recombinant viruses 
with 'mismatched' gO and gN genotypes for use in infection studies in different cell types or 
receptor blocking experiments to investigate virus-cell tropism. Immune-precipitation 
experiments could be used to look for interactions between gO or gN and other novel 
glycoproteins, many of which remain to be characterised. 
Both HCMV and HHV-6 are significant pathogens in HIV/AIDS and use of real time PCR to 
monitor loads in different body fluids or compartments may be used to identify active 
infections which would respond to treatment should drugs such as oral gancyclovir become 
available in Zambia. With overwhelming betaherpesvirus lung involvement demonstrated 
here associated with late stage AIDS, treatment with anti-betaherpesvirus drugs may be 
appropriate for HIV / AIDS patients who are failing to respond to treatment for bacterial 
pneumonias. The rate of congenital HCMV infection in Zambia is not known and we hope 
that Guthrie cards may be available for a subset of the CIGNIS cohort to establish this and to 
investigate its effects on morbidity, growth and mental development. 
Vaccine trials for HCMV have focussed entirely on populations with low HCMV 
seroprevalence, with adolescent females being the target group with a view to preventing 
primary infection during pregnancy and resulting congenital infection. These have been 
largely phase I and phase 11 trials, but if a vaccination strategy does eventually prove to be 
safe and effective, it may be of little relevance to populations of high HCMV seroprevalence. 
In countries like Zambia, vaccination would have to be administered in early infancy, and 
protection, likely with the need of periodical boosters, would have to be maintained 
throughout childhood and into the child bearing years. Another intervention may be the use of 
anti-betaherpesvirus drugs to treat HCMV viraemia in pregnant mothers to reduce the rate of 
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congenital infection, breast milk transmission and morbidity caused by infant primary 
infections, but an effect vaccine would be more economically viable. 
7.0 Conclusions 
This study of HCMV and HHV -6 infections in Zambian children has revealed some unique 
features of these infections. The distribution of HCMV genotypes differed little from that seen 
elsewhere but the predominance of HHV -6 variant A in this region, in healthy infants, is 
novel and suggests this is an emergent infection elsewhere. HCMV infection has been 
associated with increased morbidity and impaired growth in Zambian infants, and breast 
feeding is a risk factor for early transmission. Data suggest that these atypical early HCMV 
infections are factors in the poor development of HIV -1 exposed infants here. The 
micronutrient fortification did not affect these infections in HIV -1 exposed infants, although it 
did improve growth in those who were not breast fed. 
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9.1 Appendix A - Oligonucleotide primer sequence table 
Primer name Paired with sequence 5', 3' Tal'let Reference Product size (bp) 
Gene 
OrIIanlsm (Glycoprotein) 
GAPup GAPdown GCT CCC TCT TIC TTI GCA GCA AT Human GAPDH Asahi-Ozaki et al. 2006 104 
GAPdown GAPup TAC CAT GAG TCC TIC CAC GAT AC Human GAPDH Asahi-Ozaki et al. 2006 104 
GAPprobe - 6-FAM-TCCTGCACCACCAACTGCTT AGCACC-TAMRA Human GAPDH Asahi-Ozaki et al. 2006 -
I UGU47F U47R TTICCAACTCGAATCTGACAC HHV-6A/B U47(gO) Bates et al. 2009 177 
U47F U47R CGAAGAATCCTTGCGGATG HHV-6A/B U47(gO) Bates et al. 2009 208 
U47R U47F GGCTCGTCCAAAGGAAGTG HHV-6A/B U47(gO) Bates et al. 2009 208 
U47probe - 6-FAM-TTICCAACTCGAATCTGACACG-TAMRA HHV-6A/B U47(gO) Bates et al. 2009 -
U470F U470R TGGGAGCACAGTIATTIGACA HHV-6A/B U47(gO) Bates Unpublished 322 
U470R U470F TTGGTACTAGGGATATGTGGTGAT HHV-6A/B U47 (gO) Bates Unpublished 322 
U46F U46R TGTCTGCTGTTAATCACGTC HHV-6A/B U46(gN) Bates et al. 2009 312 
U46R U46F GCGATCTAATAACCCTTCAC HHV-6A/B U46(gN) Bates et al. 2009 312 
U46-Up U46-lw TAACGCTTAAGATGAGTTGTAAG HHV-6A/B U46(gN) Bates et al. 2009 251 
U46-lw U46-Up CGTCTCTGAAGCAAAAGTC HHV-6A/B U46(gN) Bates et al. 2009 251 
U460F U460R CGCTGTACATTTTICCAGGTGAC HHV-6A/B U46(gN) Bates Unpublished 627/626 
U460R U460F CACACAACCATCCAGATAACCTC HHV-6A/B U46(gN) Bates Unpublished 627/626 
G01 G02 CTCCTCTGTCATGGGGAGAAA HCMV Ul74 (gO) Mattick et al. 2004 469 
G02 G01 AGAAAGACAAGTCATGGAAGG HCMV Ul74 (gO) Mattick et al. 2004 469 
G010 G020 CAACGGTAGATGAGCAGCAA HCMV Ul74 (gO) Bates et al. 2008 791 
G020 GOlO CATGGCGTTAACCAGGTAGAA HCMV Ul74 (gO) Bates et al. 2008 791 
GO-Up GO-Iw CGACCAGAATCAGCAGTGAG HCMV Ul74 (gO) Bates et al. 2008 742 
GO-Iw GO-Up TGTACAGTIGCGTTGTGCGTA HCMV Ul74 (gO) Bates et al. 2008 742 
U730F l730R CGCGACAGTACCAGTTGAGA HCMV Ul73 (gN) Bates Unpublished 599 
L730R U730F GGGACTATCTAGACTCGCTGCT HCMV UL73 (gN) Bates Unpublished 599 
U73F L73R TTCGGTCGGTCAACATCGTAA HCMV Ul73 (gN) Bates et al. 2008 394 
L73R U73F CACCCACGTATGTAAACCTTAC HCMV Ul73 (gN) Bates et al. 2008 394 
gN-Up gN-lw TGGTGTGATGGAGTGGAAC HCMV Ul73 (gN) Bates et al. 2008 420 
gN-1w gN-Up TAGCCTTTGGTGGTGGTIGC HCMV Ul73 (gN) Bates et al. 2008 420 
gB1 gB2 GAGGACAACGAAATCCTGTTGGGCA HCMV ULS5 (gB) Mattes2004 149 
gB2 gBl TCGACGGTGGAGATACTGCTGAGG HCMV ULS5(gBI Mattes2004 149 
gBP3 - 6-FAM-CAATCATGCGTTIGAAGAGGTAGTCCACG-TAMRA HCMV ULS5 (gBI Mattes2004 
UP BUP GAAAAATTCGGTTAAGGCAG HIV GAG Nanteza et a11998 169 
BUP UP TCTGATCCTGTCTGAAGAGCTG HIV GAG Nanteza et a11998 169 
i BU3 UP TAGTATGGGCAAGCAGGGAGCT HIV GAG Nanteza et al 1998 69 
HPOl4235-2 OF HPOl4538OR CCCTACAATCCCCAAAGTCA HIV POL Bima Unpublished 324 
HPOl4538OR HPOl4235-2 OF TACTGCCCCTTCACCTTTCCA HIV POL Bima Unpublished 324 
HPOl4327IF HPOl448lIR TAAGACAGCAGTACAAATGGCAG HIV POL Bima Unpublished 175 
HPOL448lIR HPOl4327IF GCTGTCCCTGTMTAAACC~ HIV POL Bima Unpublished 175 
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9.2 Appendix B - Equations and Calculations 
i)* Mass of plasmid (~g) = Size of plasmid (bp) x Average mass of one base pair (~g) 
(m) (n) (1.096 x 10-15 ~g) 
*Derivation of DNA mass formula 
m = [ n 1 [6.023 x 1t,,"'~~~ecules (bPj [~~:J = [ n 1 [1.096 X 10" g/bp ] 
n = DNA size (bp) = [n 1 [1 096 x 10-15 /b ~ Avogadros number = 6.023e23 molecules/mole . ~g p 
Average MW of a double-stranded DNA molecule = 660 g/mole 
ii) Concentration of Miniprep (~g/ ~I) 
Mass of plasmid (~g) 
= Plasmid copies/~I 
Actual plasmid concentration (copies/ ~I) 
iii) ----------------
Desired plasmid concentration (copies/ ~I) = 
Dilution factor to achieve 
desired concentration 
*Adapted from product support literature (Applied_Biosystems, 2003) 
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•••••••••••• T ••••••••••••••••••••••••••••••••••••••••••••• -. 
............................................ '" ........... -
· ......................................................... -. 
••••.••••••••••••• T ••••••••••••••••••••••••••••••••••••••• -. 
.................................................. '" ..... -. 
.......................................... " .............. -. 
T .. c .. G .. A .. GTTA .. T .. T ..... T ........ TG. T .. TA.G .. A ......... -G 
T ..... G .. A .. GTTA .. T .. T .. G .. T ........ TG.T .. TA.G .. A ......... -G 
G .. G .. G ..... G ... A ....... Gc.G.G.C .. ACGCG.G.TGCG.TC ... CCG .. CA. 
G .. c .. G .. T .. AACA .. T ..... GT .AA. TA .. TC .. GAG. T. TGTTA .. ACC ... CGT 
G .. A .. G ...... ACC ........ G ... T .CC.CACA .. AA. GATG •. G .... TG .. C-. 
AGCTTCCCAGCCTCAAGATCTTCATCGCCGGGAACTCGGCCTACGAGTACGTGGACTACC 
• .T .••..•••...••...•••••.••••.••••••••.•••• T •• A •• T ••••.••.•. 
• .T ••.•....••.•..•...••...•••..•••••.•..••. T •• A .• T .••••••.•• 
•••••••.•• T ••.•••.•••••••••••.••••••••••••••.•••••••••.•.••• 
••••••••••••••••••••••••••••••• C •••••••••••••••••••••••••••• 
.AA.A .. T .. TACA ........ TT .AT. T .. A .. TCAT .. GC ... T ... TACC .. T .. TA 
· .A.A .. T .. TACA ..... A .. TC .AT. T .. A .. TCAT .. AC ... T ... TACC .. T .. TA 
C.TGGGA .. C.GG.GCT.CT.CACCTT.G.T.GGGG.TA.G.GTAC-.T .. A ... G ... G 
G ... AAT .. CAAG.G.T .. T ... TATTTG .. C.T.A.TA.G .. TAT- .. T.A ... T .. T. 
· .GCGA ...... AGT. CTA .... CAGT .... C ... GA.AT.C ... TC ... AAC ...... . 
gBP3 gB2 
TCTTCAAACGCATGATTGACCTCAGCAGTATCTCCACCGTCGACAGCATGATCGCCCTGG 
•••••••••••••••••••••••••••• C ••••• T •• A •••••••••••••••••••••• 
..•••.•.•••.•.••••••••.••••• C •••••••••.••••••••••••. T ••••.•• 
••••••••••••••••••••.••••••• C ••••••••••••••••••••••••••••• A. 
............................................................. 
............................................................ 
CGCAT.CGAATTC .. CGCC.A.AGAAGAC .. TGAGGTAT.G .. TGCTT.T .. TAGA .. AA 
CGCAT.CGAATTC .. CGCC.A.AGAAGAC .. TGAGGTAT.G .. TGCTT.T .. TAGA .. AA 
CG.A. TCC .A.CA.C .GAG .. G.GC .GAC ... A ........ AG .. C. T.C .... A ... CA 
GT.A.GTC .. TGAA .. C.CAG .. CATGA.G.GGGA.TGA.TAG .. CTTACG.A.ATT.AA 
A.CA.TTTAAA.CC .. C .. G .. GGA.G.C .• TG ..... C.GC.G.C.T.C ... T.A .. AA 
The forward primer gBI has one C-T mismatch against reference strain Towne. The reverse primer gB2 has a T-C 
mismatch against FIX, Toledo and Towne, with an additional C-T and C-A mismatch against FIX. Both gB2 and the probe 
(gPB3) were complementary to the coding strand shown. The pPB3 Taqman probe was labelled with the fluor 6-F AM (6-
carboxyfluorescein) and quencher T AMRA (carboxy tetramethylrhodamine) at 5' and 3' ends respectively. 
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U730F U73F gNUp _ 
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••••••••••••••••••••••• T ••••••••••• T ••••••••••••••••••••••••••••••••••••• C ••••••••••••••••••••••• G •••••••••••••••••• --- ••• 
TCTGGTAACAATTCATCCACGTCAACCTCTGCAACTACATCAAAGTCTTCTG---CTAGCG------TATCAACTACCAAACTAACAACAGTTGCAACAACTTCTGCAACAACTACGACGAC 
... A.C.G ... C .. G ........... G ... T ........ C ... GTC ..... AGT------------G.G .. G .. G.GT .... C ... T .. GAGC.T ...... C .. CA.G ........... A .. 
.......... GC ................. C ........ G. T ... A .. G .. CAGTT ...... ------ .G ..... A.G .... T. G .. G ... AC ... G ...... ---A. G .......... T .. G 
.A ........ GC ..... T ................ G .... C .G.GTC .. C .. AGTT .... T. ------ ....... GGTA ... TCG .. T .. CAGC. T ...... C .. CA ..... C ......... . 
.A ........ GC ..... T ................ G .... C .G. GTC .. C .. AGTT .... T. ------ ....... GGTA ... TCG .. T .. CAGC. T ...... C .. CA ..... C ......... . 
.A ........ GC ..... T ................ G .... C .G.GTC .. C .. AGTT .... T. ------ ....... GGTA ... TCG .. T .. CAGC. T ...... C .. CA ..... C ......... . 
.. CAA ... ---------T ..... G .. --- .. TT.GC ... C.G.GTC.C ... AGCT ... CTCGCACCT .. A .... CGTG .. GGC ... C ... AC ............. A ............ G .. G 
.. CAACC.---------T ..... G .. --- ... T.GC ... C.G.GTC.C ... AGCT ... CTCACACCTC.A.G .. CGTG .. GGC ... G .. TAC ... G ...... AG.A .... T .. GGT ... A.G 
.. CAACC.---------T ..... G .. --- ... T.GC ... C.G.GTC.C ... AGCT ... CTCACACCTC.A.G .. CGTG .. GGC ... G .. TAC ... G ...... AG.A .... T .. GGT ... A.G 
.. CAAC .. ---------T ..... G .. --- ... T.GC ... C.G.GTC ..... AGCT ... CTCGCACCTC.A .... CGTG .. GTC ... GG.T ..... G ...... AG.A .... T .. GG .... A.G 
.. CAAC .. ---------T ..... G .. --- ... T.GC ... C.G.GTC ..... AGCT ... CTCGCACCTC.A .... CGTG .. GTC ... GG.T ..... G ...... AG.A .... T .. GG .... A.G 
.. CAAC .. ---------T ..... G .. --- ... T.GC ... C.G.GTC ..... AGCT ... CTCGCACCTC.A .... CGTG .. GTC ... GG.T ..... G ...... AG.A .... T .. GG .... A.G 
.. CAAC .. ---------T ..... G .. --- ... T.GC ... C.G.GTC ..... AGCT ... CTCGCACCTC.A .... CGTG .. GTC ... GG.T ..... G ...... AG.A .... T .. GG .... A.G 
.. CAAC .. ---------T ..... G .. --- ... T.GC ... C.GCGTC.C ... AGTT ... CTCACGCCTC.A .... CGTG .. GGC ... G .. T ..... G ...... AG.A .... T .. GG .... A.G 
•. CAAC .. ---------T ........ --- ... T.GC ... C.GCGTC.C ... AGTT ... CTCACGCCTC.A .... CGTG .. GGC ... G .. T ..... G ...... AG.A .... T .. GG .... A.G 














































FIX UL 73 




••. A .• TAC ••• A •.•..•••••••• GG .•.••••• C •. T ••....•• C •••••••• A ••....••.....• T ......••.......•.•.. A .....•.•••....•..•.• C ......• 
•••••••• C ••••••••••• C •••••••• CA ••••• C •• T •• T ••••• C ••.•••••••••. A ••.••.• A. TC •••••....•.••.••••• A ..•.• T ..••.•..•.••...••••. T. 
C •• A ••• AC •• TA •• G. ---. T ••••••• CGG •••••••••. T ••• A.C .••.•.••••.•. A .••..... ATC .•....•.••.....• T •• A .....•....•.....•...... A ... . 
C •. A ••• AC •• TA •• G. ---. T •..•••• CAG •••••••••. T ••• A.C •.••••••••••• A ..•..• C .ATC •.•••••......... T .. A .................•..... A ... . 
C .• A .•• AC •. TA .. G. ---. T •.•.••• CGG •......... T ••. A.C .....•••.•••. A •••••••• ATC .........••..... T .. A ........•.............. A ... . 
C •...... C .......•..•• T ..•••••...•••. C .•.•....... C ............•••.•....•. T .•.............................. A ..............•. 
· ..... T .C ... A .. G ..... T .. C .... C .G .... C ..... T ..... C .. C ............. C ...... TC .. A ...................... T ................. A .. T. 
· ..•.. T . C ... A .. G ..... T .. C .... C . G .... C ..... T ..... C .. C ............. C ...... TC •. A ...................... T ................. A .. T . 
... ---T.C ...... G ..... T .. C .... C.G .... C ..... T ..... C .. C .. C ........ G.C ...... TC .. A ............. T ........ T .................... T. 
· .. ---T. C ...... G ..... TG. C .... C. G .... C ..... T ..... C .. C .. C .......... C ...... TC .. A ............. T ........ T .................... T. 
· .. ---T. C ...... G ..... T .. C .... C. G .... C ..... T ..... C .. C .. C .......... C ...... TC .. A ............. T ........ T .................... T. 
· .. ---T.C ...... G ..... T .. C .... C.G .... C ..... T ..... C .. C .. C .......... C ...... TC .. A ............. T ........ T .................... T. 
· .. - - -T . C ...... G ..... TG. C .... CTG .... C .. T .. T ..... C .. C .. C .......... C ...... TC .. A ............. T ........ T .................... T . 
... ---T.C ...... G ..... TG.C .... CTG .... C .. T .. T ..... C .. C .. C .......... C ...... TC .. A ............. T ........ T .................... T. 
... ---T.C ...... G ..... TG.C .... CTG .... C .. T .. T ..... C .. C .. C .......... C ...... TC .. A ............. T ........ T .................... T. 
gN1w 
CACTGTCCAGCTTTGCGGCCTGGTGGACTATGCTTAATGCTCTAATTCTCATGGGAGCTTTTTGTATTGTACTACGACATTGCTGCTTCCAGAACTTTACTGCAACCACCACCAAAGGCTAT 
•••••••••••••.•••••••••••••••••.•.••••.•••• T .••••••••••••••.•••••.• C •••••••••••••••••••.•.•••.•••••••••.•.•••. G ••••••• T ••• 
............. C ..... T ................. C ..... C ....................... C ... T ............. T ................................... . 
•••••••••••••••• A ••••••••••••••••• C •••••••• C ••••• G ••••••••••••••••• C •••••••••••••••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••• A ••••••••••••••••• C •••••••• C ••••• G ••••••••••••••••• C •••••••••••••••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••• A ••••••••••••••••• C •••••••• C ••••• G ••••••••••••••••• C •••••••••••••••••••••••••••••••••••••••••••••••••••••• 
••••.•••.•••••••••••••••••••••••••••••.•••• C .•••••••••.••••••••••.•••••.••••••••••••.••••••••••••••••••••••••••••••••••••• 
.T ••.••••..••••••••••••••••••••.•.•.•.••••• C ••••••.•••••• T ••••••••• C •••.•••••••....•. T •••.•....••.•••..•...••••..•.•...•.• 
•••••••••••••••••••••••••••••••.••••••••••• C ••••••••••••••••••••••• C ••••••••••••••••• T •••••••••••••••••••••••••••••••••••• 
................ A .................... C ..... C ..... G ........ C ........ C .................... T ................................ . 
•••• A ••••••••••• A •••••••••••••••••••• C ••••• C ••••• G •••••••• C •••••••• C ••••••••••••••••••••••••••••••••••• G •••••••••••••••••• 
•••••••••••••••• A •••••••••••••••••••• C ..... C ..... G ........ C ........ C .................... T ................................ . 
••••••••••.••••• A •••••••••••••••••••• C ••••• C ••••• G •••••••• C ••••••.• C •••••••••••••••••••• T ••••••••••••••••••••••••••.••.••• 
•••••••••••••••• A •••••••••••••••••••• C ••••• C ••••• G •••••••••••••••.• C ••• T ••••••••••••••••••••••••••••••• G •••••••••••••••••• 
•••••••••••••••• A •••••••••••••••••••• C ••••• C ••••• G •••••••••••••••.• C ••• T ••••••••••••••••••••••••••••••• G •••••••••••••••••• 
...•........... . A .................... C ..... C ..... G ................. C ... T ..............•................ G ................. . 
STOP L 73R U730R 
~GGTGGACAGATTTACAGCCCGGCGGTGTTCCGGCGGGGTAAGGTTTACATACGTGGGTGACCGGAGGCTAAAGTTACGAATCTCATCTAGAAACAGCAGCGAGTCTAGA~CCCACA 
.A .................... T .. A ........................ C .... A ......... T .... A ........... G .............. T ........................ . 
· A .................... T ....................... A ... C ..... CC .... A .. T ................ G .. T • T ...... G ........................... . 
.A .................... T .... A .................. A ... C ...... C .... A .. T ................ G .. T. T ...... G ........................... . 
.A .................... T ....................... A ... C ..... CC .... A .. T ................ G .. T.T ...... G ........................... . 
· ............ G .. C ................................. C .... T .... AC ... T . T ..... G ........ G .. T ... CT .. A ..................... A ...... . 
· ............ G .. C ................................. C .... T .... AC ... T . T .............. G .. T ... CT .. A ..... A ............... A ...... . 
•••••••••• T ••••••••••••••••••••••••••••••••••• A ••• C •••••• C •••• A. TT •••••••••••••••• G •• T. T ••••••••••••••••••••••••••••••••• T. 
.......... T ................................... A ... C ...... C .... A. TT ................ G .. T. T ................................. T. 
.......... T ................................... A ... C ...... C •••• A. TT ................ G .. T. T ••••••••••••••••••••••••••••••••• T. 
•••.•••••• T ••.•.•••.••••••.•..••••.•••.•••••.• A ••• C •.•••. C •••• A. TT ••••..•••••••••. G •• T. T ••.•.••.•••••••••••••.•...••••..• T. 
•••••••••• T •••••• G ••••••••••••••••••••.••••••• A ••• C •••••• C •••• A •• T •••••••••••••••• G •• T. T •••••••••••••••••••••.••••••••.•• T. 
•••••••••• T •••••• G •••••••.•••••••••••••••••••• A ••• C •••••• C •••• A •• T •••••••••••••••• G •• T. T •••••••••••••••••••.••••••••••••• T. 
•••••••••• T •••••• G •.•••••.•••••.••••••.••••••• A ••• C •••••• C •••• A •• T •••.•••••••••••• G •• T. T •••••••••••••••.•••••••••.••••••• T. 
202 
Reference strains Can4 and Can 1 0 are clinical isolates and no N- or C-terminal flanking sequence is available and so they have been left blank over these regions. The forward 
primer U73F contained two mismatches against strains TR and Towne. The gNUp forward primer has a detrimental 3' terminal C-A against Can4, TR and PH-like strains, with Can4 
having an additional G-C mismatch just 4 nucleotides from the 3' terminus. The reverse primer gNlw has two mismatches against strain Can 4 and a A-G mismatch against reference 
strains Toledo and Merlin just 3 nucleotides from the 3' terminus. The primer, gNlw binds directly upstream from the gene's STOP codon. The second reverse primer, L73R, 
contains up to 5 mismatches against other reference strains but the 5 nucleotides at the 3' terminus are identical across all strains. Finally, the outer UL 73 reverse primer (U730R) 
has a 3' penultimate mismatch (G-A) against reference strain 3301. Reference strains HAN 13, HAN38, 3301, HAN20, 3157 and JP were not available when primers were designed 
but are included here for reference. 
203 
9.S Appendix E - HCMV UL 74 Oligonucleotide Primer Locations 





••••••••••••••••••••••• G ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••.••••••••••••• 









....................... G ............................................................................... TA.A ............ . 
••••.•••.••••••••••••..•••...•.••••••••••.•.••..•. G •••••.•.•••.•.•...•....••••.•••••.• T ....••..••••••.. T •• M ...•.••••••• 
....................... G ............................................................................... TA.A ............ . 
Towne_UL 74 ....................................................................................................................... . 
3301 UL74 ....................... G ......................................... G ........................................ A ............ . 
Merlin_UL 74 ............................................................................ A .......................................... . 
3157_UL74 ....................................................................................................................... . 
JP UL 74 ....................................................................................................................... , 
AD169_UL74 TCATGGGGAGAAAAGA---GATGATGGTGAGAGACGTCCCTAAGATGGTGTTTCTMTATCTATATCTTTCTTGCTTGTTTCTTTCATAAACTGTAAAGTTATGTCAAAAGC---GCTTT 
DM7 _UL 74 -- ............. G---AGA .... --- .... GT .. TTT ... TT .AT. T .. C .. T .. G .. GC .. A ..... C .... AT. C ................ GG. C. GC. GT .. G. TT---ATCCG 
TR_UL 74 ............... G---AGA .... --- .... GT .. TTT ... TT .AT. C .. C .. T .. G .. GC .. A ..... C .... AT. C ................ GG. C.GC.GT .CG. TT---ATCCG 
Toledo_UL 74 ............... G---AGAC ... --- ... AG.A. TT .... AT .AT .C ... A. T ..... AC. GA .. G .. C .. T .AT ..... A.A ........... G .. CG---TC. G. C. ---A. C--
FIX_UL 74 ................ ---AGAC ... --- ... AG.A. TT .... AT .AT. C ... A. T ..... AC. GA .. G .. C .. T .AT ..... A.A ........... G .. CG---TT .G. C. ---A. C--
HAN20_UL74 ................ ---AGAC ... --- ... AG.A.TT .... AT.AT.C ... A.T ..... AC.GA .. G .. C .. T.AT ..... A.A ........... G .. CG---TT.G.C.---A.C--







· .... T .. G ...... G---AGA .... --- .... GT .. TAACTTAT .. --- ..... T .... GGC .. A ..... C .. T .GT. C. T ............... G.G. GC.CG. T---. ---A.MC 
· ............ G.G---AGA .... --- .... GT .. TAACTTAT .. --- ..... T .... GGC .. A ..... C .. T .GT.C. T ......... A ..... GAG. GC.CG. T---. ---A.MC 
· .... T .. G ...... G---AGA .... --- .... GT .. TAACTTAT .. --- ..... T .... GGC .. A ..... C .. T .GT. C. T ............... G. G. GC.CG. T---. ---A.MC 
-- ............. G---AGA .... --- .... GT .. TTT ... CT .AT ....... T ..... GT .. A .... TC .... AT ..... C. TT .G ........ GAGCGCCG ... G .. T---TT .CA 
· ............ G.G---AGA .... --- .... GT .. TTT ... TT .AT. T .. C .. T .. G .. GC .. A ..... C .... AT. C ................. GA.C .C.GT. -------------
· .............. G---AGA .... --- .... GT .. TTT ... TT .AT. C .. C .. T .. G .. GC .. A ..... C .... AT. C ................. GA.CGC .GT. -------------
Merlin_UL 74 .A ....... A ...... GAT ... A ....... A .. G.A. T ..... A .. TA .. C. C .. G .. C ...... A.G ........ CC .... CC ....... T ..... T .. AT .. GT ... CT. CAGAGGM 
3157 UL 74 .A ....... A ...... GAT ... A ....... A .. G.A. T ..... A .. TA .. C .C .. G .. C ...... A.G ........ CC .... CC ....... T ..... T .. AT .. GT ... CT .CAGAGGM 
JP UL 74 .A ....... A ...... --T .•. A ...•... A .• G .A. T ..... A .. TA .. C. C .. G .. T ...... A. G ........ CC .... CC ....... T ..... T .. AT .• GT •.. CT. CAGAGGM 
AD169_UL74 ATAATCGTCCTTGGAGGGGCTTGGTACTGTCTAAGATAGGCAAATATAAATTAGATCAGCTTMGTTAGAAATTTTGAGACAACTAGA-AACGACTATTTCTACAAAATAC--------A 
DM7 UL 74 TAGGA ... TAC ... TCA .. TAAA .......... C ......... GC .A.G.C .... CA .. T .C .. A ..... G ....... A ......... - .. A.GA ... C .A ... G ...... T-----TT. 
TR UL 74 TAGGA ... TAC ... TCA .. TAAA .......... C ......... GC .A. G.C .... CA .. T. C .. A ..... G ....... A ......... - .. A.GA ... C .A .......... T-----TT. 
Toledo_UL 74 -GGGA ... TAC ... TTA .. TACA ..... T .... C ......... GC.A ... C ..... A.AT. C ........ G ..... A.A .... T .... - .. G.GAACC .. A .......... T-----TC. 
FIX UL 74 -GGGA ... TAC ... TTA .. TACA ..... T .... C ......... GC.A ... C ..... A.AT .C ........ G ..... A.A .... T .... - .. G.GAACC .. A .......... T-----TC. 
HAN20 UL 74 -GGGA ... TAC ... TTA .. TACA ..... T .... C ......... GC .A ... C ...•. A.AT .C ........ G ..... A.A .... T .... - .. G.GAACC .. A .......... T-----TC. 










GAGGA ..... C .... TA .. TAAA .... CC ... TTA.A.T.G ... CT .... GA.C.A .. AT.G .. AA.T ........ A.AG ... T .. C.-G.GCGAC .. A.AC ........ TC-----CCC 
GAGCA.CATT.C.TCCTA.GA.ATGG.ACC.C.C.G .. TTA ... --- ... C .. A.G .. AT.A .. A ........... A ........... -.C.T.T.CC .. AC.T ... G ... C-----CAC 
GAGCA.CATT.C.TCCTA.GA.ATGG.ATC.C.C.G .. TTA ... --- .. GC .. A.G .. AT.A .. A ........... A ........... -.C.T.T.CC .. AC.T ... G ... C-----CAC 
GAGCA.CATT.C.TCCTA.GA.ATGG.ACC.C.C.G .. TTA ... --- ... C .. A.G .. AT.A .. A ........... A ........... -.C.T.T.CC .. AC.T ... G ... C-----CAC 
GACTA.CGTT.CCCTAT ... AG .... T.A .. A .. A.AT .... GGCTAGCTGA.ATAA .. TGG .. ACA .... C.G .. A.AG .. GA ... GTGCGAG.C.GGAT ... T.T.A.TT---TTTT. 
--GCG ... TT.C.----A.TAAA.AGTCA----- .. A .. CA ... G.GG .. GAGAGG .. A .. A .. A ... CGT .. AC .. CA.G ...... C-GT.A.AA.CAGG.GATT.T ... AAGTTTTTC 
--GCG ... TT.C.----A.TAAA.AGTCA----- .. A .. CA ... G.GG .. GAGAGG ..... A .. A ... CGT .. AC .. CA.G .. A ... C-GT.A.AA.CAGG.GATT.T ... AAGTTTTTC 
CA.GA ... T.C ... CC.TATACC .. G .. A ... T.TCG ... T ... G.G.TTC.GA.GA.A.AG ... GA ... T .. C .. A.A .. G.T.GAT-GT.T .. ATCA ... GACGG .... CGGTTTTT. 
CA.GA ... T.C ... CC.TATACC .. G .. A ... T.TCG ... T ... G.G.TTC.GA.GA.A.AG ... GA ... T .. C .. A.A .. G.T.GAT-GT.T .. ATCA ... GACGG .... CGGTTTTT. 








•• A. ----G.CC.G ••••• ACA •••••••••• G •••••••••••••• C ••.••••••• GG •• T •••••••••••••• A •••••••• A ••• A.C ••• G. T •••••••• T ••••• C •••••• 
• .A.----G.CC .G ••••• ACA .•••.••••• G •••••••••••..• C ••.••••••• GG •• T •••••••••••••• A ••••••.. A ••• A.C ••• G. T •••••••. T ••••. C ••.••• 
• .A. ----G.C •• G ••••• AC ••••••••••• T •••••••• T ••••• cc .................... C •••• A •• T ••••••. GA •• CG •••••••••••••••••••••. C •••••• 
• .A. ----G.C •• GG •.•• AC ••••••••••• T •••••••• T ••••• cc .................... C ••••••• T ••••••• GA •• CG •••••••••••••••••••••• C •••••• 
HAN20_UL 74 •• A. ----G.C •• GG •••• AC ••••••••••• T •••••••• T ••••• CC •••••••••••••••••••• C ••••••• T ••••••• GA •• CG •••••.••••.••••.•••••• C •••••• 





• AA. ----C .A •• CGACT. GA ••• C ••• G ••• T •.• G. T •• T ••••• C •••••••• TT. T •• T •• T ••.••••• A •• T •• T •••• GC •• CG. A ••• G •••• TC •• T •••••• A •••••. C 
• AA. ----C.A •• CGACT. GA •.• C ••• G ••• T ••• G. T •• T ••••• C •••••••• TT. T •• T •• T •••••••• A •• T •• T •••• GC •• CG .A ••• G •••• TC •• T •••••• A •••••. C 
.AA. ----C .A •• CGACT. GA ••• C ••• G ••• T ••• G. T •• T ••••• C •••••••• TT. T •• T •• T •••••••• A •• T •• T •••• GC •• CG .A ••• G •••• TC •• T •••••• A •••••• C 
CCA. ----TCC •• CTA ••• AA. GACT ••• CGCTGT. G.A. CA ••• GA. CG •••.•• CG. TA •••• T •• C •• G •• T •• T •• T ••••• A ••• G ••••••• T •••••• A ••••••• C ••••• C 
Towne_UL 74 • CA. TTCCT ••• C.G ••• AA. T. GT. T •• CA.A •.• G.AG.A •••• A. C ••••••• C. CGA. T. C •••.•.••• A •• A •• T •••• GT ••• C •••• C •• T ••• C .C •• C ••••• C •••••• 
3301_UL 74 .CA. TTCCT ••• C .G ••• AA. T. GT. T •• CA.A ••• G .AG.A •••• A.C ••••.•• C. CGA. T. C ••••••••• A •• A •• T •• C. GT ••• C ••.• C •• T ••• C.C •• C ••••• C ••••.• 
Merlin_UL 74 •••• ACCCC ••• C .G ••• AAAT •• C. TGCCA •• GT ••• T. G •••• GATA.A ••••• T ••• G •••••••••••••••• T •••••• AGA ••• G •••• C •• T ••• C •• A •••••••••• C •.• 
3157 UL 74 •••• ACCCC ••• C.G ••• AAAT •• C. TGCCA •• GT ••• T .G •••• GATA.A ••.•• T ••• G •••••••.•••••••• T •••••• AGA ••• G •••• C •• T ••• C •• A •••••••••• C ••• 
JP UL 74 •••• ACCCC •.. C. G ••• AAAT .• C. TGCCA •• GT .•• T .G ...• GATA.A •.••. T •.• G ..•...•...•...•• T .••••• AGA ••. G .••• C .• T ... C .• A .•.•.••••• C ••• 
G02 
AD169 UL74 TATAGTACCCAGCTTAGAAAACCCGCAAAATACGTTTACTCACAGTACAATCATACGGCTAAAACGATAACATTCAGACCCCCACCTTGTGGTACTGTGCCTTCCATGACTTGTCTTTCC 
DM7 _UL 74 ••••• C •• T •••••• C ••••••• G •• T •• G ••••••• T •••• G.A ••••••••••••••.••••• A ••••••••.••••••••• T •••• C ••••• G .•••••.••••••••••••••••• 
TR UL 74 ••••• C •• T •••••• C ••••••• G •• T •• G ••••••• T •••• G.A ••.••••••••••••••••• A ••••••••.••••••••• T •••• C ••••• G .•••••••••••••••••••••.• 
Toledo UL74 •••••••••••••••••••••••••• C •••••••• C •••••••••••••••••••••••••••••••••••••••••••••••• T •••••••••• A .•••••.• A •••••••••••••.• 
FIX UL74 •.•••••••••••••••••••••••• C •••••••• C •••••••••••••••••••••••.•••••••••••••••••••••••• T •••••••••• A •••••••• A ••••••••••••••• 
HAN20_UL74 •••••••••••••••••••••••••• C •••••••• C •••••••••••••••••.••••••••••••••••••••.••••••••• T •••••••••• A •••••••• A •••••••••••••.• 
SW17I5 UL 74 ••••• C •• T •• A ••• C ••••••• T •• C ••••• T •••••••• TAT ••• T ••••• A •••••• C.G.AA •• C •• G •• T •• G ••.•• G ••••• C ••••• A •••••••• T •••• A •••• T .A ••• 
PH UL 74 ••••• C •• A •••••••• G ••••• A •• C ••••• T •• A ••••• TAT ••• T ••••• C ••••• CCG •• AA ••••• G •••• A •••.•• GT .G ••••• CG.A •••••••••.••••••••••••. T 
HANI3 UL 74 ••••• C •• A ••• T •••• G ••••• A •• C ••••• T •• A ••••• CATA •• T ••••• C ••••• CCG •• AA ••.•• G •• T .A •••.••• T .G ••••• CG.A ••••••••••••••••••••••• T 
HAN38_UL 74 ••••• C •• A •••••••• G ••••• A •• C ••••• T •• A ••••• TAT ••• T ••••• C ••••• CCG •• AA ••.•• G •••• A •••••• GT. G ••••• CG.A .•••••••••••• G ••••••••. T 
SW475 UL 74 ••••••••••• A •• GC ••••••• G •• C •• G •••••••••••• G •••• T ••••• A •• A.GCCG •• A ••• G.GG •• T ••••• T ••• T ••••••• C •••••••• A •• T ••• GGC ••••• A •• T 
Towne UL 74 C. C .CG •.••• A .• CC. T .•••. G •. C .•••• T •• G •• T •. GG.A •. T .••.•.•. A.GGC .•• AA •....... TC ••.•...• T. C •••..••• GA.A ••••••••••..•• C ..... T 
3301 UL 74 C. C .CG ••••• A •• CC. T ••••• G •• C ••••• T •• G •• T •• GG.A •• T •••••.•• A.GGC ••• AA •••••••• TC •••••••• T. C •••••••• GA.A •••••••••••••• C ••••• T 
Merlin UL 74 •• C ••••• T •• A •• CC ••••••• A •• C •• G ••••• A •• T •• CG.A •• T ••••• C ••••• CC. C .AA ••.•• G •• AC ••••.•••••••• C •• C •• A •••••••• T •••• AC •• C •• A ••. 
3157 UL 74 •• C ••••• T •• A •• CC ••••••• A •• C •• G ••••• A •• T •• CG.A •• T ••••• C ••••• CC. C .AA ••••• G •• AC ••••.••••••••••• C •• A ••••• C •• T .••• AC •. C •• A ••• 
JP UL 74 •• C ••••• T •• A •• CC ••••••• A •• C •• G ••••• A •• T •• CG.A •• T ••••• C ••••• CC. C .AA ••••• G •• AC ••••••••••••• C •• C •• A ••.••••• T •••• AC •. C •• A •.• 
AD169 UL74 GAAATGCTAAACGTTTCCAAACGTAATGATACTGGCGAACAAGGTTGCGGTAATTTCACCACGTTCAACCCCATGTTTTTCAATGTACCGCGTTGGAACACCAAATTGTACGTGGGTCCG 
DM7 UL 74 ••••••••••••••••••••••••••••••••••.••••••••• C ••••• C ••••••••••.•.•.••.•••.•••••••.••••• G •• 1' •.•••••.•••• G •• G •• A •• T •. A ••• T.C 
TR UL 74 ••••••••••••••••••••••••••••.••.•........••. C ••••• C •••••••••••••••••.•••••••••••.••••• G •• A .•••••.•••• G •• G •• A •• T •• A ••• T.C 
Toledo UL 74 •••••• T •••••••••.•••••••••••.••••••••••••••• C ••••••••.•• T •..••••.••.•.•.••••••••••••.••.• A •••••••• T ••••••••••••••••••.•• 
FIX UL74 ••••• • T ••••••••••••••••••••••••••••••••••••• C ••••••••••• T •••••••••••••••••.•••••••••••••• A •••••••• T •••••••••••••••••.••• 
HAN20_UL74 •••••• T •••••••••••••••.••••••••••••••••..••. C ••.•••••••. T ••••••••••.•••••••••••••••.••••• A ••.••••• T ..•...•.•••••.••••••• 
SWl715 UL 74 •• G ••• T •••• T •••••••• G •.••••••••• C •••••• G •••• C •••••••• c .............. T •• T ••••••••••••••••••.•.•••••••.••.•••..•••.•.••••• 
PH UL74 
HAN13 UL 74 
HAN3B UL74 
••••••••••••••••••• • G ••••••••••• C •••••• G •••• C •••••••• C •• r ........... i •• i ••••••• ••••••••••••••••••••••••••••••••••••••••• 
•••••••••••••••••••• G •.•••••.••• C •••••• G •••• C •••••••• C ••••••••.••••• T •• T ••••.••••.••..••••.•••••.•••••••••••••••.••••••• 
• •••••••••••••••.••• G ••••••••••• C •.•••• G •.•• C •••••••• CC • T ••••••••••• T •• T ••••••••••••••••••.••••••••••••••••••••••••••••• 
SW475_UL 74 •• G ••• T .G ••••• A ••• TTT •.•••. A. C •• C •• A ••• G •. A.C •• T. T. • • • •• • ••••.•. T. • ... T ................ .;. .. .. .._ .. ;'~ .............. ~ .... C ........ _._.7.: 
Tmme UL 74 ••••••••••• T •• A ••• CGG ••••• CA.C •• C •. G •• GG •• AAC •• T •• C •••••••••• A •• T •• •• T •••••••• T •• •••• • A •.•.••.•••.•••• c: ............. . 
3301_UL 74 ••••••••••• T •• A ••• CGG ••••• CA. C •• C •• G •• GG •. AAC •• T •• C. • • •• • .••• A •. T •• ..................... ...... • •••• A .•••••••••••••• C •••••••••••••• 
Merlin UL74 •••••• T •••• T ••••••••••• C •••••••• C •.•••• A ••••••..••••••••.•••••••• T •• ............................. .. ....... A .................. A .... :: ........ A.n ... 7.: 
3157 UL 74 •••••• T •••. T ••••.•••••• C ••••.••• C •••••• A •.•••••.••••••••.•••••••• T •• .... T ................... .. ...... . A ................ A .... ': ........ A.A .• . Y.: 




















.AG .. A .. A ..... G .............. C .. C ... T .... CC .•...... T ..... C .......... G .............. G ................................ A .. . 
. AG .. A .. A ..... G •••••••••••••• C .. C ... T .... CC ........ T ..... C .......... G •••••••••••••• G ................................ A .. . 
••••• A •••••••••••••••••••••••••••••• T.G .............. A ••• C •••••••••••••••••••••• C ••••••••••••••••••••••••••••••••••••••• 
••••• A •••••••••••••••••••••••••••••• T.G .............. A ••• C •••••••••••••••••••••• C •••••••••••••••.••••••••••••••••••••••• 
•.••• A •••.•..........•••••••••••••.• T.G .............. A ••• C ••••.•••••.••••••••••• C ••..••.••.••.....•••.•••••••••••••••••• 
•.••• A ••••••••••••••••••••••••••••••••••••••• G •••••••••••••••••••••• G ••••••••••• C •••• G ••••••••••••••••••••••••••••••••.• 
••••• A •••••••••••••••••••••••••••••• T ••••••••••••••••.••• C •••••••••• G ••••••••••• C ••••••••••••••••••••••••••••••••••••••• 
•.••• A •••••••••••••••••••••••••••••••••••••••••.••••••••• C •••••••••• G ••••••••••• C •••••••••••••••••••••.•••••••••••••••.• 
••••• A •.•••••••••••••••••••••••••••• T •••••••••••••••••••• C •••••••••• G •••••.••••• C •••••••••••••••.•••••.••••••••••••••••• 
..... A .. C .. T •• G ........ G ..... C .. C ... T •••• CC .. G ••••••••••• C .......... G ••••• T ••••• C .... G •••••••••••••••••••••••••••••• A .. . 
.G ••• A .. C .. T •. G ..... C ..... A ......... T •••••••• G ••••••••••• C .......... G ••••• T •••••.•••• G ••• C ............................. . 
.G ••• A .. C .. T •• G ••••• C ..... A ......... T •••••••• G ••••••••••• C .......... G ••••• T •••••••••• G ••• C ............................. . 
.AC .. A .. C ..... G ........ G .. A .. C .. C ... T .G •• CC .......... A ........ A ..... G ••••• T ..... C .. T .G .••••••••••••••••••••••••••••• A .. . 
.AC .. A .. C ..... G ........ G .. A .. C .. C ... T .G •• CC .......... A ........ A ..... G ••••• T ..... C .. T .G •••••••••••••••••••••••••••••• A .. . 
. AC .. A .. C ..... G ........ G .. A .. C .. C ... T . G .. CC .......... A ........ A ..... G ..... T ..... C .. T . G .............................. A .. . 
Reference strains DM7, SWI715 and SW475 are clinical isolates and only coding sequence has been published and is available. Where sequence is unavailable for these strains in 
the N-terminal flanking region the alignment has been left blank. The forward primer GO I 0 contains one A-G mismatch against reference strains TR and PH. The inner forward 
primer gOUp is identical across all reference strains. The GO I primer bridges the UL 74 start codon and contains a C-A mismatch against reference strain Merlin, a G-T and a A-G 
mismatch against PH and a G-A against SWI715 and Merlin. The first reverse primer G02 has up to 7 mismatches (against reference strain SW475). The next reverse primer gOlw 
contains up to 4 mismatches (against reference strains Merlin, 3157 and JP). The outermost reverse primer G020 has no mismatches. The arrow (~) indicates the start codon. 
Reference strains HANI3, HAN38, 330 I, HAN20, 3157 and JP were not available when primers were designed but are included here for reference. 
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9.6 Appendix F - HHV -6 U46 Oligonucleotide Primer Locations 
U460F U46F U46Up 
HHV6A-UII02-U46 TTTTCTGAAATTGCGCTGTACATTTTTCCAGGTGACAGAGAGCTGTCTGCTGTTAATCACGTCGACGCGAAGACTAGTTGAAAA~GCTTAAGATGAGTTGTAAGAAAAGCGCAAGGC 
HHV6B-Z29-U46 ............ A ........................... G ...................................... c ........ A ..................... G ........ . 
HHV6A-UII02-U46 AAAGCTTATATGTCAGTCTCTGCCTCTTTTACATTCTTGTTTTTGCGGCCGCTACGGAAGTGGACTTTTATTCTCCAGAGTGCCATTCGCATACCTATGAGATCGTCTTGAATTCATTTT 
HHV6B-Z29-U46 .. c ................... G .................................... A .............. T ................ c ........................... . 
U461w U46R STOP 
HHV6A-UII02-U46 CTTCGATCTGGCTTTTGATAAATCTTTTTTTATTGTTATGTTCTTTCGCGATTTTCTTGAAATACTGGTGTTATAAGACTTTTGCTTCAGAGACGGTGAAGGGTTAT~TCGCGTGAG 
HHV6B-Z29-U46 ................................ C.C .. G ........ T .............. G ......................................... C ........... A ... . 
HHV6A-UII02-U46 ACTTCTATTTTAATTATAAATGTAGCATACGACAAATAAAAGCATTTTT-GTTGTGATTGGATCTTGTTTTATTATCTTCAATAGATTTTATAACGACAAAAGACAAAACTCATTTCAAA 
HHV6B-Z29-U46 .. GC ..... C ................. C ..................... T .A ... A ........ G ............. C .......... C .................. C .. G ...... G. 
HHV6A-UII02-U46 ATTGAGTTTTTATTGAAGACTGAAGATGAGCAGCTTTGGCAAACGTATGCAGTTATGTGCT----GTGTTGTTTAAATCGCGTCGTTCGTTGTATGTGTGATGCGTTGCATTTTGGGTTG 




The forward primers U460F and U46F contain no mismatches. The innennost forward primer, U46Up contains one G-A mismatch against reference strain Z29 and also bridges the 
gene's start codon. Inner reverse primers U461w and U46R are adjacent with their being just one T-C mismatch in U46R. This primer also bridges the gene's STOP codon. The 
outennost reverse primer U460R contains no mismatches. 
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9.7 Appendix G - HHV-6 U47 Oligonucleotide Primer Locations 
U470F U47F UGU47F/U47probe* 
HHV6A-UII02-U47 AAAATTCTGGGAGCACAGTTATTTGACATAAAACTAACCGAAGAATCCTTGCGGATGGCAATGAGCAAATTTTCCAACTCGAATCTGACACGGTCATTGACTTCCTTCACGTCAAAAAAC 
HHV68-Z29-U47 ............ A ...................... G ..... c .......... A ......... c .. T .................................... c .G ..... TC. TG ... T. 
U47R 
HHV6A-UII02-U47 TTCTTTAATTACACCAGCTTTGTTTACTTCTTGCTCTATAACACAACATCATGCGTCCCTTCAAATGATCAATATTTCAAACAGTCGCCAAAACCTATAAATGTTACCACTTCCTTTGGA 
HHV6B-Z29-U47 ...................................................... A ... G ................... G .... T ................................... . 
U470R 
HHV6A-UII02-U47 CGAGCCATCGTAAACTTTGATTCGATACTAACTACTACACCATCATCGAC------------GTCAGCGTCTCTCACATCACCACATATCCCTAGTACCAACATACCAACCCCAGCACCT 
HHV6B-Z29-U47 .................. c .......... G ..... G .. G ........... GCCATCATCGAC .......... A ..•........................... c ........... A ... . 
The forward Primer U470F has one G-A mismatch against reference strain Z29. U47F has two mismatches, one A-C near the 5' tenninus and one G-A five nucleotides fonn the 3' 
tenninus. The UGU47F primer and U47probe cover the same sequence, but differ in that the probe contains an additional G at the 5' tenninus. The U47 Taqman probe was labelled 
with the fluor 6-FAM (6-carboxyfluorescein) and quencher TAMRA (carboxy tetramethylrhodamine) at 5' and 3' ends respectively. The reverse primers U47R and U470R 
contained no mismatches. 
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9.8 Appendix H: HCMV sera-DNA at M6 - effects on growth 
9.8.1 Association of HCMV DNA at M6 with BMI at M6: 
. ttest zbmi6 , by(dcmv) 
Two- sample t test wit h equal var i ances 
Group I Obs Mean Std . Err. Std. Oev . [95 % Conf . In rv 11 
---------+--------------------------------------------------------------------
o I 293 . 1533106 . 0659588 1 . 129033 . 023 4956 . 283 125 
1 I 171 -. 0973099 . 0887689 1.160804 - . 2725 413 . 077 214 
---------+--------------------------------------------------------------------
combined I 464 . 0609483 . 0532019 1 . 146003 - . 0435988 . 1 54 53 
---------+--------------------------------------------------------------------
diff I . 2506205 . 109786 . 0348788 . 4 63 23 
ditf = mean(O) -
Ho: diff = 0 
mean(l) 2 . 2828 
degrees of freedom - 4 2 
Ha: dif f < 0 
Pr(T < t) - 0.9886 
Ha : diff ! = 0 Ha : di f > 0 
Pr(ITI > Itl) = 0 . 0229 Pr(T > t ) - 0 . 0114 
Mean zbmi at 6m is signi ficantl y l ower among c hildre n with detec bl DNA 
. *adjusted for education etc 
Source I SS df MS 
-------------+------------------------------
Mode l I 25 . 9411231 6 4.3 2352052 
Residual I 582 . 12766 457 1.27380232 
----- --------+- -- ---------------------~----
Tota l I 608 .0 68783 463 1. 3133235 
Number of obs -
F( 6 , 457) -





3 . 3 
0 . 0028 
0 . 0427 
0.0301 
1 . 1286 
---- ---------------- - ---------- ------------- ---------------------------- ------
zbmi 6 I Coef . St d . Err . t P> l t l [ 95% Con f . In rva1) 
-
-------------+----------------------------------------------------------------
Idcmv_yn_ 1 - . 2179099 . 1095406 -1. 99 0 . 047 - . 4331756 - . 00 26 44 3 
- Ieduc3_ 2 . 1846498 .1 289007 1. 43 0 . 153 - . 0686617 
-Ieduc3 3 .39391 2 .149013 2 . 64 0.008 .1010 763 
Isescat3=: 2 . 0487253 .1 285611 0 . 38 0.705 -.2039189 
- Isescat3_ 3 . 0734977 . 1505554 0 . 49 0.626 - . 2223689 
Ibfcat2 1 . 37 1 6934 . 1524957 2 . 44 0 .01 5 . 0720137 
-
-
-.4 059019 . 182752 4 - 2 . 22 0 . 027 - . 7650412 cons 
-
--------------------------------------------------- ------------------------ ---
9.8.2 Association ofHCMV DNA at M6 with weight at M6: 
. ttest _z wei6 , by(dcmv) 
Two-sample t test with equal variances 
---- --------------- - -- - ---------- ---------- ------------------------- ----------
Group I Obs Mean Std . Er r . Std . Oev . [9 5% Conf . In erval ) 
---------+--------------------------------------------------------------------
o I 293 -. 3179 181 .0679918 1 . 1 63832 - . 4517342 - .184102 
1 I 172 -. 5102907 . 0928319 1 . 2 17479 - . 6935348 - . 32704 6 
---------+--------------------------------------------------------------------
combined I 465 - . 3890753 . 0550134 1.186301 -.4971815 -.280969 
---------+--------------------------------------------------------------------
diff I .1923726 .11 37245 - . 0311075 . 41585 27 
---- ------- -- -- -- -------- - ----- ------------ - - - -- --- --- ------------------------
t - 1. 6916 diff = mean (O) - mean(l) 
Ho : diff = 0 degrees of freedom - 463 
Ha: diff < 0 
pr(T < t) - 0.9543 
Ha : diff ! = 0 
Pr(ITI > Itl) .. 0.0914 
Ha: diff > 0 
Some evidence that _zwei at 6m is l owe r among childre n with 
Pr(T > t) - 0 . 04 57 
detectable DNA (p- 0 . 09) 
. *adjusted for education etc 
source I SS d f MS 
-------------+------------------------------
Mo del I 45 . 4004862 6 7 . 56674769 
Residual I 607 . 591616 458 1.32661925 
-------+------------------------------
Total I 652 . 992 102 464 1 . 40731057 
Number of obs -
F( 6 , 458) -
Prob > F 
R-square d 
Adj R-s quared -
Root MSE 
465 
5 . 70 




------------------- ----- ----- -- ------------------------------------- ----------
zwei 6 I Coef . Std. Err. t P> ltl [ 95% Conf . Interval) 
------=------+----------------------------------------------------------------
Idcmv yn 1 I - . 1529556 . 11 16827 -1 . 37 0 .17 1 - . 3724297 . 0665186 
- Ied~c3=2 I . 3333333 . 1314 261 2 .54 0 . 012 .0750 605 .5916062 
209 
Ieduc3 3 .4973645 .152068 3 . 27 0.001 .1 98527 . 796202 
- -Isescat3 2 . 1852998 .1310877 1. 41 0.15 8 - . 0723081 .44 29 07 7 
-
Isescat3 3 . 2200 178 .1 536433 1. 43 0.153 - . 0819155 . 52 19511 
-Ibfcat2 1 . 5272391 .1 547035 3 . 41 0.001 . 2232224 . 8312557 
-
cons -1.1 96161 .1861598 -6 . 43 0.000 -1. 561994 - . 8303279 
-
--- ------------------------------ ----- ---- ----------------------- -------------
9.8.3 Association of HCMV DNA at M6 with subscap. skinfold at M6: 
*Unadjusted ana1ysis - Association with raw subscapu1ar skinfo1d measurement: 
xi :regress subscap6 i.dcmv 
Source ss df MS 
-------------+------------------------------
Model I 43.1315277 1 43 . 1315 277 
Residual I 1428.45067 463 3.08520664 
-------------+------------------------------
Total I 1471. 5822 464 3 . 17151337 
s ubscap6 I Coef . Std. Err. t P> ltl 
Number of obs -
F( 1, 463) . 
Prob > F 
R-squared 
Adj R-squar d • 
Root MSE 
4 5 
13 . 98 
0 . 0002 
0.0 293 
0 . 0272 
1 . 75 5 
[95 % Cont. In rv 1] 
-------------+----------------------------------------------------------------
_ Idcmv_yn_1 I - . 6308496 
_cons I 8 . 282594 
.1 687216 
. 1026144 
-3 . 74 
80 . 72 
0 . 000 
0.000 
- . 9624 04 5 
8 . 080946 
- . 2992 48 
8 . 484 241 
--- ---------------------------------------------------------------------------
*Unadjusted analysis - Association with subscapular skinfold Z score: 
xi : regress _zss 6 i . dcmv 
Source SS df MS 
-------------+------------------------------
Model I 20 .4 324219 1 20 . 43 24219 
Residual I 682.868536 463 1.47487805 
-------------+------------------------------
Total I 703 . 300958 464 1. 51573482 
Numbe r 0 
F ( 1, 




Adj R-squar d • 
Root MSE 
4 5 
13 .8 5 
0 .000 2 
0.0 29 1 
0 . 027 0 
1 . 2144 
--- ------ - ---------- - -------------------------------------- -------------------
zss6 I Coef . Std . Err. t P> l t l [95 % Conf . I n erv 1) 
-------------+----------------------------------------------------------------
Idcmv yn 1 I -.4341985 







- . 663439 
.48 94866 
- . 20 4959 
.7 683291 
-- ------------------ ------ -------------------------------------------- - -------
*Adjusted analysis - association with raw subscapular skinfold measurement, adjusted for education, 
SES , breastfeeding «6m, 6m+) 
xi :regress subscap6 i.dcmv i . educ3 i . sescat3 i . bfcat 2 
Source SS df MS 
-------------+------------------------------
Model I 122.968971 6 20.4948286 
Residual I 1348.61323 458 2.94457037 
-------------+------------------------------
Total I 1471 . 5822 464 3 . 17151337 
Number of obs -
F( 6, 458) -










-------------------- -------- -- - - - ------------------------------ ---------------
subscap6 I Coef. Std . Err. t P> ltl [95% Conf. Inte rval) 
-------------+----------------------------------------------------------------
_I dcmv_yn_ 1 -.54048 24 .1663887 -3. 25 0.001 - . 8674624 -.2135024 
Ieduc3 2 .2705099 . 195803 1. 38 0 . 168 -.1142738 .6552935 
-
-
Ieduc3 3 . 6243052 .226556 2.76 0.006 . 179087 1.0 69523 
Isescat3 - 2 -. 0016917 .1952989 -0.01 0.993 - . 385 4846 . 382 101 3 
-
-
. 0074496 . 228903 Isescat3 3 0.03 0.974 -.4423808 .4 5728 
-
- Ibfcat2 1 1.01538 . 2304825 4.41 0.000 . 5624461 1. 468315 
-
cons 7.0875 . 27 73471 25 . 55 0 . 000 6 . 54247 7 . 632531 
------ ----------------------------------------------------------------------- -
*Adjusted analysis - association with subscapular skinfold Z score, adjusted for education, SES , 
breastfeeding «6m, 6m+) 
xi :regress _zss6 i.dcmv i.educ3 i . sescat3 i . bfcat2 
Source SS df MS 
-------------+-- ----------------------------
Model I 67 .6919282 6 11 . 281988 
Residual I 635.60903 458 1.38779264 
-------------+------------------------------
Total I 703 . 300958 464 1. 51573482 
Number of obs -
F( 6 , 458) -
Prob > F 
R-squared 




0 . 0000 
0 . 096 2 
0 . 0844 
1. 178 
----- -------------------------------------------------------------------------
_zss6 I Coef. Std . Err . t P> l t l [ 95 % Conf. Interval ] 
-------------+----------------------------------------------------------------
210 
_Idcmv_yn_ 1 -.3651778 .1142 28 7 -3.20 0.001 - . 5896552 - .140700 5 
Ieduc3 2 . 2055835 .1344 22 1 1. 53 0. 127 - .058577 . 4697441 
-
-
Ieduc3 3 .4406464 . 1555346 2 . 83 0 . 00 5 .1 349965 . 7462962 
-Isescat3 2 . 0077 643 . 134076 0 . 06 0. 95 4 - . 2557161 . 271 244 
-Isescat3 3 . 0648401 .1571458 0.41 0 . 680 -.2 439762 . 373 563 
-
-
Ibfcat2 1 . 7920956 .1582301 5 . 01 0 . 000 .4811 485 1 . 10304 3 
-
cons - . 3069072 .1 904035 - 1. 61 0. 108 - . 68 10 801 .0672656 
-
--- --- ----------- - --- ------------------------- - --- --------------- -------------
9.8.4 Association of HCMV DNA at M6 with arm circ. at M6: 
*Unadjusted analysis - Association with raw arm circumference measurement: 
xi : r egres s a rrn6 i . dcrnv 
Source ss d f MS Number 0 obs - 46 5 
-- -----------+------------------- ----------- F ( 1 / 463 ) 
-Model I 16 . 035 8364 1 16 . 03 5836 4 Prob > F 0.0017 
Residual I 745 . 77 6714 463 1 . 610 74 884 R-s quar d 0 . 0210 
-------------+------------------------------ Adj R-squ r d - 0 . 018 9 
Total I 761 . 81255 1 464 1 . 64 183 739 Root MSE 1. 26 2 
-- ----------- - -- - --- -- -- ---- ------ - - ---- - --- -- - ----------------- --------------
arrn6 I Coe f. Std. Er r . t P>lt l [95 % Conf . In rv 1 1 
-------------+----------------------------------------------------------------
Idcrnv yn 1 I - .3846575 
- =cons I 14.7102 4 
. 12 19108 
.0741447 
-3. 16 
198 . 40 
0. 002 
0 .000 
- . 6242247 
14 . 56454 
- . 1450 04 
14 . 855 4 
- - - ---- -- ---------------------------- ---- - ---- - ------------------ -------------
*Unadjusted analysis - Association with arm circumference Z score: 
xi:regress zac6 i . dcrnv 
Source I SS d f MS 
-------------+------------------------------
Model I 11. 383 03 07 1 11 . 38303 07 
Residual I 546. 82 3792 463 1 .1 810 4491 
-------------+------------------------------
Total I 558. 206822 464 1.20 30 319 4 
Number 0 
F ( 1 / 





Roo t MSE 
4 5 
. 64 
0 . 00 20 
0 . 0204 
0 . 0183 
1 . 08 0 
-------- - - - ---------- -- ----------------- - ---- --------------------- -- - ---------
zac6 I Coe f. St d . Er r . t P> l t l [95 % Conf . Int rv 11 
-------------+----------------------------------------------------------------
Idcrnv yn 1 I - . 32 40 839 . 1043907 -3 .10 0 . 002 - . 529222 - . 1189457 
- =cons I . 57 14676 . 063 48 91 9 .00 0 .000 .446705 . 6962301 
-- ------------ - - -- -- --- --- --------------------- ---- - ---------------- ----------
*Adjusted analysis - association with raw arm circumference measurement, adjusted for education, SES 
, breastfeeding «6m, 6m+) 
xi:re gress arrn6 i.dcrnv i . educ 3 i. sescat3 i . b fcat 2 
Source SS df MS 
-------------+------------------------------
Model I 70.9558215 6 11. 82597 03 
Residual I 690 . 8567 29 45 8 1.5084 2081 
-------------+------------------------------
Total I 761. 812551 464 1. 641 83739 
Number of obs -
F( 6 , 458) -
Prob > F 
R-s qu a r ed 
Ad j R- s quared -
Root MSE 
465 
7 . 84 




-- ----------- - ---------- -------- --- - -------------- - --- - -- - - -------------------
arrn6 I Coef . Std . Er r . t P> ltl [95 % Conf . I n terv 11 
-------------+----------------------------------------------------------------
Idcmv_yn_1 -.3452011 .1190897 -2.90 0.004 -.5792311 -.111171 2 
- Ieduc3_2 .41 85092 . 1401424 2 . 99 0. 003 . 1431073 . 693911 
Ieduc3 3 .6033277 . 162 1533 3 . 72 0 . 00 0 . 2846709 . 92 19845 
I S"escat3= 2 . 196268 6 .13 9781 6 1. 40 0 . 161 - . 0784242 . 4709614 
Isescat3 3 .2 657147 .1 63 83 32 1. 62 0 . 106 - . 0562 432 . 5876726 
Ibfcat2_ 1 . 5418345 .1 649636 3 . 28 0 . 001 . 2176551 . 866014 
cons 13.73805 .1985061 69 . 21 0 . 00 0 13 . 347 96 14 . 12815 
- ---------------- -- -- -- - --- --- - -- - ------ -------- ---- ----- ---- - ------------- - --
*Adjusted analysis - association with arm circumference Z score/ adjusted for education, SES , 
breastfeeding «6m, 6m+) 
xi:regress _zac6 i.dcrnv i . educ 3 i . sescat 3 i . bfca t 2 
Source SS df MS 
-------------+------------------------------
Model I 56 . 6291373 6 9 .43818 955 
Residual I 501 . 57768 5 458 1.095 1477 8 
--------+------------------------------
Total I 558.2068 22 464 1. 20303194 
Numbe r of obs = 
F ( 6 / 458) " 





8 . 62 
0 . 0000 
0 . 1014 
0 . 0897 
1. 0465 
-- -- --------- - --- - --------- - ----------------- -- - ---- -- --- - --------------
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_zac6 I Coef . Std . Err . t P>ltl [95% Coni . 1nt rvalJ 
-------------+-------- --------------------------------------------------------
Idcmv yn 1 -. 2827993 .10147 27 - 2 . 79 0 . 006 - .48 22091 - . 0833894 
- Ied~c3-2 . 3728276 .1194111 3 . 12 0.002 . 138166l . 6074892 
Ieduc3 3 . 5474065 . 138166 3 . 96 0.000 . 2758887 .B18 243 
Isescat3 2 . 1514807 .1 191037 1 . 27 0 . 204 - . 0825767 .3 855381 
Isescat3_3 . 1881049 .1395973 1.35 0.178 - . 08 225 .4 243~5 
_ Ibfcat2_1 . 5545313 .14 05605 3 . 95 0.000 .2783078 . 8307548 
_cons -.3387473 .1691411 -2 . 00 0 . 046 -.671136 - . 00 358~ 
------------------------------------------------------------------------------
9.9 Appendix I: HCMV seroprevalence - effects on growth 
9.9.1 Association of HCMV antibody at M18 with length at M18 
*Unadjusted analysis - Association with raw length measurement: 
xi : regress l e ngth 18 i.hcmv 
Sou rce I ss d f MS 
-------------+------------------------------
Mode l I 112 .1 78035 1 112 .1 780 3 5 
Res idua l I 4 453 . 81355 442 10 . 07650 12 
-------------+------------------------------
Tota l I 4565.99 1 58 44 3 10 . 30697 87 
Numbe r of ob s -
F( 1 , 44 2 ) -
Prob > F 
R- s qu a r e d 




0 . 000 
0 . 024 
0. 022 4 
3 . 1744 
--- --------------------------- - ----------- --- ------------------------ - --- -----
l e n g t h 18 I Coef . Std. Err . t P> l t l [95 % Con f . I n t rv 1 ) 
-------------+----------------------------------------------------------------
Ihcmv yn 1 I - 1.356117 .4064414 -3.3 4 0.001 - 2 .1 54 91 4 - . 55 73186 
- =con s I 79 . 56986 . 3715 2 96 2 14 .17 0.000 78. 83968 80 . 30 0 05 
- - - ---------------------- --------- -- --- ------ ----- - --- --- -- ------------ -------
*unadjusted analysis - Association with length Z score: 
x i :regress _z l e n1 8 i .hcmv 
Source I SS d f MS 
-------------+--------- ---------------------
Mode l I 13 . 6076854 1 13.6076854 
Res idua l I 531.402 5 5 442 1. 202 2 682 1 
-------------+------------------------------
Total I 54 5 . 010235 4 43 1. 2 302 7141 
Numbe r o f ob s -
F( 1 , 44 2 ) -
Prob > F 
R-squa re d 
Ad j R- squared -
Root MSE 
444 
1 1. 32 
0 . 0008 
0 . 0250 
0 . 0228 
1 . 0 65 
--- -- - -------
------ -- -- - --------- - - - -- --- - -------- - --------- - - --------------- -
z l en 18 I Coef . Std . Err. t P> l t l [ 95 % Con f . In t rv 1) 
-------------+----------------------------------------------------------------
Ihcmv_yn_1 I -.4723188 .1403925 - 3.36 0.001 - .748 23 8 5 - .1 963991 
_con s I -. 703287 7 .1 283333 -5 . 48 0 . 000 - . 9555 0 69 - . 4510684 
--- ---------- - ----- - --- ----- - - -- --------------- - ----- --- - ---- --------------- --
*Adjusted analysis - association with length Z score, adjusted for education, SES , breaatfeedi nq 
«6m, 6m+) 
xi :re gress _z l e n 18 i.hc mv i. educ3 i . sescat3 i . bfcat2 
Source I SS d f MS 
-------------+------------------------------
Mode l I 82 . 088 2 412 6 13 . 681373 5 
Re sidual I 4 62 . 92 1 99 4 437 1 . 0593 1806 
-- -----------+------------------------------
To t a l I 5 45 . 0 102 35 443 1. 2302 7141 
Numbe r of ob s m 
F( 6 , 437 ) -
Prob > F 
R-square d 
Ad j R-squa r e d m 
Root MSE 
44 4 
1 2 . 92 
0 . 000 0 
0 . 1506 
0 . 1390 
1. 0292 
-- ------------------------------------- - ------ ---------- - - ------ --------------
z l e n1 8 I Coef . Std . Err . t P> l t l [95% Con f . I n te r va l] 
-------------+----------------------------------------------------------------
IhcmvJn_ 1 -.3363102 .1373785 -2.45 0.01 5 - .60 63 1 5 - . 0663 0 54 
- I e d uc3_ 2 .4 90 7333 .1 20562 4 . 07 0 . 00 0 . 253 77 98 . 72 7 6867 
- I e duc 3 3 . 54 7 6273 .14 41 021 3 . 80 0 . 000 . 26 4408 . 8308 4 66 
I se s ca t 3_ 2 . 5328886 .1 207856 4 . 41 0.0 00 . 295 4 95 7 .77 0 28 1 6 
- I s escat 3_ 3 .4 78996 .1 4274 44 3 . 36 0 . 00 1 . 19844 51 . 759547 
- Ib fc a t2_ 1 .11 57838 .13 61 658 0 . 85 0 . 396 - . 15 18375 . 3 8 340 5 
con s -1. 6104 27 .1 890431 - 8.52 0 . 000 -1 . 9B1 974 - 1. 2388B 
-
- - --------------------- --------------- ------- ------ - - --- - ------ -- ------------ -
*Adjusted analysis - association with length Z score, adjusted for education, SES , breaatfeedi nq 
«6m, 6m+) and length at M6 
. xi :re g ress _ z l en l 8 i .hcmv zl e n 6 i. educ3 i . s e scat3 i . bfca t 2 
Source I SS d f MS 
-------------+------------------------------
Mo de l I 3 46 . 5051 7 49 . 5007 286 
Re sidua l I 189 . 0463 43 435 . 434589293 
-------------+------------------------------
To t a l I 535 . 551 4 43 44 2 1 . 211 65485 
Number o f ob s = 
F ( 7 , 435 ) = 
Prob > F 
R-squa r e d 
Adj R- square d = 
Roo t MSE 
443 
11 3 . 90 
0 . 00 00 
0 . 647 0 
0 . 6413 
. 65923 
z l e n1 8 I Coef. Std. Er r . t P> l t l [95 % Conf. Interva l] 
-----=-------+----------------------------------------------------------------
_ IhCmV_yn_1 I -.188892 8 .0881969 -2.14 0.0 3 3 -.3 622 379 -.01 55 477 
213 
zl e n 6 .7 915755 . 032171 2 24 . 61 0 . 000 . 72 83 452 . 854805 
I e duc3 2 . 18658 1 . 0783885 2 .38 0 . 01 8 . 0325 1 37 . 3406483 
-
-
I e d uc3 3 . 37 48958 . 0 925725 4 . 05 0 . 000 . 19295 07 . 5568408 
I sescat3 
-
. 271 790 4 . 0782 475 3 . 47 0 . 001 2 . 11 80 00 3 . 425 5805 
-
Isesca t 3 3 . 2605946 . 09 1856 2 . 84 0 . 00 5 . 0800579 . 4 41131 4 
-
I b f c a t 2 1 -.1 68 7 652 .0 88291 2 -1. 91 0 . 057 - . 342295 7 . 00 47653 
-
con s - . 51378 2 4 . 12 877 36 - 3 . 99 0 . 000 - . 7668782 - . 2 06866 
-
--- -------- - --- - - -------- ------- --------------- - -------------------- ----- -----
me an z l e n1 8 is s ignifi c antly l ower in c hildre n wi t h detect b1e HCMV n i b ody , v n wh n djus 0 
SES , e ducat i on & b reastfeedi ng 
9.9.2 Association ofHCMV antibody at M18 with weight at M1 8 
*Unadjusted analysis - Association with raw weight measurement : 
xi : r egres s weigh t 18 i .hcmv 
Sou rce ss df MS 
-------------+------------------------------
Mode l I 8 . 14130 103 1 8 . 14 1 30 1 03 
Res i dua l I 848. 123 2 41 4 43 1 . 9144 99 42 
-------------+------------------------------
Total I 856 . 2 645 42 44 4 1 . 92 852 37 4 
Number 0 ob s -
F ( I , 4 43 ) -
Prob > F 
R-s q uared 
Ad j R-squar d -
Root MSE 
445 
4 . 25 
0 . 03 8 
0 . 00 5 
0 . 0073 
1 . 38 7 
--- ------ ----- - ------------- -- --- ---- --------------- --------------------------
we i ght1 8 I Coe f . Std . Err . t P> l tl [ 95% Con f . I n rv I J 
-------------+----------------------------------------------------------------
I h cmv yn 1 I -.3652532 . 1771229 -2.0 6 0 . 040 - . 71 335 87 - . 017 14 76 
- =co~s I 10 . 27 274 .1 61944 5 63 . 4 3 0 . 00 0 9 . 95 44 65 10 . 591 0 1 
- - -- - ----- - - - ----- - ---------- ---- - - - - ------ ----- -- ------- - ----- - ------- -------
*Unadjusted analysis - Association with weight Z score: 
xi : r eg r e s s zwe i1 8 i . h cmv 
Sou rce SS d f MS 
-------------+------------------------------
Mode l I 5 . 82850 118 1 5 . 82850 11 8 
Res idua l I 57 9 . 485 7 8 443 1 .3080 9431 
-------------+------------------------------
To t a l I 585 . 3 14 28 1 444 1.3182 75 41 
Number 0 
F ( I , 
Prob > F 
R-squar d 
ob s -
44 3 ) -
Adj R- s quared -
Roo t MSE 
445 
4 . 4 
0 . 0353 
0 . 01 0 0 
0. 0077 
1 . 14 37 
- ------------- - -
- - ------ --- -- - - ------- ------ - - - - - - -- - - - - ----------------- -----
zwei18 I Coef . Std . Err . t P> l t l [ 95 % Con f . I n t rval J 
-------------+----------------------------------------------------------------
Ihcmv yn 1 I - . 3090477 
=co~s I -. 339 178 1 
.14 64086 
. 1338622 
- 2 .11 
- 2 . 53 
0.035 
0 . 01 2 
-. 5 9678 95 - .02 13 0 6 
- . 602262 - . 07609 41 
- - - ------ - ---------- - ------------- -- - ------------- -- ------ -- - ------------ -----
*Adjusted analysis - association with weight Z score, adj uste d f or e ducation , SES , breastfeedi nq 
«6m, 6m+) 
xi : r e gre ss _zwei 18 i.hcmv i . educ3 i . sescat3 i . bfc at2 
Sou r ce Ss df MS 
-------------+------------------------------
Mode l I 67 . 40 0 9186 6 11 . 2 334864 
Residua l I 517 . 913362 438 1 . 18 2 4506 
-- -----------+-------- ----------------------
Tota l I 585.3 1 428 1 4 44 1 . 3182 7541 
Numbe r o f obs -
F ( 6 , 438 ) -
Prob > F 
R- s qua r e d 
Ad j R-squa r e d -
Root MSE 
44 5 
9 . 50 
0 . 00 00 
0 . 11 52 
0 . 1030 
1 . 087 4 
- - - ------ ----- - -- ----- ------ -- ---- -- ---- --- --- ----- - --------------------------
zwei18 I Coef . Std . Er r. t P> l t l [95 % Con f . I n terval] 
-----=-------+----------------------------------------------------------------
Ihc mv_yn_ 1 - . 1 562 73 4 .14513 64 - 1. 08 0. 282 - . 4415238 . 12897 7 
Ieduc3_ 2 .41 7 4 63 7 .1 2 72 22 1 3 . 2 8 0 . 001 . 1674 22 1 . 6675052 
- I e duc3_ 3 . 5967 047 . 152 1 61 3 . 92 0 . 000 . 297 6482 . 8957611 
I se s ca t3_ 2 . 4 18 1 968 . 127 4782 3 . 2 8 0 . 00 1 . 1 67 65 18 . 6687 4 17 
- Isescat 3_ 3 . 4 4860 0 8 . 1507 371 2 . 98 0 . 00 3 . 1 523 429 . 744 8586 
- Ibfca t 2_ 1 . 1 92 68 4 6 .1 438436 1. 34 0 . 18 1 -.0 900 25 . 47 539 41 
- cons - 1. 254767 . 1996085 - 6 . 29 0 . 000 -1. 64707 6 - . 862 457 
----------- ---- ----------- ----------- --- - - - -- - - - -- -- ---- - -- ---------------
*Adjusted analysis - association with weight Z score, adjuste d for education, SES , braastfeedinq 
«6m, 6m+) and weight at M6 
x i : r egress _ zwei 18 i . h cmv zwe i 6 i . educ3 i . sescat3 i . b fca t 2 
Source I SS df MS 
-------------+------------------------------
Mod e l I 363 . 858 4 33 7 51. 9797761 
Numbe r of ob s -
F ( 7 , 4 37) -
Prob > F 
44 5 
102 . 57 
0.000 0 
214 
Residual I 22 1. 455848 437 . 506763954 
-------------+------------------------------
Total I 585 . 314281 444 1 . 318 2 7541 




0 . 6216 
0 . 6156 
. 71187 
[95 % Con . lnt rv 1J 
-------------+----------------------------------------------------------------
lhcmv _yn_ 1 - . 1138653 . 0950302 -1. 20 0 . 23 1 - . 3006384 . 072907 
-
zwei6 . 7135963 . 0295035 24 . 19 0 . 000 .6556098 . 7715828 
leduc3 2 . 1190162 .0841954 1. 41 0 . 158 -.0464621 . 28449 4 5 
-leduc3 3 . 3366709 .1001912 3 . 36 0.001 .1 397544 . 5335874 
lsescat3 
-
. 1992673 .0839434 2 . 37 2 0 . 018 . 03 42 84 2 . 3 42504 
- lsescat3 - 3 . 2526397 . 09901 26 2 . 55 0.011 . 05803 97 . 447 23 7 
-
-
lbfcat2 1 - . 2429364 . 09587 4 6 -2.53 0 . 012 - . 4313691 - . 0545037 
- -
- . 2405023 . 1372381 -1. 75 0 . 080 - . 5102311 cons .0 2 22 4 
-
----- -----------
------- - --- - -- -- ------ -------------------------- --------------
HCMV antibody significantly associated with l ower mean weight at 18m (r w m s u r m 0 & Z sco s) io 
the univariate analysis , but not after adjusti ng for confounder s . 
9.9.3 Association of HCMV antibody at M18 with head circ. at M1 8 
*Unadjusted ana lysis - Associ ati on wi th r a w head c i r cumference measurement: 
xi :regress head18 i .hcmv 
source SS d f MS 
-------------+------------------------------
Model I 11 . 24065 14 1 11 . 2406514 
Residual I 899.729171 443 2.03099 13 6 
-------------+------------------------------
Total I 910 . 969822 444 2 . 05173383 
Number of ob s -
F( 1 , 44 3 ) -
Prob > F 
R-square d 
Adj R-squar d -
Roo t MSE 
44 5 
5 . 53 
0 . 0191 
0 . 0123 
0 . 0101 
1.4 25 1 
---- - - -- -- ---- - -- - ----------- ------------------------- ------------------------
head18 I Coef . Std. Err . t P> l t l [95 % Conf . lot rv IJ 
-------------+----------------------------------------------------------------
Ihcmv_yn_1 I -.4291833 
- _cons I 47 . 87945 
. 1824321 
. 1667987 
- 2 . 35 
2 87 . 05 
0.019 
0.000 
- . 7877231 
47.5 5164 
- . 0706435 
48.20727 
----- --------- - -------------- --------------------------- ----------------------
*unadjusted analysis - As s ociat i on wi th hea d c i rcumfe r enc e z score: 
xi :regress zhc 18 i .hcmv 
Source SS df MS 
-------------+------------------------------
Model I 5 . 88722156 1 5 . 88722156 
Residual I 437.23098 6 443 . 986977395 
-------------+------------------------------
Tota l I 443 . 118 208 444 .998013981 
Numbe r of obs -
F( 1 , 443) -
Prob > F 




5 . 9 
0 . 0150 
0 . 0133 
0.0111 
. 99347 
---------------------- - -------- -------- - - ------ ---------------- --- ------------
zh c 18 I Coef . Std. Err. t P> l tl [ 95 % Con f . lnt rv 1] 
-------------+----------------------------------------------------------------
Ihcmv-yn_ 1 I - . 3106006 . 1271747 -2.44 0 . 015 -.5605413 -.0606599 
- _cons I . 80 1 9178 .11 62766 6 . 90 0.000 .57339 56 1 . 03044 
------ ---- - --- - -- - --------- - ------------ ---- ------------- ---------------------
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*Adj usted analysis - association with head circumference Z s core, a d j usted for education, SES , 
breastf eedinq «6m, 6m+) 
xi :regress zhc18 i . hcmv i . educ3 i . sescat3 i . bfcat2 
Source SS df MS 
-------------+--- ---------------------------
Number of obs -
F( 6 , 438) -




0 . 0000 
0 . 08 2 7 
0.070 2 
. 96331 
Model I 36 . 6654945 6 6 .11 09 1575 
Residual I 406 . 452 71 3 438 . 92797423 1 
-------------+------------------------------ Ad j R-squar d -
Root MSE Total I 44 3. 118 208 444 . 998013981 
- -------- - --- - - - -- - ----- - - - -- -- - - ------------ ---------------------------------
zh c 18 I Coef. Std . Err . t P> l t l [95 % Conf . lnt rv IJ 
-------------+----------------------------------------------------------------
Ihcmv_yn_ 1 -. 23 0 6002 .1285739 -1. 79 0 . 074 - .4832989 . 022 0983 
- Ieduc3 2 .2 44 2402 .11 27 039 2 . 17 0 . 031 . 0227326 . 46 57 478 
-leduc3 3 .5357743 . 1347969 3 . 97 0 . 000 . 2708453 . 8007034 
lsesca t 3 
-
. 2289 47 6 . 11 29308 2 .03 0 . 043 . 006994 2 .4 50 011 
-lsescat3 3 . 1097963 . 1335354 0.82 0 . 411 - .1 526536 . 3722461 
-
lbfcat2 1 . 2692612 . 1274287 2 . 1 1 0 . 035 . 0188136 . 51 7089 
-
con s . 1384244 . 1768298 0 .7 8 0 . 434 - . 2 09116 .48 5 648 
-
-- --- -- -- - -- - - - --
--- --- ----------------- --------------- -----------------------
*Adjusted analysis - association with head c i rcumfere nce Z score, adjusted for eduoation, SES , 
breastfeedi nq «6m , 6m+) and head circumference a t M6 
xi : regress _z hc l8 i. hcmv zh c6 i.educ3 i . sescat3 i.bfcat2 
Source SS df MS 
-------------+------------------------------
Model I 281 .45235 7 7 40 . 2074796 
Residual I 1 61. 665851 437 . 3699 447 38 
-------------+------------------------------
Tota l I 443 . 118208 444 . 998013981 
Number of obs -
F( 7 , 437) . 
Prob > F 
R-squared 
Adj R-square d • 
Root MSE 
445 
108 . 9 
0.0000 
O. 352 
0 . 62 3 
. 08 23 
- ----- - ------ - ----- - --- - - - ----- ----------- --- - ------------------- -------------
zh c 18 I Coef . Std . Err . t P> l t l [95 % Conf . lnt rv I J 
-------------+----------------------------------------------------------------
lhcmv yn 1 - . 0787208 . 0813952 - 0 . 97 0 . 334 -.2386956 .081 25 4 
-zhc6 . 7624 4 68 . 0296404 25 . 72 0 . 000 .7041 913 . 82070 22 
led~c3_2 . 0755927 . 0714619 1.0 6 0 . 29 1 -.0648591 . 21 0445 
Ieduc3 3 . 285 7 622 . 0856631 3 . 34 0.001 .1 173993 . 454 1251 
Isescat3=2 .0 37 1113 .0 71 692 7 0 . 52 0.605 - .1 03794 2 . 1780167 
lsescat3_3 - .0041856 . 0844298 -0 . 05 0 . 960 -.1701 2 47 . 1617534 
Ibfcat2 1 -.084 367 .0816237 -1.03 0 . 302 - . 244 7 909 . 07605 8 
cons . 0576347 . 111 6934 0 . 52 0.60 6 - . 1618884 . 2771578 
------ --- ---- ---------- - ------ -- -------------- --------------------- -----
HCMV antibody no l onger s i gni ficantly associated after adjusti n g for h ad circum r nc Z scor 
6m 
216 
9.10 Appendix J: Effects of HI V-I and HCMV infections on referral rate 
9.10.1 Effect of HI V-I infection on referral rate 
*if exclude unknown - biased b/c had to survive to lBm to be known 
+--------------------------------------------------------+ 
1 chiv_f D Y Rate Lower Upper 1 
1--------------------------------------------------------I 
1 Negative 99 558.9432 0.17712 0.14545 0.21'>68 1 
1 positive 9 16.2519 0.55378 0.28814 1.06432 1 
+--------------------------------------------------------+ 
Cox regression -- Breslow method for ties 
No. of subjects 574 Number of 
No. of failures 108 
Time at risk 575.1950986 
obs 
Wald chi2(l) 




(Std. Err. adjusted for 743 clusters in subject_Id) 
Robust 
_t 1 Haz. Ratio Std. Err. z P>lzl [95¥. Cont. Interval] 
-------------+----------------------------------------------------------------
Ichiv_f_2 1 3.115142 1.148568 3.08 0.002 1.'>12292 6.416822 
*if include unknown with positive 
+----------------------------------------------------------------< 
1 chiv2 D Y Rate Lower Upper I 
1----------------------------------------------------------------1 
1 Negative 99 558.9432 0.17712 0.14545 0.21568 1 
1 Positive/unknown 51 81.2406 0.62776 0.47709 0.82602 1 
+----------------------------------------------------------------+ 
Cox regression -- Breslow method for ties 
No. of subjects 743 Number of obs 
No. of failures 150 
Time at risk 640.1838638 
Wald chi2(1) 




(Std. Err. adjusted for 743 clusters in subject id) 
t 1 Haz. Ratio 
Robust 
Std. Err. z P>lzl [95% Conf. Interval) 
-------------+----------------------------------------------------------------
Ichiv2_2 1 3.246976 .645646 5.92 0.000 2.198981 4.794425 
9.10.2 Effect of HI V-I exposure on referral rate 
*** (b) by maternal HXV overall 
+-------------------------------------------------------------+ 
1 mhiv_f D Y Rate Lower Upper 1 
1-------------------------------------------------------------1 
1 Negative 91 435.7677 0.208827 0.170042 0.256458 1 
1 positive 51 145.9877 0.349344 0.265498 0.459670 1 
1 Don't know 8 58.4285 0.136919 0.068473 0.273785 1 
+-------------------------------------------------------------+ 
Cox regression -- Breslow method for ties 
No. of subjects 743 Number of obs 
No. of failures 150 
Time at risk 640.1838638 
Wald chi2(2) 
Log pseudolikelihood -963.73444 Prob > chi2 






t 1 Haz. Ratio Std. Err. z P>lzl [95'i. Cont. Interval) 
-------------+----------------------------------------------------------------
Imhiv f 2 1 1.687752 .3303208 2.67 0.007 1.150044 2.476867 
_Imhiv=f=3 1 .6549621 .2273964 -1.22 0.223 .3316556 1.293436 
9.10.3 Effect ofHCMV sera-DNA at M6 on referral rate 
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*** (a) all children 
+---------- --------------------------------------------+ 
I dcmvyn D Y Rate Lower Upper I 
1--------------------------------- ---------------------I 
1 0 56 256 . 0768 0 . 21868 0 . 16829 0 . 28416 1 
I 1 49 154 . 7407 0 . 31666 0 . 23933 0. 41 898 I 
+------------------------------------------------------+ 
Cox r egression --
No . o f subjects 
No . of failures 
Time at risk 
Breslow method for ties 
485 
105 
410 . 8175426 
Log pseudolikelihood - 630 . 01148 
Number of ob s 
Wald c hi2( 1) 
Prob > chi2 
780 
3.07 
0 .07 99 
Robust 
_t I Haz . Ratio Std. Err. z P> l zl [ 95 % Con f . Interval ] 
-------------+----------------------------------------------------------------
_Idcmvyn_1 I 1 . 456344 .31 25847 1.75 0.080 . 9562362 2 . 218 008 
Some evidence that children with detectable DNA more l ikely to be r efe rred to hospital 
9.1 0.4 Effect of HCMV sera-DNA at M6 on referral rate sub-stratified by HIV -1 exposure 
I 






35/154.1 (22.7) 1.07 (0.66-1.74) 0.77 1.12 (0.69-1.83) 0.64 
Negative 37/178.8 (20.7) 16/103.0 (15.6) 0.75 (0.41-1 .36) 0.34 0.80 (0.43-1.47) 0.48 
Positive 14/48.1 (29.1) 17/36.6 (46.4) 1.60 (0.72-3.58) 0.25 2.23 (0.92-5.42) 0.08 
Active HCMV at 6 months shows a trend for risk of hospital referral in HIV-I exposed infants 
Referral rate is calculated for individual subjects as number of referrals to hospital per year. 'adjusted for 
socioeconomic group and breastfeeding <6 months. By KB, CIGNIS statistician, LSHTM. 
9.10.5 Effect of HCMV seroprevalence at M18 on referral rate 
*rate overal.l.. 
+----- ----------------------- ------------------------ ----+ 
I scmv -18 D Y Rate Lower Upper I 
1-----=-------------------------------------------------- I 
1 0 11 60 . 7147 0.18118 0 . 10033 0 . 327 15 1 
1 1 79 301 . 9577 0 . 26163 0 . 20985 0 . 32617 1 
+------------------------- -------------------------------+ 
Cox regression -- Breslow method for ties 
No . o f subjects 421 Number of obs 675 
No . of failures 90 
Time at risk 362 . 6723563 
Wa ld c hi2(1) 0 . 93 
Log pseudolikelihood - 529 . 23213 Prob > c hi 2 0.3339 
(S td . Err . adjusted f or 421 clusters in subject _ id) 
Robust 
_ t I Ha z . Ratio Std . Err . z P> l z l [ 95 % Conf . Interval] 
-------------+----------------------------------------------------------------
_Iscmv_yn_ - 1 I 1.439886 . 5431942 0 . 97 0 . 334 . 6874071 3 .01 6076 
Referral rates is s lightly highe r in c hildren with detectable HCMV antibody , but not 
statistically significant 
*effect of HCMV antibody, within each maternal HIV group 
+------------------ ------------------------------------------------------+ 
I mhiv_f scmv -18 D Y Rate Lower Upper 1 
1------------------------------------------------------------------------1 
I Nega tive 0 7 46 . 1466 0 . 151691 0.07 23 16 0 . 318197 I 
I Nega tive 1 41 208 .11 78 0 .1 97004 0 . 14 5057 0 . 26755 3 I 
I posi tive 0 4 12 . 3340 0.3 24306 0 .1 21718 0 . 864094 I 
I pos itive 1 35 67 . 1239 0.5 214 24 0 . 374379 0 . 726223 I 
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1 Don't know 0 0 2.2341 0.000000 . 1 
1------------------------------------------------------------------------1 
1 Don't know 1 3 26.7159 0.112292 0.036217 0.348171 1 
+------------------------------------------------------------------------+ 
Effect of HCMV antibody at lam, in HIV negative mothers! 
Cox regression 
No. of subjects 
No. of failures 
Time at risk 




Number of obs 484 
Wa1d chi 2 (1) 0.44 
Log pseudolikelihood -264.82975 Prob > chi2 0.5059 
(Std. Err. adjusted for 300 clusters in subject_id) 
t 1 Haz. Ratio 
Robust 
Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
1.293117 .4996476 0.67 0.506 .606376 2.757615 
Bffect of HCMV antibody at lam, in HIV positive mothers! 
Cox regression 
No. of subjects 
No. of failures 
Time at risk 




Number of obs 139 
Wald chi2(1) 0.37 
Log pseudolikelihood -170.19167 Prob > chi2 0.5424 
(Std. Err. adjusted for 87 clusters in subject_id) 
------------------------------------------------------------------------------
t I Haz. Ratio 
Robust 
Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
_Iscmv_yn_-1 1 1.614098 1.268676 0.61 0.542 .3458501 7.533064 
------------------------------------------------------------------------------
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9.11 Appendix K: Effects of HCMV sera-DNA and intervention on growth 
9.11.1 Length at M18 
Stratified by HCMV DNA: 
children "i th no detectable DNA: 
Two-sample t test with equal variances 
------------------------------------------------------------------------------
Group I Obs Mean Std. Err. Std. Dev. [95% Conf. Interval] 
---------+--------------------------------------------------------------------
Conventi I 113 -1.078407 .1067223 1.134474 -1.289864 -.8669504 
Micronut I III -1.07045 .1153859 1.215665 -1.299118 -.8417828 
---------+--------------------------------------------------------------------
combined I 224 -1.074464 .0783592 1.172774 -1.228884 -.920045 
---------+--------------------------------------------------------------------
diff I -.0079566 .1570764 -.3175082 .301595 
diff = mean (Conventi) - mean (Micronut) t = 
Ho: diff = 0 degrees of freedom = 
-0.0507 
222 
Ha: diff < 0 
Pr(T < t) = 0.4798 
Ha: diff != 0 
Pr(ITI > Itl) = 0.9596 
children "ith detectable DNA: 
Two-sample t test with equal variances 
Group I Obs Mean Std. Err. Std. Dev. 
Ha: diff > 0 
Pr(T > t) = 0.5202 
[95% Conf. Interval] 
---------+--------------------------------------------------------------------
Conventi I 71 -1.20338 .127094 1.070913 -1.456861 -.9498994 
Micronut I 68 -.9467647 .1415122 1.166939 -1.229224 -.6643052 
---------+--------------------------------------------------------------------
combined I 139 -1.077842 .0951882 1.122252 -1.266058 -.8896258 
---------+--------------------------------------------------------------------
diff I -.2566156 .1898528 -.6320363 .1188052 
diff = mean (Conventi) - mean(Micronut) t = -1.3517 
Ho: diff = 0 degrees of freedom = 137 
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0 
Pr(T < t) = 0.0894 Pr (I TI > I t I) = 0.1787 Pr(T > t) = 0.9106 
Stratified by HCMV DNA, adjusted for Z-score at 6m, education, SES , BFinq 
children "i th no detectable DNA: 
xi:regress _zlen18 i.treat zlen6 i.educ3 i.sescat3 i.bfcat2 if dcmv==O 
Source I SS df MS Number of obs 224 
-------------+------------------------------ F( 7, 216) 52.25 
Model I 192.836671 7 27.5480959 Prob > F 0.0000 
Residual I 113.877064 216 .527208631 R-squared 0.6287 
-------------+------------------------------ Adj R-squared 0.6167 
Total I 306.713736 223 1.37539792 Root MSE .72609 
zlen18 I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat 1 .0375975 .0975373 0.39 0.700 -.1546493 .2298443 
zlen6 .8471233 .050404 16.81 0.000 .7477766 .94647 
Ieduc3 2 .168706 .1246122 1. 35 0.177 -.0769055 .4143175 
-





2 .1254529 2.46 0.015 .0616483 .5561854 
Isescat3 3 .4070025 .1451474 
-
2.80 0.006 .1209158 .6930891 
Ibfcat2 1 -.1893989 .1478743 
-
-1.28 0.202 -.4808602 .1020624 
cons -.7156839 .1910803 
-
-3.75 0.000 -1.092305 -.3390632 
------------------------------------------------------------------------------
children with detectable DNA: 
xi:regress _zlen18 i.treat _zlen6 i.educ3 i.sescat3 i.bfcat2 if dcmv==l 
Source I SS df MS Number of obs 138 
F( 7, 130) 43.40 
Prob > F 0.0000 
R-squared 0.7003 
-------------+------------------------------
Model I 114.976746 7 16.4252494 
Residual I 49.196678 130 .378435984 
-------------+------------------------------ Adj R-squared 0.6842 
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Total I 164.173424 137 1.19834616 Root MSE .61517 
zlen18 I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-
-------------+----------------------------------------------------------------
Itreat 1 -.0410019 .1062152 -0.39 0.700 -.251136 .1691322 
-
zlen6 .739436 .053841 13.73 0.000 .6329179 .845954 
Ieduc3 2 .3620201 .1280228 2.83 0.005 .1087422 .615298 
-Ieduc3 3 .4651104 .1507775 3.08 0.002 .1668151 .7634058 
IS"escat3 
-
2 .3165401 .1245691 2.54 0.012 .0700951 .5629851 
-
Isescat3 3 .3810984 .1426175 2.67 0.009 .0989468 .6632499 
-
Ibfcat2 1 .207727 .1405344 1. 48 0.142 -.0703036 .4857576 
-
cons -1.171773 .1901899 -6.16 0.000 -1.548041 -.7955055 
-
------------ ------------------------------------------------------------------
Stratified by maternal HIV , HCMV DNA: 
HIV negative mother, no detectable DNA 
Source I SS df MS 
-------------+------------------------------
Model I 1.89625046 1 1.89625046 
Residual I 224.687777 157 1.43113234 
-------------+------------------------------
Total I 226.584028 158 1.43407612 
zlen18 I Coef. Std. Err. t P>ltl 
Number of obs 
F( 1, 157) 










[95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat 1 I .2184177 .1897492 1.15 0.251 -.1563728 .5932083 
_cons I -1.185 .1337503 -8.86 0.000 -1.449182 -.9208178 
HIV negative mother, detectable DNA 
Source I ss df MS 
-------------+------------------------------
Model I .608019743 
Residual I 95.2452237 
1 .608019743 
90 1. 05828026 
-------------+------------------------------
Total I 95.8532435 91 1.05333235 
zlen18 I Coef. Std. Err. t 
-
P>ltl 
Number of obs 92 
F( 1, 90) 0.57 
Prob > F 0.4504 
R-squared 0.0063 
Adj R-squared -0.0047 
Root MSE 1.0287 
[95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat 1 I .1626288 .2145552 0.76 0.450 -.2636225 .5888802 
cons I -.9117778 .1533536 -5.95 0.000 -1.216442 -.607114 
HIV positive mother, no detectable DNA 
Source I SS df MS Number of obs 43 
-------------+------------------------------ F( 1, 41) 2.39 
Model I 2.6309828 1 2.6309828 Prob > F 0.1296 
Residual I 45.0777939 41 1.09945839 R-squared 0.0551 
-------------+------------------------------ Adj R-squared 0.0321 
Total I 47.7087767 42 1.13592326 Root MSE 1.0486 
zlen18 I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat_l I -.4948485 





Hrv positive mother, detectable DNA 
Source I SS df MS 
-------------+------------------------------
Model I 2.5821375 1 2.5821375 
Residual I 47.3092154 32 1.47841298 
-------------+------------------------------
Total I 49.8913529 33 1.51185918 






Number of obs 
FI 1, 32) 












[95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat_l I .5550175 .4199668 1.32 0.196 -.3004267 1.410462 
_cons I -1.963684 .2789466 -7.04 0.000 -2.53188 -1.395489 
------------------------------------------------------------------------------
Subgroup whara wa saw an affect on zlen at 18m: Hrv positive mothars, braastfaadin9 las. than 
6m, stratifiad by HCMV DNA: 
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HIV positive mothers' not Bfi nq , wi th no detectable DNA : 
Source I ss df MS 
-------------+------------------------------
Model I 19.0156657 
Residual I 5 . 57146768 
63.16927761 
17 . 327733393 
-------------+------------------------ ------
Total I 24.587133 3 23 1 . 0690058 
zlen18 I Coef . Std . Err . t 
Number of obs 
F( 6 , 17) 




P> l t l [ 95 % Con f. 
24 
9 . 67 
0 . 0001 
0 . 7734 
0 . 6934 
.57248 
I n terval] 
-------------+----------------------------------------------------------------
Itreat 1 . 0563431 . 2539298 0 . 22 0.827 - . 4794019 .5920882 
zlen6 .8389379 .1151548 7 . 29 0 . 000 . 5959825 1 . 081893 
Ieduc3 2 . 130012 .3111235 0 . 42 0 . 681 - . 5264012 . 7864252 
-
Ieduc3 3 . 6930915 . 3363875 2 .06 0.055 - .0166241 1. 402807 
Isescat3 
-
.0140946 . 3476718 0 .04 2 0 . 968 - .7194288 . 7476179 
-
Isescat3 3 - . 2826425 . 3982 756 -0 . 71 0 . 488 -1.122931 . 55 76456 
-
cons - . 494002 . 3939334 -1. 25 0 . 227 - 1. 325129 . 3371249 
-
- --------- -- - - ------ ----- --- --------- - -- ------ ---- - ------- --- -----------
HIV positive mothers' not Bfinq , with detect able DNA: 
Source I SS df MS 
-------------+------------------------------
Model I 28 . 8667247 
Residual I 5.12558961 
6 4.81112078 
14 . 366113544 
-------------+--- ---------------------------
Total I 33.9923143 20 1.69961571 
zlen18 I Coef . Std. Err. t 
Number of obs 
F( 6 , 14) 




P> l t l [ 95 % Conf . 
2 1 
13.14 
0 . 0000 
0.8492 




Itreat 1 .5878893 .306295 1. 92 0 . 076 - .0690483 1 . 244827 
-
zlen6 .8201381 .1441625 5 . 69 0 . 000 . 5109402 1.129336 
Ieduc3 2 .9508052 . 3938488 2 .4 1 0 . 030 .1 060835 1.795527 
-
Ieduc3 3 1. 074236 .3886774 2 .76 0 . 015 . 2406058 1 . 907866 
Isescat3 - .2947788 .3750167 0.79 0 . 445 -.5095519 2 1. 09911 
- -Isescat3 3 - . 3130847 . 4073449 - 0.7 7 0 . 455 - 1 . 186753 . 5605832 
-
cons -1 .512388 . 4326791 -3.50 0.004 - 2 . 440393 - . 5843837 
-
-- ---- - ----- - --------- - ------ -------- --- - ------- --- ----- - - --------------------
There wa s some evidence that length is greater in c hildren in MF arm, i n subgroup of c hildren 
with HIV pos mother , not Bfing , wi th detectable HCMV DNA 
9.11.2 Weight at M18 
stratified by HCMV DNA: 
chi ldren with no detectable DNA: 
Two - sampl e t test with equal variances 
Group I Obs Mean Std . Err. Std . Dev . [95 % Conf . Interval] 
---------+--------------------------------------------------------------------
Conventi I 113 - . 5138053 . 118034 1 . 254 718 - .7 476745 - . 279936 1 
Micronut I 112 - . 5253571 . 1197174 1.26697 -. 7625852 -.2881291 
---------+--------------------------------------------------------------------
combined I 225 -. 5195556 .0838685 1. 258027 -. 6848277 -.3542834 
---------+--------------------------------------------------------------------
diff I . 0115518 .1 681125 -. 3197406.3428443 
diff = mean(Conventi) - mean (Micronut) t ~ 0 . 0687 
Ho : diff = 0 degrees of freedom = 223 
Ha: diff < 0 Ha: diff ! = 0 Ha : diff > 0 
Pr(T < t) = 0.5274 Pr (I TI > I t I) = 0 . 9453 Pr(T > t) = 0 . 4726 
children with detectable DNA: 
Two-sample t test with equal variances 
- ---------- --- ------- ----------- - ----- -------------------------------------- - -
Group lObs Mean Std . Err . Std . Dev. [ 95 % Conf. I n terval ] 
---------+--------------------------------------------------------------------
Conventi I 71 - . 70873 24 . 1380537 1 .1 63261 - . 9840719 - . 4333929 
Micronut I 68 -. 4470588 . 1305923 1 . 076892 -. 7077221 - . 1863955 
---------+--------------------------------------------------------------------
combined I 139 - . 5807194 .0954606 1.125 464 - . 769474 - . 3919648 
---------+--------------------------------------------------------------------
diff I - . 2616736 .190353 -. 6380836 . 1147365 
---------- - ----- - -- -- -- - - - -- - --- - ----- ------- - ---- -- ----- - --------------------
222 
diff = mean(Conventi) - mean (Micronut) t = -1.3747 
Ho: diff = 0 degrees of freedom = 137 
Ha: diff < 0 Ha: diff 1= 0 Ha: diff > 0 
Pr(T < t) = 0.0857 Pr (IT I > I t I) = 0.1715 Pr(T > t) = 0.9143 
stratified by HCMV DNA, adjusted for Z score at 6m, education, SES , BFing 
children with no detectable DNA: 
Source I SS df MS 
-------------+------------------------------
Model I 238.85891 7 34.1227015 
Residual I 115.650845 217 .532953204 
-------------+------------------------------
Total I 354.509756 224 1.58263284 
Number of obs 
F( 7, 217) 











zwei18 I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat 1 .0900794 .0979741 0.92 0.359 -.1030233 .2831821 
-
zwei6 .8350369 .0436669 19.12 0.000 .7489714 .9211024 
Ieduc3 2 .1647528 .1253821 1. 31 0.190 -.0823699 .4118755 
-
Ieduc3 3 .3494835 .1403944 2.49 0.014 .0727722 .6261948 
Isescat3 
-
2 .2497903 .1253322 1. 99 0.048 .0027661 .4968146 
-
Isescat3 3 .3518137 .1453621 2.42 0.016 .0653113 .638316 
-
Ibfcat2 1 -.3633285 .1497178 -2.43 0.016 -.6584158 -.0682412 
-
cons -.3536646 .1873196 -1. 89 0.060 -.7228633 .015534 
children with detectable DNA: 
Source I SS df MS Number of obs 139 
-------------+------------------------------ F( 7, 131 ) 43.87 
Model I 122.531543 7 17.5045062 Prob > F 0.0000 
Residual I 52.2687847 131 .398998357 R-squared 0.7010 
-------------+------------------------------ Adj R-squared 0.6850 
Total I 174.800328 138 1.26666904 Root MSE .63166 
zwei18 I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-
-------------+----------------------------------------------------------------
Itreat 1 -.119195 .1098638 -1. 08 0.280 -.3365318 .0981417 
-
zwei6 .7729896 .0495706 15.59 0.000 .6749272 .871052 
Ieduc3 2 .048744 .129169 0.38 0.707 -.2067832 .3042712 
-
Ieduc3 3 .3459919 .153613 2.25 0.026 .0421086 .6498751 
Isescat3 
-
2 .3470495 .1266923 2.74 0.007 .0964218 .5976771 
-
-
.4403339 .14549l4 3.03 0.003 .1525172 .7281506 Isescat3 3 
-
Ibfcat2 1 -.0367305 .1438587 -0.26 0.799 -.3213173 .2478563 
-
cons -.4515715 .1821957 -2.48 0.014 -.8119981 -.0911449 
------------------------------------------------------------------------------
Stratified by maternal. HIV & HCMV DNA: 
HIV negative mother, no detectable DNA 
Source I SS df MS Number of obs 159 
-------------+------------------------------ F( 1, 157) 1. 43 
Model I 2.36321017 1 2.36321017 Prob > F 0.2339 
Residual I 259.791172 157 1.65472084 R-squared 0.0090 
-------------+------------------------------ Adj R-squared 0.0027 
Total I 262.154382 158 1. 65920495 Root MSE 1. 2864 
------------------------------------------------------------------------------
zwei18 I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat_l I .2438323 .2040339 1.20 0.234 -.1591733 .6468379 
_cons I -.58725 .1438194 -4.08 0.000 -.8713205 -.3031795 
------------------------------------------------------------------------------
HIV negative mother, detectable DNA 
Source I SS df MS Number of obs 92 
-------------+------------------------------ F( 1, 90) 0.62 
Model I .629237373 1 .629237373 Prob > F 0.4329 
Residual I 91.2498181 90 1.01388687 R-squared 0.0068 
-------------+------------------------------ Adj R-squared -0.0042 
Total I 91.8790554 91 1.00965995 Root MSE 1. 0069 
------------------------------------------------------------------------------
zwei18 I Coef. Std. Err. t P>ltl [95% Cont. Interval] 
-
-------------+----------------------------------------------------------------
Itreat_1 .1654421 .2100069 0.79 0.433 -.2517732 .5826574 
223 
_con s I -. 4328889 . 1501027 - 2 . 88 
HIV positive mother, no detectable DNA 
Source I SS df MS 
-------------+------------------------------
Model I 4 . 2 7814545 1 4 .278 14 545 
Residual I 53 . 3357727 42 1. 26989935 
-------------+------------------------------
Total I 57.6139182 43 1. 33985856 
zwe i18 I Coef . St d . Er r. t 
0 . 005 
P> l t l 
-.7 310 9 41 - . 13 46837 
Number o f obs 
F ( 1, 42 ) 
Pr ob > F 
R-squared 
Ad j R- s quared = 
Roo t MSE 
44 
3 . 37 
0 . 0735 
0 . 0743 
0 . 0 52 2 
1 .1 269 
[ 95 % Conf . I n terval ) 
-------------+----------------------------------------------------------------
_Itreat_l I -.6236364 
_cons I - .3768 182 
.3397726 
. 2402 555 
-1. 84 
-1. 57 
HIV positive mother, no detectable DNA 
Source I ss d f MS 
-------------+------------------------------
Mod e l I 1 . 94 1 4722 1 1. 94 14 722 
Residual I 62 .7392337 32 1. 96060 105 
-------------+------------------------------
Tota l I 64 . 6807059 33 1. 96002 139 
0.074 
0 .1 2 4 
-1. 309325 
- . 86 1 67 3 4 
Numbe r of obs 
F ( 1, 32 ) 
Prob > F 
R- squared 





0 . 9 9 
0 . 327 1 
0 . 0300 
-0 . 0003 
1 . 400 2 
---------------------------------- - --------- ------- --- - --- -- --- ------ --- - -----
zwe i1 8 I Coef . Std . Err. t P> l t l [ 95 % Conf . In terva l) 
-------------+----------------------------------------------------------------
Itrea t _ 1 I . 48 12632 
_cons I -1 .3 15263 
.4 836282 
. 32 12313 
1. 00 
- 4 . 09 
0.327 
0 . 000 
-. 5038553 
-1. 9695 9 
1 . 46 638 2 
- . 6609365 
------------------------------------------------- ----------- -- -- - - - - - - - -- - - - --
9.11.3 BMI at M18 
Stratified by HCHV DNA: 
children with no detectable DNA: 
Two - sample t test with equa l vari a nc es 
-------- - --------------- - --------------------------------- - ------- ---- - - - - - ---
Group I Obs Mean Std. Er r. Std . Dev . [9 5% Con f . In t e rval ) 
---------+--------------------------------------------------------------------
Convent i I 113 .1 970 7 96 . 10 71 4 44 1.1 38961 -. 0152 133 . 40937 2 6 
Mi cronut I 111 . 167117 1 . 10 154 94 1 .069889 - . 0341 29 9 . 36836 41 
---------+--------------------------------------------------------------------
combined I 224 .1 82232 1 . 0736904 1.102897 . 0 370 135 . 327 4508 
---------+--------------------------------------------------------------------
diff I . 029962 5 . 14770 46 -. 2 6111 99 .32 104 5 
------------------------------------------------------- - ---- - --------- -- - -----
diff = mean(Convent i) - mean (Mi c r onut) t = 0 . 2 029 
Ho : dif f = 0 degrees o f f r eed om = 222 
Ha : dif f < 0 Ha : di ff != 0 Ha : diff > 0 
Pr (T < t) = 0 . 5803 Pr ( ITI > I t I ) = 0 . 8394 Pr( T > t) = 0 . 4197 
children with detectable DNA : 
Two-sa mple t test with e qual va riance s 
------------------------------------------------------------- - - -- --------- -- - -
Group lObs Mean Std . Err . St d . Dev . [ 95 % Conf . I nt e rval) 
---------+--------------------------------------------------------------------
Conventi I 71 . 03 1690 1 .12 11 205 1 . 02058 -. 209877 1 . 2 73 257 4 
Mi c r onut I 68 . 18 77 941 .11 21033 . 92 44 2 78 - .035965 1 . 4115533 
---------+--------------------------------------------------------------------
combined I 139 . 1080576 .0826439 . 9743566 -. 055354 4 . 2 71 4695 
---------+--------------------------------------------------------------------
diff I -.1 56104 .1 6539 1 6 -. 483 15 46 .1 709466 
- mean (Mi c r onu t) t = d i f f = mean (Conventi ) 
Ho : d i ff = 0 degrees of f reedom = 
- 0 . 9438 
13 7 
Ha : diff < 0 
Pr (T < t ) = 0 . 1735 
Ha : dif f ! = 0 
Pr ( ITI > Itl) = 0 . 3 469 
Ha : d iff > 0 
Pr( T > t) 0 . 82 65 
*Stratified by HCMV DNA, adjusted for Z score at 6m, education, SES & BFing 
children with no detectable DNA: 
Source I SS d f MS 
-------------+------------------------------
Number of ob s 
F( 7, 216 ) 
22 4 
32 . 70 
224 
Model I 139.554415 




Total I 271.253084 223 1.21638154 
zbmi18 I Coef. Std. Err. t P>ltl 








[95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat_1 .0705824 .1050875 0.67 0.503 -.1365458 .2777106 
zbmi6 .6918595 .0483801 14.30 0.000 .596502 .787217 
reduc3_2 .1318378 .1341655 0.98 0.327 -.1326034 .396279 
Ieduc3 3 .1898153 .1504219 1.26 0.208 -.1066674 .4862981 
Isescat3=2 .1076496 .1338547 0.80 0.422 - .156179 .3714782 
Isescat3 3 .1701265 .1552702 1.10 0.274 - .1359122 .4761652 
-
Ibfcat2 1 -.2441667 .1605204 -1. 52 0.130 -.5605535 .0722202 
-
cons .0542771 .1955162 0.28 0.782 -.3310868 .4396411 
------------------------------------------------------------------------------
children with detectable DNA: 
Source I SS df MS 
-------------+------------------------------
Model I 70.0530414 7 10.0075773 
Residual I 60.5105992 130 .465466148 
-------------+------------------------------
Total I 130.563641 137 .953019274 
Number of obs 
F( 7, 130) 











zbmi18 I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-
-------------+----------------------------------------------------------------
Itreat 1 -.0711162 .1183583 -0.60 0.549 -.3052739 .1630415 
-
zbmi6 .6619408 .0558477 11. 85 0.000 .5514528 .7724288 
Ieduc3 2 -.2352765 .1391539 -1. 69 0.093 -.5105759 .0400228 
-
Ieduc3 3 .1146766 .1643002 0.70 0.486 -.2103717 .4397248 
Isescat3 
- 2 .1565689 .1381071 1.13 0.259 -.1166595 .4297973 
-
Isescat3 3 .2208122 .1583628 1. 39 0.166 -.0924897 .5341142 
-
Ibfcat2 1 -.1604435 .1532274 -1. 05 0.297 -.4635856 .1426985 
-
cons .3035977 .1806845 1. 68 0.095 -.0538649 .6610604 
------------------------------------------------------------------------------
Stratified by maternal Hrv & HCMV DNA: 
Hrv negative mother, no detectable DNA 
Source I SS df MS Number of obs 159 
-------------+------------------------------ F( 1, 157) 0.84 
Model I 1.04521686 1 1.04521686 Prob > F 0.3613 
Residual I 195.730656 157 1.24669208 R-squared 0.0053 
-------------+------------------------------ Adj R-squared -0.0010 
Total I 196.775873 158 1.24541692 Root MSE 1.1166 
------------------------------------------------------------------------------
zbmi18 I Coef. Std. Err. t P>ltl [95% Conf. Interval) 
-------------+----------------------------------------------------------------
Itreat_1 I .1621598 .1771004 0.92 0.361 -.187647 .5119667 
_cons I .180625 .1248345 1.45 0.150 -.0659467 .4271967 
------------------------------------------------------------------------------
Hrv negative mother, detectable DNA 
Source I SS df MS Number of obs 92 
-------------+------------------------------ F( 1, 90) 0.29 
Model I .241111933 1 .241111933 Prob > F 0.5903 
Residual I 74.3305489 90 .825894988 R-squared 0.0032 
-------------+------------------------------ Adj R-squared -0.0078 
Total I 74.5716609 91 .819468801 Root MSE .90879 
------------------------------------------------------------------------------
zbmi18 I Coef. Std. Err. t P>ltl [95% Conf. Interval) 
-------------+----------------------------------------------------------------
Itreat 1 I .1024113 .1895401 0.54 0.590 -.2741432 .4789659 
_co~s I .1633333 .1354741 1.21 0.231 -.1058095 .4324762 
Hrv positive mother, no detectable DNA 
Source I SS df MS Number of obs 43 
-------------+------------------------------ F( 1, 41) 2.84 
Model I 3.13124676 1 3.13124676 Prob > F 0.0995 
Residual I 45.1837439 41 1.10204254 R-squared 0.0648 
-------------+------------------------------ Adj R-squared 0.0420 
Total I 48.3149907 42 1.15035692 Root MSE 1.0498 
------------------------------------------------------------------------------
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zbmi18 I Coef . Std. Err . t P> ltl [ 95 % Conf . I nterva l ] 
------------ -+----------------------------------------------------------------
_ Itreat_1 I -.5398485 





HIV positive mother, detectable DNA 
Source I SS d f MS 
-------------+------------------------------
Model I . 33588261 1 
Residual I 47 . 8027439 
1 .335882611 
32 1. 49383575 
-------------+------------------------------
Total I 48 .1 386265 33 1. 458 74 626 
zbmi18 I Coe f. Std . Err . t 
0.099 
0.28 4 
P> l tl 
-1.186641 
-. 2088203 
Number of obs 
F( 1 , 32) 
Prob > F 
R- squared 
Ad j R-s quared 
Root MSE 
.106944 2 
. 695 184 
34 
0 . 22 
0.6386 
0 . 0070 
-0 . 024 1 
1.2222 
[ 95 % Conf . I nterval ] 
-------------+--- ----------------------------------------- --------------------
Itreat_1 I . 2001754 
_ cons I -. 1468 42 1 
9.11.4 Stunting at M18 
stratified by HCHV DNA: 
. 422 1516 
. 2803978 
children with no detectable DNA: 
treat 
18 stunted Conve ntio Micronutr 
0 .4 7 
- 0 .52 
Total 
-----------+----------------------+----------
No I 94 87 I 181 
I 51 . 93 48 . 07 I 100.00 
-----------+----------------------+----------
Yes I 19 24 I 43 
I 44 .1 9 55 . 81 I 100 . 00 
-----------+----------------------+----------
Total I 113 11 1 I 224 
I 50.45 49 . 55 I 100 . 00 
0.639 
0 . 604 
Pearson ch i 2(1) 0 . 8343 Pr = 0 . 361 
children with detectable DNA: 
treat 
18 stunted Conventio Mic r onutr Total 
-----------+----------------- -----+----------
No I 55 55 I 110 
I 50.00 50 . 00 I 100 . 00 
-----------+----------------------+----------
Yes I 16 13 I 29 
I 55 .1 7 44 . 83 I 100 . 00 
-----------+----------------------+----------
Total I 71 68 I 139 
I 5 1. 08 48 . 92 I 100 . 00 
Pearson chi2(1) 0 . 2457 Pr = 0 . 620 




Stratified by HCHV DNA, adjusted for Z score at 6m, education, SES & BFing 
children with no detectable DNA : 
Logistic regression 
Log likel ihood = - 73 . 513736 
stunted18 I Odds Ra t io Std. Err. z 
Numbe r of obs 
LR c hi2( 7 ) 
Prob > c h i2 
Pseudo R2 
224 
72 . 07 
0 . 0000 
0 . 3289 
P> l z l [ 95 % Conf . Inte r va l] 
-- ---- -------+-------------------------------------------------------- --------
I treat 1 1 . 543006 . 6651188 1. 01 0 . 31 4 . 6629089 3 . 591546 
zlen6 . 1528839 . 0485164 - 5 . 92 0 . 000 . 0820805 .2847629 
Ieduc3 2 1.244853 . 6117859 0 . 45 0.656 . 47 51087 3 . 26 1693 
-
Ieduc3 3 . 3024915 . 1947346 -1. 86 0. 063 . 0856517 1. 068293 
Isesca t3 
-
. 9390758 . 4875549 - 0 .1 2 0 . 904 2 . 3394 446 2 . 59 7 96 
-
Isescat3 3 1 . 693998 1. 02 1083 0 . 87 0 . 382 . 51 98022 5 . 52061 6 
-
Ibfcat2 1 2 . 829974 2 . 159243 1. 36 0. 17 3 . 6343 429 12 . 62528 
-
--- - - - --- - --- - -------- --------- --- ---
------ ------ -------- - ---- - - -- - - - -- ----- --
children with detectable DNA: 
226 
Logistic regression 
Log likelihood = -26.205735 
stunted18 I Odds Ratio Std. Err. z 
Number of obs 
LR chi2(7) 
Prob > chi2 
Pseudo R2 







Itreat 1 2.549371 2.149987 1.11 
zlen6 .0429277 .0295534 -4.57 
Ieduc3 2 .2588153 .2208699 -1. 58 
-
Ieduc3 3 .4352586 .418192 -0.87 
Isescat3 
- 2 .4356262 .3650352 -0.99 
-
Isescat3 3 .0603376 .0702105 -2.41 
-
Ibfcat2 1 .1629692 .1513232 -1. 95 
-
Stratified by maternal. HIV &; HCHV DNA: 
HIV negative mother, no detectabl.e DNA 
Logistic regression 
Log likelihood = -81.002588 








Number of obs 
LR chi2(1) 













P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
1.278689 .5017932 0.63 
HIV negative mother, detectable DNA 
Logistic regression 
Log likelihood = -35.377791 
0.531 .592556 
Number of obs 
LR chi2(1) 







stunted18 I Odds Ratio Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat_1 I .6462585 .4051286 -0.70 0.486 .1891483 2.208056 
------------------------------------------------------------------------------
HIV positive mother, no detectabl.e DNA 
Logistic regression 
Log likelihood = -18.987923 
Number of obs 
LR chi2 (1) 







stunted18 I Odds Ratio Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
1.490196 1.242111 0.48 0.632 .2909031 7.633759 
------------------------------------------------------------------------------
HIV positive mother, detectable DNA 
Logistic regression 
Log likelihood = -22.691181 
Number of obs 
LR chi2(1) 






stunted18 I Odds Ratio Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat_1 I .5555556 .3971769 -0.82 0.411 .136832 2.255627 
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9.12 Appendix L: Effects of intervention on growth among HCMV 
seropositive, HIV -1 exposed infants breast fed <6 months 
9.12.11engthatM18 
in all children with no detectable antibody 
Source I SS df MS Number of obs 73 
-------------+------------------------------ F( 1, 71 ) 0.12 
Model I .137877124 1 .137877124 Prob > F 0.7321 
Residual I 82.8593338 71 1.16703287 R-squared 0.0017 
-------------+------------------------------ Adj R-squared -0.0124 
Total I 82.997211 72 1.15273904 Root MSE 1. 0803 
zlen18 I Coef. Std. Err. t P>ltl [95% Conf. Interval) 
-------------+----------------------------------------------------------------
Itreat_1 I .0869925 .2530913 0.34 0.732 -.4176572 .5916421 
cons I -.7485714 .1826028 -4.10 0.000 -1.112671 -.3844717 
in all children with detectable HCMV antibody 
Source I SS df MS Number of obs 371 
-------------+------------------------------ F( 1, 369 ) 0.01 
Model I .012308075 1 .012308075 Prob > F 0.9199 
Residual I 448.39303 369 1.21515726 R-squared 0.0000 
-------------+------------------------------ Adj R-squared -0.0027 
Total I 448.405339 370 1.21190632 Root MSE 1.1023 
------------------------------------------------------------------------------
zlen18 I Coef. Std. Err. t P>ltl [95% Conf. Interval) 
-------------+----------------------------------------------------------------
Itreat_1 I .01152 











in children of HIV positive mothers, breastfeed:i.ng <6m, no detectable HCMV 
-> treat = Conventional porridge 
Variable I Obs Mean Std. Err. [95% Conf. Interval) 
-------------+---------------------------------------------------------------
zlen18 I 8 -.4825 .4821631 -1.622635 .6576345 
-> treat = Micronutrient-fortified 
Variable I Obs Mean Std. Err. [95% Conf. Interval) 
-------------+---------------------------------------------------------------
zlen18 I 7 -.8085714 .3415889 -1.644409 .0272666 
-----------------------------------------------------------------------------
effect of d:i.et group on _zlen at lam, adjusted for baseline _zlen, education' SES, in 
children of HIV positive mothers, breastfeed:i.ng <6m, 
with no detectable HCMV antibody: 
xi:regress _zlen18 i.treat zlen6 i.educ3 i.sescat3 if mhiv f==2 & bfcat2==0 & hcmv==O 
Source ss df MS Number of obs 15 
-------------+------------------------------ F( 6, 8 ) 8.62 
Model I 15.8628648 6 2.6438108 Prob > F 0.0039 
Residual I 2.45370852 8 .306713565 R-squared 0.8660 
-------------+------------------------------ Adj R-squared 0.7656 
Total I 18.3165733 14 1.30832667 Root MSE .55382 
------------------------------------------------------------------------------
zlen18 I Coef. Std. Err. t P>ltl [95% Conf. Interval) 
-
-------------+----------------------------------------------------------------
Itreat_1 .100187 .3224355 0.31 0.764 -.6433507 .8437246 
zlen6 .7833414 .1869969 4.19 0.003 .3521257 1.214557 
Ieduc3_2 .5609843 .6684728 0.84 0.426 -.9805168 2.102485 
Ieduc3 3 .9993354 .9022472 1.11 0.300 -1.08125 3.079921 
Isescat3=2 .0999833 .5708017 0.18 0.865 -1.216288 1.416254 
Isescat3_3 -.6935022 .5991472 -1.16 0.280 -2.075138 
.6881337 
cons -.4716463 .8403178 -0.56 0.590 -2.409423 1. 46613 
228 
*children of HIV positive mothers , breastfeeding <Gm, with detectable HCMV 
- > treat = Conventional porridge 
Variable 1 Obs Mean Std . Err . [95 % Conf . Interval ] 
------------ -+---------------------- --- ------------- -- ----- ------------------
zlen18 1 22 - 1 . 6 . 2710034 - 2 .1 63582 -1.036418 
- > treat = Micronutrient - fortified 
variable 1 Obs Mean Std . Err . [95 % Conf . Interval] 
-------------+--------------------------- ------------------------------------
zlen18 1 20 - . 954 . 2339876 - 1 . 443742 - . 464 25 83 
*effect of diet group on _zlen at l8m , adjusted for baseline _zlen, education & SES, i n 
children of HIV positive mothers , breastfeeding <Gm, 
with detectable HCMV antibody: 
xi : regress zlen18 i.treat zlen 6 i.educ3 i . sescat3 if mhiv f ==2 & bfcat2== 0 & h c mv== l 
Source SS df MS 
------------ -+------------------------------
Model 1 30.7486496 6 5 . 12477493 
Residual 1 19.8762529 34 . 584595672 
------------ -+----------------------- -------
Total 1 50 . 6249024 40 1.26562256 
zlen18 1 Coef . Std. Err . t P> lt l 
Number of obs 
F( 6 , 34) 




[95 % Conf . 
41 
8.77 
0 . 0000 
0 . 6074 
0 . 5381 
. 76459 
I n terval] 
------ -- - ----+----------------------- -- ---- -----------------------------------
Itreat 1 . 6103 258 . 2 550021 2 . 39 0 . 022 .09209 91 1 . 12 85 5 3 
- -
zlen6 . 8530996 . 135202 6 . 31 0 . 000 . 578336 1 . 127863 
Ieduc3 2 . 3406602 . 3159672 1. 08 0 . 289 - . 30 1 4624 .98 27828 
-
Ieduc3 3 . 6279317 . 3305551 1. 90 0.066 - . 0438372 1. 299701 
-
Isescat3 2 - .0363417 . 2943238 -0.12 0.902 - . 6344796 . 561 7961 
-
Isescat3 3 -. 2812359 . 3792457 - 0 . 74 0 .4 63 - 1.051956 .489484 2 
cons - .7522426 . 3109424 - 2 . 42 0 . 021 - 1. 384 154 - . 1203316 
-
-- - ---- -- --- - --------- - - - ------- -------------------- -- - -------- -----------
9.13 Appendix M: Effects of intervention on referral rate 
*** (e) rate by treatment arm 
*overall 
+----------- ---------------- --- ---------------------------------- -------+ 
1 treat D Y Rate Lowe r Up per 1 
1-- ---------------------------------- ----------------------------------- 1 
1 Conventional porridge 69 322 . 2454 0 . 21 41 2 0.16912 0 . 27110 1 
1 Micronutrient - fortified 8 1 317 . 9385 0 . 25 477 0 . 20491 0 . 31675 1 
+------------------------------- -------------------- -- -- ----------------+ 
Cox regression -- Breslow met h od for 
No. of subjects 743 
No . of failu r es 1 50 
Time at risk 640 . 1 838638 
Log pseudolikelihood 
1 
_t 1 Haz . Ratio 
- 968 . 90636 
(Std . Er r . 
Robust 
Std . Er r. 
ties 
Number of obs 1188 
Wa 1d chi2(1) 1. 01 
Prob > ch i 2 0.3143 
adjus t ed for 743 clus t ers in subject_id) 
z P>lz l [95 % Conf . Interval] 
----- - -- --- - -+- ---------------------------- -----------------------------------
_Itreat_1 1 1 . 192269 . 208357 1 . 01 0 . 314 . 8464885 1 . 679297 
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9.14 Appendix N: Effects of HI V exposure and intervention on referral rate 
9.14.1 Effects oftreatment within HIV-lunexposed and exposed infants 
*effect of treatment arm, within each maternal HIV group 
+---------------------------------------------------------------------------------------+ 1 mhiv_f treat D Y Rate Lower Upper I 
1---------------------------------------------------------------------------------------1 1 Negative Conventional porridge 46 219.1242 0.209927 0.157241 0.280266 1 
1 Negative Micronutrient-fortified 45 216.6435 0.207715 0.155088 0.278200 1 
1 positive Conventional porridge 19 74.4915 0.255063 0.162693 0.399877 1 
1 positive Micronutrient-fortified 32 71.4962 0.447576 0.316515 0.632906 1 
1 Don't know Conventional porridge 4 28.6297 0.139715 0.052437 0.372258 1 
1---------------------------------------------------------------------------------------1 
1 Don't know Micronutrient-fortified 4 29.7988 0.134234 0.050380 0.357653 I 
+---------------------------------------------------------------------------------------+ 
Effect of treatment arm, in HIV negative mothers: 
Cox regression -- Bres10w method for ties 
No. of subjects 519 Number of obs 850 
No. of failures 91 
Time at risk 435.767657 
Wald chi2(1) 0.00 
Log pseudo1ikelihood -553.09829 Prob > chi2 0.9815 
(Std. Err. adjusted for 519 clusters in subject_id) 
_t I Haz. Ratio 
Robust 
Std. Err. z P>lzl [95% Conf. Interval} 
-------------+----------------------------------------------------------------
Itreat_1 1 .9949989 .2156026 -0.02 0.982 .6506971 1.52148 
Effect of treatment arm, in HIV positive mothers: 
Cox regression -- Breslow method for ties 
No. of subjects 157 
No. of failures 
Time at risk 
51 
145.9877064 
Number of obs 232 
Wald chi2(1) 3.25 
Log pseudolikelihood -251.9958 Prob > chi2 0.0713 
(Std. Err. adjusted for 157 clusters in subject_id) 
t 1 Haz. Ratio 
Robust 
Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat_1 1 1.761532 .5530078 1.80 0.071 .9520678 3.259215 
Effect of treatment arm, in HIV unknown mothers: 
Cox regression --
No. of subjects 
No. of failures 







Number of obs 
Wald chi2 (1) 




(Std. Err. adjusted for 67 clusters in subject_id) 
Robust 
t I Haz. Ratio Std. Err. z P>lzl [95% Conf. Interval} 
-------------+----------------------------------------------------------------
Itreat_1 1 .9570646 .6377706 -0.07 0.947 .2592483 3.533187 
------------------------------------------------------------------------------
9.14.2 Effects ofHIV-1 exposure within treatment arms 
*effect of maternal HIV within each trial arm 
+---------------------------------------------------------------------------------------+ 
1 treat mhiv_f D Y Rate Lower Upper 1 
1---------------------------------------------------------------------------------------1 
1 Conventional porridge Negative 46 219.1242 0.209927 0.157241 0.280266 1 
1 Conventional porridge Positive 19 74.4915 0.255063 0.162693 0.399877 1 
1 Conventional porridge Don't know 4 28.6297 0.139715 0.052437 0.372258 I 
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1 Micronutrient-fortified Negative 45 216 . 6435 0 . 207715 0 . 155088 0 . 278200 1 
1 Micronutrient - fortified Positive 32 71 . 496 2 0 . 447576 0 . 316515 0 . 632906 1 
1--- ------------------------------------------------------------------------------------1 
1 Micronutrient -fortified Don ' t know 4 29 . 7988 0 .1 34234 0 . 050380 0 . 357653 1 
+-- --------------- ------------------------------- ---------------------------------------+ 
Effect of materna1 HIV , within the basa1 diet group : 
Cox regression --
No . of subjects 
No . of failures 
Time at risk 
Bres10w method for ties 
373 
69 
322 . 2453585 
Number of obs 582 
Wa1d chi2(2) 1. 55 
Log pseudo1ike1ihood -397 . 30745 Prob > chi2 0 . 4618 
(Std . Err . adjusted for 373 clusters in s ubj ect_id ) 
t 1 Haz . Ratio 
Robust 
Std. Err. z P>lz l [95 % Conf . Interval] 
----- --------+----------------------------------------------------------------






0 . 79 
- 0 . 82 
0 . 432 
0 . 413 
. 7321229 
. 2572746 
2 . 073376 
1 . 747341 
Effect of materna1 HIV , within the fortified diet group : 
Cox regression -- Breslow method for ties 
No . of subjects 370 Number o f obs 606 
No . of failures 81 
Time at risk 317 . 9385053 
Wald c h i2(2) 10 . 18 
Log pseudolikelihood - 460 . 9492 Prob > chi2 0 . 0062 
t 1 Haz . Ratio 
(Std . Err . adjusted for 370 clusters in s ubj ec _id) 
Robust 
Std . Err. z P>lz l [95 % Conf . Interval ] 
-------------+----------------------------------------------------------------
Imhiv f 2 1 2 .176068 .5950566 2 .84 0.004 1 . 27323 3 . 719099 
Imhiv=f=3 1 . 6433506 . 3179236 - 0.89 0.372 .2442365 1 . 694668 
9.15 Appendix 0: Effects of HCMV sera-DNA and intervention on referral 
rate 
*effect of HCMV DNA at 6m within each treatment group 
+------------------------------------------------ ----------------------------------+ 
1 treat dcmv_y-6 D Y Rate Lower Upper 1 
1----------------- ----------------------------------------------------------- ---- --1 
1 Conventional porridge 0 25 131 . 3595 0 . 19032 0 . 12860 0 . 28166 1 
1 Conventional porridge 1 23 77 . 4155 0 . 29710 0.19743 0 . 44708 1 
1 Micronutrient - fortified 0 31 124 . 7174 0.24856 0 . 17481 0 . 35344 1 
1 Micronutrient-fortified 1 26 77 . 3251 0 . 33624 0 . 22894 0 . 49384 1 
+----------------------------------------------------------------------------------+ 
Effect of HCMV DNA at 6 m/ in basal diet group: 
Cox regression -- Bres10w method for ties 
No . of subjects 248 
No . of failures 48 
Time at risk 208 . 7750257 
Log pseudolikelihood - 254 . 40394 
Number of obs 
Wald c hi2 ( 1) 
Prob > c hi 2 
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2 . 42 
0 . 1199 
(Std . Err. adjus ted for 248 clusters in subject_id) 
1 
_t 1 Haz . Ratio 
Robust 
Std. Err . z P>lzl [95 % Conf . Interval] 
-------------+--------------- -------------------------------------------------
1 . 555134 .44 15014 1. 56 0 . 120 . 8914812 2 . 712834 
Effect of HCHV DNA at 6 m, in fortified diet group : 
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Cox regression --
No. of subjects 
No. of failures 
Time at risk 




Log pseudolikelihood -302.60063 
Number of obs 
Wald chi2(l) 




(Std. Err. adjusted for 237 clusters in subject id) 
t I Haz. Ratio 
Robust 
Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
1.37513 .4320589 1. 01 0.311 .7428486 2.545581 
--------_ ........ _ ... --_ ....... _-------------_ .. _------_ ............ _ ..... _---_ ... _--_ .. _ .. 
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9.16 Appendix P: Effects of HCMV seroprevalence and intervention on referral rate 
9.16.1 Effect of HCMV seroprevalence within each trial arm 
*effect of HCMV antibody within each treatment group 
+-------------------------------------------------------------------------------------+ 
1 treat scmv_-18 D Y Rate Lower Upper 1 
1-------------------------------------------------------------------------------------1 
1 Conventional porridge 0 4 23.1102 0.173084 0.064961 0.461165 1 
1 Conventional porridge 1 38 156.5668 0.242708 0.176604 0.333555 1 
I Micronutrient-fortified 0 7 37.6044 0.186148 0.088743 0.390466 I 
1 Micronutrient-fortified 1 41 145.3909 0.281998 0.207640 0.382985 1 
+-------------------------------------------------------------------------------------+ 
Effect of HCMV antibody at l8m, in basal diet group: 
Cox regression Breslow method for ties 
No. of subjects 205 Number of obs 322 
No. of failures 42 
Time at risk 179.6770673 
Wald chi2(1) 0.49 
Log pseudolikelihood 
-216.50684 Prob > chi2 0.4825 
t Haz. Ratio 
(Std. Err. adjusted for 205 clusters in subject_id) 
Robust 
Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
_Iscmv_yn_-1 I 1.404665 .6795667 0.70 0.482 .5442117 3.625583 
Effect of HCMV antibody at l8m, in fortif:ied diet group: 
Cox regression Breslow method for ties 
No. of subjects 
No. of failures 
Time at risk 
Log pseudolike1ihood 








Number of obs 353 
Wald chi2(1) 0.59 
Prob > chi2 0.4427 
adjusted for 216 clusters in subject_id) 
z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
_Iscmv_yn_-l 1 1.501174 .7943848 0.77 0.443 .5321034 4.235125 
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9.16.2 Effect of treatment within HCMV seroprevalence groups 
*Effect of diet qroup on referra1s, and association with HCMV 
*** <a> stratified by HCMV 
+-------------------------------------------------------------------------------------+ 
1 hcmvy-18 treat 0 Y Rate Lower Upper 1 
1-------------------------------------------------------------------------------------1 
1 0 Conventional porridge 6 29.3443 0.204469 0.091860 0.455123 1 
1 0 Micronutrient-fortified 7 35.5893 0.196688 0.093768 0.412574 1 
1 1 Conventional porridge 40 170.3601 0.234797 0.172229 0.320095 1 
1 1 Micronutrient-fortified 46 160.7502 0.286158 0.214340 0.382040 1 
*no detectab1e HCMV 
Cox regression no ties 
No. of subjects 76 
No. of failures 13 
Time at risk 64.93366059 
Log pseudolikelihood 
t Haz. Ratio 








Cox regression -- Bres10w method for ties 
No. of subjects 
No. of failures 




Log pseudo1ike1ihood -498.40773 
t Haz. Ratio 






Number of obs 
Wald chi2(1) 




P>lzl [95% Conf. Interval] 
0.948 .3298987 
Number of obs 
Wald chi2 (1) 





P>lzl [95% Conf. Interval] 
0.405 .759143 1.979414 
9.16.3 Effect of intervention stratified by HCMV seroprevalence and HIV exposure 
*** <b> stratified by HCMV & materna1 HIV 
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+------------------------------------------------------------------------------------------------+ 
\ mhiv_f hcmvy~18 treat D Y Rate Lower Upper \ 
\------------------------------------------------------------------------------------------------\ 
\ Negative 0 Conventional porridge 2 15 . 6797 0 . 127553 0.031901 0 . 510015 \ 
1 Negative 0 Micronutrient-fortified 4 21.5168 0 . 185901 0.069772 0.495 317 1 
1 Negative 1 Conventional porridge 31 119.1540 0.260167 0.18 2967 0.36994 2 1 
1 Negative 1 Micronutrient-fortif i e d 2 4 117 . 2896 0 . 204622 0.1371 52 0.305283 1 
1 Positive 0 Conventional porridge 2 7 . 7317 0 . 258676 0 . 064694 1.034 299 1 
1------------------------------------------------------------ ------------------------------------1 
1 Positive 0 Micronutrient - fortified 3 10 . 034 2 0 . 298977 0.096426 0. 92699 8 1 
1 Positive 1 Conventional porridge 8 36 .7 310 0 . 217800 0.10892 1 0.435 514 1 
1 Positive 1 Micronutrient-fortified 20 30 . 5407 0 . 654863 0 . 422 490 1 . 015045 1 
+------------------------------------------------------------------------------------------------+ 
*HIV positive, no detectable HCHV 
No . of subj ects 
No. of failures 







Number of obs 
Wald chi2(1) 




_ t I Ha z . Ratio Std . Err. z P> l zl [95 % Conf . Interval] 
-------------+----------------------------------------------------------------
Itreat 1 I 1 . 188938 .9629272 
*HIV positive, detectable HCHV 
Cox regression Breslow method for ties 
No . of subjects 
No . of failures 




67 . 27173169 
-114.18506 
t I Haz. Ratio 
Robust 
Std. Err. 
0 . 2 1 
z 
0.831 . 2 430897 
Number of obs 
Wald chi2(1) 
Prob > chi2 




P> lzl [95 % Conf. Interval] 
-------------+----------------------------------------------------------------
_Itreat_1 2.991643 1.440442 2.28 0.023 1 .164303 7.68694 
In children of HIV negative mothers, effect of treatment does not depend on HCMV status . In children of HIV positive mothers, risk of referral 
is higher in micronutrient arm if have detectable HCMV 
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9.16.4 Effect of intervention stratified by HCMV seroprevalence, HIV exposure and baseline anaemia 
••• (e) by maternal Hrv, HCMV & hgb at baseline 
----------------------------
I mhiv_f hcmvy-18 hgb_yn treat D Y Rate Lower Upper 
1-------------------------------------------------------------------------------------------------------
Negative 0 0 Conventional porridge 8.4983 0.117671 0.016576 0.835353 
Negative 0 0 Micronutrient-fortified 1 10.6639 0.093774 0.013209 0.665709 
Negative 0 1 Conventional porridge 1 7.1814 0.139249 0.019615 0.988538 
Negative 0 Micronutrient-fortified 3 9.8672 0.304037 0.098059 0.942688 
Negative 0 Conventional porridge 16 73.7467 0.216959 0.132916 0.354142 
Negative 1 0 Micronutrient-fortified 12 72.4079 0.165728 0.094118 0.291820 
Negative 1 1 Conventional porridge 15 44.4244 0.337652 0.203559 0.560079 
Negative 1 1 Micronutrient-fortified 11 42.9651 0.256022 0.141785 0.462300 
Positive 0 0 Conventional porridge 5.3060 0.188467 0.026548 1.337944 
Positive 0 0 Micronutrient-fortified 1 5.7084 0.175180 0.024676 1. 243614 
Positive 0 Conventional porridge 1 2.4257 0.412246 0.058070 2.926564 
Positive 0 Micronutrient-fortified 2 4.3258 0.462342 0.115631 1.848645 
Positive 0 Conventional porridge 7 22.3600 0.313059 0.149246 0.656674 
Positive 1 0 Micronutrient-fortified 6 12.3313 0.486567 0.218596 1.083040 
Positive 1 1 Conventional porridge 1 13.3771 0.074754 0.010530 0.530687 
Positive 1 1 Micronutrient-fortified 14 16.1807 0.865228 0.512434 1.460912 
••• (c) effect of diet in Hrv positive mothers, by child hiv 
-------------------------
chiv2 hcmvy-18 treat D Y Rate Lower upper 
------------------------------------------------------------------------------
1 0 Conventional porridge 2 6.9651 0.287146 0.071815 1.148136 
1 0 Micronutrient-fortified 2 9.1143 0.219435 0.054880 0.877398 
1 Conventional porridge 5 30.1081 0.166068 0.069122 0.398983 
1 1 Micronutrient-fortified 5 22.1081 0.226161 0.094134 0.543359 
-----------------------------------------------
2 0 Conventional porridge 0 0.7666 0.000000 
2 0 Micronutrient-fortified 1 0.9199 1. 087054 0.153126 7.717071 
2 1 Conventional porridge 3 6.6229 0.452976 0.146095 l. 404485 
2 1 Micronutrient-fortified 15 8.4326 1.778815 1.072387 2.950598 
Rates of referrals is higher in micronutrient-fortified arm if child is HIV positive/unknown & has detectable HCMV 
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*Hrv positive mother, HIV negative child , with detectable HCMV 
Cox regression no ties 
No . of subj ects 52 
No . of failures 10 
Time at risk 52.21629021 
Log pseudolikelihood 




Number of obs 80 
Wald chi2(1) 0 . 24 
Prob > chi2 0 . 6277 
z P>lzl [95 % Conf. Interval] 
-------------+----------------------------------------------------------------
Itreat 1 1.363636 . 8721721 0 . 48 0 . 628 .389292 6 4.776623 
*HIV positive mother , HIV positive or unknown child, with detectable HCMV 
Cox regression -- Breslow method for ties 
No. of subjects 
No . of failures 




15 . 05544148 
- 46 . 834164 
t Haz . Ratio 
Robust 
Std . Err. z 
Number of obs 
Wald chi2(1) 
Prob > chi2 
40 
5.07 
0 . 0244 
P>lzl [95 % Conf. Interval] 
-------------+----------------------------------------------------------------
_ Itreat_ 1 3 . 805198 2 .258861 2 .25 0.024 1.188729 12.18069 
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9.17 Appendix Q: Breast feeding and risk of HCMV transmission 
% HCMV seropositive Unadjusted OR (95% Cl) P 
Duration of breast feeding 
Never 48% (14/29) 
< 6 months 86% (38/44) 6.79 (2.19-20.96) < 0.001 
> 6 months 86% (332/387) 6.48 (2.96-14.14) < 0.001 
Duration of breast feeding among HIV-l 
exposed infants 
Never 50% (12/24) 
< 6 months 89% (29/33) 7.25 (1.94-27.04) 0.003 
>6 months 95% (40/42) 20 (3.91-102.1) < 0.001 
HCMV seroprevalence is linked to duration of breast feeding, especially among HIV-t exposed infants. 
Analysis by KB. study statistician 
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9.18 Appendix R: Conventional vs Micronutrient fortification 
category/ Nutritional Intervention 
month Conventional fortification Micronutrient fortification P 
DemOlraphlcs 
Gender 
Male 51% (191/373) 45% (166/370) 
Female 49% (182/373) 55% (204/370) .084· 
low 34% (127/373) 33% (123/370) 
Socioeconomic status Medium 41% (151/373) 37% (136/370) .354 
High 26% (95/373) 30% (111/370) 
Never 6% (22/373) 6%(21/370) 
Breast feeding at baseline No 11% (39/373) 8%(29/370) .453 
Yes 84% (312/373) 87% (320/370) 
Morbidity 
Un-protective 2%(6/281) 3%(7/265) 
Polio Ab neutralization titre 
low 10% (28/281) 8%(21/265) 
Medium 65% (182/281) 64% (170/265) .790 
High 23% (65/281) 25% (67/265) 
6 11% (42/373) 14% (53/370) .211 
Fever 18 10% (23/229) 12% (27/223) .484 
6 38% (140/368) 41% (149/362) .389 
Anaemic 18 40% (114/286) 22% (63/282) <.001*" 
HCMV active infection 
6 37% (87/233) 37% (85/232) .876 
18 34% (63/183) 35% (58/167) .952 
HCMV seropositive 84% (184/219) 83% (189/227) .829 
HHV-6 active infection 
6 6% (16/275) 5% (15/283) .789 
18 15% (28/185) 13% (21/167) .488 
HIV-l infected 3% (9/291) 3%(8/283) .851 
HIV-1 exposed 22% (74/332) 23% (74/329) - .950 
Referral Rate 0.21 0.25 .314 
Died 1.9% (7/373) 1.4% (5/370) .570 
Growth 
Stunted 
6 14% (52/373) 11% (41/370) .239 
18 19% (58/301) 20% (61/301) .759 
Conventional fortification Micronutrient fortification 
N= Mean N= Mean P 
6 372 0.0084 370 0.0118 0.970 
BMI-for-age 18 275 0.0907 268 0.1430 0.566 
6 372 -0.5010 370 -0.4516 0.584 
Weight-for·age 18 275 -0.6149 271 -0.5222 0.372 
6 373 -0.8691 370 -0.8065 0.450 
length/height-for-age 18 275 -1.1176 268 -1.0446 0.464 
6 373 -0.1909 370 -0.1409 0.523 
Triceps skinfold-for-age 18 275 0.1130 270 0.2183 0.188 
Subscapular skinfold-for-age 6 
373 0.4275 370 0.4099 0.845 
18 275 0.4823 270 0.5186 0.678 
Arm circumference-for-age 
6 373 0.2787 370 0.3354 0.500 
18 274 0.0478 270 0.0781 0.750 
Head circumference-for-age 
6 373 0.5646 370 0.7005 o.on*t 
18 275 0.4909 270 0.6088 0.178 
Appendix R, Table 1: Micronutrient fortification reduced prevalence of anaemia but did not affect 
prevalence of beta herpesvirus active infections or HCMV seroprevalence and did not reduce stunting 
Effect of micronutrient fortified feed supplement on prevalence of beta herpesvirus active infections (detection of 
sera-DNA), HCMV seroprevalence (detection of antibody at 18 months), HIV -I infection (detection of antibody at 
18 months), HIV-I exposure (determined by maternal antenatal HIV-I status), polio antibody titres (measured by 
neutralization assay with titres binned as un-protective «I/g), low (l /g_I /32)' medium (I/wl/m) or high (>1/512)), 
prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as defined by Hb levels 
of < 10.5 glL) at both the month 6 and month 18 visits and anthropometric markers of growth. Stunting was defined 
by a length-for-age z score of < -2.0. Mean z-scores were compared by independent sample T test assuming equal 
variance and P values for nominal variables were by Pearson Chi Squared. White boxes highlight significant 
findings, light grey indicates trends. Asterisks denote degree of significance * < 0.1, ** <0.05, *** <0.005. ND = 
not done, NA = not applicable t = groupings that were not randomized between treatment arms at baseline. From 
S.Filteau and CIGNIS study team. 
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\ w 
\ tate&orw/ \\\\1-1 un~y.\\osed HIV-l exposed -- tatelory/ 
I month Conventional Micronutrient p month Conventional Micronutrient p fortification fortification fortification fortification 
Morbidity 
Un-protective 2% (3/187) 0.6% (1/177) Un·protective 0%(0/64) 5%(3/56) 
Polio Ab neutralization titre low 9% (16/187) 7% (13/177) 
.588 Polio Ab neutralization titre low 13% (8/64) 11% (6/56) .308 (12 months) Medium 66% (123/187) 63% (112/177) (12 months) Medium 70%(45/64) 66% (37/56) 
High 24% (45/187) 29% (51/177) High 17% (11/64) 18% (10/56) 
6 11% (28/258) 13% (34/255) .389 6 14% (10/74) 14% (10/74) 1.0 Fever 18 10% (15/156) 13% (21/159) .316 Fever 18 9% (4/46) 10% (4/41) .864 
6 39% (99/254) 38% (96/251) .866 6 32% (23/73) 47% (34/72) .053-t 
Anaemic 18 40% (75/189) 23% (43/190) <.001--- Anaemic 18 41%(27/66) 20% (12/60) .011--
6 36% (58/162) 35% (58/164) .934 6 41% (17/42) 45% (18/40) .679 
HCMV sera-DNA 18 35% (44/127) 39% (46/119) .514 HCMV sera-DNA 18 26% (9/35) 25% (7/28) .948 
-
HCMVantibody 18 86% (129/150) 83% (128/154) .487 HCMVantibody 18 80% (37/46) 85% (40/47) .551 
6 6% (12/192) 6% (12/201) .908 6 4% (2/52) 2% (1/51) .569 HHV-6 sera-DNA 18 15% (19/128) 13% (15/119) .610 HHV-6 sera-DNA 18 17% (6/35) 11% (3/28) .469 
Referral Rate 0.21 0.21 .982 Referra I Rate 0.26 0.45 .071-
Died 1.2% (3/258) 0%(0/255) .084- Died 4.1% (3/74) 6.8% (5/74) .467 
Growth 
6 14% (35/258) 9%(23/255) .104 6 16% (12/74) 19% (14/74) .666 Stunted 18 17% (32/184) 18% (33/185) .901 Stunted 18 30%(18/60) 31%(16/52) .930 
Conventional Micronutrient Conventional Micronutrient 
fortification fortification fortification fortification 
N= Mean N= Mean P N= Mean N= Mean P 
6 257 0.0219 255 0.1733 .140 6 74 -0.1231 74 -0.2500 .533 
8MI-for-age 18 184 0.0944 185 0.2570 .139 BMI-for-age 18 60 0.0140 52 -0.0242 .852 
6 257 -0.4467 255 -0.3030 .176 6 74 -0.6604 74 -0.8222 .443 
Weight-for-age 18 184 -0.5653 187 -0.3851 .149 Weight-for-age 18 60 -0.8262 52 -0.9160 .709 
6 
-
258 -0.7989 255 -0.7606 .682 6 74 -0.9861 74 -1.0986 .511 




258 -0.1208 255 -0.0471 .422 6 74 -0.3627 74 -0.2418 .515 Triceps skinfold-for-age 18 184 0.1757 186 0.3335 .105 Triceps skinfold-for-age 18 60 -0.0283 52 0.1017 .485 
6 
-
258 0.5250 255 0.5325 .942 6 74 0.1116 74 0.1305 .934 Subscapular skinfold-for-age 18 184 0.5633 186 0.6232 .558 Subscapular skinfold-for-age 18 60 0.3747 52 0.4271 .808 
-
6 - 258 0.3672 255 0.5109 .137 6 74 -0.0216 74 -0.1004 .702 Arm circumference-for-age 18 183 0.1257 186 0.2599 .218 Arm circumference-for-age 18 60 -0.2380 52 -0.2975 .812 
---
6 258 0.6509 255 0.8007 .095t 6 74 0.3350 74 0.4109 .654 Head circumference-for-age 
18 184 0.5657 186 
_Q·L31.2.._ .101 
Head circumference-for-age 18 60 0.2472 52 0.2852 .857 
Appendix R, Table 2: Micronutrient fortification reduced anaemia at 18 months irrespective of HIV-I exposure 
Effect of micronutrient fortified feed supplement sub-stratified by HIV -I exposure, on prevalence of beta herpesvirus active infections (detection of sera-DNA), HCMV 
seroprevalence (detection of antibody at 18 months), polio antibody titres (measured by neutralization assay with titres binned as un-protective «'/s), low (' /s-' /32), medium (' /64-' /512) 
or high (> 1/5\2» , prevalence of reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as defined by Hb levels of < 10.5 glL) at both the month 6 and month 18 
visits and anthropometric markers of growth. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores were compared by independent sample T test assuming equal 
variance and P values for nominal variables were by Pearson Chi Squared. White boxes highlight significant findings, light grey indicates trends. Asterisks denote degree of 
sign ificance * < 0.1 , ** <0.05, *** <0.005. NO = not done, NA = not applicable t = groupings that were not randomized between treatment arms at baseline. 
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~orv/ Conventlona\ fortii\cat\on Clutor'I/ Micronutrient fortlfIcatlon 
month I HIV-1 unexposed HIV-1 exposed month I month .1 HIV-1 unexposed HIV-1exposed P 
Morbidity 
Un-protective 2% (3/187) 0%(0/64) Un-protective 0.6% (1/177) 5% (3/56) 
Polio Ab neutralization titre Low 9% (16/187) 13% (8/64) 
.398 Polio Ab neutralization titre Low 7% (13/177) 11%(6/56) .040" (12 months) Medium 66% (123/187) 70%(45/64) (12 months) Medium 63% (112/177) 66% (37/56) 
High 24% (45/187) 17% (11/64) High 29% (51/177) 18% (10/56) 
Fever 6 11% (28/258) 14% (10/74) .526 6 13% (34/255) 14% (10/74) .968 
18 10% (15/156) 9% (4/46) .851 Fever 18 13% (21/159) 10%(4/41) .551 
Anaemic 6 39% (99/254) 32%(23/73) .245 Anaemic 6 38% (96/251) 47% (34/72) .171 18 40% (75/189) 41% (27/66) .861 18 23% (43/190) 20% (12/GO) .668 
HCMV sera-DNA 6 36% (58/162) 41% (17/42) .576 HCMV sera·DNA 6 35% (58/164) 45% (18/40) .258 18 35% (44/127) 26% (9/35) .319 18 39% (46/119) 25% (7/28) .176 
HCMVantibody 18 86% (129/150) 80%(37/46) .359 HCMVantibody 18 83% (128/154) 85% (40/47) .747 
HHV-6 sera-DNA 6 6% (12/192) 4%(2/52) .508 6 6% (12/201) 2% (1/51) .248 
18 15% (19/128) 17% (6/35) .738 HHV-6 sera·DNA 18 13% (15/119) 11% (3/28) .784 
Referra I Rate 0.21 0.26 .432 Referral Rate 0.21 0.45 .004 
Died 1.2% (3/258) 4.1% (3/74) .100 Died 0% (0/255) 6.8% (5/74) <.001'" 
Growth 
Stunted 6 14% (35/258) 16% (12/74) .564 Stunted 6 9% (23/255) 19% (14/74) .01S·· 
18 17% (32/184) 30% (18/GO) .036" 18 18% (33/185) 31% (16/52) .042" 
HIV·l unexposed HIV·l exposed HIV·l unexposed HIV-l exposed 
N= Mean N= Mean P N= Mean N= Mean P 
BMI-for-age 6 257 0.0219 74 -0.1231 .338 BMI·for-age 6 255 0.1733 74 -0.2500 .008'· 
18 184 0.0944 60 0.0140 .618 18 185 0.2570 52 -0.0242 .085· 
Weight-for-age 6 257 -0.4467 74 -0.6604 .166 Weight·for-age 6 255 ·0.3030 74 -0.8222 .002·'· 
lS 184 -0.5653 60 -0.8262 .144 18 187 ·0.3851 52 -0.9160 .006·· 
Length/height-for-age 6 258 -0.7989 74 -0.9861 .153 Length/height-for-age 6 255 ·0.7606 74 -1.0986 .023'· 
18 184 -1.0473 60 -1.3598 .053· 18 185 ·0.9567 52 -1.4588 .009'· 
Triceps skinfold·for-age 6 258 -0.1208 74 -0.3627 .on· 6 255 -0.0471 74 -0.2418 .173 
18 184 0.1757 60 -0.0283 .152 Triceps skinfold-for-age 18 186 0.3335 52 0.1017 .114 
Subscapular skinfold-for-age 6 258 0.5250 74 0.1116 .010·· Subscapular skinfold·for-age 6 
255 0.5325 74 0.1305 .015'· 
18 184 0.5633 60 0.3747 .213 18 186 0.6232 52 0.4271 .223 
, Arm circumference-for-age 6 258 0.3672 74 -0.0216 .007·· Arm circumference-for-age 6 255 0.5109 74 -0.1004 .000··· 
18 183 0.1257 60 -0.2380 .031" 18 186 0.2599 52 -0.2975 .001'·' 
Head circumference-for-age 6 258 0.6509 74 0.3350 .019" 6 255 
0.8007 74 0.4109 .004··· 
18 184 0.5657 60 0.2472 .037" 
Head circumference· for-age 
18 186 0.7372 52 0.2852 .006·· 
Appendix R, Table 3: Negative anthropometric outcomes due to HIV-I exposure were more prevalent in infants on the micronutrient fortified feed supplement 
Effect ofHIV-J exposure sub-stratified by treatment arm, on prevalence of beta herpesvirus active infections (detection of sera-ON A), HCMV seroprevalence (detection of antibody 
at 18 months), polio antibody titres (measured by neutralization assay with titres binned as un-protective «I/S)' low e /S-I/32)' medium (1/64-1/512) or high (>1/512», prevalence of 
reported fever (in the 3 days prior to clinic visit) and prevalence of anaemia (as defined by Hb levels of < J 0.5 glL) at both the month 6 and month 18 visits and anthropometric 
markers of growth. Stunting was defined by a length-for-age z score of < -2.0. Mean z-scores were compared by independent sample T test assuming equal variance and P values for 
nominal variables were by Pears on Chi Squared. White boxes highlight significant findings, light grey indicates trends. Asterisks denote degree of significance * < 0.1, ** <0.05, *** 
<0.005. NO = not done, NA = not applicable 
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